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Over the past two decades, there has been remarkable progress in the understanding 
of pathogenesis of rheumatic disease, which has in turn led to dramatic improvements 
in the ability to control inflammation. In documenting some of the advances that have 
taken place, this book demonstrates the therapeutic possibilities that fields such as 
pharmacogenomics might bring, while highlighting the current challenges in 
rheumatology, such as prevention of treatment-related opportunistic infection and the 
control of chronic pain. 
The first section is concerned with the pathogenesis mechanisms that underlie 
rheumatic diseases, beginning with a review of autoantibodies and their role in 
disease pathogenesis. There is a chapter on adipokines; the inflammatory mediators 
produced by adipose tissue, and the relationship between metabolism and 
inflammation. The results of microarray studies are outlined within a review on gene 
expression profiling in rheumatoid arthritis. The role of vitamin D in autoimmune 
disease is deliberated and there is a chapter that examines the effects of rheumatoid 
arthritis on bone metabolism. The first section concludes with a review of great clinical 
relevance – the contribution of TNF inhibitors to the risk of infection in rheumatoid 
arthritis. 
The second section narrows the focus to discuss various aspects of one particular 
rheumatic disease; Sjögren’s syndrome. This section is not intended to be a monograph 
on this disease, but more of a collection of reviews that put the spotlight on specific 
interesting facet of Sjögren’s syndrome: diagnosis and prognosis, mechanisms of 
decreased glandular secretion, oral manifestations and salivary proteomics. 
The final section of the book moves away from somatic physiology and pathology and 
examines the impact of the rheumatic diseases on higher functions. The role of 
psychological stress in the presentation of rheumatic disease is reviewed, and there is 
a chapter on assessment and management of pain. The transition of JIA patients, from 
childhood to adulthood, is reviewed in the final chapter of this section. 
The hope is, that this book will serve as a resource for those seeking comprehensive 
reviews of these topics. In its entirety, this book demonstrates the breadth and depth 
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of knowledge that has been accumulated in rheumatology from the molecular level to 
the highest level of human function. 
 
Dr. Andrew Harrsion 






of knowledge that has been accumulated in rheumatology from the molecular level to 
the highest level of human function. 
 
Dr. Andrew Harrsion 





Pathogenic Mechanisms in Rheumatic Disease 
Part 1 
Pathogenic Mechanisms in Rheumatic Disease 
 1 
Natural and Pathologic Autoantibodies 
Péter Németh and Diána Simon 
 University of Pécs, Department of Immunology and Biotechnology 
Hungary 
1. Introduction 
Detection and characterization of autoantibodies reacting with self-antigens is generally 
used in laboratory diagnostics. However, the presence of different autoantibodies in the 
blood serum doesn’t mean automatically a pathologic condition. Autoantibodies are present 
both in different diseases as autoimmune diseases, chronic inflammation or infections, and 
in healthy individuals without any symptoms. The present paper discusses the detailed 
analysis of recognition pattern and fine epitope specificity of these autoantibodies to better 
understand of their occurrence and evolution, and their role in physiologic and pathologic 
conditions. 
1.1 Evolution of the immunological recognition 
Microorganisms present in the environment continuously come into contact with the human 
body through external or internal surfaces. Most microorganisms are neutral or useful, but 
others – so called pathogens - are dangerous for the other living beings including human 
individuals. During evolution all multicellular organisms have developed defence 
mechanisms capable of eliminating these invading pathogens without causing damage to 
self structures. All vertebrates and invertebrates manage self and non-self discrimination. 
Consequently, discriminating self from non-self is of key importance for directing immune 
functions effectively, operating on the basis of distinct recognition systems. Any attempt to 
answer questions concerning recognition must consider the universality of receptor-
mediated responses. These may be designated to two forms: pattern recognition receptors 
and rearranging clonally distributed antigen-specific receptors that distinguish between self 
and non-self. 
1.1.1 Pattern recognition as a basic immune function  
Innate immunity serves as first line of defence against pathogens. Its early evolutionary 
appearance is indicated by its presence in all multicellular organisms including plants, 
invertebrates and vertebrates. Since invertebrate species rely on innate defence mechanisms 
only, survival of the species in the presence of environmental pathogens is achieved at the 
level of the population, which means that individual members, up until a fraction of total 
population, are dispensable (Kvell et al., 2007). Innate immunity uses receptors that are 
ancient in their evolutionary origin. These non-clonally distributed receptors have to be able 
to recognize a wide variety of molecular structures associated with pathogens without 
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damaging self-structures. The problem lies in the discrepancy between the vast 
heterogeneity of pathogens and the limited number of possible recognizing receptors in the 
genome. This implies that the relatively few available specific receptors must recognize 
structures shared by large groups of pathogens, and that the recognized structures have to 
be pathogen-specific molecular patterns rather than particular molecules specific for 
pathogens. These pathogen associated molecular patterns (PAMPs) are conserved products of 
microbial metabolism, they are highly glycosylated, and are essential for microbial survival. 
The receptors recognizing these PAMPs are termed pattern recognition receptors (PRRs). We 
distinguish three functional classes of PRRs: endocytic receptors such as cellular C-type lectins, 
scavenger receptors and Mac-1 (CD11b:Cd18), which facilitate opsonisation and phagocytosis. 
This type of recognition is predominantly based on sugar-sugar interactions. The second set of 
PRRs are secreted proteins including mannose binding lectin, C1q, pulmonary surfactant 
proteins A and D, C-reactive protein and lipopolysaccharide binding proteins, respectively. 
These molecules facilitate opsonisation for phagocytosis and aid the complement system in 
destroying pathogens that have been bound by these secreted proteins (Medzhitov 2001). The 
third functional group is constituted by signalling receptors such as the Toll-like receptors 
(TLRs), which activate several intracellular signalling cascades, eventually leading to the 
activation of many immune response genes. PAMPs are targets for many PRRs in innate 
immunity. PRRs are expressed on cells positioned strategically in the first line of pathogen 
encounter such as surface epithelia, marginal zone of spleen, and on antigen presenting cells 
(APCs) such as macrophages and dendritic cells. It is important to note that the relatively 
broad spectrum of ligands recognized by TLR family members also includes glycoproteins, 
which points toward the adaptive recognition system (Klein & Nikolaidis 2005). Thus, the TLR 
family possibly represents an important milestone on the way to a recognition system 
characteristic for adaptive immunity (Cooper et al., 2006).  
Recognition of PAMPs can activate direct effector mechanisms of innate immunity such as 
phagocytosis, secretion of antimicrobial peptides and induction of nitric oxide synthase in 
macrophages. Activation of innate immunity results in the secretion of several inflammatory 
cytokines such as interleukin-1, interleukin-6, tumor necrosis factor-α, type I interferon and 
many chemokines. One of the most important events caused by PAMPs recognition is the 
surface expression of CD80 (B7.1) and CD86 (B7.2) co-stimulatory molecules on APCs, 
which is necessary for the priming of T-dependent adaptive immune responses. Therefore in 
addition to activate direct first line defence mechanisms, innate immunity substantially 
contributes to the adaptive response as well. It is important to note that while PRRs 
recognize molecular patterns instead of specific molecules, and significant redundancy and 
promiscuity exists in the molecular nature of the recognized ligands, PRRs discriminate 
infectious non-self from self perfectly. One plausible explanation for this is that PRRs were 
selected and genetically stabilized over an evolutionary time scale creating an advantage for 
survival, and organisms possessing self reactive PRRs were eventually eliminated. This 
process prevents autoimmunity in those organisms which have only the innate recognition 
system (Cooper et al., 2006; Kvell et al., 2007). 
1.1.2 Antigen specific recognition  
The adaptive immune system containing specialized organs (bone marrow, thymus, spleen, 
lymph nodes, highly structured lymphatic tissues associated with the wet and dry body 
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surfaces), that provide appropriate microenvironment for cells which are committed to 
antigen specific immune defence (T and B cells), appeared later during the evolution. It can 
be generally found in jawed vertebrates, however the earliest species with a variable antigen 
receptor based adaptive-like recognition system are jawless fish (lamprey, hagfish). These 
fish have non-immunoglobulin like clonally distributed receptors with leucine-rich repeats 
(similar to TLRs) generated with a gene rearrangement mechanism other than the 
recombination activating genes (RAG-1:RAG-2) characteristic for jawed vertebrates (Pancer 
et al., 2004). The appearance of adaptive immune system in jawed vertebrates gives the 
impression of a “sudden” change between jawless and jawed fish. This “big bang” 
hypothesis concerning gene duplication events, acquisition of a retrotransposon and the 
appearance of molecules such as major histocompatibilty complex, T- and B-cell receptors 
(Abi Rached et al., 1999) has been challenged by showing that integration of minor changes 
accumulated over an extended evolutionary time lead to the appearance of adaptive 
immune system (Klein & Nikolaidis 2005). Taking into consideration the major 
immunological recognition and activation theories from Janeway’s self/non-self recognition 
to Polly Matzinger’s danger hypothesis and from Burnet’s clonal selection to Smith’s 
quantal theory recently, there is a trend to synthesize the self/non-self vs. danger models, 
particularly proving that receptors distinguish pathogen and danger signals simultaneously 
(Liu et al. 2009). 
In vertebrates the adaptive immunity generates a virtually indefinite pool of recognizing 
molecules: the T and B cell receptors (TCR, BCR), which repertoire makes the adaptation of 
each individual to pathogenic challenges possible. According to the clonal selection 
hypothesis these receptors are clonally distributed, each of them represented by single cell 
clone. The benefit of the high number of available antigen receptors in adaptive immunity 
comes with the cost of potentially dangerous recognition of self-structures, leading to 
autoimmunity. Therefore carefully organized selection mechanisms exist to select the 
potentially useful clones, and to eliminate or inactivate the autoreactive ones. Germline 
genes encoding T and B cell receptors are rearranged by the site specific recombinases RAG-
1, RAG-2. Once these antigen receptors appear on the cell surface, the cell carrying them has 
to survive two types of selection. The first of these is probing the utility of the expressed 
receptor by testing whether it is capable to recognize its ligand in the microenvironment. 
This selection step is termed positive selection, since in the case of the appropriate 
engagement of antigen receptor the cell survives. Although the process was described first 
and in more detail for T cells maturing in the thymus, it was also clearly demonstrated for B 
cell maturing in the bone marrow and spleen (Cancro & Kearney, 2004). The ligand that 
activates the antigen receptor is self-peptide-MHC complex and possibly soluble 
immunoglobulin for T and B cells, respectively. Positive selection operates on a thin margin, 
the strength of the signal generated by antigen receptor engagement must be lower than in 
full activation, thus it provides a partial activation signal. The second selection step 
eliminates clones that possess antigen receptors, which recognize self too strongly, and 
termed negative selection. This mechanism is based on the full activation of antigen receptor 
mediated signalling pathways by self antigens and eventually leads either to the deletion of 
the cell clone, or to long term unresponsiveness of the cell to subsequent stimuli (anergy). 
Alternatively, in the case of B cells, the recombination machinery could be re-activated and 
the other immunoglobulin gene harbouring allele could be rearranged (receptor editing), 
giving the cell a second chance to produce an antigen receptor not reacting with self 
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structures above threshold. Thus, the selection of antigen receptor bearing cells, irrespective 
of whether they belong to the T or B cell pool, is governed by interaction with self ligands 
instead of non-self ligands. The generation of the adaptive immune repertoire is therefore 
strongly self-referential (Janeway 2001). 
2. Natural immunity 
Since the innate recognition system discriminates self from non-self perfectly, the 
contribution of innate immunity to the activation of adaptive responses seems to be of vital 
importance for maintaining tolerance at the periphery. The appearance of co-stimulatory 
molecules on APC surface is critical for the activation of both T and B cells. In the absence of 
appropriate co-stimulation the activation signal remains below threshold level and the 
adaptive immune response will not be activated. The innate and adaptive arms of the 
immune system differ from each other in several important features and their cooperation is 
essential for the correct function of immune defence. As a connection bridging the 
evolutionarily oldest innate and the newly evolved adaptive systems a third compartment 
of immune machineries, the natural immune system has recently been described. A distinct 
set of lymphocytes – both T and B cells – with characteristic phenotypes and specialized 
functions participates in this system. These subsets of cells exhibit common phenotypic 
characteristics and posses both innate and adaptive features, suggesting a transitional stage 
in the immune system’s evolution. The most important cellular components of the natural 
immune system according to recent knowledge are the invariant natural killer T (iNKT) 
cells, mucosa associated invariant T (MAIT) cells, γδ T cells and B1 B cells. The functional 
character of antigen recognition by these cells (and the immunoglobulins produced by B1 B 
cells) are closer to the pattern recognition features than to the classical adaptive type 
immunological recognition, however, the recognizing molecules are genuine T and B cell 
surface receptors. 
2.1 Cellular elements of natural immune system 
Among unconventional T cells, only two subsets display both a TCR and selecting MHC 
class Ib molecules highly conserved between species, the iNKT cells and the mucosal 
associated invariant T (MAIT) cells. These two populations express highly restricted TCR 
repertoires consisting of an invariant TCRα chain. Both subsets are selected by 
hematopoietic cells expressing evolutionarily conserved non-polymorphic MHC class Ib 
molecules, CD1d for iNKT cells and MHC-related molecule 1 (MR1) for MAIT cells. CD1d-
restricted iNKT cells and MR1-restricted MAIT cells constitute two subsets of 
unconventional T cells that are phylogenetically conserved. Therefore, they are thought to 
play an essential role within the immune system of mammals (Treiner et al., 2005). 
MAIT cells are selected by MR1 in the thymus on a non-B non-T hematopoietic cell, and 
acquire a memory phenotype and expand in the lamina propria of the gastrointestinal tract 
and in mesenterial lymph nodes in a process dependent both upon B cells and the bacterial 
flora. Thus, their development follows a unique pattern at the crossroad of iNKT and γδ T 
cells. These features suggest that MAIT cells could be involved in tolerance or immunity to 
infections in the gut. The function of MAIT cells is unknown, but intuitively we can argue 
that it is related to their localization in the gut mucosa. MAIT cells could somehow be 
 
Natural and Pathologic Autoantibodies 
 
7 
involved in the defense against orally acquired pathogens or in non-immune function 
important for gut mucosa homeostasis. MAIT cells might also control the type of the gut 
immune response and/or be involved in oral tolerance. Controlling the balance between 
tolerance and immune response in the gastrointestinal tract is highly important, and could 
explain the striking conservation of the MAIT cells across species. The functional relevance 
of MAIT cells is also underlined by the fact that they represent 1-4% of peripheral T cells in 
human blood (Treiner et al., 2005).  
iNKT cells are selected, expand, and acquire their innate-like phenotype and functions in the 
thymus. They accumulate in the liver and the spleen, independently of the presence of any 
exogenous stimuli such as the normal bacterial flora. INKT cells play an important role in 
both protective and regulatory responses. The nature of the response is determined by the 
initial cytokine environment: interaction with IL-10-producing cells induces regulatory T 
cell type iNKT cells and that with IL-12 producing cells results in Th1 type responses, while 
their production of IFNγ activates both innate and adaptive immune systems. Upon 
activation of iNKT cells tumor cells can be efficiently eliminated and they also play a role in 
the development of obesity (Lynch et al., 2009).  
The γδ TCR repertoire similarly to the repertoire of innate immune receptors could have 
been selected through evolution. Thymic selection does little to constrain γδ T cell antigen 
specificities, but instead determines their effector fate. In general, it is believed that γδ T 
cells recognize host antigens and play a role in epithelial cell maintenance. Intraepithelial 
lymphocytes (IEL) ontogeny can show minimal dependency upon the thymus, as they can 
escape the thymus at a very early stage and migrate into the gut mucosa where they achieve 
maturation. They may even develop directly from bone marrow derived precursors in 
specific intestinal lymphoid aggregates called cryptopatches. The absence of positive 
selection, and the lack of antigen specific priming, seems ideal for γδ T cells to function in 
the first line of defence. When activated through the T cell receptor, antigen-experienced 
cells make IFNγ, whereas antigen-unexperienced γδ T cells produce IL-17, a major initiator 
of inflammation. One of the main functions of IL-17 is to promote the expansion and 
maturation of neutrophils in the bone marrow. Therefore the rapid IL-17 response mounted 
by antigen-inexperienced γδ T cells would play a critical role at the onset of an acute 
inflammatory response to pathogens that the host encounters for the first time, or to host 
antigens that are only revealed by injury. Furthermore, by acting early in the inflammatory 
response, γδ T cells may affect the development of antigen specific αβ T cell and B cell 
responses. Thus γδ T cells may play a much larger role in the adaptive immune response 
than previously recognized. Since γδ T cells contribute to host immune competence in 
several ways it is understandable why these cells have been maintained throughout 
vertebrate evolution, even when αβ T cells and B cells are also present (Konigshofer & Chien 
2006). 
B1 B cells were originally distinguished from B2 cells on the basis of their expression of CD5, 
a glycoprotein marker previously considered to be T cell specific. CD5 is a type I 
transmembrane glycoprotein with three scavenger receptor cysteine rich domains and a 
highly conserved intracellular domain. Its role in signalling was extensively studied both in 
T and B cells. As it is associated with antigen receptor signalling complexes, the CD5 
molecule considered to be a negative regulator of TCR and BCR signalling. Later on a CD5- 
B1 B cell population was also identified and termed B1b B cells. Differences in the function 
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flora. Thus, their development follows a unique pattern at the crossroad of iNKT and γδ T 
cells. These features suggest that MAIT cells could be involved in tolerance or immunity to 
infections in the gut. The function of MAIT cells is unknown, but intuitively we can argue 
that it is related to their localization in the gut mucosa. MAIT cells could somehow be 
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and developmental requirements of the two B1 B cell subgroups are poorly characterized; 
however, it seems that the BCR/CD19 complex is of crucial importance in developmental 
decisions between B1a and B1b B cells (Haas et al., 2005). 
In addition to surface phenotype, B1 B cells have several unique properties distinguishing 
them from conventional B2 cells. B1 B cells represent a self-renewing population found in 
high number in the peritoneal and pleural cavities, while they are virtually absent from 
peripheral lymph nodes and can be found in low number among splenic B cells. They are 
long lived in vitro, can be forced with phorbol esters to proliferate, and they could not be 
activated through BCR crosslinking. The immunoglobulin repertoire of B1 B cells is 
restricted in the number of immunoglobulin genes used; it is dominated by rearrangement 
of J-proximal V genes and has significantly fever N insertions than the repertoire of B2 cells 
(Kantor et al. 1997). 
There is a long-standing dispute over the developmental origin of B1 B cells in literature 
(Haas et al., 2005). According to the lineage model, B1 B cells are generated from fetal 
precursors present in the fetal liver, omentum and splanchnopleura. This view is 
substantiated by the ability of fetal precursors to reconstitute both the B1 and B2 
compartments in irradiated mice, while adult bone marrow-derived cells reconstitute B2 
cells only. The induced differentiation model of B1 B cell development proposes that the B1 
phenotype is a consequence of T-independent-2 like activation event, thus the specificity of 
BCR is the key factor which determines the B1 phenotype. The differential ability of fetal vs. 
adult precursors to generate B1 B cells is due to the different antigen receptor repertoire of 
these precursors. This argument is supported by several transgenic models in which the 
origin and specificity of the immunoglobulin transgene determined the B1 phenotype 
(Chumley et al., 2000). 
Functions of B1a cells include the participation in the early phases of immune responses and 
most importantly the production of natural antibodies with dominantly IgM isotype, which 
is substantiated by the ability of B1 cells transferred adoptively into irradiated mice to 
restore normal IgM level. These lines of evidence and the properties of B1 B cell produced 
natural antibodies indicate that B1 B cells represent an intermediate stage of evolution 
between innate and adaptive immunity. 
2.2 Natural (auto)antibodies 
Natural antibodies are immunoglobulins mostly of IgM isotype, and are secreted by B1 cells 
without immunization with antigen. These antibodies can recognize genetically conserved 
sequences of pathogens and may serve in the first line of immune defence during an 
infection. In contrast, natural autoantibodies present in the serum of both healthy humans 
and patients with chronic inflammatory or systemic autoimmune diseases recognize a set of 
self-structures that have been conserved during evolution. Most of natural autoantibodies 
belong to the IgM or IgG isotype, and show polyreactivity with a broad range of affinities 
for the recognized epitopes (Lacroix-Desmazes et al., 1998).  
Several functions have been suggested for natural autoantibodies: they may participate in 
the selection of immune repertoires, play a role in the acceleration of primary immune 
responses, and the clearance of apoptotic cells, possess anti-inflammatory effects and 
contribute to the maintenance of immune homeostasis (Lacroix-Desmazes et al., 1998).  
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Discrimination of natural antibodies from natural autoantibodies is somewhat artificial since 
given the limited B1 immunoglobulin gene repertoire driving natural antibody production 
and the numerous distinct antigens recognized it is probable that specificities with self non-
self cross reactivity exist. Based on the above properties of natural antibodies, these 
molecules could be considered as the “innate like arm” of humoral immune system 
(Czömpöly et al., 2008). 
3. Physiologic and pathologic autoantibodies 
The phenomena that natural autoantibodies could recognize self antigens which are also 
targeted by antibodies in autoimmune diseases are not unprecedented. Several lines of 
evidence indicate that antibodies recognizing factor VIII, thyreoglobulin, DNA, endothelial 
cell membrane components etc., are present in sera of both healthy individuals and patients 
with autoimmune diseases. These findings raise the question whether these detected 
antibodies are pathologic autoantibodies or belong to the pool of natural antibodies. It is 
possible that the fine epitope pattern recognized by natural antibodies and disease 
associated autoantibodies within the targeted antigen is different. 
3.1 Characterization of fine epitope structure of the antibodies   
There is a need for epitope mapping on circulating autoantibodies both in the basic and 
clinical immunology and in the immuno-biotechnological research and development. A 
mixture of different natural and pathologic autoantibodies is present in human blood 
samples with various antigen specificity. All the classical physico-chemical and 
immunochemical methods used in antibody characterization are technically difficult in the 
case of autoantigens.  
3.1.1 Methods for determination of epitope specificity  
Several techniques are available for the chemical determination of fine specificity of 
recognition molecules; however, a large scale analysis on serum samples from healthy 
individuals and patients with autoimmune and other diseases is both theoretically and 
technically difficult. Epitope mapping with overlapping synthetic peptides is a useful 
technique, but its constraints include the uncertainties linked to in silico B cell epitope 
prediction used for selection of antigenic regions, the partial coverage of primary sequence 
by synthetic peptides and the possible loss of all unpredicted or conformational epitopes. 
Synthetic overlapping peptides are suitable in the case of well characterized autoantigens. 
Limited proteolysis and the following mass spectroscopic analysis are generally used 
techniques in monoclonal antibody characterizations. Random peptide libraries were 
developed for characterization of epitope specificity on circulating autoantibodies by M13 
filamentous phage system. The method was optimized on monoclonal antibodies and 
applied for serum samples. During our further development lambda phages were used to 
display fragments of previously determined antigens. Bacteriophage surface display of 
peptides is a recently used technique for a variety of applications. This technique resembles 
most the physiological antigen conformation and does not require prior epitope prediction. 
The technology is based on the expression of recombinant peptides or proteins fused to a 
phage coat protein. Its key advantage is in the physical coupling of the displayed protein to 
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the nucleic acid coding for it, making the repeated affinity selection and amplification 
possible. The most commonly used systems are based on fusion to a filamentous phage coat 
protein. However, the life cycle of these phages limits the size of the displayed peptide, 
therefore we have chosen phage lambda for the epitope mapping of naturally occurring and 
pathologic autoantibodies in our different studies. The library contains fragments of the 
antigen with random starting point and length, consequently it overcomes the theoretical 
and technical limitations associated with pre-designed fragments or overlapping synthetic 
peptides (Czömpöly et al., 2008). 
3.1.2 Epitope mapping of naturally occurring antibody family specific for the 
mitochondrial citrate synthase protein antigen 
The basic structural elements of living cells such as the cytoskeleton, metabolic organelles, 
transporters, molecular components of transcription and translation etc., are genetically 
conserved. The maintainence of immunological tolerance against these structures is a basic 
functional duty of immune machinery in all of the three levels. The mitochondrion is 
absolutely necessary for eukaryotic cell function. Genetic alterations which affect 
mitochondrial proteins have serious consequences, if the mutation is compatible with life at 
all. Because of their endosymbiotic evolutionary origin, proteins compartmentalized into 
mitochondria represent an interesting transition from prokaryotic foreign to essential self 
molecules. To date there are only a limited number of epitope mapping analyses performed 
on human antigens that are recognized by natural autoantibodies. In particular, little is 
known about the possible overlap between recognized epitopes of innate and self-reactive 
natural antibodies. The structural and functional conservation of mitochondrial components 
makes them candidate antigens for detailed analysis of evolutionary connections between 
the innate and adaptive immune response. No classical mitochondrion-targeted 
autoimmune disease – with the exception of the primary biliary cirrhosis is known, 
suggesting a well established tolerance both at the innate and adaptive level. The inner 
membrane enzymes, especially the citric acid cycle enzymes offer appropriate models for 
testing their immunoreactivity, because they are in continuous connection with both innate 
and adaptive components of the immune system during physiologic turnover of cells. The 
immunological recognition and the immunoreactivity with these molecules are less studied, 
and the possible changes in physiological autoreactivity under pathologic autoimmune 
conditions remain largely unclear (Czömpöly et al., 2006). To address these issues we have 
chosen a mitochondrial inner membrane enzyme, citrate synthase (CS) as model antigen for 
epitope mapping using sera of healthy individuals and patients having various systemic 
autoimmune disease (systemic lupus erythematosus (SLE), rheumatoid arthritis, 
undifferentiated connective tissue disease, polymyositis/dermatomyosits, systemic sclerosis 
(SSc), Raynaud’s syndrome and Sjögren’s syndrome). The CS enzyme is not only a 
theoretically appropriate model – this is one of the first living protein during the evolution – 
but has also been studied at gene, protein structure and functional levels. 
We demonstrated the presence of antibodies recognizing CS in the sera of both healthy 
individuals and systemic autoimmune patients. The enzyme specific antibodies with IgM 
isotype were more frequently present in all investigated groups than those of IgG or IgA 
isotypes and the incidence of autoantibodies with IgM isotype was significantly higher in 
autoimmune patients compared to the healthy controls. We found that the reactivity against 
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CS of individual sera remained permanently constant over a five year period (Fig.1.), in 
opposite to the anti-CS antibodies with IgG isotype which showed various titer during the 
investigated period on the same individuals. Our findings, that the majority of these 
antibodies have IgM isotype, are already present in infants, and the long term stability of 
their serum titers in adults indicate that these specificities belong to the natural 
autoantibody repertoire established early in postnatal life. The occurrence of anti-CS 
antibodies with IgG isotype we can explain as the physiologic dynamics of normal immune 























Fig. 1. CS reactivity in healthy individuals – 52 blood donors - followed up during a five 
year period with IgM isotype specific indirect ELISA. 
To compare epitopes recognized by natural autoantibodies in healthy individuals with those 
recognized in systemic autoimmune patients we performed the epitope mapping of anti-CS 
antibodies under physiological and pathologic (systemic autoimmune) conditions. Epitope 
mapping with overlapping synthetic peptides is a widely used technique, but its constraints 
include the uncertainties linked to in silico B-cell epitope prediction used for selection of 
antigenic regions, the partial coverage of primary sequence by synthetic peptides and the 
possible loss of all unpredicted or conformational epitopes. Since these effects could have 
influenced our results, we sought to perform the epitope mapping using a basically different 
technique. Bacteriophage surface display of peptides is an extensively used technique for a 
variety of applications. The most commonly used systems are based on fusion to a 
filamentous phage coat protein. However, the life cycle of these phages limits the size of the 
displayed peptide, therefore we have chosen phage lambda for construction of a CS antigen 
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fragment library to analyze the fine epitope structure of anti-CS autoantibodies (Czömpöly 
et al., 2006). The library contains fragments of CS with random starting point and length; 
consequently it overcomes the theoretical and technical limitations associated with the 
overlapping synthetic peptide approach. With this phage display based approach we 
compared the epitope patterns recognized by anti-CS autoantibodies found in sera of 
healthy individuals and patients with systemic autoimmune diseases. According to our 
results there is no favoured region of the CS molecule recognized exclusively either by 
healthy individuals or patients with systemic autoimmune diseases, but the fine epitope 
pattern is different in the two groups examined (Fig. 2.). 
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Fig. 2. Amino acid sequences of CS recognized by healthy individuals (A) and patients with 
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3.1.3 Epitope mapping of pathologic autoantibodies specific for a well conserved 
nuclear antigen, DNA topoisomerase I 
Previously described experiments underlined the necessity for the epitope mapping of an 
autoantibody which is specific for a well defined pathologic condition and has a high 
diagnostic value. Our aim was to decide whether the target antigen of the disease associated 
autoantibody is also recognized by naturally occurring autoantibodies. We assumed that 
comparison of the epitope patterns recognized by natural and disease-associated 
autoantibodies would contribute to the better understanding of the differences between 
natural and pathologic autoantibodies. To address these issues we chose DNA 
topoisomerase I as a model antigen, since anti-topoisomerase I antibodies are important in 
the diagnosis of SSc. 
Using the phage display technique previously developed in our department and optimized 
by analyzing epitopes of anti-CS antibodies, we performed the epitope mapping of anti-
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topoisomerase I autoantibodies and examined whether the target antigen of the disease 
associated autoantibody is also recognized by naturally occurring autoantibodies (Simon et 
al., 2009).  
With the help of the bacteriophage lambda library containing fragments of topoisomerase I 
with random starting point and length we compared the epitope patterns recognized by 
anti-topoisomerase I autoantibodies found in sera of patients with diffuse cutaneous SSc 
(dcSSc), limited cutaneous SSc (lcSSc), and SLE. The results showed that the pattern of 
recognized epitopes is different between dcSSc, lcSSc and SLE patients (Fig. 3.).  
 
Human DNA topoisomerase I amino acids 
Fig. 3. The pattern of recognized topoisomerase I epitopes is different between dcSSc, lcSSc 
and SLE patients 
A common fragment recognized by all patients’ sera was located in the region of amino acid 
sequence (AA) 450-600, which is in agreement with previously published results. In addition 
to this, sera of dcSSc patients recognized several short fragments at the N-terminal part of 
the molecule. Previous studies performed with fusion proteins covering the N-terminal 
domain starting from AA 70 reported that this part of the molecule is recognized by anti-
topoisomerase I antibodies. However, the opposite has also been reported by using a fusion 
protein covering the entire length of the N-terminal domain and showing that this part of 
the molecule is not targeted by anti-topoisomerase I antibodies. These seemingly 
contradictory results may be explained by the different methods and antigen constructs 
used, and most importantly by possible conformational factors, which could influence the 
accessibility of short epitopes buried in the tertiary structure. It is important to note that the 
majority of new epitope containing fragments we identified at the N-terminal part spans 
only 20-30 AA. The 5-25 AA fragment of the N-terminal part of the molecule contains an 
experimentally proven granzyme B cleavage site, thus it is possible that in vivo cleavage of 
topoisomerase I by granzyme B released during T cell mediated cytotoxic responses results 
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in the formation of a neo-antigenic determinant represented by this fragment. In vitro assays 
using the full length antigen or the full length N-terminal domain may fail to detect 
antibodies recognizing these short epitopes suggesting strong conformational sensitivity. 
On the basis of fragments identified by library selection nine maltose binding protein-
topoisomerase I fusion proteins were constructed and expressed (Fig. 4.).  
 
Human DNA topoisomerase I amino acids 
Fig. 4. The constructed and expressed maltose binding protein-topoisomerase I fragment 
fusion proteins 
First we tested recognition of these fusion proteins with sera of healthy individuals and 
found that a significant portion of healthy individuals posses antibodies with IgM and IgG 
isotype against fragment F4. Fragment F4 represent a 150 AA long, genetically conserved 
sequence of topoisomerase I. Using a large number of sera we showed that the presence of 
antibodies against fragment F4 is essentially independent of the age and geographical origin 
of healthy individuals. In addition antibodies against fragment F4 could also be detected in 
sera of patients with inflammatory rheumatic diseases other than SSc and SLE. Anti-F4 
antibodies with IgM isotype are present in the highest titer in sera of anti-topoisomerase I 
antibody positive SSc or SLE patients. It is important to note that all 67 sera from anti-
topoisomerase I antibody positive SSc or SLE patients were found to be positive for anti-F4 
antibodies with IgG isotype, and the titer of these antibodies was the highest in this group 
among all groups tested. The fact that these sera were shown to be negative for anti-
topoisomerase I antibody by a conventional ELISA test using the full length antigen could 
indicate that the sequence represented by fragment F4 could be hidden in the three 
dimensional structure of the full length molecule. These findings raise the possibility that 
antibodies against fragment F4 present in sera of healthy individuals and patients with 
systemic autoimmune diseases could belong to the pool of naturally occurring antibodies. 
To our knowledge these are the first results demonstrating that natural antibodies against 
topoisomerase I are present in human sera. 
It is not unprecedented that natural autoantibodies recognize self antigens which are also 
targeted by antibodies in autoimmune diseases. Since anti-topoisomerase I antibodies can 
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disease, primer biliary cirrhosis and in some cases of chronic hepatitis C virus infection 
induced liver diseases the question arises whether these detected antibodies are pathologic 
autoantibodies or belong to the pool of natural antibodies. Fragment F4 represents a 150 
amino acids long sequence of topoisomerase I, consequently it is possible that the fine 
epitope pattern recognized by natural antibodies and disease associated autoantibodies 
within this part of topoisomerase I is different. 
The recognition of the majority of fragments (F2, F3, F5-7, F9) seemed to be characteristic for 
the individual patient sera used for library screening, instead of being characteristic for the 
given disease subgroup. This is in agreement with result of Henry et al., who found both 
individual and longitudinal differences in the recognized topoisomerase I epitopes. 
However, antibodies recognizing the common F4 fragment were detected in all patients’ 
sera tested. In addition to this immunodominant part of topoisomerase I, we identified two 
new regions (F1 and F8) which were previously not shown to be targeted by anti-
topoisomerase I antibodies. Fragment F1 (an evolutionarily relatively new sequence, specific 
for vertebrates) was recognized by 26% of dcSSc patients and antibodies against fragment F8 
(a highly conserved sequence) could be detected in 50% of SLE patients, indicating that 
these fragments could represent characteristic epitopes for dcSSc and SLE, respectively. 
Longitudinal analysis showed that reactivity to fragment F4 was stable, while the reactivity 
to F1 and F8 fragments varied over time. 
3.2 Comparative analysis of fine epitope pattern of natural and pathologic 
autoantibodies  
It is possible that the presence of natural antibodies is essential for the appearance of disease 
associated autoantibodies, since natural autoantibodies can, under appropriate conditions; 
provide the templates for the emergence of higher affinity and class-switched pathogenic 
autoantibodies. IgG isotyped disease associated autoantibodies may recognize genetically 
determined epitopes (epitope patterns) and can be detected in genetically predisposed 
individuals, which was also suggested by a study examining monozygotic twins suffering 
from SLE (Silverman et al., 2008). Thus tolerance against conservative antigens might mostly 
be genetically determined. The permanent impairment of the development and maintenance 
of tolerance can lead to autoimmune disorders. Pattern recognition mechanisms were 
thought to be specific for innate immunity and considered to be the defence mechanisms of 
evolutionarily ancient species. According to our results natural autoantibodies, in terms of 
their antigen recognizing characteristics, resemble the pattern recognition receptors and 
recognize epitope patterns. Pathologic autoantibodies detected in autoimmune diseases 
however are directed mainly against a well defined, disease associated sequence (epitope). 
4. Conclusion  
A large number of circulating antibodies directed against functional structures of the cell 
(nucleic acid, nuclear molecules, receptors, or other functional cell components) can be 
detected in systemic autoimmune diseases. Their presence plays a central role in the 
diagnosis and classification of this kind of disorder. Moreover, several longitudinal cohort 
studies have shown that patients may carry autoantibodies many years before they manifest 
clinical symptoms and detecting these antibodies in serum has been shown to have strong 
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predictive value. Primary structure homologies between the antigens targeted in some 
autoimmune diseases and conserved sequences of different pathogens (viruses and bacteria) 
are well known. Although this so called “molecular mimicry” has been extensively studied, 
direct causality of infections in the development of autoimmune diseases has only been 
verified in a few patients. Apart from the homologies in primary structure, the similarities in 
the physico-chemical molecular shape between the mammalian antigens and the structures 
of microorganisms could provide a real structural basis for the biological recognition 
suggesting a pivotal role of three-dimensional shape of conserved antigens in both targeting 
type immunity and tolerance (Czömpöly et al., 2008). 
According to the orthodox view of phylogenetic development, immunity has reached its 
zenith with the emergence of the adaptive immune system. Consequently, we tend to be 
influenced by anthropocentric views and overlook how other highly developed organisms 
manage living in hostile environments. As recently more data have become available 
regarding non-traditional animal models, it has been suggested that the emergence of 
adaptive immunity is perhaps not the culmination of the evolution of immunity, but simply 
a successful alternative to using innate immunity alone. For millions of years, many species 
could keep-up in the continuous arms-race between pathogen and host called co-evolution 
without the surveillance of adaptive immunity. The complexity of biology should never be 
underestimated as it turns out that those animals lacking RAG-dependent adaptive 
immunity can make up for an equal amount of diversity using highly variable elements of 
innate immunity finally exhibiting adaptive features. On the other hand, in vertebrates, 
adaptive immunity often simply serves as a sophisticated targeting device that recognizes 
and then processes the antigen but finally leaves the messy job of actually clearing up 
pathogens to the immense capacity of innate immunity. Therefore, once again we see that 
borders are blurring and the strict distinction between innate and adaptive immunity might 
need revision (Kvell et al. 2007). Network of natural immunity – including wiled range of 
different cellular elements and naturally occurring antibodies – could explain as the missing 
evolutionary chain between the “classic” innate and adaptive immune system. 
4.1 Clinical relevance of detection of autoantibodies 
Analyzing the recognition of epitopes of natural and pathologic autoantibodies could 
contribute to diagnosis and better understanding of pathomechanisms of systemic 
autoimmune diseases. The onset of the disease may correlate with a switch from production 
of IgM to IgG isotyped antibodies. Nevertheless, the exact role of autoreactive IgM in the 
autoantibody response and the switch to other isotypes is not known. It has to be mentioned 
that IgM isotyped natural autoantibodies can have a role in protection from autoimmunity 
by facilitating the removal of apoptotic cells and increasing the tolerance of B cells to self 
antigen. Since one of the essential functions of the immune system is the prevention of self 
antigens to stimulate an inflammatory reaction, the presence of autoantibodies is the 
consequence of a breakdown or failure of B cell tolerance toward the corresponding 
autoantigens. The timing of exposure, the level of affinity of the autoreactive IgM 
autoantibodies and their local concentration may determine which scenario applies, i.e., 
autoimmunity or tolerance. Detection of autoantibodies reacting with self antigens is 
generally used in laboratory diagnostics. However, their presence in serum samples doesn’t 
mean automatically a pathologic condition. Natural autoantibodies could recognize self 
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antigens which are also targeted by antibodies in autoimmune diseases. The immune 
response could be explained by a general recognition of the immunodominant part of the 
molecule, followed by appearance of antibodies directed against disease associated 
sequences (Czömpöly et al., 2009). Detection of autoantibodies recognizing different 
epitopes of these antigens could be a useful tool in laboratory diagnostics (Simon et al., 
2009). 
4.1.1 Diagnostic issues of natural and pathologic autoantibodies  
Early diagnosis and initiation of adequate therapy as soon as possible is crucial in systemic 
autoimmune diseases such as SSc and SLE, because after insidious onset of the disease the 
development of internal organ manifestations can lead to death of the patient in a few years. 
Anti-topoisomerase I autoantibodies are considered to be associated with dcSSc. However, 
the presence of anti-topoisomerase I autoantibodies is not entirely restricted to this subset, 
since anti-topoisomerase I antibodies have been demonstrated in lcSSc, SLE and other 
inflammatory diseases. The fact that anti-F4 antibodies were detected in sera which were 
tested negative for anti-topoisomerase I antibody by a conventional ELISA kit using the full 
length antigen indicates that an ELISA test using recombinant F4 fragment might be a more 
sensitive way to determine anti-topoisomerase I positivity and could contribute to early 
diagnosis and monitoring the activity of SSc (Simon et al., 2009). 
4.1.2 Prognostic value of epitope pattern  
In systemic autoimmune diseases the prognosis is mostly determined by the activity of the 
disease and the extent of the developed irreversible lesions. Since anti-topoisomerase I 
autoantibody is found to be associated with increased mortality, pulmonary fibrosis, 
musculoskeletal and cardiac involvement, proteinuria and the level of anti-topoisomerase I 
autoantibody correlates with the extent of fibrosis of the skin and internal organ 
involvement in dcSSc, it may serve as an activity marker of disease (Minier et al., 2010). 
Statistical analysis of clinical data (extent of skin involvement, hand contractures, azotemia 
and/or malignant hypertension, cardiac involvement, pulmonary artery hypertension, 
dysmotility and stricture/dilatation of esophagus, extent of lung fibrosis, forced vital 
capacity) failed to demonstrate associations between anti-topoisomerase I antibody epitope 
specificity and clinical presentation of the disease. This is in agreement with results also 
reporting lack of clear association between changes in the anti–topoisomerase I antibody 
response and clinical parameters (Henry et al., 2005). However, there was a significant 
difference between F1 negative and F1 positive groups of dcSSc patients in average age and 
the duration of the disease. The difference in the duration of disease between anti-F1 
antibody positive and negative dcSSc patients, together with findings of our longitudinal 
analysis, may indicate that the anti-topoisomerase I immune response could be explained by 
a general recognition of the immunodominant part on the molecule (fragment F4), and the 
disease associated autoantibodies may target the N-terminal part later during the course of 
the disease. Thus autoantibodies against fragment F1 may represent a new marker of late 
stage dcSSc (Simon et al., 2009). 
Comparison of clinical data of anti-F8 positive and anti-F8 negative SLE patients suggested 
that SLE patients with antibody against fragment F8 have Raynaud’s phenomenon and a 
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inflammatory diseases. The fact that anti-F4 antibodies were detected in sera which were 
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diagnosis and monitoring the activity of SSc (Simon et al., 2009). 
4.1.2 Prognostic value of epitope pattern  
In systemic autoimmune diseases the prognosis is mostly determined by the activity of the 
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Comparison of clinical data of anti-F8 positive and anti-F8 negative SLE patients suggested 
that SLE patients with antibody against fragment F8 have Raynaud’s phenomenon and a 
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milder presentation of the disease (lack of arthritis, central nervous system and kidney 
involvement). 
Discrimination between naturally occurring and pathologic autoantibodies is available 
according to their recognition patterns, and this is not only a theoretical question but holds 
important practical – diagnostic and prognostic – consequences in the daily laboratory 
routine.  
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1. Introduction 
The cloning of leptin in 1994 introduced a novel concept about white adipose tissue (WAT) 
(Zhang et al., 1994). Actually, WAT has been recognized as an active tissue able to produce a 
wide variety of factors, called adipokines. These molecules participate through endocrine, 
paracrine, autocrine or juxtacrine cross-talk in a great variety of physiological or 
physiopathological processes, including food intake, insulin sensitivity, immunity and 
inflammation (Trayhurn & Wood, 2004, 2005). 
Moreover, adipokines represent a new family of compounds that can be currently 
considered as key players of the complex network of soluble mediators involved in the 
pathophysiology of rheumatic diseases. Adipokines include classic pro-inflammatory 
proteins such as TNF-α and IL-6, both secreted by adipocytes, but synthesized also by 
immune cells infiltrating WAT, such as macrophages (Flower et al., 2003; Hotamisligil et al, 
1993; Trayhurn et al., 2006). 
These pro-inflammatory adipokines appear to significantly contribute to the so-called “low 
grade inflammation” of obese subjects, a condition associated with increased risk of cancer, 
type 2 diabetes, cardiovascular complications, autoimmune and inflammatory diseases 
including rheumatic diseases such as rheumatoid arthritis (RA), osteoarthritis (OA) and 
systemic lupus (SLE) (Ahima et al, 1996). For instance, it has been reported that obesity that 
is characterized by abnormal fat accumulation and dysfunction increases the incidence of 
osteoarthritis (OA). A prevailing hypothesis is that obesity increases mechanical loading on 
the articular cartilage that finally leads to its degeneration. However, obesity is also 
associated with OA in non-weight bearing joints such as hand joints, which suggest that 
metabolic factors, as adipokines, contribute to the high prevalence of OA in obese subjects 
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(Felson, 2005; Oliveria et al., 1999). Furthermore, adipokines play a pivotal role in other 
autoimmune and rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE). 
In this book chapter we review the role of adipokines in inflammation and immune 
response in the context of rheumatic diseases. 
2. Leptin 
Leptin is the protein product of the ob gene, the murine homologue of the human gene LEP, 
cloned in 1994 (Zhang et al, 1994). This adipokine is mainly produced by white adipose cells 
and its plasma concentration is directly correlated with the body-fat stores. It has a central 
role in fat metabolism; in fact leptin is considered a major regulator of body weight by 
suppressing appetite and stimulating energy expenditure via hypothalamic receptors. This 
hormone decreases food intake by inducing anorexigenic factors as cocaine amphetamine 
related transcript (CART) and increases energy consumption by suppressing orexigenic 
neuropeptides such as neuropeptide Y (NPY). The biological activity of leptin is mediated 
by specific receptors (Ob-R) that belong to the class 1 cytokine receptor superfamily, and are 
encoded by the gene diabetes (db). Alternative splicing of the db gene produce multiple 
isoforms, but only the long isoform Ob-Rb, appears to be capable of transducing the leptin 
signal.  
Leptin is a hormone with pleiotropic actions. In fact, in addition to regulation of food intake, 
it also affects a variety of other physiological functions, including fertility, bone metabolism, 
inflammation, infection, immune responses and others. Recent evidence demonstrates an 
involvement of leptin in promoting the pathogenesis of different autoimmune and 
rheumatic diseases such as rheumatoid arthritis, multiple sclerosis and SLE. Several authors 
have demonstrated a dependence between the risk of aggressive course of RA and leptin 
levels (Kadowaki & Yamauchi, 2005; Lee et al., 2007; Targonska-Stepniak et al., 2008; 
Whitehead et al., 2006). It is widely accepted that leptin levels are elevated in patients with 
RA and that there is a correlation between serum leptin and synovial fluid/serum leptin 
ratio and disease duration and parameters of RA activity (Olama et al., 2010). Generally, 
leptin is considered to be pro-inflammatory, but this hormone has been also reported to 
reduce radiographic joint damage (Rho et al., 2009). This effect could be related to some 
leptin anabolic effects, such as the stimulation of the synthesis of insulin-like growth factor-1 
(IGF-1) and transforming growth factor-β (TGF- β) at both the messenger RNA (mRNA) and 
protein levels (Dumond et al., 2003) 
The actions of leptin in RA are not only targeted to articular tissues, this adipokine also 
exerts direct modulatory effects on activation, proliferation, maturation and production of 
inflammatory mediators in a variety of immune cells, including lymphocytes, NK cells, 
monocytes/macrophages, dendritic cells, neutrophils and eosinophils (Lam & Lu, 2007). In 
particular, it is known that leptin is able to modulate T regulatory cells that are potent 
suppressors of autoimmunity. The group of Matarese et al, has recently demonstrated that 
leptin secreted by adipocytes sustains Th1 immunity by promoting effector T cell 
proliferation and by constraining Treg cells expansion. Weight loss, with concomitant 
reduction in leptin levels, induces a reduction in effector T cell proliferation and an 
increased expansion of Treg cells leading to a down-regulation of Th1 immunity and cell-
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mediated autoimmune diseases associated with increased susceptibility to infections. On the 
other hand, an increase in adipocyte mass leads to high leptin secretion, which results in 
expansion of effector T cells and reduction of T-Reg cells. This effect determines an overall 
enhancement of the pro-inflammatory immunity and of T cell-mediated autoimmune 
disorders. These data suggests that leptin can be considered as a link between immune 
tolerance, metabolic function and autoimmunity and that future strategies aimed at 
interfering with leptin signaling may represent innovative therapeutic tools for autoimmune 
disorders. 
Very recently it has been demonstrated that leptin can activate the mammalian target of 
rapamycin (mTOR) and regulate the proliferative capacity of regulatory T (TReg) cells. The 
study of Procaccini et al describes the leptin–mTOR signalling pathway as an important link 
between host energy status and TReg cell activity. The authors conclude that oscillating 
mTOR activity is necessary for TReg cell activation and suggest that this may explain why 
TReg cells are unresponsive to TCR stimulation in vitro, where high levels of leptin and 
nutrients may sustain mTOR activation (De Rosa et al., 2007; Procaccini et al., 2010).  
Leptin also may acts as a catabolic factor involved in the pathogenesis of osteoarthritis. 
In fact, Otero et al have demonstrated that in cultured human and murine chondrocytes 
type 2 nitric oxide synthase (NOS2) is synergistically activated by the combination of leptin 
plus interferon-γ, and NOS2 activation by IL-1β is increased by leptin via a mechanism 
involving JAK2, PI3K, and mitogen activated kinases (MEK1 and p38) (Otero M et al., 2003, 
2005). Nitric oxide (NO), which is induced by a wide range of pro-inflammatory cytokines, 
is a well-known pro-inflammatory mediator on joint cartilage, where it triggers chondrocyte 
phenotype loss, apoptosis, and metalloproteinases (MMPs) activation. 
Recently, it was demonstrated that leptin is able to induce also the expression of MMPs 
involved in OA cartilage damage, such as MMP-9 and MMP-13 (Toussirot et al., 2007). 
Leptin alone and in combination with IL-1β up-regulates MMP-1 and MMP-3 production in 
human OA cartilage through the transcription factor NF-κB, protein kinase C and MAP 
kinase pathways. This hormone is also correlated positively to MMP-1 and MMP-3 in 
synovial fluid (SF) from OA patients (Koskinen et al., 2011).  
It is noteworthy that leptin was recently shown to increase IL-8 production in human 
chondrocytes (Lago et al., 2008). 
Bao et al have defined that leptin enhanced both gene and protein levels of catabolic factors 
such as MMP-2 y MMP-9, while down-regulated the anabolic factors such as bFGF in 
articular cartilage of rats. Additionally, the gene expression of ADAMTS-4 and -5 were 
markedly increased and was observed a depletion of proteoglycan in articular cartilage after 
treatment with leptin (Bao et al., 2010) 
Leptin also could contribute to abnormal osteoblast function in OA. In fact, the elevated 
production of leptin in OA abnormal subchondral osteoblast is correlated with the increased 
levels of ALP (alkaline phosphatase), OC, collagen type I and TGF-β1 inducing a 
dysregulation of osteoblast function (Mutabaruka et al., 2010). 
Leptin’s and leptin receptor (Ob-Rb) expression levels were significantly increased in 
advanced OA cartilage and in SF. The induction by leptin of IL-1β production y MMP-9 and 
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MMP-13 protein expression in chondrocytes indicates a pro-inflammatory and catabolic role 
of this hormone on cartilage metabolism (Simopoulou et al., 2007). 
Ku et al have demonstrated a relation of SF leptin concentrations with the radiographic 
severity of OA in OA patients, suggesting a role of leptin as an effective marker for 
quantitative detection of OA (Ku et al., 2009).  
All these data have focused on the pro-inflammatory effect of leptin in vitro that seems to 
have an adverse effect on cartilage homeostasis. Very recently, Griffin et al, showed that the 
incidence of OA was not higher in ob/ob and db/db female obese mice than in control 
background strain (C57BL/6J). Nevertheless, in this study, no standard was set for the 
incidence of OA in obese control mice without leptin mutation (Griffin et al., 2009). 
This recent result suggested that obesity alone is insufficient to induce systemic 
inflammation and knee OA and that leptin has a necessary role in the pathophysiology of 
OA associated with obesity. 
It is also found a relationship between leptin and lupus disease related factors. In fact, 
patients with SLE have increased concentrations of leptin and these concentrations are 
associated with insulin resistance, BMI (Body Mass Index) and CRP (C-reactive protein) in 
















































Fig. 1. Schematic representation of the effects of leptin in the brain, immune system, and 
articular cartilage. 
 




Adiponectin, also known as GBP28, apM1, Acrp30 or AdipoQ, is a 244-residue protein that 
is produced mainly by WAT. Adiponectin has structural homology with collagens VIII and 
X and complement factor C1q, and it circulates in the blood in relatively large amounts in 
different molecular forms (trimers, hexamers and also 12-18-mer forms) (Kadowaki & 
Yamauchi, 2005; Oh et al., 2007). It increases fatty acid oxidation and reduces the synthesis 
of glucose in the liver. Ablation of the adiponectin gene has no dramatic effect on-knock-out 
mice on a normal diet, but when placed on a high fat/sucrose diet they develop severe 
insulin resistance and exhibit lipid accumulation in muscles (Whitehead et al., 2006). 
Circulating adiponectin levels tend to be low in morbidly obese patients and increase with 
weight loss and with the use of thiazolidinediones which enhance sensitivity to insulin 
(Kadowaki & Yamauchi, 2005; Maeda et al., 2001). 
Adiponectin acts via two receptors, one (AdipoR1) found predominantly in skeletal muscle 
and the other (AdipoR2) in liver. Transduction of the adiponectin signal by AdipoR1 and 
AdipoR2 involves the activation of AMPK, PPAR-α, PPAR-γ and other signalling molecules 
(Kadowaki & Yamauchi, 2005). To note, targeted disruption of AdipoR1 and AdipoR2 
causes abrogation of adiponectin binding and all its metabolic actions (Yamauchi et al., 
2007). 
There is evidence that adiponectin has a wide range of effects in pathologies with 
inflammatory component, such as cardiovascular disease, endothelial dysfunction, type 2 
diabetes, metabolic syndrome, OA and RA (Matsuzawa, 2006). Adiponectin acts as a potent 
modulator of both B and T cells; moreover, it modulates the activity of immune innate 
response by inducing relevant anti-inflammatory factors such as IL 1 receptor antagonist 
and IL-10 (Kadowaki & Yamauchi, 2005).  
In contrast to its previously described protective role in vascular diseases, there is evidence 
that adiponectin might act as a pro-inflammatory factor in joints and it could be involved in 
matrix degradation. Of note, these discrepancies in the functions of adiponectin are linked to 
the level of oligomerization of the protein and opposite actions have been described for both 
low molecular weight and high molecular isoforms (Neumeier et al., 2006). 
Adiponectin levels in RA patients are higher than in healthy subjects (Otero M et al., 2006) 
and multiple studies correlated these adiponectin elevated levels with severity of RA (Ebina 
et al., 2009). Giles and collaborators identified a cross sectional association between serum 
adiponectin levels and radiographic damage in RA patients (Giles et al., 2009), suggesting 
that this adipokine may be a mediator of the paradoxical relationship between increasing 
adiposity and protection from radiographic damage in RA, due to adiponectin circulating 
levels decreasing as adiposity increases. Therefore, considering that adiponectin may have 
negative effects on the joint, this adipokine could be a relevant mediator to the inverse 
relationship between increasing adiposity and radiographic damage observed in RA studies.  
In human synovial fibroblasts adiponectin induces IL-6, one of the main mediators of RA, 
via AMPK, p38, IKKα-β and NF-κB, (Tang et al., 2007). Similarly, IL-8 is induced by 
adiponectin through an intracellular pathway involving NF-κB (Katano et al., 2009). A 
recent publication confirms the role of adiponectin in pathogenesis of RA. The authors 
showed that adiponectin is able to induce the expression of vascular endothelial growth 
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factor, MMP-1 and MMP-13, in synovial cells, at the same levels as IL-1β (Choi et al., 2009). 
In line with this, it has been reported that adiponectin, in RA synovial fibroblasts (RASFs), 
increases cyclooxygenase 2 (COX-2), membrane-associated PGE synthase 1 (mPGES-1) and 
prostaglandin E2 (PGE2) mRNA and protein expression in a dose-dependent manner 
(Kusunoki et al., 2010). This increase was inhibited by siRNA against adiponectin receptors 
(AdipoR1 and AdipoR2) or using inhibitors of specific proteins involved in adiponectin 
signal transduction (Kusunoki et al., 2010). 
Adiponectin is also implicated in OA pathogenesis. In chondrocytes this hormone is able 
to induce several pro-inflammatory mediators such as nitric oxide, IL-6, MCP-1, MMP-3 
and MMP-9 as well as IL-8 (Gomez et al., 2011; Lago R et al., 2008), generating a pro-
inflammatory environment at joint level. However, the implication of adiponectin in OA 
development is also supported by clinical observations. Laurberg TB et al have reported 
that plasma adiponectin levels were significantly higher in OA patients than in healthy 
subjects (Laurberg et al., 2009). Moreover, elevated plasma adiponectin levels were 
observed in female patients with erosive compared with non-erosive hand OA (Filkova et 
al., 2009). In addition, adiponectin levels in synovial fluid correlating with osteoarthritis 

































Fig. 2. Schematic representation of the interaction of adiponectin with immune cells, 
chondrocytes, and synovial fibroblasts. 
 




Resistin, known as adipocyte-secreted factor (ADSF) or found in inflammatory zone 3 
(FIZZ3), was discovered in 2001 and was proposed as potential link between obesity and 
diabetes (Steppan et al., 2001). It was secreted by adipose tissue, but has been found also in 
macrophages, neutrophils and other cell types. Serum resistin levels increases with obesity 
in mice, rats and humans (Degawa-Yamauchi et al., 2003; McTernan et al., 2002). Increasing 
evidence indicates its important regulatory roles in various biological processes, including 
several inflammatory diseases.  
There are demonstrations that resistin may be involved in the pathogenesis of RA. It has 
previously been observed increased levels of this adipokine in synovial fluid from patients 
of rheumatoid arthritis (RA) compared to patients with non-inflammatory rheumatic 
disorders (Schaffler et al., 2003). Resistin may be a significant mediator in the inflammatory 
process of RA, in fact the serum resistin levels are associated with disease activity and acute 
phase reactants, including C-reactive protein and IL-1Ra antagonizing IL-1β (Forsblad 
d´Elia et al., 2008; Senolt et al., 2007).  
Resistin has been found in the plasma and synovial fluid of RA patients, and injection of 
resistin into joints of mice induces an arthritis-like condition, with leukocyte infiltration of 
synovial tissues, hypertrophy of the synovial layer, and pannus formation (Bokarewa et al., 
2005; Senolt et al., 2007). Bokarewa et al have showed that resistin induces and is induced by 
several pro-inflammatory cytokines, such as TNF-α or IL-6, in peripheral blood 
mononuclear cells, via NF-kB pathway, indicating that resistin can increase its own activity 
by a positive feedback mechanism (Bokarewa et al., 2005). 
The pro-inflammatory profile of resistin, together with its association with obesity, suggests 
that this adipokine might be another potential mediator that links OA with inflammation 
and obesity. It was demonstrated that this adipokine is elevated in both serum and SF after 
traumatic joint injuries. Recombinant resistin stimulated proteoglycan degradation in mouse 
femoral head cultures and the induction of inflammatory cytokines and PGE2 production. 
Moreover, it inhibited proteoglycan synthesis in human cartilage explants (Lee et al., 2009). 
However, Berry et al have not identified any association between baseline serum levels of 
resistin and cartilage volume loss (Berry et al., 2011). 
In addition, resistin has a role as a marker of inflammation in other rheumatic diseases, such 
as systemic lupus erythematous (SLE). In fact, Almehed et al have demonstrated a positive 
correlation between serum resistin levels, inflammation, bone mineral density and renal 
functions in patients with SLE (Almehed et al., 2008). Figure 3. 
5. Visfatin 
Visfatin, also named pre-B-cell colony-enhancing factor (PBEF) and nicotinamide 
phosphoribosyltransferase (Nampt), was originally discovered in liver, skeletal muscle and 
bone marrow as a growth factor for B-lymphocyte precursors, however it is also secreted by 
visceral fat (Fukuhara et al.,2005; Samal et al., 1994). It is supposed that visfatin had insulin 
mimetic properties, but the role of this adipokine in the modulation of glucose metabolism, 
as well as its binding to insulin receptors is still debate (Fukurara et al., 2005, 2007). 
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Fig. 3. Schematic representation of resistin interaccion among adipocytes, immune cells and 
bone and cartilage cells. 
It has been reported that visfatin is increased in obesity. Moreover, leucocytes from obese 
patients produce higher amounts of visfatin compared with lean subjects, and specifically, 
granulocytes and monocytes are the major visfatin producing cells (Catalan et al., 2011; 
Friebe et al., 2011). However, leucocytes are not the only non-fat cell-type that synthesizes 
visfatin. Macrophages have also been described as a source for visfatin production (Curat et 
al., 2006) and interestingly, this adipokine promoted macrophage survival by reducing 
apoptosis (Li et al., 2008). 
Our group demonstrated that visfatin was increased in RA patients (Otero M et al., 2006), 
these data were also further confirmed by other authors (Rho et al., 2009). To note, enhanced 
visfatin levels are associated with augmented joint damage (Rho et al., 2009). Brentano and 
colleagues reported that visfatin was localized in the site of invasion of synovial tissue in 
joints of RA patients. Moreover it is able to induce IL-6, MMP-1 and MMP-3 in RA synovial 
fibroblasts, as well as IL-6 and TNF-α in monocytes (Brentano et al., 2007), concluding that 
visfatin has relevant pro-inflammatory and catabolic roles in RA pathogenesis and it could 
be considered a potential therapeutic target. 
A recently published study by Busso et al. shows that visfatin is a key mediator in 
inflammatory arthritis. The administration of a visfatin inhibitor to mice with collagen-
induced arthritis reduced arthritis severity with similar effect to that produced by TNF-α 
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inhibitor (Busso et al., 2008). Moreover, pharmacological inhibition of visfatin led to low 
levels of intracellular NAD in inflammatory cells and decreased the production of TNF-α 
and IL-6 in affected joints (Busso et al., 2008). However, the mechanism by which visfatin 
exerts its catabolic effect in arthritic joints is incompletely understood. 
At cartilage level, OA chondrocytes are able to produce visfatin and its expression is 
increased after IL-1β treatment (Gosset et al., 2008). Visfatin administration, like IL-1β, 
enhances PGE2 release. In line with this, visfatin also increases MMP-3 and MMP-13 
synthesis and release, and ADAMTS-4 and ADAMTS-5 expression in mouse articular 
chondrocytes (Gosset et al., 2008). Visfatin decreases aggrecan expression, probably due to 
this increase in the expression of matrix degradative enzymes (Gosset et al., 2008). Taken 
together, these data suggest that visfatin has a catabolic function in cartilage. Table 1. 
6. Chemerin  
Chemerin, also known as tazarotene-induced gene 2 and retinoic acid receptor responder 2 
(RARRES2), is a novel identified chemoattractant adipokine (Wittamer et al., 2003). It is 
secreted as an 18 kDa inactive proprotein and activated by post-translational C-terminal 
cleavage (Zabel et al., 2005). Chemerin acts via the G-coupled receptor chemokine-like 
receptor 1 (CMKLR1 or ChemR23) (Wittamer et al., 2003). Chemerin and its receptor are 
mainly expressed, but not exclusively, in adipose tissue (Bozaoglu et al., 2007), for instance, 
dendritic cells and macrophages express chemerin receptor (Luangsay et al., 2009). 
Endothelial cells also express ChemR23 and it is up regulated by pro-inflammatory 
cytokines such as TNF-α, IL-1β and IL-6 (Kaur et al., 2010). Moreover, chemerin exogenous 
challenge promotes in vitro angiogenesis by inducing cell proliferation, endothelial 
migration and capillary tube formation, critical steps in the development of angiogenesis 
(Kaur et al., 2010). 
Interestingly, chondrocytes express chemerin and its receptor (Berg et al., 2010; Conde et al., 
2011) and IL-1β is able to increase chemerin expression (Conde et al., 2011). In the same way, 
Berg et al. have demonstrated that recombinant chemerin enhances the production of 
several pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-8), as well as different MMPs 
(MMP-1, MMP-2, MMP-3, MMP 8 and MMP-13) in human articular chondrocytes (Berg et 
al., 2010). These factors play a role in the degradation of the extracellular matrix, by causing 
a breakdown of the collagen and aggrecan framework, which results in the irreversible 
destruction of the cartilage in OA and RA. Moreover, these authors reported that the 
intracellular signalling after ChemR23 activation occurs through p42/44 MAPK and Akt 
phosphorylation. 
Chemerin and ChemR23 expression was found in SLE skin biopsies (Vermi et al., 2005). In 
vitro experiments showed that chemerin acts as a chemotactic factor for plasmacytoid DCs. 
The tissue distribution of this adipokine, located at the luminal side of inflamed blood 
vessels suggest that chemerin is involved in the migration of plasmacytoid DCs and the 
accumulation of this cells in inflamed tissues in SLE patients (Vermi et al., 2005). Moreover, 
De Palma et al. found chemerin expression in renal tubular epithelial cells from SLE patients 
with nephritis (De Palma et al., 2011). These authors, using a transendothelial chemotaxis 
assay, demonstrated that the recruitment of plasmacytoid DCs by TNF-α was mediated by 
chemerin/ChemR23 interaction, may be due to the induction of the cleavage of pro-
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a breakdown of the collagen and aggrecan framework, which results in the irreversible 
destruction of the cartilage in OA and RA. Moreover, these authors reported that the 
intracellular signalling after ChemR23 activation occurs through p42/44 MAPK and Akt 
phosphorylation. 
Chemerin and ChemR23 expression was found in SLE skin biopsies (Vermi et al., 2005). In 
vitro experiments showed that chemerin acts as a chemotactic factor for plasmacytoid DCs. 
The tissue distribution of this adipokine, located at the luminal side of inflamed blood 
vessels suggest that chemerin is involved in the migration of plasmacytoid DCs and the 
accumulation of this cells in inflamed tissues in SLE patients (Vermi et al., 2005). Moreover, 
De Palma et al. found chemerin expression in renal tubular epithelial cells from SLE patients 
with nephritis (De Palma et al., 2011). These authors, using a transendothelial chemotaxis 
assay, demonstrated that the recruitment of plasmacytoid DCs by TNF-α was mediated by 
chemerin/ChemR23 interaction, may be due to the induction of the cleavage of pro-
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chemerin by TNF-α through the local production of serine proteases in proximal tubular 
epithelial cells (De Palma et al., 2011; Kanalas & Hopfer, 1997; Zabel et al., 2005). Table 1. 
7. Lipocalin 2 
Lipocalin 2 (LCN2), also termed siderocalin, 24p3, uterocalin and neutrophil gelatinase-
associated lipocalin, is a 25 kDa glycoprotein isolated from neutrophil granules, although 
white adipose tissue (WAT) is thought to be the main source (Triebel et al., 1992). The LCN2 
protein has been isolated as a 25 kDa monomer, as a 46 kDa homodimer and in a covalent 
complex with MMP-9, and its cellular receptor, megalin (GP330), was recently described 
(Devireddy et al., 2001). LCN2 is involved in apoptosis of haematopoietic cells (Devireddy 
et al., 2001), transport of fatty acids and iron (Chu et al.,1998), modulation of inflammation 
(Cowland & Borregaard, 1997) among other processes.  
LCN2 has recently been identified in chondrocytes (Owen et al., 2008). In these cells IL-1β, 
leptin, adiponectin, LPS and dexamethasone act as potent modulators of LCN2 expression 
(Conde et al., 2011). Lipocalin 2 is likely to be involved in matrix degradation since it forms 
molecular complexes with MMP-9 (Gupta et al., 2007). 
Recently, Katano and colleagues confirmed that the level of NGAL in SF was significantly 
higher in patients with RA than in those with osteoarthritis. Through proteome analysis 
Katano et al have showed that GM-CSF may contribute to the pathogenesis of RA by the 
upregulation of LCN2 in neutrophils, followed by induction of Catepsin D, transitional 
endoplasmic reticulum ATPase (TERA) and transglutaminase 2 (tg2) in synoviocytes 
(Katano et al., 2009). These enzymes may contribute to the proliferation of synovial cells and 
infiltration of inflammatory cells inside the synovia (Katano et al., 2009). 
Finally, LCN2 is also a candidate biomarker for the early detection of LN (lupus nephritis) 
that is an inflammation of the kidney caused by systemic lupus erythematosus (SLE), which 
is very common in childhood-onset SLE (cSLE). Hinze et al. have demonstrated that urinary 
and plasma NGAL (U-NGAL and P-NGAL) is an excellent candidate as predictive 
biomarker for worsening of cSLE renal and global disease activity. (Hinze et al., 2009).  
Table 1. 
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1. Introduction 
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that primarily affects 
the joints. Aetiology of RA is unknown. Once symptoms are present RA manifests itself as a 
heterogeneous disease with a clinical spectrum ranging from mild to severe disease, and 
variable involvement in secondary organ systems. The heterogeneous nature is reflected by 
variation in responsiveness to treatment. The heterogeneity most likely has its origin in its 
multifactorial nature, whereby specific combinations of environmental factor(s) and genetic 
factors are likely to influence not only susceptibility but also the disease severity and 
prognosis. Unfortunately, our understanding of the molecular complexity of RA is 
incomplete, and criteria for subtyping of patients, e.g. for prognosis to select those patients 
who will benefit from a specific treatment, are currently lacking.  
By definition, nearly every aspect of a disease phenotype should be represented in the 
pattern of active genes and subsequent transcripts and proteins that are expressed. DNA 
microarray technology is a powerful technique that enables studying of mRNA levels of all 
the genes in the genome simultaneously. Application of large-scale gene expression 
profiling using DNA micro arrays (genomics) of blood and tissue samples from patients 
with RA allows an open-ended survey to identify comprehensively the fraction of active 
genes that are specific for a clinical condition (figure 1). This information provides insight in 
biological pathways contributing to disease and to identify classifiers for early diagnosis, 
prognosis, and response prediction.  
Due to the complexity of the microarray technology and sometimes not optimal powered 
studies, and high costs associated with use of this technology, several important aspects 
need to be considered when analyzing micro array data. In almost all cases, the number of 
transcripts that is measured on an array is much higher than the number of samples 
included in a study and therefore there is a high change of ‘false positives’ of which one 
should be aware and account for in the analysis. Thus, good laboratory proficiency for data 
acquisition needs to be ensured and appropriate and properly used data analyses practices 
are essential. 
Initially several pitfalls were experienced using this multistage technology. Factors that 
could influence the sensitivity and reproducibility range from differences in sample storage 
and processing, variation in amount and quality of starting RNA, RNA amplification and 
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1. Introduction 
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that primarily affects 
the joints. Aetiology of RA is unknown. Once symptoms are present RA manifests itself as a 
heterogeneous disease with a clinical spectrum ranging from mild to severe disease, and 
variable involvement in secondary organ systems. The heterogeneous nature is reflected by 
variation in responsiveness to treatment. The heterogeneity most likely has its origin in its 
multifactorial nature, whereby specific combinations of environmental factor(s) and genetic 
factors are likely to influence not only susceptibility but also the disease severity and 
prognosis. Unfortunately, our understanding of the molecular complexity of RA is 
incomplete, and criteria for subtyping of patients, e.g. for prognosis to select those patients 
who will benefit from a specific treatment, are currently lacking.  
By definition, nearly every aspect of a disease phenotype should be represented in the 
pattern of active genes and subsequent transcripts and proteins that are expressed. DNA 
microarray technology is a powerful technique that enables studying of mRNA levels of all 
the genes in the genome simultaneously. Application of large-scale gene expression 
profiling using DNA micro arrays (genomics) of blood and tissue samples from patients 
with RA allows an open-ended survey to identify comprehensively the fraction of active 
genes that are specific for a clinical condition (figure 1). This information provides insight in 
biological pathways contributing to disease and to identify classifiers for early diagnosis, 
prognosis, and response prediction.  
Due to the complexity of the microarray technology and sometimes not optimal powered 
studies, and high costs associated with use of this technology, several important aspects 
need to be considered when analyzing micro array data. In almost all cases, the number of 
transcripts that is measured on an array is much higher than the number of samples 
included in a study and therefore there is a high change of ‘false positives’ of which one 
should be aware and account for in the analysis. Thus, good laboratory proficiency for data 
acquisition needs to be ensured and appropriate and properly used data analyses practices 
are essential. 
Initially several pitfalls were experienced using this multistage technology. Factors that 
could influence the sensitivity and reproducibility range from differences in sample storage 
and processing, variation in amount and quality of starting RNA, RNA amplification and 
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labeling strategies, solid-phase DNA sequences and hybridization conditions. In addition 
the lack of standardized approaches for normalization and usage of data analysis algorithms 
could influence the outcome. Hence, the application of perfectly standardized conditions is 
crucial to generate high quality data points. Moreover, verification of results became an 
essential step in microarray studies. In order to set quality criteria for performing and 
publishing microarray studies, standards for microarray experiments and data analysis 
were created (Brazma et al., 2001).  
Cluster algorithms are very useful in visualizing huge datasets obtained with microarray 
experiments. Data can be clustered according a predetermined separation of the patient 
samples (supervised), or driven by molecular variation (unsupervised). Very often the data 
set becomes more comprehensive by selecting only genes that are differentially expressed 
between groups of patients/samples. Filtering of expression data by applying a threshold 
for a certain fold change compared to the median expression levels in at least a certain 
number of patients studied results in a condense and informative set of differentially 
expressed genes. Additional, pathway-level analyses, and classifier and prediction 
algorithms can provide more insight in the functional pathways or biological processes and 
markers for stratification, prognosis and response prediction.  
Now, after years of technical and analytical improvement, the technology and algorithms 
for data analysis are robust and reproducible across properly designed and controlled 
experiments between different research groups. In addition the introduction of PAXgene 
(PreAnalytix, GmbH, Germany) whole blood aspiration system, whereby cells are directly 
lysed and the RNA stabilized, excludes ex vivo processing artifacts and forms an essential 
step in the standardization process. However, careful standardization is still required for 
cell subsets and tissues that are obtained via ex vivo manipulation. 
This review describes developments in transcriptomics research to identify novel pathways 
that contribute to disease and to uncover clinically relevant biomarkers. Ultimately this 
information may help clinicians to improve disease management.  
2. Gene expression profiling in affected target tissues and cells 
2.1 The rheumatoid synovium 
Since synovitis is the hallmark of rheumatoid arthritis, gene expression analysis was initially 
aimed to provide insight in the molecular features and biological pathways at play in the 
affected synovium. The first study on gene expression profiling in rheumatoid synovium 
highlighted the increased expression of genes involved in chronic inflammation such as 
immunoglobulins and HLA-DR in RA synovium when compared with normal synovium 
(Zanders et al., 2000) Comparative analysis of synovial tissue specimen from RA and 
osteoarthritis (OA) patients revealed that these diseases were characterized by distinct 
synovial gene signatures (van der Pouw Kraan et al., 2003a; van der Pouw Kraan et al., 
2003b; Sha et al. 2003; Devauchelle et al., 2004; Kato et al. 2007; Nzeusseu et al. 2007; Huber 
et al. 2008). The finding that genes involved in the adaptive immunity (B and T cell 
regulation) were upregulated in RA tissues confirmed histological findings of increased 
infiltration of T cells and B cells in the rheumatoid synovium compared to OA. In addition, a 
number of non-immune genes were found to be differentially expressed between the RA 
and OA synovium, which were involved in diverse biological processes such as extracellular 
 
Gene Expression Profiling in Rheumatoid Arthritis 
 
41 
matrix biology (e.g. fibronectin, fibulin-3 and collagen type IIIa1), transcription and cell 
cycle regulation (CAK, DNA replication licensing factor, CDK7, FOS, CHD2), 
receptor/signaling (GBP1 IL1R1, CXCL2, PDGFRA), protease biology (Cathepsin L and 
Cathepsin D, adhesion paxillin, integrina2, D66) and apoptosis (BECN1). Analysis of 3265 
genes led to the discovery of a 21 gene discriminator between RA and OA synovial tissue 
(Kato et al. 2007). Devauchelle found a 48 gene discriminator out of 5670 genes studied 
(Devauchelle et al. 2004). Using an array with 1050 gene sequences with a combination of a 
binary probit model with bayesian variable selection, Sha and colleagues found several 
small gene sets that led to good classification results. A similar study was performed by 
Huber and colleagues (Huber et al. 2008) who identified three pathways with significantly 
higher variances in RA (e.g. B-cell receptor signaling and vascular endothelial growth factor 
signaling) compared to OA. Functionally, the majority of the identified pathways are 
involved in the regulation of inflammation, proliferation, cell survival and angiogenesis. 
Additional comparative analyses of synovial biopsy tissue from patients with RA, OA and 
systemic lupus erythematosus (SLE) confirmed and extended observations that distinct 
diseases were characterized by distinct molecular synovial signatures (Nzeusseu et al. 2007). 
Overall, tissue profiling in RA and other rheumatic diseases has led to an increase in our 
understanding of disease pathogenesis. These findings highlight the molecular differences 
between the RA, OA and SLE synovia and demonstrate that transcriptome analysis provide 
a rich source for the establishment of diagnostic tools and may lead to identification of novel 
drug targets.  
2.1.1 Heterogeneity between rheumatoid synovial tissues 
The lack of a consistent comprehensive transcript profile in RA synovium may be due to the 
small samples sizes, heterogeneity between disease tissues, differences in appropriate 
control tissues, and/or technical differences such as the variation in the type and the 
complexity of the arrays used by the different research groups. 
A large-scale gene expression profiling study of 30 synovial tissue specimens from patients 
with erosive RA revealed considerable heterogeneity among patients (van der Pouw Kraan 
et al., 2003a; van der Pouw Kraan et al., 2003b). Also Huber and colleagues noted the broad 
intra-group inter-individual expression variances in RA for genes representing different 
pathways (e.g. Toll-like receptor signaling pathway, T-cell receptor signaling pathway, Fc 
epsilon receptor I signaling pathway, adherence junction, classical TGF-β sub-pathway and 
the anti-apoptotic sub-complex (Huber et al., 2008). Accordingly, Lindberg and colleagues 
showed that synovial biopsies had gene expression signatures that were unique for each 
patient (Lindberg et al., 2006a). Heterogeneity is not surprising known the variation in 
clinical presentation, differences in treatment outcome and complex pathogenesis that 
changes over time.  
Systematic characterization of the differentially expressed genes highlighted the existence of 
at least two molecularly distinct forms of RA tissues (van der Pouw Kraan et al., 2003a; 
2003b). One group, referred to as the RA high inflammation group, was characterized by 
genes involved in inflammation and adaptive immune response. The genes involved in the 
high inflammation tissues consist of immunoglobulin genes and genes indicative for an 
activated IFN/STAT-1 pathway. Seven of these (TIMP2, PDGFRA, GBP1, Fos, CTSL, TUBB 
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labeling strategies, solid-phase DNA sequences and hybridization conditions. In addition 
the lack of standardized approaches for normalization and usage of data analysis algorithms 
could influence the outcome. Hence, the application of perfectly standardized conditions is 
crucial to generate high quality data points. Moreover, verification of results became an 
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expressed genes. Additional, pathway-level analyses, and classifier and prediction 
algorithms can provide more insight in the functional pathways or biological processes and 
markers for stratification, prognosis and response prediction.  
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number of non-immune genes were found to be differentially expressed between the RA 
and OA synovium, which were involved in diverse biological processes such as extracellular 
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matrix biology (e.g. fibronectin, fibulin-3 and collagen type IIIa1), transcription and cell 
cycle regulation (CAK, DNA replication licensing factor, CDK7, FOS, CHD2), 
receptor/signaling (GBP1 IL1R1, CXCL2, PDGFRA), protease biology (Cathepsin L and 
Cathepsin D, adhesion paxillin, integrina2, D66) and apoptosis (BECN1). Analysis of 3265 
genes led to the discovery of a 21 gene discriminator between RA and OA synovial tissue 
(Kato et al. 2007). Devauchelle found a 48 gene discriminator out of 5670 genes studied 
(Devauchelle et al. 2004). Using an array with 1050 gene sequences with a combination of a 
binary probit model with bayesian variable selection, Sha and colleagues found several 
small gene sets that led to good classification results. A similar study was performed by 
Huber and colleagues (Huber et al. 2008) who identified three pathways with significantly 
higher variances in RA (e.g. B-cell receptor signaling and vascular endothelial growth factor 
signaling) compared to OA. Functionally, the majority of the identified pathways are 
involved in the regulation of inflammation, proliferation, cell survival and angiogenesis. 
Additional comparative analyses of synovial biopsy tissue from patients with RA, OA and 
systemic lupus erythematosus (SLE) confirmed and extended observations that distinct 
diseases were characterized by distinct molecular synovial signatures (Nzeusseu et al. 2007). 
Overall, tissue profiling in RA and other rheumatic diseases has led to an increase in our 
understanding of disease pathogenesis. These findings highlight the molecular differences 
between the RA, OA and SLE synovia and demonstrate that transcriptome analysis provide 
a rich source for the establishment of diagnostic tools and may lead to identification of novel 
drug targets.  
2.1.1 Heterogeneity between rheumatoid synovial tissues 
The lack of a consistent comprehensive transcript profile in RA synovium may be due to the 
small samples sizes, heterogeneity between disease tissues, differences in appropriate 
control tissues, and/or technical differences such as the variation in the type and the 
complexity of the arrays used by the different research groups. 
A large-scale gene expression profiling study of 30 synovial tissue specimens from patients 
with erosive RA revealed considerable heterogeneity among patients (van der Pouw Kraan 
et al., 2003a; van der Pouw Kraan et al., 2003b). Also Huber and colleagues noted the broad 
intra-group inter-individual expression variances in RA for genes representing different 
pathways (e.g. Toll-like receptor signaling pathway, T-cell receptor signaling pathway, Fc 
epsilon receptor I signaling pathway, adherence junction, classical TGF-β sub-pathway and 
the anti-apoptotic sub-complex (Huber et al., 2008). Accordingly, Lindberg and colleagues 
showed that synovial biopsies had gene expression signatures that were unique for each 
patient (Lindberg et al., 2006a). Heterogeneity is not surprising known the variation in 
clinical presentation, differences in treatment outcome and complex pathogenesis that 
changes over time.  
Systematic characterization of the differentially expressed genes highlighted the existence of 
at least two molecularly distinct forms of RA tissues (van der Pouw Kraan et al., 2003a; 
2003b). One group, referred to as the RA high inflammation group, was characterized by 
genes involved in inflammation and adaptive immune response. The genes involved in the 
high inflammation tissues consist of immunoglobulin genes and genes indicative for an 
activated IFN/STAT-1 pathway. Seven of these (TIMP2, PDGFRA, GBP1, Fos, CTSL, TUBB 
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and BHLHB2) were also described by Devauchelle and colleagues, of which 2 (GBP1 and 
CTSL) are known to be regulated by type I IFN (Devauchelle et al., 2004). The second group 
of RA tissues was characterized by a low inflammation gene signature that was reminiscent 
of that of tissues from patients with OA. While inflammation and immune-related genes 
were decreased, these tissues showed an increased expression of genes involved in tissue 
remodeling activity, which is associated with fibroblast dedifferentiation. Remarkably, the 
high and low inflammation tissues revealed reciprocal expression of specific matrix 
metalloproteinases (MMP). Whereas levels of MMP11 and 13 were increased in low 
inflammation tissues, levels of MMP1 and 3 were increased in high inflammation tissues 
(van der Pouw Kraan et al., 2003a). 
Histological analyses already revealed the existence of different tissue types in the 
rheumatoid synovium that are related to differences in the cell distribution (Takemura et al., 
2001). In approximately 10% of synovial tissues T cells, B cells, and follicular dendritic cells 
(FDCs) are organized into germinal centres (GC) like structures. The other tissue types lack 
FDCs and show either a diffuse or an aggregated T-cell and B-cell infiltrate.  
The tissues with these so called ectopic GCs were selectively present in the high 
inflammation tissues. These tissues revealed increased Ig transcript expression with the 
concomitant presence of B cells and/or plasma cells, which may support local production of 
antibodies. Gene expression revealed concomitant expression of genes encoding the 
chemokines CXCL12 and CCL19 and the associated receptors CXCR4 and CXCR5, which 
are important for the attraction of T cells, B cells, and dendritic cells, in GC containing 
tissues (Timmer et al., 2007). In addition genes involved in T-cell and B-cell specific 
pathways, and Fc-receptor type I and JAK/STAT signaling. Elevated expression of IL-7 
receptor (IL-7R )/IL-2Rγ chains and IL-7) suggest a role for the IL-7 pathway in synovial 
lymphoid neogenesis in RA. Tissues with a diffuse type of infiltrate exert evidence of 
repressed angiogenesis and increased extracellular matrix remodeling.  
Overall, the gene expression profiling of rheumatoid synovium has provided insight into 
the molecular basis of the heterogeneous nature of synovial disease pathogenesis in RA and 
may facilitate subclassification of patients based on a synovial marker profile (figure 1). 
However, it remains to be determined if a specific molecular profile applies to all affected 
synovia in a single patient, and if the profile is stable during the course of disease. 
2.2 Gene expression in mesenchymal cells derived from affected target tissues 
Fibroblast-like synoviocytes (FLS) are major players in joint destruction in RA. FLS have a 
transformed phenotype and act as sentinel cells that contribute to leucocyte migration and 
local immune response through the production of various immune modulators (Smith et al., 
1997; Hogaboam et al., 1998; Brouty-Bové et al. 2000). Reversibly, the soluble factors, such as 
cytokines and growth factors released from the immune cells, in combination with cell-cell 
interactions likely activate FLS and influence their behavior. One of the first gene expression 
analyses of in-vitro cultured FLS clearly demonstrated over-expression of genes responsible 
for tumor-like growth (Watanabe et al., 2002). Analysis of the expression of 588 known 
cancer-related genes revealed increased expression of PDGFRα, PAI-1 and SDF1A by FLS 
from five patients with RA compared to FLS from five traumatic control patients. Galligan 
and colleagues performed a comparative gene expression analysis on FLS cultured from RA 
 




Fig. 1. Schematic outline for disease subclassification in RA  
Legend: RA patients reveal a striking heterogeneity based on clinical, biological and molecular 
criteria. Categorization of patients is crucial for decision making in clinical practice. Recent 
developments in high-throughput screening technologies makes it possible to characterize patients 
based on their molecular profile. Application of DNA-microarrays enables the generation of a 
transcript profile (barcode) of an individual patient. When associated with clinical read-outs clinical 
useful molecular markers could be selected and applied in day-to-day clinical practice. The procedure 
starts with collecting biosamples (e.g. peripheral blood cells) from each patient. The biosample can be 
processed to isolate mRNA and then further analyzed using DNA-microarray technology. 
Subsequently, computational algorithms will be applied to select biomarkers that allow subtyping of 
patients. This approach helps to elucidate the distinct pathological mechanisms that can explain the 
inter-patient variation, disease progression, and treatment response. 
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(17), OA (20) and trauma (6) joint tissue using affymetrix microarrays (Galligan et al., 2007). 
A total of 34 genes were significant differentially expressed between RA and OA FLS. Genes 
highly and exclusively expressed by RA FLS are HOXD10, HOXD11, HOXD13, CCL8 and 
LIM homeobox 2. Genes encoding CLU, sarcoglycan-y, GPR64, POU3F3, peroxisome 
proliferative activated receptor-y and tripartite motif-containing 2 were exclusively 
expressed in OA FLS. Interestingly, only a few of the significant differently expressed in FLS 
also differed between the total synovial tissue expression profiles, suggesting that the 
contribution of the synovial lining cells is not dominant in the total tissue profile. 
Alternatively, the transcriptome of in-vitro cultured FLS may not be representative for the 
genuine transcriptome of in situ FLS. Evidence that in vitro cultured FLS gene expression 
changes are beyond the 10% when passaged less than 6 times, as was done by Galligan and 
colleagues, suggest that this was not the case (Nuemann et al., 2010). However, formal proof 
by comparison of in-vitro cultured FLS with in-situ FLS (via e.g. Laser Capture Microscopy 
derived cells) is lacking. 
Others investigated the effects of tumour necrosis factor (TNF) and IL-1b on FLS. TNF and 
IL-1b have been shown to be of primary importance in the effector phase of the disease. 
Defining TNF-α and IL-1b response signatures in FLS may be instrumental for application 
in pharmacology studies to monitor the effects of TNF and IL-1b blockade. In an early 
microarray study 96 inflammatory genes were studied in cytokine-stimulated RA-FLS cells. 
A number of cytokine-regulated genes such as IL-6, CXCL8, CXCL1, MMP-1, MMP-3, MMP-
8 and VCAM-1 were identified (Heller et al., 1997). Additional studies using arrays with 
higher complexity (12.600 genes) revealed that TNF affected the expression of genes 
representing cytokines and inflammatory mediators, extracellular matrix and adhesion 
molecules, cell cycle and proliferation related proteins, transcription related proteins, and 
apoptotic mediators (Gallagher et al., 2003). One of these TNF-response genes, Nef-
associated factor-1 (Naf1, an A20-binding, nuclear factor kappa B (NFkB) inhibitory 
protein), was identified as indicator for TNF-bioactivity. This analysis revealed higher 
expression in synovial biopsies from patients with active RA and seronegative arthropathy 
than in those from patients with OA. Taberner and colleagues showed that there exists a 
broad overlap between TNF- and IL-1b response genes. Out of 12600 genes tested 126 genes 
were regulated by both TNF and IL-1b, 65 genes were specifically regulated by IL-1b (e.g. G-
CSF, CXCL6, CCL4, PAI-1, OAS 40kD and VEGF) and 21 genes by TNF (e.g. CXCL19, 
CXCL11, PIAS3, ID1, MAPKKK4) (Taberner et al., 2005). It is likely that these response 
signatures contain numerous genes that contribute critically to the pathogenesis of RA and 
provide a framework to unravel IL-1b and TNF driven effector pathways. 
Detailed analysis of the gene expression profiles clearly revealed that the profiles are not 
uniform between RA patients, analogous to the gene expression of the synovial tissues. 
Transcriptome analysis of FLSs derived from 19 RA patients using microarrays with a 
complexity of 24,000 cDNA elements, revealed 3 molecular profiles, indicative for the 
existence of 3 FLS subtypes (Kasperkovitz et al., 2005). Accordingly, others also noted 
marked heterogeneity in both the gene expression profile (Galligan et al. 2004) as well as the 
sensitivity to proinflammatory cytokines between FLS derived from different RA patients 
(Taberner et al. 2007). Correlation studies of paired synovial tissue and FLS clustering 
revealed that heterogeneity at the synovial tissue level is associated with a specific 
phenotypic characteristic of the cultured resident FLS (Kaperkovitz et al., 2005). The high 
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inflammation tissues were associated with an FLS subtype that exhibits similarity with so-
called myofibroblasts. The myofibroblast is a specialized fibroblast that has acquired the 
capacity to express α-smooth muscle actin, an actin isoform that is typical of vascular 
smooth muscle cells. The myofibroblast is a specialized fibroblast that plays a key role in 
connective tissue remodelling and contributes to cell infiltration. These cells are 
characterized by a markedly increased expression of genes that represent the transforming 
growth factor (TGF)-β response programme. Among these response genes were SMA, 
SERPINE1, COL4A1 (type IV collagen-α chain), IER3 (immediate early response 3), TAGLN 
(transgelin) and the gene encoding activin A, which is a potential agonist for the induction 
of the TGF-β response programme. Similar cells were recently identified in the human 
TNF+/-transgenic mouse model of arthritis (Aidinis et al., 2005). Moreover, Pohlers and 
colleagues noted constitutive activation of the TGF-β pathway in RA FLS (Pohlers et al., 
2007). A significant positive correlation were observed between the constitutive expression 
of TGF-β1 mRNA (but not protein) and the serum levels of C-reactive protein was observed. 
Myofibroblasts may play a crucial role in angiogenesis through the production of 
extracellular matrix proteins, chemokines and growth factors, as has been shown in the field 
of oncology. Hence, it is proposed that these cells contribute to angiogenesis in the 
rheumatoid synovium. This finding supports the hypothesis that phenotypic variation 
between FLS may be causally related to the inflammation status of the target tissue. 
2.3 Gene expression in rheumatoid bone marrow 
Evidence exists that bone marrow-derived mononuclear cells (BMMC) contribute to the 
pathogenesis of RA (Ochi et al., 1988; Jongen-Lavrencic et al., 1997; Hirohata et al., 2004). 
The bone marrow harbors three types of stem cells: the mesenchymal stem cells, the 
hematopoietic stem cells and the endothelial stem cells. The local cell-cell interactions and 
soluble factors act in a sophisticated network that regulates the proliferation and 
differentiation of these cells. Elevated levels of IL-6 and IL-8 in RA bone marrow serum 
was reported to be associated with synovial hyperplasia (Tanabe et al., 1994). 
Comparative gene expression profiling between RA and OA BMMC revealed marked 
variation between the two diseases (Nakamura et al., 2006; Lee et al., 2011). Transcriptome 
analysis identified 2,674 genes which were differentially expressed between RA and OA 
BMMC (Lee et al., 2011). Marked upregulated genes were classified as immune response 
genes, which were highly relevant to the antigen presentation pathway (e.g. HLA-E, 
HLA-F, HLA-G, tapasin (TAP), TAP binding protein) and interferon (IFN) signaling (e.g. 
IFITM1, IFITM3, IFI16, MAPK14, MyD88, IL8). In a third network IFNɣ played a central 
role (e.g. PSM8, PSM9, CLEC5A, CLEC4E). A fourth network was centered around HNF4 
and involved in lipid metabolism, coagulation and negative regulation of cell growth. The 
downregulated genes were dominantly related to cell cycle and DNA metabolism. These 
findings provide important information to abnormal BMMC biology in RA. It remains to 
be determined why these processes are disturbed and how these abnormalities contribute 
to the pathogenesis of RA.  
2.4 Gene expression in blood cells 
Known the systemic nature of RA and the communication between the systemic and organ 
specific compartments, whole blood and/or peripheral blood mononuclear cells (PBMC) is a 
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useful compartment to study the disease-related gene expression profiles. Because of the 
low-invasiveness blood aspiration this compartment is extremely suitable for explorative 
studies in large cohorts of patients to identify clinically relevant biomarkers.  
Several investigators studied gene expression levels in peripheral blood cells to address the 
question, whether disease specific features were present in peripheral blood cells. Bovin and 
colleagues identified 25 genes immune related genes (e.g. calcium-binding proteins S100A8 
and S100A12) that discriminated between PBMC of RA patients (n=14) and healthy controls 
(n=7) (Bovin et al., 2004). S100A8 and S100A12 (calgranulins C) belong to a class of 
inflammatory mediators, and function as heterodimers. These proteins are released by e.g. 
activated monocytes upon interaction with activated endothelial cells under inflammatory 
conditions and mediate leukocyte migration and adhesion to vascular endothelium. Liao et 
al. used tandem mass spectrometry (MS/MS), coupled with multidimensional liquid 
chromatography (LC) to identify biomarkers of disease severity in the synovial fluid and 
serum of patients with RA (Liao et al., 2004). Levels of CRP, S100A8, S100A9 and S100A12 
were elevated in the serum of patients with erosive disease compared with patients with 
non-erosive RA. No significant differences between RF positive and RF negative RA were 
observed. In a larger study with 29 RA patients and 21 healthy controls Batliwalla and 
colleagues identified 81 differentially expressed genes (e.g glutaminyl cyclase, IL1RA, 
S100A12 and Grb2-associated binding protein (GAB2) as the main discriminators. This 
profile correlated with an increased monocyte count (Batliwalla et al., 2005). Studies with a 
preselected set of 96 genes in PBMC from IBD, psoriasis and RA patients, and healthy 
controls revealed genes (e.g. ADM, AQQ9, CXCL12, IL10, NAMPT) that were specific for 
the chronic inflammatory diseases in general, and disease specific genes (Mesko et al., 2010). 
Genes that were specific for RA included mainly downregulated genes e.g CCL4, CCL5, 
CDNK1C, CYP51A1, FGL2, HMGB1, IL23R, and PTPN22, and only IL-8 as upregulated 
gene. Additional studies on peripheral blood cells, including analyses on whole blood cell 
samples (PAXgene) confirmed and further extended the molecular differences between the 
peripheral blood compartment between healthy controls and RA patients (van der Pouw 
Kraan et al., 2007; 2008; Teixeira et al., 2009). Additional genes that Teixeira and colleagues 
identified include Ly96/MD2, NFAT5, thioredoxin, CAP/LL37, ORM1, ORM2, SLC11A1, 
PGLyRP1 and Factor V.  
Van der Pouw Kraan and colleagues observed that a prominent cluster of IFN-response 
genes was significantly upregulated in patients with RA indicating that this pathway is 
systemically activated in RA (van der Pouw Kraan et al., 2007). This cluster contains highly 
correlated genes such as IFRG28 (28 kDa interferon-responsive protein), IFI35 (interferon-
induced protein 35), IFI44L (interferon-induced protein 44-like), IFIT1 (interferon-induced 
protein with tetratricopeptide repeats 1), IFIT2, IRF2 (interferon-regulatory factor 2), IRF7, 
GIP2 (interferon a-inducible protein 2), GIP3, SERPING1 (serine proteinase inhibitor clade G 
member 1, C1 inhibitor), OAS1 (29-59-oligoadenylate synthetase 1), OAS2, MX1 (Myxovirus 
resistance 1), ISG15 (interferon-induced protein 15) and RSAD2 (radical S-adenosyl 
methionine domain containing 2). These findings have now been replicated in several other 
studies using independent cohorts (Thurlings et al., 2010; O’Hanlon et al., 2011; Higgs et al., 
2011; Vosslamber et al., 2011). Moreover, IFN-bioactivity was measured in RA serum. 
Comparative analyses on the extent of the IFN response activity in the blood cells of RA and 
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SLE patients revealed a 5-fold higher level of expression in SLE compared to RA patients 
(Higgs et al. 2011, Vosslamber et al., unpublished observation). 
2.4.1 Gene expression heterogeneity in blood vs. synovial tissue 
Synovial tissue heterogeneity is likely to reflect differences in the underlying disease 
pathogenesis. Because of the migration of immune cells to and from lesional sites via the 
blood as well as the recirculation of immune cells between central and peripheral 
lymphoid organs, the PB compartment could be an easy accessible compartment to 
monitor the (immune)pathophysiology of the synovial tissue. Hence, a critical question to 
answer is whether molecular heterogeneity at the synovial tissue level is reflected in the 
blood. The identification of processes and biomarkers in PB may facilitate informative 
studies of a relation between tissue type and clinical parameter. The notion that molecular 
heterogeneity is present in both the synovial as well as the PB compartment makes it 
tempting to speculate on molecular and biological features that reflect the tissue 
pathology (van Baarsen et al., 2010b). However, paired analysis of peripheral blood and 
affected synovium from 17 patients with RA revealed that differential tissue pathology 
was not reflected in the PB by differential expression of single genes. Pathway-level 
analysis showed that co-ordinately regulated genes involved in protein synthesis in PB 
were associated with high-inflammation tissue types. The increased protein synthesis 
activity in PB could provide a framework for further studies to identify PB biomarkers 
representative for the tissue inflammation status. 
2.4.2 A type I IFN response signature in the peripheral blood of a subset of RA 
patients 
The significantly differential expression of the IFN-response genes indicates that this 
pathway is activated systemically in RA. Van der Pouw Kraan provided evidence that this 
signature is specific for type I IFNs (IFNα/β) (van der Pouw Kraan et al., 2006). Thus this 
type I IFN signature may be a direct reflection of increased type I IFN activity or other 
ligands known to activate the type I IFN/STAT-1 pathway. The fact that the serum IFN 
bioactivity could be inhibited by neutralizing antibodies directed against IFNα and IFNβ, 
provides evidence for a role of both type I IFNs in the induction of IFN type I response 
activity in RA (Mavragani et al., 2009). Upregulation of type I IFN-response genes has now 
been observed in peripheral blood cells and/or target tissues of (a subset of) patients with 
autoimmune diseases such as RA, SLE (Baechler et al. 2005), SSc (Tan et al, 2006; Bos et al., 
2009), SS (Mavragani & Crow, 2010), multiple sclerosis (Van Baarsen et al., 2006) and type 1 
diabetes. These findings suggest that an activated IFN response gene expression program is 
a common denominator in chronic inflammatory diseases in general. 
Interestingly, the increased expression of the type I IFN response genes was characteristic 
of not all, but approximately half of the RA patients, consistent with the heterogeneous 
nature of RA. Moreover, the immune defense gene program that was activated in the 
subgroup of RA patients was reminiscent to that of virus-infected macaques (van der 
Pouw Kraan et al., 2008). Comparative analysis between paired tissue and peripheral 
blood profile revealed that there exists no concordance in the presence of IFN-response 
activity between the two compartments (van Baarsen et al., 2010a) 
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2.5 Monozygotic twins and first degree relatives 
O’Hanlon and colleagues studied gene expression profiles of monozygotic (MZ) twin pairs 
discordant for RA, SLE and idiotypic inflammatory myopathies, their unaffected twins and 
healthy controls (O’Hanlon et al., 2011). Probands differed significantly in gene expression 
for 92 genes involving several pathways including immune responses, signaling pathways, 
transcription/translation regulators, and metabolic functions. As part of the immune 
response genes they observed that IFN-response genes (IFI27, OASF, PLSCR1, EIF2AK2, 
TNFAIP6, and TNFSF10) were up-regulated in probands compared to unrelated controls. In 
unaffected twins intermediate ordering was observed for 84 of the 104 transcripts whose 
expression differed significantly between probands and unrelated controls. Suggesting that 
unaffected twins may be in a transitional or intermediate state of immune dysregulation 
between twins with an autoimmune disease and unrelated controls, perhaps predisposing 
them to the development of systemic autoimmune diseases given the necessary and 
sufficient environmental exposures. Maas and colleagues, reported similar results when 
comparing gene expression profiles between PBMCs from patients and unrelated unaffected 
individuals (Maas et al., 2005). A total of 127 genes was shared between patients with 
autoimmune diseases and unaffected first-degree relatives. This commonality between 
affected and unaffected first-degree relatives suggests a genetic basis for these shared gene 
expression profiles.  
2.6 B-lymphocytes 
Szodoray and colleagues compared gene expression differences in pooled peripheral 
blood B cells from 8 RA patients to the pool of B cells from 8 healthy controls (Szodoray et 
al., 2006). A total 536 genes were differentially expressed between rheumatoid  
and healthy B-cells (e.g. S100A9, S100A9, CNNM4, BARD1, U5-116KD, TLR9, IL5-RA, IL-
10, IL12A, PTX3, CRLF1, CHRNB1, DRD2, MMP28, VEGFC and FOXo3a). These genes 
were involved in diverse processes including cell–cycle regulation, proliferation, 
apoptosis, autoimmunity, cytokine networks, angiogenesis and neuron-immune 
regulation. E.g. the overexpression of FoxO3a in B cells from patients with RA is reported 
by others and may increased survival of blood PMNs and T lymphocytes. Functional 
pathway analysis demonstrated that many of these genes were regulated by cytokine and 
growth factor activity and correlated with significantly increased serum levels of IL-1b, 
IL-5, IL-6, IL-10, IL-12p40, IL-17 and VEGF, whereas 231 genes were downregulated in  
RA B cells.  
2.7 CD4 T-lymphocytes 
Gene expression analysis of CD4 T cells from 21 patients with RA revealed marked 
heterogeneity between patients reflected by differential expression of 29 genes (including 
IFI27, Col6A1, RASD1, TLR4, APOA1, SPP1) in processes such as Toll-like receptor signaling 
pathway, Calcium signaling pathway, cell adhesion molecules, PPAR signaling pathway, 
and fatty acid metabolism. The differential expression of IFI27 between patients is in line 
with earlier observations of interindividual differences in IFN type I response activity 
among RA patients (Chen et al., 2010).  
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3. Clinical relevant gene signatures 
The success of novel insight in molecular patterns and biological processes in disease 
pathogenesis and the ability to categorize patients based on molecular criteria held out the 
promise that this approach might yield clinical useful information. Hence, the next research 
challenge is to use this information on molecular interindividual heterogeneity to the benefit 
of patients. Research in this field has primarily focused on (very) early diagnosis, prognosis 
and prediction of therapy responsiveness.  
3.1 Genes and signatures involved in disease activity 
Molecular heterogeneity at the tissue level can be a consequence of disease stage and 
duration. Van Baarsen and colleagues studied the synovial tissue gene expression profiles in 
relation to immunohistochemical scores and disease parameters. The results demonstrated 
an excellent correlation between molecular and immunohistochemical scoring (van Baarsen 
et al., 2010b). Moreover, the high inflammation tissue type was predominantly observed in 
patients with high disease activity and short disease duration, suggesting temporal 
differences in the inflammatory status during the course of the disease (Firestein & Zvaifler, 
2002). These findings support the hypothesis that RA progresses from an inflammatory, and 
T- and B-cell driven disease to a more immune-independent process that may be driven by 
”transformed” FLS (Firestein & Zvaifler, 2002). 
The strong association of FLS subtype with synovial tissue inflammation status suggests 
that FLS markers correlate with disease parameters. Galligan and colleagues showed several 
significant correlations; (HLA)-DQA2 with HAQ score; Clec12A with RF; MAB21L2, 
SIAT7E, HAPLN1 and BAIAP2L1 with CRP level; RGMB and OSAP with ESR. Liu and 
colleagues (2009) identified 19 genes (e.g. COL4A1, TFCP2, FHL3, SKIL, F2RL, PPP1R12B, 
LTBR, GADD45A, ACYP1) that enabled prediction of future disease activity (Liu et al., 
2009). 
3.2 Genes and signatures involved in early vs. late RA 
Studies on differences in the PBMC gene expression profiles between early (disease duration 
less than 2 years) and established RA (with an average disease duration of 10 years) marked 
53 genes with a three-fold difference in expression. A total of 9 genes, including colony 
stimulating factor 3 receptor, cleavage stimulation factor, and TGFβ receptor II, were 
upregulated in the early RA group. The deregulated genes were involved in immunity and 
cell cycle regulation. Since a quarter of the early arthritis genes overlapped with an 
influenza-induced gene set it was suggested that the early arthritis signature may partly 
reflect the response to an unknown infectious agent (Olsen et al., 2004). Accordingly, van 
der Pouw Kraan and colleagues observed similarity with a common virus response 
signature in a subset of RA patients (van der Pouw Kraan et al., 2008). Not surprisingly, the 
majority of these patients had an activated IFN-response program. Although no formal 
proof for a direct involvement of an infectious agent in RA, these findings suggest at least 
the presence of an activated pathogen response program in a subset of the patients. A 
comparative analysis between synovial tissues of RA patients suggested molecular 
differences between early (< 9 months) and late (> 4years) RA (Lequerre et al., 2009). 
However, due to the very limited sample size and role of confounding factors (age, 
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treatment, serology) the authors could not exclude a contribution of these factors for the 
observed differences. 
Tsubaki and colleagues applied laser capture microscopy technology to evaluate the 
synovial lining cells in early (<12 months) and late RA (>5 years) patients (Tsubaki et al., 
2005). First, they demonstrated that tissue heterogeneity within RA can already be observed 
in the phase of RA. The early RA patients could be divided in at least two different groups 
based on their gene expression profiles. A subgroup with exclusively early RA synovia was 
characterized by abundant expression of fibronectin1, B2-microglobulin, syndecan, 
cathepsin B, STAT-1, integrin-b2 and IFNGR2. The other group with cases of both long 
standing RA and early RA had an increased expression of CASP9, p53-induced gene 11, 
cathepsin G, CSF2RB, TNFRSF1A and IL-10RB. where expressed at a lower level. Gene 
expression profiling of synovial tissue of early versus long-standing rheumatoid arthritis 
suggest stage specific molecular patterns indicative for involvement of different 
pathophysiological mechanisms during the disease course of RA. A picture emerges that 
early RA is characterized by elevated expression of genes involved in immune-defense 
mechanisms, stress response and apoptosis, whereas long-standing RA showed increased 
expression of genes involved in proliferative processes. 
3.3 Pharmacogenomics in RA towards personalized medicine  
Gene expression profiling may also proof valuable for the predicting responses to therapy. 
In general a substantial percentage of patients do not respond to anti-rheumatic therapies, 
either DMARDs or biological. In particular expensive therapies with biologicals to target 
proinflammatory mediators of TNF, T- and B-lymphocytes, which are approved worldwide 
for the treatment of RA urged the need for predictors for therapy response. Clinical 
experience showed that the targeted therapies with biologicals are not effective for 
approximately 30-40% of the patients. Given the destructive nature of RA, the risk of 
adverse effects, and considerable costs for biologics therapy, there is a strong need to make 
predictions on success before the start of therapy.  
In the late 1990s the term pharmacogenomics was introduced to frame gene expression 
profiling studies to delineate processes and identify biomarkers that correlate with the 
differential clinical outcome of pharmacological intervention. Pharmacogenomics is defined 
as: “The investigation of variations of DNA (genetics) and RNA (transcriptomics) 
characteristics as related to drug response”. The value of pharmacogenomics in guiding 
clinical management has been highly appreciated in the field of oncology, as can be 
exemplified by the use of a gene signature to predict the response outcome of patients with 
breast cancer (Van ‘t Veer et al., 2002).  
3.3.1 Pharmacogenomics of TNF-blockade 
In the field of rheumatology specifically the response to TNF-blockers gained much 
attention. Currently 5 different TNF blockers are registered for clinical use in RA: A soluble 
TNF-receptor-Fc fusion protein Enbrel® (Etanercept), and 4 monoclonal antibodies directed 
against TNF Remicade® (Infliximab), Humira® (Adalumimab), Cinzia® (Certolizumab) and 
Simponi® (Golimumab). 
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3.3.2 Pharmacodynamics of TNF-blockade 
Initial studies focused on the pharmacological effects of TNF blockade in the peripheral 
blood compartment in order to gain a comprehensive understanding of the mode of action. 
Global qualitative and quantitative pharmacogenomic analysis on peripheral blood cells 
suggest that all RA patients treated revealed an overall similar pharmacological response 
pattern, indicative of the presence of bioactive TNF in the circulation irrespective of clinical 
response (Van Baarsen et al., 2010c; Batliwalla et al., 2008). These findings suggest a model 
for the parallel presence of TNF-dependent and TNF-independent disease pathways in the 
individual patient, whereby the effect of anti-TNF therapy may be dependent on the relative 
contribution of the TNF-independent pathways. Meugnier and colleagues studied changes 
in PBMC gene expression after 12 wk of treatment with either etanercept or adalimumab 
from responder RA patients (Meugnier et al., 2011). Two hundred fifty-one genes displayed 
significant changes. Genes encoding S100A12 and A8, CD14 antigen, Selectin P, or 
ribosomal protein L39, reported to be upregulated in RA patients, were found to be 
decreased upon TNF-blockade. Pathway level analysis revealed that inflammation, immune 
response, apoptosis, protein synthesis, and mitochondrial oxido-reduction were the most 
affected pathways in response to anti-TNF-α treatment. Detailed analyses in search of 
(subtle) differences in the pharmacodynamic changes between responders and non-
responders identified IFN-response genes as an informative sets of genes. The regulation of 
IFN-response genes by infliximab in RA turned out not to be as consistent as previously 
described for patients with SOJIA (Palucka et al., 2005), but varies between patients. A 
decrease in IFN-activity appears to be associated with good clinical responses (van Baarsen 
et al., 2010d; Sekiguchi et al., 2008). Koczan and colleagues reported that early 
downregulation of genes involved in different pathways and cellular processes such as 
TNFα signalling via NFκB, NFκB-independent signalling via cAMP, and the regulation of 
cellular and oxidative stress response (e.g. NFKBIA, CCL4, IL8, IL1B, TNFAIP3, PDE4B, 
PPP1R15A and ADM) were associated with a good clinical outcome to etanercept-based on 
ΔDAS >1.2. (Koczan et al., 2008). These studies demonstrated that observing the dynamics 
of the TNF-blocker intervention may provide insight into the biology of TNF blockade. 
3.3.3 Prediction of response to TNF blockade 
In an attempt to predict the response prior to treatment several studies have been 
performed. Initial analyses of synovial tissue gene expression profiles prior to the start of 
infliximab therapy suggested that patients with features of an activated immune status in 
their tissue compartment are more likely to benefit from anti-TNF treatment based on 
ΔDAS28 response criteria (Van der Pouw Kraan et al., 2008; Lindberg et al., 2006). Similar 
findings were reported for baseline serum markers associated with responsiveness 
(Hueber et al., 2009). In contrast, Badot and colleagues identified 439 genes involved in 
cell division and regulation of immune response (e.g. cytokines, chemokines and their 
receptors) that were associated with poor response based on EULAR criteria (Badot et al., 
2009). A recent study performed in 62 RA patients by Lindberg et al. demonstrated an 
overrepresentation of lymphoid aggregates in EULAR responders (infliximab), in line 
with the earlier described relationship between inflammation and clinical outcome 
(Lindberg et al. 2010). These authors also caution for the confounding effect of cellular 
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treatment, serology) the authors could not exclude a contribution of these factors for the 
observed differences. 
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in the phase of RA. The early RA patients could be divided in at least two different groups 
based on their gene expression profiles. A subgroup with exclusively early RA synovia was 
characterized by abundant expression of fibronectin1, B2-microglobulin, syndecan, 
cathepsin B, STAT-1, integrin-b2 and IFNGR2. The other group with cases of both long 
standing RA and early RA had an increased expression of CASP9, p53-induced gene 11, 
cathepsin G, CSF2RB, TNFRSF1A and IL-10RB. where expressed at a lower level. Gene 
expression profiling of synovial tissue of early versus long-standing rheumatoid arthritis 
suggest stage specific molecular patterns indicative for involvement of different 
pathophysiological mechanisms during the disease course of RA. A picture emerges that 
early RA is characterized by elevated expression of genes involved in immune-defense 
mechanisms, stress response and apoptosis, whereas long-standing RA showed increased 
expression of genes involved in proliferative processes. 
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proinflammatory mediators of TNF, T- and B-lymphocytes, which are approved worldwide 
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experience showed that the targeted therapies with biologicals are not effective for 
approximately 30-40% of the patients. Given the destructive nature of RA, the risk of 
adverse effects, and considerable costs for biologics therapy, there is a strong need to make 
predictions on success before the start of therapy.  
In the late 1990s the term pharmacogenomics was introduced to frame gene expression 
profiling studies to delineate processes and identify biomarkers that correlate with the 
differential clinical outcome of pharmacological intervention. Pharmacogenomics is defined 
as: “The investigation of variations of DNA (genetics) and RNA (transcriptomics) 
characteristics as related to drug response”. The value of pharmacogenomics in guiding 
clinical management has been highly appreciated in the field of oncology, as can be 
exemplified by the use of a gene signature to predict the response outcome of patients with 
breast cancer (Van ‘t Veer et al., 2002).  
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attention. Currently 5 different TNF blockers are registered for clinical use in RA: A soluble 
TNF-receptor-Fc fusion protein Enbrel® (Etanercept), and 4 monoclonal antibodies directed 
against TNF Remicade® (Infliximab), Humira® (Adalumimab), Cinzia® (Certolizumab) and 
Simponi® (Golimumab). 
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3.3.2 Pharmacodynamics of TNF-blockade 
Initial studies focused on the pharmacological effects of TNF blockade in the peripheral 
blood compartment in order to gain a comprehensive understanding of the mode of action. 
Global qualitative and quantitative pharmacogenomic analysis on peripheral blood cells 
suggest that all RA patients treated revealed an overall similar pharmacological response 
pattern, indicative of the presence of bioactive TNF in the circulation irrespective of clinical 
response (Van Baarsen et al., 2010c; Batliwalla et al., 2008). These findings suggest a model 
for the parallel presence of TNF-dependent and TNF-independent disease pathways in the 
individual patient, whereby the effect of anti-TNF therapy may be dependent on the relative 
contribution of the TNF-independent pathways. Meugnier and colleagues studied changes 
in PBMC gene expression after 12 wk of treatment with either etanercept or adalimumab 
from responder RA patients (Meugnier et al., 2011). Two hundred fifty-one genes displayed 
significant changes. Genes encoding S100A12 and A8, CD14 antigen, Selectin P, or 
ribosomal protein L39, reported to be upregulated in RA patients, were found to be 
decreased upon TNF-blockade. Pathway level analysis revealed that inflammation, immune 
response, apoptosis, protein synthesis, and mitochondrial oxido-reduction were the most 
affected pathways in response to anti-TNF-α treatment. Detailed analyses in search of 
(subtle) differences in the pharmacodynamic changes between responders and non-
responders identified IFN-response genes as an informative sets of genes. The regulation of 
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3.3.3 Prediction of response to TNF blockade 
In an attempt to predict the response prior to treatment several studies have been 
performed. Initial analyses of synovial tissue gene expression profiles prior to the start of 
infliximab therapy suggested that patients with features of an activated immune status in 
their tissue compartment are more likely to benefit from anti-TNF treatment based on 
ΔDAS28 response criteria (Van der Pouw Kraan et al., 2008; Lindberg et al., 2006). Similar 
findings were reported for baseline serum markers associated with responsiveness 
(Hueber et al., 2009). In contrast, Badot and colleagues identified 439 genes involved in 
cell division and regulation of immune response (e.g. cytokines, chemokines and their 
receptors) that were associated with poor response based on EULAR criteria (Badot et al., 
2009). A recent study performed in 62 RA patients by Lindberg et al. demonstrated an 
overrepresentation of lymphoid aggregates in EULAR responders (infliximab), in line 
with the earlier described relationship between inflammation and clinical outcome 
(Lindberg et al. 2010). These authors also caution for the confounding effect of cellular 
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complexity, suggesting the use of microdissected cell population for explorative genomic 
synovial tissue analyses. 
In the ideal situation a prediction should be made prior to the start of therapy in an easily 
accessible biosample, such as peripheral blood. Ultimately, this may lead to apply therapy to 
each patient that is best suited for the patient, also called "personalized medicine". A 
number of studies focussed on the delineation of baseline differences in peripheral blood 
cells (whole blood and PBMC) with the purpose of predicting response (Lequerre et al.2006; 
Koczan et al., 2008; Sekiguchi et al. 2008; Tanino et al. 2009; Julia et al., 2009a; Bienkoska et 
al., 2009; Van Baarsen et al., 2010c, 2010d; Stuhlmuller et al., 2010). The results of these 
studies made clear that identification of predictors in the blood compartment is not trivial. 
Whereas several groups reported the absence of significant gene expression differences 
between responders and non-responders others were able to identify such markers. In 2006 
Lequerre and colleagues report promising results of a study with 33 patients (13 patients in 
the test group and 20 patients in a validation group) using a in-house made microarray 
covering 10,000 unique genes, wherein they identified a gene set (consisting of AKAP9, 
COX7AL2, ELMOD2, EPS15, FBOX5, HLA-DPB1, LAMR1, MCP, MRLP22, MTCBP1, 
PFKFB4, PSMB9, PTPN12, QIL1, RASGRP3, RPL35, RSP16, RSP28, SCAM1 and TBL2) that 
predicts the response to infliximab based on the ΔDAS28>1.2 score after 3 months (Lequerre 
te al. 2006). A selected set of 8 gene transcripts (MTCBP1, AKAP9, RASGRP3, PTPN12, 
RSP28, HLA-DPB1, MRPL22 and EPS15) allowed them to predict the response with a 
sensitivity of 80% and a specificity of 100%. Julia and colleagues performed a gene 
expression analysis using a 47k gene bead array on whole blood RNA samples from 43 RA 
patients starting infliximab therapy (training set 29 and validation set 14) (Julia et al., 2009a). 
The clinical response was determined at week 14 using the EULAR criteria. They found an 8 
gene classifier consisting of HLA-DRB3, SH2D1B, GNLY, CAMP, SLC2A3, IL2RB, MXD4 
and TLR5 that predicted response with a sensitivity of 91.6% and specificity of 50%. In 
parallel, they observed a significantly higher number of CD4+CD25+ cells (i.e. regulatory T 
cells) in the responder group compared to the non responder group at baseline. Tanino and 
colleagues studied whole blood of 68 patients (training set 42 and validation set 26) using a 
44k gene microarrays to study. They measured EULAR response criteria at week 14 and 
discovered a 10 transcript biomarker set consisting of PSPH, CLGN, C21orf58, TBC1D8, 
LOC643981, ATP51, ANKRD55, TMEM141 and an EST (A_32_P1144), that had a positive 
predictive value of 80% and a negative predictive value of 44.4% (Tinino et al., 2009). 
Bienkowska and colleagues constructed a predictor based on 8 gene (CLTB, MXRA7, 
CXorf52, COL4A3BP, YIPF6, BOD1L, SFRS2 and PGK1) using PBMC of 46 RA patients prior 
to the start of adalimumab, etanercept, or infliximab. Response status at 14 weeks was based 
on EULAR criteria (Bienkowska et al. 2009). The accuracy (86%), sensitivity and specificity 
of the predictor is confirmed by an independent validation data set of 11 patients. 
Stuhlmuller and colleagues identified a predictor for adalimumab monotherapy using 
purified monocytes from 77 RA patients (training set of 7 patients and validation set of 70 
patients). Clinical outcome was based on the ACR response >20 criteria. They identified 
CD11c as predictive marker for adalumimab monotherapy (sensitivity 100% and specificity 
91.7%). However, CD11c was not predictive of response to adalumimab in combination with 
MTX (Stuhlmuller et al. 2010). 
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An important conclusion is that the study results are inconsistent and that the predictive 
genes from the different studies showed no overlap. How relevant this is for proper 
prediction and whether this is the consequence of differences in cell source, technological 
variation (e.g. array platform), data analysis system used, differences in study populations 
and/or differences in clinical management of the patients remains to be determined. Clearly 
there is a high need for independent validation and standardization in protocols and 
technology to understand the basis for the varying results. 
3.4 Pharmacogenomics of anakinra 
Anakinra is an IL-1-receptor that neutralizes IL-1 activity. Anakinra has proven effective in 
reducing joint inflammation, pain and bone destruction. However, as with all therapies in 
RA a substantial percentage of patients do not respond to anakinra. A gene expression study 
of PBMC of 32 patients (training set of 14 patients and validation set of 18 patients) using an 
in-house made microarray with a complexity of 10,000 genes identified a 7 gene set 
(GTF2F2, CCT3, CROT, HNRPA3, ARL15, TMED5, NRG3) that proofed capable to identify 
responders and non-responders with a sensitivity of 80% and a specificity of 87.5% based on 
the ΔDAS28>1.2 criteria (Bansard et al., 2011). Strikingly, there was no overlap between 
genes that were differentially expressed between anakinra and infliximab specific 
responders and non-responders. (Lequerre et al. 2006) that would be expected based on the 
crossregulation of IL-1 and TNF. (Lequerre et al. 2006) These results are promising but 
require validation in a larger independent cohort. 
3.5 Pharmacogenomics of rituximab 
B cell depletion therapy via rituximab (an anti-CD20 antibody) was shown to be highly 
effective for suppression of disease activity in RA (Edwards et al., 2004 ). CD20 is expressed 
on immature to mature B cells, as well as memory cells, but not on stem cells or precursor 
cells and, importantly, antibody producing plasma cells. Currently, rituximab is generally 
used after failure of at least one TNF antagonist. Clinical studies have demonstrated that not 
all patients show a favorable response to rituximab therapy. Especially the fact that 
rituximab directly depletes specific B cell populations in all patients treated, irrespective of 
clinical outcome, has raised questions regarding the mechanism of action. 
3.5.1 Pharmacodynamics of rituximab 
Gene expression profiling on whole blood cells of 13 RA patients demonstrated that 
pharmacological responses under the influence of rituximab treatment are highly 
heterogeneous between patients (Vosslamber et al. 2011). A difference in the kinetics of only 
a cluster of type I IFN-response genes during rituximab treatment that distinguishes 
responders from non-responders was observed. Responders exhibited an increase in IFN-
response activity after three months treatment with rituximab, whereas the IFN-response 
activity remained stable during treatment in the non-responders. Thus, whereas rituximab 
depletes B cells in all patients treated irrespective of their clinical response, gene expression 
data show that a drug-induced increase of type I IFN-response activity is associated with 
clinical response. Gutierrez-Roelens and colleagues showed that immunoglobulin genes and 
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complexity, suggesting the use of microdissected cell population for explorative genomic 
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studies made clear that identification of predictors in the blood compartment is not trivial. 
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Lequerre and colleagues report promising results of a study with 33 patients (13 patients in 
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sensitivity of 80% and a specificity of 100%. Julia and colleagues performed a gene 
expression analysis using a 47k gene bead array on whole blood RNA samples from 43 RA 
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The clinical response was determined at week 14 using the EULAR criteria. They found an 8 
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discovered a 10 transcript biomarker set consisting of PSPH, CLGN, C21orf58, TBC1D8, 
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genes involved in chemotaxis, leukocyte activation, and immune responses were 
dowregulated in the synovium at 3 months after the start of therapy (Gutierrez et al., 2011). 
3.5.2 Prediction of response to rituximab 
Gene expression studies were also performed to search for molecular biomarkers present in 
RA patients before the start of treatment in relation to the clinical outcome. Julia and 
colleagues studied whole blood, T cell and B cell profiles of 9 RA patients (Julia et al., 2009). 
The clinical outcome was determined using the relative improvement of DAS28 activity 
(relDAS28) after 24 weeks. Several genes were identified that were differential expressed 
between responders and non-responders at baseline (eg. ARG1, TRAF-1 and TLR4). In 
another study it was observed that the clinical outcome (based on ΔDAS28 and EULAR 
criteria) to rituximab is significantly associated with the IFN-response activity prior to the 
start of treatment (Vosslamber et al., 2011). Good responders have a low or absent IFN-
response activity at baseline, whereas non-responders have an activated type I IFN-systems 
before the start of treatment. During therapy the IFN-activity increases in the IFNlow patients 
and remains stable in the IFNhigh patients. The association between baseline type I IFN levels 
and clinical response is in line with previous findings wherein it was demonstrated in two 
different cohorts (n=20 and n=31) that patients with a low IFN signature had a significantly 
greater reduction in the DAS28 and more often achieved a EULAR response at weeks 12 and 
24 (Thurlings et al., 2010). The clinical utility of the IFN-signature to predict non-responders 
was demonstrated in an independent study by Receiver Operating Characteristic (ROC)-
curve characteristics analyses (unpublished observation).  
Overall the above studies demonstrate that it may be feasible to select gene-expression 
based prognostic biomarkers for rituximab response outcome from the peripheral blood that 
have clinical relevance.  
4. Gene expression in the preclinical (asymptomatic) phase of RA  
One of the main goals in the prevention of the disease lies in early diagnosis followed by 
timely start of effective treatment in order to induce remission. Ideally, early diagnosis in 
the asymptomatic/preclinical phase is required. Several studies have documented the 
appearance of anti–citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) 
prior to the onset of RA (Rantapaa-Dahlqvist et al., 2003; Nielen et al., 2004)  
The results of those studies indicate that ACPA and/or RF may serve as predictive 
biomarkers for the development for RA, which would allow the selection of candidates for 
preventive therapy. However, because RA does not ultimately develop in all ACPA and/or 
RF-positive individuals, the requirements to drive this process are likely to be different 
between individuals who are at risk (Klareskog et al., 2004). Hence, either additional factors 
are needed to result in a chronic inflammatory response ultimately leading to RA or some 
individuals may have a protective immune profile which suppresses disease development 
despite the presence of autoantibodies. The pathogenic or protective immune response 
might be selectively induced in susceptible individuals (Klareskog et al., 2004). It was 
suggested that increased levels of pro-inflammatory cytokines and/or chemokines are 
associated with the generation of ACPA as amplifiers of inflammatory responses (Rantapaa-
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Dahlqvist, et al., 2007). The chemotactic activity could be related to cell migration. However, 
the exact nature of the pathogenic and/or protective response remains to be determined. 
4.1 Gene expression profiles predict arthritis development, independent of ACPA 
levels 
Gene expression profiling blood samples of persons at risk who do and who do not develop 
RA, revealed new insights in the pathogenic and protective mechanisms in the pre-clinical 
phase of RA. Gene expression signatures playing either a pathogenic or a protective role 
were identified in whole blood transcriptome of ACPA/RF positive patients at risk for RA. 
A total of 109 ACPA/RF positive arthralgia patients at risk for RA were clinically followed 
for progression to arthritis up to 5 years following inclusion, and clinical features were 
compared to whole genome expression profiles (Van Baarsen et al. 2010a). 
Initial comparison of whole genome expression profiles of 19 autoantibody positive 
arthralgia patients at inclusion and healthy subject already revealed a marked increase in 
several immune-related processes in the arthralgia patients. A total of 554 genes were 
identified whose transcript levels deviated more than two-fold from the median expression 
level in at least four patients. Two-way hierarchical cluster analysis on these 554 
differentially expressed genes clearly indicated that the autoantibody positive arthralgia 
patients were separated in different subgroups. Pathway-level analysis revealed that these 
gene clusters represent genes involved in different modes of immune activation e.g. IFN-
response activity, B- cell mediated immunity, and chemokine and cytokine mediated 
signaling. These results were validated in an independent cohort of 90 arthralgia patients 
again showing considerable heterogeneity among the at risk individuals. 
Interim follow-up analysis revealed that 20 autoantibody positive arthralgia patients out of 
the 109 patients followed had developed arthritis after a median of 7 months (IQR 4-15; 
median follow-up of all patients is 30 [IQR 22-39] months) in a median of 3 joints (IQR 3-5). 
Analyzing the distribution of arthritis converters (follow-up time of 12 months (n=102) and 
corrected for ACPA levels) over the different subgroups revealed that the subgroup that is 
characterized by an increased expression of genes involved in IFN-mediated immunity and 
cytokine-chemokine mediated immunity, is associated with arthritis development (OR 21.0; 
95% C.I. 2.8-156.1; P=0.003) while the subgroup that is characterized by a relative increased 
expression of genes involved in B-cell mediated immunity is associated with absence of 
arthritis (OR 0.38; 95% C.I. 0.21-0.70; P=0.002).  
It is speculated that the IFN response programme could be associated with activation of 
immature monocyte-derived DCs, which regulate deletion of autoreactive lymphocytes. 
Subsequently, IFN-matured DCs may activate autoreactive T cells, leading to autoreactive B-
cell development, representing the first level of autoimmunity. Loss of tolerance may lead to 
autoantibody production. The decreased B cell gene expression with concomitant increased 
chemokine activity in the blood of at risk patients who converted to RA may be a 
consequence of extravasation of lymphocytes from the blood to sites of inflammation 
and/or lymphoid organs. 
Collectively, these analyses reveal that autoantibody positive arthralgia patients with high 
expression of genes involved in IFN-mediated immunity or chemokine/cytokine mediated 
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genes involved in chemotaxis, leukocyte activation, and immune responses were 
dowregulated in the synovium at 3 months after the start of therapy (Gutierrez et al., 2011). 
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The clinical outcome was determined using the relative improvement of DAS28 activity 
(relDAS28) after 24 weeks. Several genes were identified that were differential expressed 
between responders and non-responders at baseline (eg. ARG1, TRAF-1 and TLR4). In 
another study it was observed that the clinical outcome (based on ΔDAS28 and EULAR 
criteria) to rituximab is significantly associated with the IFN-response activity prior to the 
start of treatment (Vosslamber et al., 2011). Good responders have a low or absent IFN-
response activity at baseline, whereas non-responders have an activated type I IFN-systems 
before the start of treatment. During therapy the IFN-activity increases in the IFNlow patients 
and remains stable in the IFNhigh patients. The association between baseline type I IFN levels 
and clinical response is in line with previous findings wherein it was demonstrated in two 
different cohorts (n=20 and n=31) that patients with a low IFN signature had a significantly 
greater reduction in the DAS28 and more often achieved a EULAR response at weeks 12 and 
24 (Thurlings et al., 2010). The clinical utility of the IFN-signature to predict non-responders 
was demonstrated in an independent study by Receiver Operating Characteristic (ROC)-
curve characteristics analyses (unpublished observation).  
Overall the above studies demonstrate that it may be feasible to select gene-expression 
based prognostic biomarkers for rituximab response outcome from the peripheral blood that 
have clinical relevance.  
4. Gene expression in the preclinical (asymptomatic) phase of RA  
One of the main goals in the prevention of the disease lies in early diagnosis followed by 
timely start of effective treatment in order to induce remission. Ideally, early diagnosis in 
the asymptomatic/preclinical phase is required. Several studies have documented the 
appearance of anti–citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) 
prior to the onset of RA (Rantapaa-Dahlqvist et al., 2003; Nielen et al., 2004)  
The results of those studies indicate that ACPA and/or RF may serve as predictive 
biomarkers for the development for RA, which would allow the selection of candidates for 
preventive therapy. However, because RA does not ultimately develop in all ACPA and/or 
RF-positive individuals, the requirements to drive this process are likely to be different 
between individuals who are at risk (Klareskog et al., 2004). Hence, either additional factors 
are needed to result in a chronic inflammatory response ultimately leading to RA or some 
individuals may have a protective immune profile which suppresses disease development 
despite the presence of autoantibodies. The pathogenic or protective immune response 
might be selectively induced in susceptible individuals (Klareskog et al., 2004). It was 
suggested that increased levels of pro-inflammatory cytokines and/or chemokines are 
associated with the generation of ACPA as amplifiers of inflammatory responses (Rantapaa-
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Dahlqvist, et al., 2007). The chemotactic activity could be related to cell migration. However, 
the exact nature of the pathogenic and/or protective response remains to be determined. 
4.1 Gene expression profiles predict arthritis development, independent of ACPA 
levels 
Gene expression profiling blood samples of persons at risk who do and who do not develop 
RA, revealed new insights in the pathogenic and protective mechanisms in the pre-clinical 
phase of RA. Gene expression signatures playing either a pathogenic or a protective role 
were identified in whole blood transcriptome of ACPA/RF positive patients at risk for RA. 
A total of 109 ACPA/RF positive arthralgia patients at risk for RA were clinically followed 
for progression to arthritis up to 5 years following inclusion, and clinical features were 
compared to whole genome expression profiles (Van Baarsen et al. 2010a). 
Initial comparison of whole genome expression profiles of 19 autoantibody positive 
arthralgia patients at inclusion and healthy subject already revealed a marked increase in 
several immune-related processes in the arthralgia patients. A total of 554 genes were 
identified whose transcript levels deviated more than two-fold from the median expression 
level in at least four patients. Two-way hierarchical cluster analysis on these 554 
differentially expressed genes clearly indicated that the autoantibody positive arthralgia 
patients were separated in different subgroups. Pathway-level analysis revealed that these 
gene clusters represent genes involved in different modes of immune activation e.g. IFN-
response activity, B- cell mediated immunity, and chemokine and cytokine mediated 
signaling. These results were validated in an independent cohort of 90 arthralgia patients 
again showing considerable heterogeneity among the at risk individuals. 
Interim follow-up analysis revealed that 20 autoantibody positive arthralgia patients out of 
the 109 patients followed had developed arthritis after a median of 7 months (IQR 4-15; 
median follow-up of all patients is 30 [IQR 22-39] months) in a median of 3 joints (IQR 3-5). 
Analyzing the distribution of arthritis converters (follow-up time of 12 months (n=102) and 
corrected for ACPA levels) over the different subgroups revealed that the subgroup that is 
characterized by an increased expression of genes involved in IFN-mediated immunity and 
cytokine-chemokine mediated immunity, is associated with arthritis development (OR 21.0; 
95% C.I. 2.8-156.1; P=0.003) while the subgroup that is characterized by a relative increased 
expression of genes involved in B-cell mediated immunity is associated with absence of 
arthritis (OR 0.38; 95% C.I. 0.21-0.70; P=0.002).  
It is speculated that the IFN response programme could be associated with activation of 
immature monocyte-derived DCs, which regulate deletion of autoreactive lymphocytes. 
Subsequently, IFN-matured DCs may activate autoreactive T cells, leading to autoreactive B-
cell development, representing the first level of autoimmunity. Loss of tolerance may lead to 
autoantibody production. The decreased B cell gene expression with concomitant increased 
chemokine activity in the blood of at risk patients who converted to RA may be a 
consequence of extravasation of lymphocytes from the blood to sites of inflammation 
and/or lymphoid organs. 
Collectively, these analyses reveal that autoantibody positive arthralgia patients with high 
expression of genes involved in IFN-mediated immunity or chemokine/cytokine mediated 
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immunity combined with a decreased expression of B-cell markers are more likely to 
develop arthritis.  
5. Gene expression and genetics in RA 
Sugino and colleagues studied the correlation between the RA susceptibility genes from 
genome-wide association studies (GWAS) - namely, CD244, PADI4, SLC22A2, PTPN22, 
CTLA4, TRF1/C5, CD40, CCL21 and STAT4 (Sugino et al., 2010). Gene expression analysis 
gene expression analysis in RA patients and healthy individuals from a Asian (Japanese) 
cohort showed that the expressions of four of these genes (CD244, PADI4, SLC22A2, and 
PTPN22) were significantly higher in RA patients than in healthy individuals, whereas 
STAT4 expression was significantly downregulated in the RA group. Data on the 
upregulated genes is in agreement with results from in vitro studies, which revealed the 
individual upregulation of CD244, PADI4, SLC22A2, and PTPN22 by the mutant alleles. 
6. Systems biology 
Unique to transcriptome analyses is the identification of gene signatures that represent 
biological networks that are relevant in disease pathogenesis and thus provide a starting 
point for a systems biology approach, i.e. a computational modeling approach aimed to 
understand the structure and dynamics of cellular and organismal functions. Successive 
research activities on these networks, together with approaches using complementary 
platforms such as (epi)genetics, multiplex fluorescence-activated cell sorting and 
advanced metabolomics/proteomics, will provide a complete insight into the mechanism 
and other network components of processes and pathways relevant to disease. Thus, 
besides identifying clinically relevant transcriptome markers, DNA-microarray 
technology provides a basis for an evidence-based systems biology approach to delineate 
pathogenic processes and reveal other relevant markers. Meta-analysis methods will be 
instrumental in helping to select those exploratory markers for further biomarker 
validation, which will pave the way for clinical development and benefit patients. Wu and 
colleagues devised a method to construct a systemic network of interactions of the 
processes ongoing in patients affected by RA (Wu et al., 2010) . The network is based on 
high-throughput data from gene expression profiling and other technology platforms, 
refined semi-automatically with carefully curated literature-based information. This 
global network has then been topologically analysed, as a whole and tissue-specifically, in 
order to translate the experimental molecular connections into topological motifs 
meaningful in the identification of tissue-specific markers and targets in the diagnosis, 
and possibly in the therapy, of RA. They demonstrated some nodes in the network that 
prove to be topologically important, in particular AKT2, IL6, MAPK1 and TP53. Moreover 
they suggest CRKL as a novel potentially relevant molecule for the diagnosis or treatment 
of RA. This type of finding proves that the massive amounts of data from high-
throughput technologies like gene expression sources create an excellent basis for in silico 
analyses able to produce highly refined hypotheses, based on vast experimental data, to 
be tested further and more efficiently. The network is freely available in a standardised 
and easily exportable .xml Cell Designer format at 
'www.picb.ac.cn/ClinicalGenomicNTW/temp.html' and 'www.celldesigner.org' 
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Moreover, Xing and colleagues described a data analysis strategy for predicting gene 
expression measures using a combination of comprehensive genotyping, whole blood gene 
expression profiles and the component of clinical measures (Xing et al., 2011). They 
identified a total of 22 genes that may have a role in modulating DAS28 score; 6 genes 
(including CD86, a T-cell costimulatory molecule) could be an alternative target to TNF-
blockers and 59 genes are predicted to affect tender and swollen joints. The genes and 
pathways identified in the networks ensembles represent are potentially promising targets 
for future investigations.  
7. Concluding remarks  
Gene expression profiling approaches have fuelled insight into the complexity of RA 
pathogenesis and provide a framework to identify pathogenic processes and biomarkers as 
promising tool for future clinical applications. Molecular profiling of blood cells and tissue 
samples of RA patients has already revealed important information, such as e.g. an 
activated IFN-system in a subset of patients, that is likely to contribute to the spectrum of 
diversity in RA. Future efforts are directed on integration of data from different technology 
platforms combined with information from literature towards a systems biology approach 
to construct a systemic network of interactions between molecular interactions that reflect 
disease processes that are ongoing in RA. 
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immunity combined with a decreased expression of B-cell markers are more likely to 
develop arthritis.  
5. Gene expression and genetics in RA 
Sugino and colleagues studied the correlation between the RA susceptibility genes from 
genome-wide association studies (GWAS) - namely, CD244, PADI4, SLC22A2, PTPN22, 
CTLA4, TRF1/C5, CD40, CCL21 and STAT4 (Sugino et al., 2010). Gene expression analysis 
gene expression analysis in RA patients and healthy individuals from a Asian (Japanese) 
cohort showed that the expressions of four of these genes (CD244, PADI4, SLC22A2, and 
PTPN22) were significantly higher in RA patients than in healthy individuals, whereas 
STAT4 expression was significantly downregulated in the RA group. Data on the 
upregulated genes is in agreement with results from in vitro studies, which revealed the 
individual upregulation of CD244, PADI4, SLC22A2, and PTPN22 by the mutant alleles. 
6. Systems biology 
Unique to transcriptome analyses is the identification of gene signatures that represent 
biological networks that are relevant in disease pathogenesis and thus provide a starting 
point for a systems biology approach, i.e. a computational modeling approach aimed to 
understand the structure and dynamics of cellular and organismal functions. Successive 
research activities on these networks, together with approaches using complementary 
platforms such as (epi)genetics, multiplex fluorescence-activated cell sorting and 
advanced metabolomics/proteomics, will provide a complete insight into the mechanism 
and other network components of processes and pathways relevant to disease. Thus, 
besides identifying clinically relevant transcriptome markers, DNA-microarray 
technology provides a basis for an evidence-based systems biology approach to delineate 
pathogenic processes and reveal other relevant markers. Meta-analysis methods will be 
instrumental in helping to select those exploratory markers for further biomarker 
validation, which will pave the way for clinical development and benefit patients. Wu and 
colleagues devised a method to construct a systemic network of interactions of the 
processes ongoing in patients affected by RA (Wu et al., 2010) . The network is based on 
high-throughput data from gene expression profiling and other technology platforms, 
refined semi-automatically with carefully curated literature-based information. This 
global network has then been topologically analysed, as a whole and tissue-specifically, in 
order to translate the experimental molecular connections into topological motifs 
meaningful in the identification of tissue-specific markers and targets in the diagnosis, 
and possibly in the therapy, of RA. They demonstrated some nodes in the network that 
prove to be topologically important, in particular AKT2, IL6, MAPK1 and TP53. Moreover 
they suggest CRKL as a novel potentially relevant molecule for the diagnosis or treatment 
of RA. This type of finding proves that the massive amounts of data from high-
throughput technologies like gene expression sources create an excellent basis for in silico 
analyses able to produce highly refined hypotheses, based on vast experimental data, to 
be tested further and more efficiently. The network is freely available in a standardised 
and easily exportable .xml Cell Designer format at 
'www.picb.ac.cn/ClinicalGenomicNTW/temp.html' and 'www.celldesigner.org' 
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Moreover, Xing and colleagues described a data analysis strategy for predicting gene 
expression measures using a combination of comprehensive genotyping, whole blood gene 
expression profiles and the component of clinical measures (Xing et al., 2011). They 
identified a total of 22 genes that may have a role in modulating DAS28 score; 6 genes 
(including CD86, a T-cell costimulatory molecule) could be an alternative target to TNF-
blockers and 59 genes are predicted to affect tender and swollen joints. The genes and 
pathways identified in the networks ensembles represent are potentially promising targets 
for future investigations.  
7. Concluding remarks  
Gene expression profiling approaches have fuelled insight into the complexity of RA 
pathogenesis and provide a framework to identify pathogenic processes and biomarkers as 
promising tool for future clinical applications. Molecular profiling of blood cells and tissue 
samples of RA patients has already revealed important information, such as e.g. an 
activated IFN-system in a subset of patients, that is likely to contribute to the spectrum of 
diversity in RA. Future efforts are directed on integration of data from different technology 
platforms combined with information from literature towards a systems biology approach 
to construct a systemic network of interactions between molecular interactions that reflect 
disease processes that are ongoing in RA. 
8. References 
Aidinis V, Carninci P, Armaka M, et al., Cytoskeletal rearrangements in synovial fibroblasts 
as a novel pathophysiological determinant of modeled rheumatoid arthritis. PLoS 
Genet 2005, 1:e48. 
Badot V, Galant C, Nzeusseu Toukap A, et al., Gene expression profiling in the synovium 
identifies a predictive signature of absence of response to adalimumab therapy in 
rheumatoid arthritis. Arthritis Res Ther. 2009;11(2):R57.  
Bansard C, Lequerre T, Derambure C, et al., Gene profiling predicts rheumatoid arthritis 
responsiveness to IL-1Ra (anakinra). Rheumatology 2011;50:283-292 
Batliwalla FM, Baechler EC, Xiao X, et al., Peripheral blood gene expression profiling in 
rheumatoid arthritis. Genes Immun 2005, 6:388-397. 
Batliwalla F, Li W, Bienkowska J, Damle A, Khalili H, Hueber W, Allaire M, Mcrann M, 
Robinson W, Kern M, Carulli JP, Gregersen PK: Differential peripheral blood gene 
expression profile of rheumatoid arthritis in response to anti-TNF treatment 
[abstract]. Arthritis Rheum 2007, 56:S700 
Baechler EC, Batliwalla FM, Karypis G, et al., Interferon-inducible gene expression signature 
in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 
2003, 100:2610-2615 
Bienkowska JR, Dalgin GS, Batliwalla F, et al., Convergent Random Forest predictor: 
methodology for predicting drug response from genome-scale data applied to anti-
TNF response. Genomics. 2009 Dec;94(6):423-32. 
Bos CL, van Baarsen LGM, Timmer TCG, et al., Molecular subtypes of systemic sclerosis in 
association with anti-centromer antibodies and digital ulcers. Genes Immun. 2009 
Apr;10(3):210-8 
Bovin LF, Rieneck K, Workman C, Nielsen H, Sorensen SF, Skjodt H, Florescu A, Brunak S, 
Bendtzen K: Blood cell gene expression profiling in rheumatoid arthritis. 
Discriminative genes and effect of rheumatoid factor. Immunol Lett 2004, 93:217-226. 
 
Insights and Perspectives in Rheumatology 
 
58
Brazma A, Hingamp P, Quackenbush J, et al., Minimum information about a microarray 
experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001; 
29(4):365-371 
Brouty-Bové D, Pottin-Clemenceau C, Doucet C et al., Chemokines and CD40 expression in 
human fibroblasts. Eur. J. Immunol. 2000;30(3):914-919 
Lu C, Xiao C, Chen G, et al., Cold and heat pattern of rheumatoid arthritis in traditional 
Chinese medicine: distinct molecular signatures indentified by microarray 
expression profiles in CD4-positive T cell. Rheumatol Int. 2010, [E-pub ahead] 
Devauchelle V, Marion S, Cagnard N, et al., DNA microarray allows molecular profiling of 
rheumatoid arthritis and identification of pathophysiological targets. Genes Immun 
2004, 5:597-608. 
Edwards JC, Szczepanski L, Szechinski J, et al., Efficacy of B-cell-targeted therapy with 
rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350:2572-2581. 
Firestein GS and Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis?: II. 
T cell-independent mechanisms from beginning to end. Arthritis Rheum. 2002 
Feb;46(2):298-308. 
Gallagher J, Howlin J, McCarthy C, et al., Identification of Naf1/ABIN-1 among TNF-alpha-
induced expressed genes in human synoviocytes using oligonucleotide 
microarrays. FEBS Lett. 2003 Sep 11;551(1-3):8-12. 
Gallagher J, Howlin J, McCarthy C, et al., Identification of Naf1/ABIN-1 among TNF-alpha-
induced expressed genes in human synoviocytes using oligonucleotide 
microarrays. FEBS Lett 2003, 551:8-12. 
Galligan CL, Baig E, Bykerk V, et al., Distinctive gene expression signatures in rheumatoid 
arthritis synovial tissue fibroblast cells: correlates with disease activity. Genes 
Immun. 2007 Sep;8(6):480-491 
Guttierrez-Roelens I, Galant C, Theate I, et al., Rituximab treatment induces the expression 
of genes involved in healing processes in the rheumatoid arthritis synovium. 
Arthritis Rheum. 2011 May;63(5):1246-1254.  
Heller RA, Schena M, Chai A, et al. Discovery and analysis of inflammatory disease-related 
genes using cDNA microarrays. Proceedings of the National Academy of Sciences 
of the United States of America 1997; 94: 2150–2155 
Higgs BW, Liu Z, White B, et al., Patients with systemic lupus erythematosus, myositis, 
rheumatoid arthritis and scleroderma share activation of a common type I 
interferon pathway. Ann Rheum Dis. 2011 Jul 28. [Epub ahead of print] 
Hirohata S, Yanagida T, Nampei A et al., Enhanced generation of endothelial cells from 
CD34+ cells of the bone marrow in rheumatoid arthritis: possible role in synovial 
neovascularization. Arthritis Rheum 2004;50, 3888-3896 
Hogaboam CM, Steinhauser ML, Chensue SW et al., Novel roles for chemokines and 
fibroblasts in interstitial fibrosis. Kidney Int. 1998 54(6):2152-2159 
Hueber W, Tomooka BH, Batliwalla F, et al., Blood autoantibody and cytokine profiles 
predict response to anti-TNF therapy in rheumatoid arthritis. Arthritis Res Ther 
2009, 11:R76. 
Huber R, Hummert C, Gausmann U, et al., Identification of intra-group, inter-individual, 
and gene-specific variances in mRNA expression profiles in the rheumatoid 
arthritis synovial membrane. Arthritis Res Ther. 2008;10(4):R98 
Jiang M, Xiao C, Chen G, et al., Correlation between cold and hot pattern in traditional 
Chinese medicine and gene expression profiles in rheumatoid arthritis. Front Med. 
2011 ,5;:219-228. 
 
Gene Expression Profiling in Rheumatoid Arthritis 
 
59 
Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ. 
Elevated levels of inflammatory cytokines in bone marrow of patients with 
rheumatoid arthritis and anemia of chronic disease. J Rheumatol. 1997;24, 241-245 
Julià A, Barceló M, Erra A, Palacio C, Marsal S. Identification of candidate genes for 
rituximab response in rheumatoid arthritis patients by microarray expression 
profiling in blood cells. Pharmacogenomics 2009a, 10.1697-708 
Julià A, Erra A, Palacio C, et al., An eight-gene blood expression profile predicts the 
response to infliximab in rheumatoid arthritis. PLoS One. 2009b Oct 22;4(10):e7556. 
Kasperkovitz PV, Timmer T, Verbeet NL, et al., Fibroblast-like synoviocytes show the 
imprint of synovial tissue heterogeneity in rheumatoid arthritis: Evidence for a link 
between the presence of myofibroblast-like cells and high inflammatory synovitis. 
Arthr Rheum. (2005) 52:430-441  
Kasperkovitz PV, Verbeet NL, Smeets TJ, et al., Activation of the STAT1 pathway in 
rheumatoid arthritis. Ann Rheum Dis. 2004; 63(3):233-239 
Kato H, Matsumine A, Wakabayashi T, et al., Large-scale expression profiles, differentially 
repressed in osteoarthritis synovium of the knee joint using cDNA microarray 
technology. Biomarkers 2007;12:384-402 
Klareskog L, Alfredsson L, Rantapaa-Dahlqvist S, et al., What precedes development of 
rheumatoid arthritis? Ann Rheum Dis 2004; 63 Suppl 2: ii28–31. 
Koczan D, Drynda S, Hecker M, et al., Molecular discrimination of responders and 
nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. 
Arthritis Res Ther. 2008;10(3):R50. 
Lee HM, Sugino H, Aoki C, et al., Abnormal networks of immune response-related 
molecules in bone marrow cells from patients with rheumatoid arthritis as revealed 
by DNA microarray analysis. Arthritis res Ther. 2011 Jun 16;13(3):R89 
Lequerré T, Gauthier-Jauneau AC, Bansard C, et al., Gene profiling in white blood cells 
predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther. 
2006;8(4):R105 
Lequerré T, Bansard C, Vittecoq O, et al., Early and long-standing rheumatoid arthritis: 
distinct molecular signatures identified by gene-expression profiling in synovia. 
Arthritis Res Ther. 2009;11(3):R99 
Liao H, Wu J, Kuhn E, et al., Use of mass spectrometry to identify protein biomarkers of 
disease severity in the synovial fluid and serum of patients with rheumatoid 
arthritis. Arthritis Rheum. 2004, 50: 3792–3803 
Lindberg J, af Klint E, Ulfgren AK, et al., Variability in synovial inflammation in rheumatoid 
arthritis investigated by microarray technology. Arthritis Res Ther 2006a, 8:R47 
Lindberg J, af Klint E, Catrina AI, et al., Effect of infliximab on mRNA expression profiles in 
synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006b, 8:R179. 
Lindberg J, Wijbrandts CA, van Baarsen LG, et al., The gene expression profile in the 
synovium as a predictor of the clinical response to infliximab treatment in 
rheumatoid arthritis. PLoS One. 2010 Jun 25;5(6):e11310. 
Liu Z, Sokka T, Maas K, et al., Prediction of Disease Severity in Patients with early 
rheumatoid arthritis by gene expression profiling. Human Genomics and 
Proteomics 2009,484351 
Maas K, Chen H, Shyr Y, et al., Shared gene expression profiles in individuals with 
autoimmune disease and unaffected first-degree relatives of individuals with 
autoimmune disease. Hum Mol Genet 2005, 14:1305-1314. 
Mavragani CP, La DT, Stohl W, et al., Association of the response to tumor necrosis factor 
antagonists with plasma type I interferon activity and interferon-beta/alpha ratios 
 
Insights and Perspectives in Rheumatology 
 
58
Brazma A, Hingamp P, Quackenbush J, et al., Minimum information about a microarray 
experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001; 
29(4):365-371 
Brouty-Bové D, Pottin-Clemenceau C, Doucet C et al., Chemokines and CD40 expression in 
human fibroblasts. Eur. J. Immunol. 2000;30(3):914-919 
Lu C, Xiao C, Chen G, et al., Cold and heat pattern of rheumatoid arthritis in traditional 
Chinese medicine: distinct molecular signatures indentified by microarray 
expression profiles in CD4-positive T cell. Rheumatol Int. 2010, [E-pub ahead] 
Devauchelle V, Marion S, Cagnard N, et al., DNA microarray allows molecular profiling of 
rheumatoid arthritis and identification of pathophysiological targets. Genes Immun 
2004, 5:597-608. 
Edwards JC, Szczepanski L, Szechinski J, et al., Efficacy of B-cell-targeted therapy with 
rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004, 350:2572-2581. 
Firestein GS and Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis?: II. 
T cell-independent mechanisms from beginning to end. Arthritis Rheum. 2002 
Feb;46(2):298-308. 
Gallagher J, Howlin J, McCarthy C, et al., Identification of Naf1/ABIN-1 among TNF-alpha-
induced expressed genes in human synoviocytes using oligonucleotide 
microarrays. FEBS Lett. 2003 Sep 11;551(1-3):8-12. 
Gallagher J, Howlin J, McCarthy C, et al., Identification of Naf1/ABIN-1 among TNF-alpha-
induced expressed genes in human synoviocytes using oligonucleotide 
microarrays. FEBS Lett 2003, 551:8-12. 
Galligan CL, Baig E, Bykerk V, et al., Distinctive gene expression signatures in rheumatoid 
arthritis synovial tissue fibroblast cells: correlates with disease activity. Genes 
Immun. 2007 Sep;8(6):480-491 
Guttierrez-Roelens I, Galant C, Theate I, et al., Rituximab treatment induces the expression 
of genes involved in healing processes in the rheumatoid arthritis synovium. 
Arthritis Rheum. 2011 May;63(5):1246-1254.  
Heller RA, Schena M, Chai A, et al. Discovery and analysis of inflammatory disease-related 
genes using cDNA microarrays. Proceedings of the National Academy of Sciences 
of the United States of America 1997; 94: 2150–2155 
Higgs BW, Liu Z, White B, et al., Patients with systemic lupus erythematosus, myositis, 
rheumatoid arthritis and scleroderma share activation of a common type I 
interferon pathway. Ann Rheum Dis. 2011 Jul 28. [Epub ahead of print] 
Hirohata S, Yanagida T, Nampei A et al., Enhanced generation of endothelial cells from 
CD34+ cells of the bone marrow in rheumatoid arthritis: possible role in synovial 
neovascularization. Arthritis Rheum 2004;50, 3888-3896 
Hogaboam CM, Steinhauser ML, Chensue SW et al., Novel roles for chemokines and 
fibroblasts in interstitial fibrosis. Kidney Int. 1998 54(6):2152-2159 
Hueber W, Tomooka BH, Batliwalla F, et al., Blood autoantibody and cytokine profiles 
predict response to anti-TNF therapy in rheumatoid arthritis. Arthritis Res Ther 
2009, 11:R76. 
Huber R, Hummert C, Gausmann U, et al., Identification of intra-group, inter-individual, 
and gene-specific variances in mRNA expression profiles in the rheumatoid 
arthritis synovial membrane. Arthritis Res Ther. 2008;10(4):R98 
Jiang M, Xiao C, Chen G, et al., Correlation between cold and hot pattern in traditional 
Chinese medicine and gene expression profiles in rheumatoid arthritis. Front Med. 
2011 ,5;:219-228. 
 
Gene Expression Profiling in Rheumatoid Arthritis 
 
59 
Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ. 
Elevated levels of inflammatory cytokines in bone marrow of patients with 
rheumatoid arthritis and anemia of chronic disease. J Rheumatol. 1997;24, 241-245 
Julià A, Barceló M, Erra A, Palacio C, Marsal S. Identification of candidate genes for 
rituximab response in rheumatoid arthritis patients by microarray expression 
profiling in blood cells. Pharmacogenomics 2009a, 10.1697-708 
Julià A, Erra A, Palacio C, et al., An eight-gene blood expression profile predicts the 
response to infliximab in rheumatoid arthritis. PLoS One. 2009b Oct 22;4(10):e7556. 
Kasperkovitz PV, Timmer T, Verbeet NL, et al., Fibroblast-like synoviocytes show the 
imprint of synovial tissue heterogeneity in rheumatoid arthritis: Evidence for a link 
between the presence of myofibroblast-like cells and high inflammatory synovitis. 
Arthr Rheum. (2005) 52:430-441  
Kasperkovitz PV, Verbeet NL, Smeets TJ, et al., Activation of the STAT1 pathway in 
rheumatoid arthritis. Ann Rheum Dis. 2004; 63(3):233-239 
Kato H, Matsumine A, Wakabayashi T, et al., Large-scale expression profiles, differentially 
repressed in osteoarthritis synovium of the knee joint using cDNA microarray 
technology. Biomarkers 2007;12:384-402 
Klareskog L, Alfredsson L, Rantapaa-Dahlqvist S, et al., What precedes development of 
rheumatoid arthritis? Ann Rheum Dis 2004; 63 Suppl 2: ii28–31. 
Koczan D, Drynda S, Hecker M, et al., Molecular discrimination of responders and 
nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. 
Arthritis Res Ther. 2008;10(3):R50. 
Lee HM, Sugino H, Aoki C, et al., Abnormal networks of immune response-related 
molecules in bone marrow cells from patients with rheumatoid arthritis as revealed 
by DNA microarray analysis. Arthritis res Ther. 2011 Jun 16;13(3):R89 
Lequerré T, Gauthier-Jauneau AC, Bansard C, et al., Gene profiling in white blood cells 
predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther. 
2006;8(4):R105 
Lequerré T, Bansard C, Vittecoq O, et al., Early and long-standing rheumatoid arthritis: 
distinct molecular signatures identified by gene-expression profiling in synovia. 
Arthritis Res Ther. 2009;11(3):R99 
Liao H, Wu J, Kuhn E, et al., Use of mass spectrometry to identify protein biomarkers of 
disease severity in the synovial fluid and serum of patients with rheumatoid 
arthritis. Arthritis Rheum. 2004, 50: 3792–3803 
Lindberg J, af Klint E, Ulfgren AK, et al., Variability in synovial inflammation in rheumatoid 
arthritis investigated by microarray technology. Arthritis Res Ther 2006a, 8:R47 
Lindberg J, af Klint E, Catrina AI, et al., Effect of infliximab on mRNA expression profiles in 
synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006b, 8:R179. 
Lindberg J, Wijbrandts CA, van Baarsen LG, et al., The gene expression profile in the 
synovium as a predictor of the clinical response to infliximab treatment in 
rheumatoid arthritis. PLoS One. 2010 Jun 25;5(6):e11310. 
Liu Z, Sokka T, Maas K, et al., Prediction of Disease Severity in Patients with early 
rheumatoid arthritis by gene expression profiling. Human Genomics and 
Proteomics 2009,484351 
Maas K, Chen H, Shyr Y, et al., Shared gene expression profiles in individuals with 
autoimmune disease and unaffected first-degree relatives of individuals with 
autoimmune disease. Hum Mol Genet 2005, 14:1305-1314. 
Mavragani CP, La DT, Stohl W, et al., Association of the response to tumor necrosis factor 
antagonists with plasma type I interferon activity and interferon-beta/alpha ratios 
 
Insights and Perspectives in Rheumatology 
 
60
in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic 
cohort. Arthritis Rheum. 2010 Feb;62(2):392-401 
Mavragani CP, Crow MK. Activation of type I interferon pathway in primary Sjogren's 
syndrome. J Autoimmun 2010; 35:225-231. 
Mesko B, Poliska S, Szegedi A, et al., Peripheral blood gene expression patterns discriminate 
among chronic inflammatory diseases and healthy controls and identify novel 
targets. BMC Med Genomics. 2010 May 5;3:15 
Meugnier E, Coury F, Tebib J, et al., Gene expression profiling in peripheral blood cells of 
patients with rheumatoid arthritis in response to anti-TNF-alpha treatments. 
Physiol Genomics. 2011 Apr 12;43(7):365-371 
Nakamura N, Shimaoka Y, Tougan T, et al., Isolation and expression profiling of genes 
upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis 
patients. DNA Research. 2006;13, 169-183 
Neumann E, Riepl B, Knedla A, et al., Cell culture and passaging alters gene expression 
pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis 
Res Ther. 2010;12(3):R83.  
Nielen MM, van Schaardenburg D, Reesink HW et al., Specific autoantibodies precede the 
symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. 
Arthr Rheum 2004; 50, 380-386 
Nzeusseu TA, Galant C, Theate I, et al., Identification of distinct gene expression profiles in 
the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 
2007, 56:1579-1588. 
Ochi T, Hakomori S, Adachi M et al. The presence of a myeloid cell population showing 
strong reactivity with monoclonal antibody directed to difucosyl type 2 chain in 
epiphyseal bone marrow adjacent to joints affected with rheumatoid arthritis (RA) 
and its absence in the corresponding normal and non-RA bone marrow. J 
Rheumatology 1998;15, 1609-1615 
O'Hanlon TP, Rider LG, Gan L, et al., Gene expression profiles from discordant 
monozygotic twins suggest that molecular pathways are shared among multiple 
systemic autoimmune diseases. Arthritis Res Ther. 2011 Apr 26;13(2):R69. 
Olsen N, Sokka T, Seehorn CL, et al., A gene expression signature for recent onset 
rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 
2004,63;1387-1392 
Palucka AK, Blanck JP, Bennet L, et al., Cross-regulation of TNF and IFN-alpha in 
autoimmune diseases. Proc. Natl. Acad. Sci USA 2005;102,3372-3377 
Pohlers D, Beyer A, Koczan D, et al., Constitutive upregulation of the transforming growth 
factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther. 
2007;9(3):R59. 
Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated 
peptide and IgA rheumatoid factor predict the development of rheumatoid 
arthritis. Arthr Rheum 2003;48, 2741-2749  
Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte 
chemoattractant protein-1 expression in anti-citrulline antibody and 
immunoglobulin M rheumatoid factor positive subjects precedes onset of 
inflammatory response and development of overt rheumatoid arthritis. Ann 
Rheum Dis 2007; 66: 121–3. 
Sekiguchi N, Kawauchi S, Furuya T, et al., Messenger ribonucleic acid expression profile in 
peripheral blood cells from RA patients following treatment with an anti-TNF-
 
Gene Expression Profiling in Rheumatoid Arthritis 
 
61 
alpha monoclonal antibody, infliximab. Rheumatology (Oxford). 2008 
Jun;47(6):780-788. 
Sha N, Vannucci M, Brown PJ, et al.,. Gene selection in arthritis classification with large-
scale microarray expression profiles. Comp Funct Genomics. 2003;4(2):171-181.  
Smith RS, Smith TJ, Blieden TM, et al., Fibroblasts as sentinel cells. Synthesis of chemokines 
and regulation of inflammation. Am. J. Pathol. 1997; 151(2):317-322 
Szodoray P, Alex P, Frank MB, et al., A genome-scale assessment of peripheral blood B-cell 
molecular homeostasis in patients with rheumatoid arthritis. Rheumatology 
(Oxford). 2006 Dec;45(12):1466-1476. 
Taberner M, Scott KF, Weininger L, et al., Overlapping gene expression profiles in 
rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines 
interleukin-1 beta and tumor necrosis factor. Inflamm Res. 2005 Jan;54(1):10-6. 
Tan FK, Zhou X, Mayes MD, et al., Signatures of differentially regulated interferon gene 
expression and vasculotrophism in the peripheral blood cells of systemic sclerosis 
patients. Rheumatology (Oxford) 2006;45:694–702 
Stuhlmüller B, Häupl T, Hernandez MM, et al., CD11c as a transcriptional biomarker to 
predict response to anti-TNF monotherapy with adalimumab in patients with 
rheumatoid arthritis. Clin Pharmacol Ther. 2010; Mar;87(3):311-321 
Sugino H, Lee HM, Nishimoto N. DNA microarray analysis of rheumatoid arthritis 
susceptibility genes identified by genome-wide association studies. Arthritis Res 
Ther. 2010;12(2):401. Epub 2010 Mar 12. Erratum in: Arthritis Res Ther. 
2010;12(3):403. 
Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, Nakagawa S, Ono K., 
Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow 
serum of patients with rheumatoid arthritis.J Rheumatolog 1994, 21, 830-835 
Tanino M, Matoba R, Nakamura S, et al., Prediction of efficacy of anti-TNF biologic agent, 
infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome 
analysis of white blood cells. Biochem Biophys Res Commun. 2009 Sep 
18;387(2):261-5. 
Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J 
Immunol 2001;167:1072–1080. 
Teixeira VH, Olaso R, Martin-Magniette ML, et al., Transcriptome analysis describing new 
immunity and defense genes in peripheral blood mononuclear cells of rheumatoid 
arthritis patients. PLoS One. 2009 Aug 27;4(8):e6803. 
Thurlings RM, Boumans M, Tekstra J, et al., The relationship between the type I interferon 
signature and the response to rituximab in rheumatoid arthritis. Arthritis Rheum. 
2010, 62:3607-3614 
Timmer TC, Baltus B, Vondenhoff M, et al., Inflammation and ectopic lymphoid structures 
in rheumatoid arthritis synovial tissues dissected by genomics technology: 
identification of the interleukin-7 signaling pathway in tissues with lymphoid 
neogenesis. Arthritis Rheum 2007, 56:2492-2502. 
Tsubaki T, Arita N, Kawakami T, Shiratsuchi T, et al., Characterization of histopathology 
and gene-expression profiles of synovitis in early rheumatoid arthritis using 
targeted biopsy specimens. Arthritis Res Ther. 2005;7(4):R825-36. 
Turrel-Davin F, Tournadre A, Pachot A, et al., FoxO3a involved in neutrophil and T cell 
survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum 
Dis. 2010 Apr;69(4):755-760 
Ungethuem U, Haupl T, Witt H, et al., Molecular signatures and new candidates to target 
the pathogenesis of rheumatoid arthritis Physiol. Genomics 2010;42A:(4) 267-282 
 
Insights and Perspectives in Rheumatology 
 
60
in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic 
cohort. Arthritis Rheum. 2010 Feb;62(2):392-401 
Mavragani CP, Crow MK. Activation of type I interferon pathway in primary Sjogren's 
syndrome. J Autoimmun 2010; 35:225-231. 
Mesko B, Poliska S, Szegedi A, et al., Peripheral blood gene expression patterns discriminate 
among chronic inflammatory diseases and healthy controls and identify novel 
targets. BMC Med Genomics. 2010 May 5;3:15 
Meugnier E, Coury F, Tebib J, et al., Gene expression profiling in peripheral blood cells of 
patients with rheumatoid arthritis in response to anti-TNF-alpha treatments. 
Physiol Genomics. 2011 Apr 12;43(7):365-371 
Nakamura N, Shimaoka Y, Tougan T, et al., Isolation and expression profiling of genes 
upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis 
patients. DNA Research. 2006;13, 169-183 
Neumann E, Riepl B, Knedla A, et al., Cell culture and passaging alters gene expression 
pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis 
Res Ther. 2010;12(3):R83.  
Nielen MM, van Schaardenburg D, Reesink HW et al., Specific autoantibodies precede the 
symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. 
Arthr Rheum 2004; 50, 380-386 
Nzeusseu TA, Galant C, Theate I, et al., Identification of distinct gene expression profiles in 
the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 
2007, 56:1579-1588. 
Ochi T, Hakomori S, Adachi M et al. The presence of a myeloid cell population showing 
strong reactivity with monoclonal antibody directed to difucosyl type 2 chain in 
epiphyseal bone marrow adjacent to joints affected with rheumatoid arthritis (RA) 
and its absence in the corresponding normal and non-RA bone marrow. J 
Rheumatology 1998;15, 1609-1615 
O'Hanlon TP, Rider LG, Gan L, et al., Gene expression profiles from discordant 
monozygotic twins suggest that molecular pathways are shared among multiple 
systemic autoimmune diseases. Arthritis Res Ther. 2011 Apr 26;13(2):R69. 
Olsen N, Sokka T, Seehorn CL, et al., A gene expression signature for recent onset 
rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 
2004,63;1387-1392 
Palucka AK, Blanck JP, Bennet L, et al., Cross-regulation of TNF and IFN-alpha in 
autoimmune diseases. Proc. Natl. Acad. Sci USA 2005;102,3372-3377 
Pohlers D, Beyer A, Koczan D, et al., Constitutive upregulation of the transforming growth 
factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther. 
2007;9(3):R59. 
Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated 
peptide and IgA rheumatoid factor predict the development of rheumatoid 
arthritis. Arthr Rheum 2003;48, 2741-2749  
Rantapaa-Dahlqvist S, Boman K, Tarkowski A, Hallmans G. Up regulation of monocyte 
chemoattractant protein-1 expression in anti-citrulline antibody and 
immunoglobulin M rheumatoid factor positive subjects precedes onset of 
inflammatory response and development of overt rheumatoid arthritis. Ann 
Rheum Dis 2007; 66: 121–3. 
Sekiguchi N, Kawauchi S, Furuya T, et al., Messenger ribonucleic acid expression profile in 
peripheral blood cells from RA patients following treatment with an anti-TNF-
 
Gene Expression Profiling in Rheumatoid Arthritis 
 
61 
alpha monoclonal antibody, infliximab. Rheumatology (Oxford). 2008 
Jun;47(6):780-788. 
Sha N, Vannucci M, Brown PJ, et al.,. Gene selection in arthritis classification with large-
scale microarray expression profiles. Comp Funct Genomics. 2003;4(2):171-181.  
Smith RS, Smith TJ, Blieden TM, et al., Fibroblasts as sentinel cells. Synthesis of chemokines 
and regulation of inflammation. Am. J. Pathol. 1997; 151(2):317-322 
Szodoray P, Alex P, Frank MB, et al., A genome-scale assessment of peripheral blood B-cell 
molecular homeostasis in patients with rheumatoid arthritis. Rheumatology 
(Oxford). 2006 Dec;45(12):1466-1476. 
Taberner M, Scott KF, Weininger L, et al., Overlapping gene expression profiles in 
rheumatoid fibroblast-like synoviocytes induced by the proinflammatory cytokines 
interleukin-1 beta and tumor necrosis factor. Inflamm Res. 2005 Jan;54(1):10-6. 
Tan FK, Zhou X, Mayes MD, et al., Signatures of differentially regulated interferon gene 
expression and vasculotrophism in the peripheral blood cells of systemic sclerosis 
patients. Rheumatology (Oxford) 2006;45:694–702 
Stuhlmüller B, Häupl T, Hernandez MM, et al., CD11c as a transcriptional biomarker to 
predict response to anti-TNF monotherapy with adalimumab in patients with 
rheumatoid arthritis. Clin Pharmacol Ther. 2010; Mar;87(3):311-321 
Sugino H, Lee HM, Nishimoto N. DNA microarray analysis of rheumatoid arthritis 
susceptibility genes identified by genome-wide association studies. Arthritis Res 
Ther. 2010;12(2):401. Epub 2010 Mar 12. Erratum in: Arthritis Res Ther. 
2010;12(3):403. 
Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, Nakagawa S, Ono K., 
Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow 
serum of patients with rheumatoid arthritis.J Rheumatolog 1994, 21, 830-835 
Tanino M, Matoba R, Nakamura S, et al., Prediction of efficacy of anti-TNF biologic agent, 
infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome 
analysis of white blood cells. Biochem Biophys Res Commun. 2009 Sep 
18;387(2):261-5. 
Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J 
Immunol 2001;167:1072–1080. 
Teixeira VH, Olaso R, Martin-Magniette ML, et al., Transcriptome analysis describing new 
immunity and defense genes in peripheral blood mononuclear cells of rheumatoid 
arthritis patients. PLoS One. 2009 Aug 27;4(8):e6803. 
Thurlings RM, Boumans M, Tekstra J, et al., The relationship between the type I interferon 
signature and the response to rituximab in rheumatoid arthritis. Arthritis Rheum. 
2010, 62:3607-3614 
Timmer TC, Baltus B, Vondenhoff M, et al., Inflammation and ectopic lymphoid structures 
in rheumatoid arthritis synovial tissues dissected by genomics technology: 
identification of the interleukin-7 signaling pathway in tissues with lymphoid 
neogenesis. Arthritis Rheum 2007, 56:2492-2502. 
Tsubaki T, Arita N, Kawakami T, Shiratsuchi T, et al., Characterization of histopathology 
and gene-expression profiles of synovitis in early rheumatoid arthritis using 
targeted biopsy specimens. Arthritis Res Ther. 2005;7(4):R825-36. 
Turrel-Davin F, Tournadre A, Pachot A, et al., FoxO3a involved in neutrophil and T cell 
survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum 
Dis. 2010 Apr;69(4):755-760 
Ungethuem U, Haupl T, Witt H, et al., Molecular signatures and new candidates to target 
the pathogenesis of rheumatoid arthritis Physiol. Genomics 2010;42A:(4) 267-282 
 
Insights and Perspectives in Rheumatology 
 
62
van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, et al., A subtype of multiple sclerosis 
defined by an activated immune defense program. Genes Immun. 2006;7:522–531 
van Baarsen LG, Bos WH, Rustenburg F, et al., Gene expression profiling in autoantibody-
positive patients with arthralgia predicts development of arthritis. Arthritis 
Rheum. 2010a;62:694-704  
van Baarsen LG, Wijbrandts CA, Timmer TC, et al. Synovial tissue heterogeneity in 
rheumatoid arthritis in relationship to disease activity and biomarkers in peripheral 
blood. Arthritis Rheum. 2010b ;62:1602-1607 
Van Baarsen LG, Wijbrandts C, Gerlag D, et al., Pharmacogenomics of infliximab treatment 
using peripheral blood cells of patients with rheumatoid arthritis. Genes 
Immun.2010c;11:622-629 
van Baarsen LG, Wijbrandts CA, Rustenburg F, et al., Regulation of IFN response gene 
activity during infliximab treatment in rheumatoid arthritis is associated with 
clinical response to treatment. Arthritis Res Ther. 2010d;12:R11  
Van der Pouw Kraan TCTM, Van Galen FA, Huizinga TWJ, et al., Discovery of distinctive 
gene expression profiles in rheumatoid arthritis using cDNA microarray 
technology: Evidence for the existence of multiple pathways of tissue destruction 
and repair. Genes & Immunity 2003a;4, 187-196  
Van der Pouw Kraan TCTM, Van Galen FA, Kasperkovitz PV, et al., Rheumatoid arthritis is 
a heterogeneous disease: Evidence for differences in the activation of the STAT1 
pathway between rheumatoid tissues. Arthr. Rheum. 2003b;48, 2132-2145  
Van der Pouw Kraan TC, Wijbrandts CA, Van Baarsen LG, et al., Rheumatoid Arthritis subtypes 
identified by genomic profiling of peripheral blood cells: Assignment of a type I 
interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66, 1008-1014  
Van der Pouw Kraan TC, Van Baarsen LG, Wijbrandts CA, et al., Expression of a pathogen-
response program in peripheral blood cells defines a subgroup of Rheumatoid 
Arthritis patients. Genes Immun. 2008;9:16-22  
Van ‘t Veer LJ, Dai H, van de Vijver MJ, et al., Gene expression profiling predicts clinical 
outcome of breast cancer. Nature 2002;415:530-536 
Vosslamber S, Raterman HG, van der Pouw Kraan CTM, Schreurs MWJ, von Blomberg 
BME, Nurmohamed MT, Lems WF, Dijkmans BAC, Voskuyl AE, Verweij CL. 
Pharmacological induction of IFN type I activity following therapy with rituximab 
determines clinical response in rheumatoid arthritis. Ann Rheum Dis 
2011,70(6):1153-1159 
Watanabe N, Ando K, Yoshida S, et al., Gene expression profile analysis of rheumatoid 
synovial fibroblast cultures revealing the overexpression of genes responsible for 
tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun 2002 
Jun 28;294(5):1121-1129.  
Wu G, Zhu L, Dent JE, Nardini C. A comprehensive molecular interaction map 
forrheumatoid arthritis. PLoS One. 2010 Apr 16;5(4):e10137. Erratum in: PLoS 
One.2010;5(4). doi:10.1371/annotation/f67a90fb-3e4e-4484-bffe-fcfafbfe88c7 
Xing H, McDonagh PD, Bienkowska J, et al., Causal modeling using network ensemble 
simulations of genetic and gene expression data predicts genes involved in 
rheumatoid arthritis. PLoS Comput Biol. 2011 Mar;7(3):e1001105. 
Zanders ED, Goulden MG, Kennedy TC, Kempsell KE: Analysis of immune system gene 
expression in small rheumatoid arthritis biopsies using a combination of 
subtractive hybridization and high-density cDNA arrays. J Immunol Methods 2000, 
233:131-140. 
4 
Vitamin D and Autoimmune Disease 
Ayah M. Boudal1 and Suzan M. Attar2 
1Jeddah 
2Department Of Internal Medicine  
King Abdul-Aziz University  
Consultant Rheumatology & Internal Medicine 
King Abdul-Aziz University Hospital  
Kingdom of Saudi Arabia  
1. Introduction 
During the past decade, important advances in the study of vitamin D have been made as 
vitamin D insufficiency is emerging as a clinical problem at a global level. In addition to 
its important role in skeletal development and maintenance, evidence is mounting  
that vitamin D produce beneficial effect on extraskeletal tissues. Recent evidence shows 
that vitamin D deficiencies contribute autoimmune diseases susceptibility and severity. 
This chapter will provide a systematic review of the importance of vitamin D in 
preexisting autoimmune diseases and whether its deficiency predispose patients to such 
disorders.  
2. Agenda 
 Overview of vitamin D: structure, sources and metabolism 
 Mechanism of vitamin D modulation of the immune responses, the difference between 
the bone and autoimmune tissues and the role of the vitamin D receptors.  
 The optimum serum level of vitamin D for skeletal health  
 Vitamin D and autoimmune disease: list of al the autoimmune diseases in which 
vitamin D is related to  
 Rheumatoogical 
 Non rheumatoogical 
 Vitamin D level and vitamin D supplementation in  
 RA 
 SLE 
 Scleroderma  
 Ankylosing spondylitis  
 Undifferentiated connective tissue disease  
 The immunological basis for the vitamin D role in preventing autoimmunity 
 Summary  
 Appendix: 1 Abbreviation  
 
Insights and Perspectives in Rheumatology 
 
62
van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, et al., A subtype of multiple sclerosis 
defined by an activated immune defense program. Genes Immun. 2006;7:522–531 
van Baarsen LG, Bos WH, Rustenburg F, et al., Gene expression profiling in autoantibody-
positive patients with arthralgia predicts development of arthritis. Arthritis 
Rheum. 2010a;62:694-704  
van Baarsen LG, Wijbrandts CA, Timmer TC, et al. Synovial tissue heterogeneity in 
rheumatoid arthritis in relationship to disease activity and biomarkers in peripheral 
blood. Arthritis Rheum. 2010b ;62:1602-1607 
Van Baarsen LG, Wijbrandts C, Gerlag D, et al., Pharmacogenomics of infliximab treatment 
using peripheral blood cells of patients with rheumatoid arthritis. Genes 
Immun.2010c;11:622-629 
van Baarsen LG, Wijbrandts CA, Rustenburg F, et al., Regulation of IFN response gene 
activity during infliximab treatment in rheumatoid arthritis is associated with 
clinical response to treatment. Arthritis Res Ther. 2010d;12:R11  
Van der Pouw Kraan TCTM, Van Galen FA, Huizinga TWJ, et al., Discovery of distinctive 
gene expression profiles in rheumatoid arthritis using cDNA microarray 
technology: Evidence for the existence of multiple pathways of tissue destruction 
and repair. Genes & Immunity 2003a;4, 187-196  
Van der Pouw Kraan TCTM, Van Galen FA, Kasperkovitz PV, et al., Rheumatoid arthritis is 
a heterogeneous disease: Evidence for differences in the activation of the STAT1 
pathway between rheumatoid tissues. Arthr. Rheum. 2003b;48, 2132-2145  
Van der Pouw Kraan TC, Wijbrandts CA, Van Baarsen LG, et al., Rheumatoid Arthritis subtypes 
identified by genomic profiling of peripheral blood cells: Assignment of a type I 
interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66, 1008-1014  
Van der Pouw Kraan TC, Van Baarsen LG, Wijbrandts CA, et al., Expression of a pathogen-
response program in peripheral blood cells defines a subgroup of Rheumatoid 
Arthritis patients. Genes Immun. 2008;9:16-22  
Van ‘t Veer LJ, Dai H, van de Vijver MJ, et al., Gene expression profiling predicts clinical 
outcome of breast cancer. Nature 2002;415:530-536 
Vosslamber S, Raterman HG, van der Pouw Kraan CTM, Schreurs MWJ, von Blomberg 
BME, Nurmohamed MT, Lems WF, Dijkmans BAC, Voskuyl AE, Verweij CL. 
Pharmacological induction of IFN type I activity following therapy with rituximab 
determines clinical response in rheumatoid arthritis. Ann Rheum Dis 
2011,70(6):1153-1159 
Watanabe N, Ando K, Yoshida S, et al., Gene expression profile analysis of rheumatoid 
synovial fibroblast cultures revealing the overexpression of genes responsible for 
tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun 2002 
Jun 28;294(5):1121-1129.  
Wu G, Zhu L, Dent JE, Nardini C. A comprehensive molecular interaction map 
forrheumatoid arthritis. PLoS One. 2010 Apr 16;5(4):e10137. Erratum in: PLoS 
One.2010;5(4). doi:10.1371/annotation/f67a90fb-3e4e-4484-bffe-fcfafbfe88c7 
Xing H, McDonagh PD, Bienkowska J, et al., Causal modeling using network ensemble 
simulations of genetic and gene expression data predicts genes involved in 
rheumatoid arthritis. PLoS Comput Biol. 2011 Mar;7(3):e1001105. 
Zanders ED, Goulden MG, Kennedy TC, Kempsell KE: Analysis of immune system gene 
expression in small rheumatoid arthritis biopsies using a combination of 
subtractive hybridization and high-density cDNA arrays. J Immunol Methods 2000, 
233:131-140. 
4 
Vitamin D and Autoimmune Disease 
Ayah M. Boudal1 and Suzan M. Attar2 
1Jeddah 
2Department Of Internal Medicine  
King Abdul-Aziz University  
Consultant Rheumatology & Internal Medicine 
King Abdul-Aziz University Hospital  
Kingdom of Saudi Arabia  
1. Introduction 
During the past decade, important advances in the study of vitamin D have been made as 
vitamin D insufficiency is emerging as a clinical problem at a global level. In addition to 
its important role in skeletal development and maintenance, evidence is mounting  
that vitamin D produce beneficial effect on extraskeletal tissues. Recent evidence shows 
that vitamin D deficiencies contribute autoimmune diseases susceptibility and severity. 
This chapter will provide a systematic review of the importance of vitamin D in 
preexisting autoimmune diseases and whether its deficiency predispose patients to such 
disorders.  
2. Agenda 
 Overview of vitamin D: structure, sources and metabolism 
 Mechanism of vitamin D modulation of the immune responses, the difference between 
the bone and autoimmune tissues and the role of the vitamin D receptors.  
 The optimum serum level of vitamin D for skeletal health  
 Vitamin D and autoimmune disease: list of al the autoimmune diseases in which 
vitamin D is related to  
 Rheumatoogical 
 Non rheumatoogical 
 Vitamin D level and vitamin D supplementation in  
 RA 
 SLE 
 Scleroderma  
 Ankylosing spondylitis  
 Undifferentiated connective tissue disease  
 The immunological basis for the vitamin D role in preventing autoimmunity 
 Summary  
 Appendix: 1 Abbreviation  
 
Insights and Perspectives in Rheumatology 
 
64
3. Vitamin D structure 
Vitamin D is a secosteroid which carries a structure similar to steroid except that two of 
the B-ring carbon atoms (C9 and 10) of the typical four steroid rings are broken, in this 
case by ultraviolet B sunlight. It is considered as a prohormone. The main source of 
vitamin D is denovosynthesis in the skin through ultravioletirradiation of 7-
dehydrocholesterol. It is biologically inert and mustbe metabolized to 25-hydroxyvitamin 
D3in the liver and then to1α, 25-dihydroxyvitamin D3in the kidney before it becomes 
functional Figure 1. (1, 2) 
 
Fig. 1. Structure of vitamin D3, or cholecalciferol 
4. Source of vitamin D 
The main source of vitamin D is de novo synthesis in the skin. Although vitamin D is present 
in food, dietary intake alone is often insufficient, supplying only 20% of the body’s 
requirements (3). It is not found in plant materials (eg, vegetables, fruits, or grains) and is 
present in low levels in meats and other animal food sources, except in rare cases such as 
fish liver oils (2).  
5. Metabolism of vitamin D 
The terminology related to the biochemistry of vitamin D can be confusing. Vitamin D has 2 
forms and several metabolites. The 2 forms are vitamin D2 and vitamin D3, also called 
ergocalciferol and cholecalciferol, respectively (4).  
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Both forms of vitamin D undergo identical metabolism (Figure 2). Some evidence indicates 
that vitamin D2 may be metabolized more rapidly than vitamin D3, but with regular daily 
intake they can be considered bioequivalent. Both forms of vitamin D are converted to 25-
hydroxyvitamin [25(OH)D] in the liver, and the serum level of 25(OH) D is measured to 
determine the adequacy of vitamin D status. In the kidney, 25(OH)D is hydroxylated to 1, 
25-dihydroxyvitamin D [1, 25(OH)2 D], which is the only biologically active form of vitamin 
D. Acting principally on the duodenum, 1, 25(OH)2 D increases calcium absorption. It also 
acts on bone cells, both osteoblasts and osteoclasts, to mobilize calcium. The synthesis of 1, 
25(OH)2 D is tightly regulated and stimulated primarily by serum parathyroid hormone 
(PTH) (4).  
 
Fig. 2. Vitamin D metabolism. Ca = calcium; 1, 25(OH)2D = 1, 25-dihydroxyvitamin D; 
25(OH)D =25-hydroxyvitamin D; PTH = parathyroid hormone.  
6. Vitamin D and autoimmune disease 
Vitamin D and its prohormones have been the focus of a growing number of studies in past 
years, demonstrating their function not only in calcium metabolism and bone formation, but 
also their interaction with the immune system. This is not surprising, since vitamin D 
receptors (VDR) are expressed in different tissues, such as brain, heart, skin, bowel, gonads, 
prostate, breasts, and the immune cells(3).  
Epidemiological studies have linked vitamin D status with autoimmune disease 
susceptibility and severity (5). Potentially, vitamin D deficiency could be a clinical problem 
of global proportions.  
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3. Vitamin D structure 
Vitamin D is a secosteroid which carries a structure similar to steroid except that two of 
the B-ring carbon atoms (C9 and 10) of the typical four steroid rings are broken, in this 
case by ultraviolet B sunlight. It is considered as a prohormone. The main source of 
vitamin D is denovosynthesis in the skin through ultravioletirradiation of 7-
dehydrocholesterol. It is biologically inert and mustbe metabolized to 25-hydroxyvitamin 
D3in the liver and then to1α, 25-dihydroxyvitamin D3in the kidney before it becomes 
functional Figure 1. (1, 2) 
 
Fig. 1. Structure of vitamin D3, or cholecalciferol 
4. Source of vitamin D 
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forms and several metabolites. The 2 forms are vitamin D2 and vitamin D3, also called 
ergocalciferol and cholecalciferol, respectively (4).  
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Both forms of vitamin D undergo identical metabolism (Figure 2). Some evidence indicates 
that vitamin D2 may be metabolized more rapidly than vitamin D3, but with regular daily 
intake they can be considered bioequivalent. Both forms of vitamin D are converted to 25-
hydroxyvitamin [25(OH)D] in the liver, and the serum level of 25(OH) D is measured to 
determine the adequacy of vitamin D status. In the kidney, 25(OH)D is hydroxylated to 1, 
25-dihydroxyvitamin D [1, 25(OH)2 D], which is the only biologically active form of vitamin 
D. Acting principally on the duodenum, 1, 25(OH)2 D increases calcium absorption. It also 
acts on bone cells, both osteoblasts and osteoclasts, to mobilize calcium. The synthesis of 1, 
25(OH)2 D is tightly regulated and stimulated primarily by serum parathyroid hormone 
(PTH) (4).  
 
Fig. 2. Vitamin D metabolism. Ca = calcium; 1, 25(OH)2D = 1, 25-dihydroxyvitamin D; 
25(OH)D =25-hydroxyvitamin D; PTH = parathyroid hormone.  
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7. The mechanisms of vitamin D immunomodulation 
Dendritic cells (DCs) are primary targets for the immunomodulatory activity of 1, 
25(OH)2D3, as indicated by inhibited DC differentiation and maturation, leading to down-
regulated expression of MHC-II, costimulatory molecules (CD40, CD80 and CD86) and 
decreased production of IL-12. Moreover, 1, 25(OH)2D3 enhances IL-10 production and 
promotes DC apoptosis. Together, these effects of 1, 25(OH)2D3 inhibit DC-dependent T-cell 
activation. In particular, the active synthesis of 1, 25(OH)2D3 seems to exert an 
autoregulatory function by inhibiting the differentiation of monocyte precursors into 
immature DCs and the subsequent ability of the immature DCs to undergo terminal 
differentiation in response to maturation stimuli (Fig. 3).  
 
Fig. 3. Mechanisms involved in vitamin D modulation of the immune responses. DCs are 
primary targets for the immunomodulatory activity of 1, 25(OH)2D3, as indicated by 
inhibited DC differentiation and maturation, together with inhibition of differentiation of 
monocyte precursors into immature DCs. 1, 25(OH)2D3 suppresses Th1 (and Th17)driven 
cytokine responses, induces Treg cells, induces IL-4 production (Th2) and enhances NKT-
cell function. Differentiation and maturation of B cells is also inhibited. Th are CD4+ helper 
cell subsets (Th1, Th2, Th3-Treg, Th17) originating from nave T cell (Th0). Thin arrows (left) 
indicate cytokines that induce differentiation of Th0 cells and thicker arrows (right) indicate 
cytokines produced by activated Th cell subsets. All T cells that have been tested express the 
VDR. B cells and NKT cells are also reported. The yellow circles indicate the 
cytokines/activities inhibited by vitamin D. On the contrary, the green circles indicate the 
cytokines enhanced by vitamin D.  
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Target cell population Actions mediated by 1. 25(oH)3 D3 
APCs (monocytes, macrophages, 
dendritic cells) 
inhibits the expression of class II MHC 
molecules inhibits the expression of 
costimulating molecules (CD40, CD80, and 
CD86) and other maturation inducing 
proteins (CD1a, CD83) increases chemotaxis 
and phagocytosis of monocytes and 
cytotoxicity against tumor cells and bacteria 
inhibits the maturation of dendritic cells 
induces tolerogenic dendritic cells capable 
of inducing Treg cells inhibits the release of 
IL-12 p70 inhibitsproinflammatory cytokines 
(IL-1 and TNF) by monocytes and 
macrophages.  
 
T lymphocytes inhibits T cell proliferation, secretion of 
cytokines, and progression of the cellular 
cycle from G1a to G1b increases the 
production of IL-4, IL-5, IL-10  
inhibits IL-12, INF-γ, and IL-2 
inhibits activation of antigenspecific T 
lymphocytes inhibits the expression of FasL 
by activated T lymphocytes 
 
B cells Expresses vDR 
Suppresses IgE secretion 
NK cells inhibits INF-γ 
Table 1. Actions of vitamin D in the immune system 
Tolerogenic DCs induced by a brief treatment with1, 25(OH)2D3or its analogues can induce 
CD4+ CD25+ T regulatory (Treg) cells that are able to mediate transplantation tolerance and 
arrest the development of autoimmunity (i. e. autoimmune diabetes). Tolerogenic DCs, 
however, may not always be necessarily involved in the generation of T-reg cells by VDR 
agonists and a combination of 1, 25(OH)2D3 and dexamethasone has been shown to induce 
naïve CD4+ T cells (Th0) to differentiate in vitro into IL-10-producing Treg cells, even in the 
absence of antigen-presenting cells. VDR agonists not only favour induction of CD4+CD25+ 
Treg cells and enhance their suppressive activity, but can also promote their recruitment at 
inflammatory sites. Furthermore, 1, 25(OH)2D3 treatments induced natural killer (NK) T-
cell functions in vitro and in vivo. NKT cells are early innate regulatory cells that can alter the 
outcome of autoimmunity. Therefore, two types of cells are induced by 1, 25(OH)2D3; the 
Treg and the NKT cells; induction of these regulatory cells and direct inhibition of Th1 cells 
are the mechanisms by which 1, 25(OH)2D3 suppresses experimental autoimmunity. In 
addition, treatment with VDR agonists inhibits the T-cell production of IL-17, a pro-
inflammatory cytokine that is produced by pathogenic T cells (Th17) in various models of 
organ-specific autoimmunity in the brain, heart, synovium and intestines.  
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nmol/L ng/mL Health status 
<30 <12 Associated with vitamin D deficiency, leading to rickets in infants 
and children and osteomalacia in adults 
30–50 12–20 Generally considered inadequate for bone and overall health in 
healthy individuals 
≥50 ≥20 Generally considered adequate for bone and overall health in 
healthy individuals 
>125 >50 Emerging evidence links potential adverse effects to such high 
levels, particularly >150 nmol/L (>60 ng/mL) 
Table 2. Classification of Vitamin D Status by 25(OH)D Concentration 
Interestingly, IL-17 production is sustained by IL-23, an IL-12 family member consisting of 
p19 and p40 chains, the latter of which is strongly inhibited by VDR agonists. Recently, 1, 
25(OH)2D3 treatment induced a significant inhibition of normal lymphoid cell progenitors 
growth of both T and B lineage and inhibited significantly also the growth of malignant 
Bcell lineage lymphoid progenitors, without inducing cytotoxic effect. More recently, by 
testing the effects of 1, 25(OH)2D3 on B-cell responses, it was found that it inhibited the 
ongoing proliferation of activated B cells and induced their apoptosis, whereas initial cell 
division was unimpeded.  
The generation of plasma cells and post-switch memory B cells was significantly inhibited 
by 1, 25(OH)2D3 although the up-regulation of genetic programs involved in B-cell 
differentiation was only modestly affected. B cells expressed mRNAs for proteins involved 
in vitamin D activity, including 1α-hydroxylase, 24-hydroxylase and the VDR, each of which 
was regulated by 1, 25(OH)2D3 and/or activation. Interestingly, 1, 25(OH)2D3 up-regulated 
the expression of p27, but not of p18 and p21, which may be important in regulating the 
proliferation of activated B cells and their subsequent differentiation in plasma cells.  
The net effect of 1, 25(OH)2D3 is enhancement of the innate immune system (protective) and 
down regulation of the adaptive immune system(acquired). Therefore, 25(OH)D deficiency 
may theoretically lead to autoimmune diseases.  
8. The optimum serum level of vitamin D for skeletal health  
Determination of vitamin D status is not based on measurement of serum 1, 25(OH)D 
concentrations. It is assessed by measuring the prohormone 25(OH)D, which is an indicator 
of supply rather than function. The most stable and plentiful metabolite of vitamin D in 
human serum, 25(OH)D, has a half-life of about 3 weeks, making it the most suitable 
indicator of vitamin D status (4). Using PTH elevation as a biomarker reflecting physiologic 
low levels of vitamin D, recent reports indicate that vitamin D deficiency would be more 
accurately defined as a 25D concentration of less than 32 ng/ml (80 nmol/l). The optimal 
serum concentrations of 25(OH)D begin at 75 nmol/L (30 ng/mL), and the best are between 
90-100 nmol/L (36–40 ng/mL) (7). Whether 'normal' serum levels of vitamin D are sufficient 
for immune homeostasis is not known. In 2009, a standard reference material for 25(OH)D 
became available that permits standardization of values across laboratories and may 
improve method-related variability.  
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9. Vitamin D and autoimmune diseases  
Observational studies in humans suggest an association between vitamin D deficiency and 
many rheumatological and non-rheumatological disorders, listed in Table 3.  
Rheumatological Non Rheumatologicl 
1. Rheumatoid Arthritis "RA" (3, 7, 8).  
2. Undifferentiated Connective tissue (8).  
3. SLE (8).  
4. Scleroderma (11).  
5. Ankylosing spondylitis (12).  
6. Behcet's disease (15).  
7. Psoriasis (16).  
8. Fibromylgia (17) 
1. Multiple Sclerosis "MS" (7, 8, 12, 14).  
2. Independent Diabetes Mellitus 
"IDDM" (6, 8, 12).  
3. Allergic asthma in children (9, 10).  
4. Allergic rhinitis (10).  
5. Grave's disease (13).  
SLE: Systemic lupus erythematosis, 25(OH)D: serum vitamin D level 
Table 3. Disorders that have been linked to 25(OH)D 
10. Vitamin D level and vitamin D supplementation in autoimmune diseases  
10.1 Rheumatoid Arthritis (RA) 
Rheumatoid arthritis is an immune-mediated disease, mainly driven by Th1 cells. The 
characteristic features of the disease are erosive arthritis and joint destruction, which lead to 
severe disability and increased mortality. In various animal models of RA, such as CIA in 
mice, the disease-modifying effect of VDR ligands has been widely investigated. With 1, 
25(OH)2D3 vitamin treatment in the early phase, collagen-induced arthritis was preventable 
to a certain extent and the progression of arthritis decreased (18).  
 In the last few years, the possible role of vitamin D in the pathogenesis, activity, and 
treatment of RA has been raised based on the results and observations of clinical and 
laboratorial studies(3). There have been 7case control studies evaluating vitamin D in RA 
patients. Two studies showed lower level of 25(OH)D than controls but 5 did not. In these 
studies the prevalence of low 25(OH)D was found to be between 30-63%. The rationale for 
relating vitamin D deficiency and RA is based on two facts: evidence indicate that patients with 
RA have vitamin D deficiency and the presence of 1, 25(OH) and VDR in macrophages, 
chondrocytes, and synovial cells in the joints of these patients with RA (3).  
Low sun exposure and reduced body mass index (BMI) are well established risk factors for 
vitamin D deficiency in RA patients (19). Few studies have examined dietary or nutritional 
intake prior to RA onset, and none have assessed the association of vitamin D with disease 
onset. Linda et al. found that greater intake (highest versus lowest tertile) of total daily 
vitamin D was inversely associated with risk of RA. Inverse associations were apparent for 
both dietary and supplemental vitamin D. (20). The relationship between polymorphisms of 
the VDR gene and the onset of RA activity has been demonstrated in a study in which 
patients with BB or Bb genotypes for VDR had higher indices in the health assessment 
questioner (HAQ), erythrocyte sedimentation rate (ESR), cumulative dose of corticosteroids, 
and number of disease-modifying anti-rheumatic drugs (DMARDs) when compared to 
patients with the BB genotype (3).  
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In collagen-induced arthritis models, dietarian supplementation or oral administration of 
vitamin D prevented the development or delayed the progression of arthritis(3). In an open 
labeled study with 19 patients with RA treated with traditional DMARDs, oral 
supplementation with high doses of alfacalcidol for three months reduced the severity of the 
symptoms in 89% of the patients, 45% of which achieved complete remission and 44% had 
satisfactory results. Higher incidence of side effects, such as hypercalcemia, was not 
observed (3).  
There also seem to be an inverse relationship between disease activity and the concentration 
of vitamin D metabolites in patients with inflammatory arthritis. A UK study that involved 
206 patients demonstrated that at baseline in the pre-treatment patients, there was an 
inverse association between levels of 25(OH)D and the number of painful joints, DAS28, and 
HAQ. For each increase in 10 ng/mL in vitamin D serum levels, the DAS28 reduced by 0. 3 
points and the levels of CRP by 25%. But at 1 year the only observation is the inverse 
association with HAQ score (3).  
10.2 Systemic Lupus Erythematous (SLE) 
Several studies have demonstrated a higher prevalence of vitamin D deficiency in SLE 
patients when compared to individuals with other rheumatologic diseases and healthy 
controls(3). Huisman et al. observed that 50% of SLE patients had vitamin D deficiency (cut 
off <50 nmol/L or 20 ng/mL) (21).  
Patients with systemic lupus erythematosus have multiple risk factors for 25(OH)D 
deficiency:(3) 
1. Photosensitivity: 
Is the characteristic of the disease, and the recommendation to apply sunscreen are 
responsible for lower sun exposure, decreasing the production of vitamin D in the skin.  
2. Chronic treatment with corticosteroids and hydroxichloroquine: 
These medications seem to affect vitamin D metabolism, although the evidence for this is 
not yet clear.  
3. Severe renal involvement:  
This affects the hydroxylation step of 25(OH)D.  
4. African descent: 
Severe lupus is more prevalent in people of African descent. It is believed that vitamin D 
deficiency in this group is a consequence of not only genetic factors, but it is speculated that 
lower serum concentrations of 25(OH)D, due to the lower cutaneous conversion rate 
secondary to skin color, would be another important factor.  
It has been observed that critical levels of vitamin D (<10 ng/mL) are more common in 
patients with renal involvement and photosensitive skin lesions (4).  
The association between low 25(OH)D and disease activity scores, according to the SLEDAI 
(Systemic Lupus Erythematosus Disease Activity Index) and ECLAM (European Consensus 
Lupus Activity Measurement) has been documented (3).  
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Thudi et al. demonstrated that functional assessment using combined scores (modified HAQ, 
global VAS by the patient, and fatigue scale) was worse in patients with probable or 
confirmed diagnosis of lupus and vitamin D deficiency. However, this study did not 
demonstrate an association between vitamin D deficiency and the levels of auto-antibodies, 
including anti-DNA (22).  
Carvalho et al. investigated the presence of anti-vitamin D antibodies in the serum of SLE 
patients to better explain vitamin D deficiency in autoimmune diseases. One-hundred and 
seventy-one SLE patients were investigated and 4% of them had vitamin D antibodies but 
the levels of 25(OH)D were similar in patients with or without those autoantibodies. Among 
the clinical and laboratorial associations investigated, the presence of anti-dsDNA was the 
only one that showed a strong relationship with anti-vitamin D antibodies (23).  
10.3 Ankylosing Spondylitis AS 
Osteoprosis is frequent in AS and high disease activity which assessed by Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) is associated with an alteration in vitamin D 
metabolites and increased levels of bone resorption (11).  
The inflammatory activity in AS itself plays a major role in the pathophysiology of bone 
loss, this may be mediated in AS by substances regulating both the inflammatory process 
and bone turnover. High levels of proinflammatory cytokines such asinterleukin-1 and 
tumor necrosis factor α (TNFα) are thought to play a major role in chronic inflammation and 
act on osteroblasts and osteoclasts(12). A prospective study demonstrated a significant loss 
of bone mass in early AS with a strong association with inflammatory activity (24).  
Factors may contribute to the development of osteopenia/osteoporosis in AS: (12) 
1. Treatment of AS.  
2. Hormone disorder.  
3. Decreased mobility or physical activity.  
Patients with AS and osteoporosis had significantly higher values for ESR, CRP, and urine-
cross-links, and significantly decreased results in 1. 25 D3, 25 D3 and PTH, but no 
differences in serum calcium, serum calcium corrected for albumin, bone-AP and daily renal 
calcium excretion were observed (12).  
Clinical studies have reported the impact of vitamin D in AS as an endogenous immune 
modulator, suppressing activated T cells and cell proliferation that may accelerate the 
inflammation process (25).  
10.4 Undifferentiated Connective Tissue Disease (UCTD) 
A study by Zold et al. demonstrated the presence of a seasonal variation in the levels of 
25(OH)D in patients with UCTD and that those levels were lower in this population than in 
the control population. In this same study, 21. 7% of patients with UCTD and vitamin D 
deficiency developed established connective tissue disease (especially RA, SLE, Sjgren’s 
syndrome, and mixed connective tissue disease); their mean 25(OH)D was lower than that 
of patients who remained with undifferentiated disease, 14. 7 ± 6. 45 ng/mL vs  
33. 0 ± 13. 4 ng/mL, P =0. 0001 respectively (26). The presence of dermatological symptoms 
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Thudi et al. demonstrated that functional assessment using combined scores (modified HAQ, 
global VAS by the patient, and fatigue scale) was worse in patients with probable or 
confirmed diagnosis of lupus and vitamin D deficiency. However, this study did not 
demonstrate an association between vitamin D deficiency and the levels of auto-antibodies, 
including anti-DNA (22).  
Carvalho et al. investigated the presence of anti-vitamin D antibodies in the serum of SLE 
patients to better explain vitamin D deficiency in autoimmune diseases. One-hundred and 
seventy-one SLE patients were investigated and 4% of them had vitamin D antibodies but 
the levels of 25(OH)D were similar in patients with or without those autoantibodies. Among 
the clinical and laboratorial associations investigated, the presence of anti-dsDNA was the 
only one that showed a strong relationship with anti-vitamin D antibodies (23).  
10.3 Ankylosing Spondylitis AS 
Osteoprosis is frequent in AS and high disease activity which assessed by Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) is associated with an alteration in vitamin D 
metabolites and increased levels of bone resorption (11).  
The inflammatory activity in AS itself plays a major role in the pathophysiology of bone 
loss, this may be mediated in AS by substances regulating both the inflammatory process 
and bone turnover. High levels of proinflammatory cytokines such asinterleukin-1 and 
tumor necrosis factor α (TNFα) are thought to play a major role in chronic inflammation and 
act on osteroblasts and osteoclasts(12). A prospective study demonstrated a significant loss 
of bone mass in early AS with a strong association with inflammatory activity (24).  
Factors may contribute to the development of osteopenia/osteoporosis in AS: (12) 
1. Treatment of AS.  
2. Hormone disorder.  
3. Decreased mobility or physical activity.  
Patients with AS and osteoporosis had significantly higher values for ESR, CRP, and urine-
cross-links, and significantly decreased results in 1. 25 D3, 25 D3 and PTH, but no 
differences in serum calcium, serum calcium corrected for albumin, bone-AP and daily renal 
calcium excretion were observed (12).  
Clinical studies have reported the impact of vitamin D in AS as an endogenous immune 
modulator, suppressing activated T cells and cell proliferation that may accelerate the 
inflammation process (25).  
10.4 Undifferentiated Connective Tissue Disease (UCTD) 
A study by Zold et al. demonstrated the presence of a seasonal variation in the levels of 
25(OH)D in patients with UCTD and that those levels were lower in this population than in 
the control population. In this same study, 21. 7% of patients with UCTD and vitamin D 
deficiency developed established connective tissue disease (especially RA, SLE, Sjgren’s 
syndrome, and mixed connective tissue disease); their mean 25(OH)D was lower than that 
of patients who remained with undifferentiated disease, 14. 7 ± 6. 45 ng/mL vs  
33. 0 ± 13. 4 ng/mL, P =0. 0001 respectively (26). The presence of dermatological symptoms 
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(photosensitivity, erythema, and chronic discoid rash) and pleuritis was associated with low 
levels of vitamin D.  
11. The immunological basis for the vitamin D role in preventing 
autoimmunity 
Prospective studies available for the 4 major autoimmune diseases:RA, SLE, MS, and type 1 
DM, have demonstrated the beneficial effects of vitamin D supplementation in modulating 
the components of the immune system responsible for the inflammation, such as the 
expression of cytokines, growth factors, nitrous oxide, and metalloproteinase(3). A recent 
systematic review concluded that total number of studies are small, so no conclusion could 
be made with regards to the importance of 25(OH)D in preventing autoimmune disease.  
12. Summary 
The vitamin D endocrine system is recognized as an important immune modulatory factor 
involved in autoimmune diseases. VDR agonists seem primarily to inhibit DC 
differentiation, pathogenic pro-inflammatory T cells such as Th1 and Th17 cells and, under 
appropriate conditions, they seem to favour a deviation to the Th2 pathway. These 
immunomodulatory and anti-inflammatory activities might be particularly efficient in RA, 
SLE, Ankylosing spondylitis and UCTD patients and support a therapeutic role of 1, 
25(OH)2D in such a disease.  
In addition, vitamin D may play an important role in the maintenance of B-cell homeostasis, 
and the correction of vitamin D deficiency may be useful in the treatment of B cell-mediated 
autoimmune rheumatic disorders such as SLE.  
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Osteoporosis in Rheumatoid Arthritis  
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Santa Maria del Prato Hospital, Feltre 
Italy 
1. Introduction  
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis in adults and 
is characterized by chronic, progressive, systemic inflammation leading to substantial pain, 
disability, and other morbidities1. Osteoporosis (OP) is more frequent in patients with RA 
than in the general population due to active systemic inflammation as well as the use of 
corticosteroids and immobility. OP is characterized by low bone mass, and 
microarchitectural deterioration of bony tissue, with a consequent increase in bone fragility 
and susceptibility to fractures. According to the WHO criteria (Tab. 1), osteoporosis can also 
be defined as a value of bone mineral density (BMD) more than - 2.5 standard deviations 
below the young normal mean. Subsequent disability may lead to loss of independence and 
quality of life. Underlining the clinical significance of BMD in RA, the risk of hip2 and 
vertebral fractures3 and the associated morbidity, mortality and healthcare costs are 
increased in patients with RA (Fig.1). 
T - Score Diagnosis
0 to > -1 Normal bone density
-1 to >-2,5 Osteopenia
<  -2,5 Osteoporosis
< -2,5 with fracture Severe osteoporosis
Table 1. WHO T-score criteria for Bone Mineral Density 
Localized bone loss in the form of bone erosions and periarticular osteopenia constitutes an 
important radiographic criterion for the diagnosis of RA. In addition, generalized bone loss 
has been demonstrated in RA, systemic lupus erythematosus, and ankylosing spondylitis in 
several observational and some longitudinal studies using markers of bone turnover, bone 
histomorphometry, and bone densitometry4.  
                                                 
1 Pattison DJ, Harrison RA, Symmons DP. The role of diet in susceptibility to rheumatoid arthritis: a 
systematic review. J Rheumatol. 2004;31(7):1310-9. 
2 Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann 
Rheum Dis 1995;54:49–52.  
3 Arai, T. & Kragic, D. Van Staa TP, Geusens P, Bijlsma JWJ, Leufkens HGM, Cooper C. Clinical 
assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 
2006;54:3104–12.  
4 Eggelmeijer F, Papapoulos SE, Westedt ML, Van Paassen HC, Dijkmans BA, Breedveld FC: Bone 
metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol 1993, 32: 387-391.  
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Fig. 1. In osteoporosis, the cortex becomes thinner and more brittle, while the inner 
trabecular bone develops larger holes 
OP occurs in two forms during the course of the AR5: 
1. periarticular osteopenia in close proximity to inflamed joints, which is a typical 
phenomenon in early and prolonged rheumatoid disease;  
2. generalized osteoporosis, which affects the axial and appendicular bones. Inflammation 
has the effect of provoking more severe and accelerated bone loss in the hand as 
compared with hip and spine. 
In all inflammatory diseases, use of glucocorticoids (GC) is a common therapy. There is no 
doubt about the deleterious effect of GC in bone metabolism, suppressing bone formation 
and enhancing bone resorption. The addition of GC to osteoprogenitor cells in vitro actually 
increases their bone-forming capacity but it also increases apoptosis of mature osteoblasts 
and osteocytes and therefore affects capacity of bone formation. This potent anti-
inflammatory drug reduces production of pro-inflammatory cytokines (IL-1, IL-6, and TNF-
α), but provokes bone resorption by increasing the synthesis of RANKL and inhibiting OPG 
production with consequent induction of osteoclastogenesis6. 
Systemic inflammation and GC use accelerates bone loss independent of other risk factors7 
but other factors must be valorized. Immobilization due to pain from inflamed joints, 
impairment of physical activity, reduced calcium intake, and poor nutrition associated with 
enhanced basal energy expenditure are also risk factors related to low BMD, common is this 
population. In children, delayed puberty and stunted growth can adversely affect bone 
remodeling8. 
                                                 
5 Sambrook PN: The skeleton in rheumatoid arthritis: common mechanism for bone erosion and 
osteoporosis? J Rheumatol 2000, 27:2541-2542. Gregório LH, Lacativa PG, Melazzi AC, Russo LA.  
6 Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metab. 2006;50(4):793-801. 
7 Roldán JF, Del Rincón I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients 
with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J 
Rheumatol. 2006;33(3):508-16. 
8 Viswanathan A, Sylvester FA. Chronic pediatric inflammatory diseases: effects on bone. Rev Endocr 
Metab Disord. 2008;9(2):107-22.  
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Consequently, increase in bone resorption, both focal and systemic, are common in patients 
with RA. In patients with active RA compared to matched controls and patients with 
inactive RA serum osteocalcin which reflects bone formation was found to be significantly 
lower and crosslinked N-telopeptidases of type 1 collagen (NTX) and deoxypyridinoline 
(DPD) which reflect bone resorption, were significantly higher. There were positive 
correlations between these bone markers and disease activity9. 
2. Epidemiology and prevalence 
Rheumatoid arthritis is a chronic inflammatory and destructive joint disease that affects 0.5-
1% of the world’s population and commonly leads to significant disability and consequent 
impairment of quality of life10. It is two or three times more frequent in women than in men 
and can start at any age, with its peak incidence between the fourth and sixth decades of 
life11. Generalized osteoporosis is an extra-articular complication of rheumatoid arthritis that 
results in increased risk of fractures and associated morbidity, mortality, and healthcare 
costs. The incidence of osteoporosis among patients with rheumatoid arthritis is 15-20% at 
the hip and spine12. Haugeberg elegantly showed a twofold increase in osteoporosis in 
women with RA and a twofold increase of reduced bone mass in men with RA, compared 
with patients without RA in a population based study13. Italian research, performed with 
patients with established RA, reported disease-related factors, such as long disease duration, 
high disease activity, joint damage, functional disability and corticosteroid use, as 
determinants of osteoporosis or reduced BMD14 . Hence, patients with long-standing RA 
with destructive disease, functional disability or immobilisation, or who are on longterm 
corticosteroid treatment are at high risk for osteoporosis15. This could be explained by the 
fact that generalised osteoporosis is more associated with long-standing, destructive and 
disabling RA,whereas early RA is associated with periarticular osteoporosis. This is further 
supported by the fact that longer symptom duration is independently associated with more 
generalised osteoporosis in studies. 
                                                 
9 Seriolo B, Ferretti V, Sulli A, Caratto E, Fasciolo D, Cutolo M. Serum osteocalcin levels in 
premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci. 2002;966:502-7. 
10 Brandão L, Ferraz MB, Zerbini CAF. Avaliação da qualidade de vida na artrite reumatóide: revisão 
atualizada [Evaluation of quality of life in rheumatoid arthritis]. Rev Bras Reumatol. 1997;37(5):275-81. 
11 Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27(2):269-81. 
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Fig. 1. In osteoporosis, the cortex becomes thinner and more brittle, while the inner 
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Consequently, increase in bone resorption, both focal and systemic, are common in patients 
with RA. In patients with active RA compared to matched controls and patients with 
inactive RA serum osteocalcin which reflects bone formation was found to be significantly 
lower and crosslinked N-telopeptidases of type 1 collagen (NTX) and deoxypyridinoline 
(DPD) which reflect bone resorption, were significantly higher. There were positive 
correlations between these bone markers and disease activity9. 
2. Epidemiology and prevalence 
Rheumatoid arthritis is a chronic inflammatory and destructive joint disease that affects 0.5-
1% of the world’s population and commonly leads to significant disability and consequent 
impairment of quality of life10. It is two or three times more frequent in women than in men 
and can start at any age, with its peak incidence between the fourth and sixth decades of 
life11. Generalized osteoporosis is an extra-articular complication of rheumatoid arthritis that 
results in increased risk of fractures and associated morbidity, mortality, and healthcare 
costs. The incidence of osteoporosis among patients with rheumatoid arthritis is 15-20% at 
the hip and spine12. Haugeberg elegantly showed a twofold increase in osteoporosis in 
women with RA and a twofold increase of reduced bone mass in men with RA, compared 
with patients without RA in a population based study13. Italian research, performed with 
patients with established RA, reported disease-related factors, such as long disease duration, 
high disease activity, joint damage, functional disability and corticosteroid use, as 
determinants of osteoporosis or reduced BMD14 . Hence, patients with long-standing RA 
with destructive disease, functional disability or immobilisation, or who are on longterm 
corticosteroid treatment are at high risk for osteoporosis15. This could be explained by the 
fact that generalised osteoporosis is more associated with long-standing, destructive and 
disabling RA,whereas early RA is associated with periarticular osteoporosis. This is further 
supported by the fact that longer symptom duration is independently associated with more 
generalised osteoporosis in studies. 
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Numerous studies have investigated the relation between demographic and disease related 
variables on the one hand, and bone mass on the other, in patients with RA. These studies 
tried to identify patients at high risk of osteoporosis16. Studies investigating the variables 
associated with BMD17 showed some inconsistencies, which might be caused by differences 
in methodological aspects, such as sample size and patient selection. Moreover, the complex 
interaction between inflammation, immobility, and corticosteroid use may contribute to the 
lack of unanimous results. 
Only a few studies focusing on BMD in patients with early RA have been performed; 
however the disease duration in some was up to 5 years18. Very little is known about the 
extent of osteoporosis and the influence of disease-associated factors on BMD in patients 
with recently diagnosed RA19. These data are required in order to unravel the common 
mechanisms between generalised osteoporosis and RA. 
Symptom duration and the presence of RF were the only RAspecific markers for 
osteoporosis and reduced BMD in this study. It is known that seropositive RA is associated 
with more aggressive joint disease and is more commonly complicated by extra-articular 
manifestations than is seronegative RA20 21. Previous studies showed an independent 
association between the presence of RF and osteoporosis or reduced BMD in established and 
recent onset RA. 
3. Etiology and pathophysiology 
3.1 Bone remodeling  
Throughout life, normal skeletal maintenance occurs by a tightly coupled process of bone 
remodeling. It consists of a sequential process of bone resorption by osteoclasts followed by 
deposition of new bone by osteoblasts. Osteoblasts are derived from precursor cells that can 
also be stimulated to become muscle, fat or cartilage; however, under the right conditions 
these cells change (or differentiate) to form new bone, producing the collagen that forms the 
scaffolding or bone matrix. This calcium- and phosphate-rich mineral is added to the matrix 
to form the hard, yet resilient, tissue that is healthy bone. The osteoclasts remove bone by 
dissolving the mineral and breaking down the matrix in a process that is called bone 
resorption. The osteoclasts come from the same precursor cells in the bone marrow that 
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produce white blood cells. These precursor cells can also circulate in the blood and be 
available at different sites in need of bone breakdown. Osteoclasts are formed by fusion of 
small precursor cells into large, highly active cells with many nuclei. Removal and 
replacement of bone in the remodeling cycleis controlled by local and systemic factors that 
regulate bone remodeling to fulfill both its structural and metabolic functions. The 
activation of this process involves an interaction between cells of the osteoblastic lineage 
and the precursors that will become osteoclasts. The differentiation of myeloid progenitor 
cells into committed osteoclast lineage is characterized by the appearance of the mRNA and 
protein for vitronectin receptor, cathepsin K, tartrate-resistant acid phosphatase, and 
calcitonin receptor22 23.This process of osteoclastogenesis requires the presence of receptor 
activator of nuclear factor-B ligand (RANKL; also known as OPGL, TRANCE, ODF, and 
SOFA) and the permissive factor, macrophage colony stimulating factor (M-CSF) secreted 
by the local osteoblast/stromal cells. RANKL binds to its receptor RANK expressed on the 
surface of osteoclast precursor cells and stimulates their differentiation into mature 
osteoclasts24. The osteoblast/stromal cells also secrete osteoprotegerin (OPG; also known as 
OCIF, TR-1, FDCR-1, and TNFRSF-11B), a soluble decoy receptor protein that binds to 
RANKL and prevents its binding to RANK on the preosteoclast cells. The biologic effects of 
OPG are, therefore, the opposite of those of RANKL, i.e. OPG inhibits osteoclastogenesis 
and osteoclast function and promotes osteoclast apoptosis25. The production and activity of 
both RANKL and OPG are influenced by several cytokines, inflammatory mediators, and 
calcitropic hormones that ‘converge’ onto these proteins. The net RANKL/OPG balance 
determines the differentiation, activation, and survival of osteoclasts, which in turn 
determine bone loss26. 
3.2 Focal bone erosion in rheumatoid arthritis: The role of the rank/rankl/OPG system 
and the TNF-α 
Although the mechanisms of cartilage destruction in rheumatoid arthritis (RA) are well 
described, the mechanisms responsible for bone erosion in this disease have only recently 
been studied. The role of osteoclasts in bone erosion in RA has been suspected for many 
years on the basis of indirect evidence, including the identification of multinucleated cells 
with phenotypic features of osteoclasts at sites of erosion in human RA27 28.  
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Inflammation modulates bone resorption mainly by two mechanisms. Firstly, pro-
inflammatory cytokines have a final common mediator of osteoclast function: receptor 
activator of nuclear factor-B (RANK) and its functional ligand (RANKL), also known as 
TRANCE (TNF-related activation induced cytokine)29 30. Secondly, osteoclastogenesis can be 
regulated through the modulation of macrophage colony stimulating factor (M-CSF). 
RANKL is a membrane-bound tumor necrosis factor (TNF) receptor expressed on 
osteoblast precursor cells that recognize RANK on the osteoclast surface through a direct 
cell-cell interaction. This process is essential for osteoclast differentiation, activation and 
survival. RANKL is considered the key osteoclastogenic cytokine as the RANKL-RANK 
interaction stimulates several transcription factors and all three families of MAP kinases31. 
The osteoblast/stromal cells also secrete osteoprotegerin (OPG), a soluble decoy receptor 
protein that binds to RANKL and prevents its binding to RANK on the preosteoclast cells. 
The biologic effects of OPG are, therefore, the opposite of those of RANKL; infact, it 
inhibits osteoclastogenesis and osteoclast function and promotes osteoclast apoptosis32. 
The net RANKL/OPG balance determines the differentiation, activation, and survival of 
osteoclasts, which in turn determine bone loss33. Synovial tissues provide a source of 
RANKL that could influence osteoclastogenesis. Synovial fibroblasts from patients with 
RA produce mRNA   and protein for RANKL. RANKL is also expressed by T lymphocytes 
from RA synovial tissues34. Adjuvant-induced arthritis (AIA) is an animal model of T 
lymphocyte mediated inflammatory arthritis characterized by destruction of bone and 
cartilage similar to that in RA. In this model, activated T cells express RANKL protein on 
their surface, and through binding of RANKL to RANK on preosteoclasts, these cells 
promote osteoclastogenesis and subsequent bone loss. Co-culture experiments using RA 
synovial fibroblasts and peripheral blood mononuclear cells as a source of osteoclast 
precursors demonstrate that osteoclast-like cells are generated, and the generation of 
these cells is inhibited by the addition of OPG (Fig.2) Similarly, activated T cells 
expressing RANKL induce osteoclasts from autologous peripheral blood monocytes, a 
process that is also inhibited by OPG35.  
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Fig. 2. A schematic overview of the RANK/RANKL/OPG system 
Synovial tissues may also provide a source of osteoclast precursor cells, as macrophages 
isolated from RA synovial tissues differentiate into osteoclasts in the presence of M-CSF 
plus RANKL. More recent studies have extended these findings. Cells digested from RA 
synovial tissue samples generate TRAP positivemultinucleated cells that form resorption 
pits on dentine slices36 a definitive demonstration that these cells are osteoclasts. Synovial 
fibroblasts in rheumatoid synovium may also contribute significantly to localized bone loss. 
These cells produce chemokines such as macrophage inflammatory peptide 1, regulated-
upon-activation normal T cell expressed and secreted, IL-8, and IL-16, which promote 
lymphocyte infiltration and support lymphoproliferation via secretion of various colony-
stimulating factors37. This results in a large pool of RANKL-expressing lymphocytes 
supporting osteoclastogenesis and local bone loss. Furthermore, synovial fibroblasts may 
directly contribute to local bone destruction by expressing RANKL on their surface38 and by 
secreting cathepsins. Elevated levels of tumor necrosis factor (TNF)-a have been 
demonstrated by immunoassays in several inflammatory arthritides. TNF-a promotes 
expression of adhesion molecules, activation of leukocytes, recruitment of leukocytes, and 
production of proinflammatory cytokines (e.g. IL-1, IL-6, and IL-8) in RA. There are two 
mechanisms by which TNF-α acts in osteoclasts, both marrow stromal cells and osteoclast 
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precursors express TNF-α receptors. The main process occurs when stromal cells are 
exposed to TNF-α and produce RANKL, M-CSF, and IL-1, which promote osteoclast 
formation and activation. TNF-α and RANKL are synergistic, and minimal levels of one 
markedly enhances the osteoclastogenic capacity of the other39 (Fig. 3).  
 
Fig. 3. Activated human T cells induce osteoclastogenesis from human monocytes 
TNF-α also has potent antiapoptotic effects on osteoclasts, prolonging their lifespan40. The 
second mechanism occurs when the inflammatory process becomes more aggressive and 
TNF-α may promote osteoclast formation by directly stimulating its precursors in the 
absence of stromal cells responsive to the cytokine, perhaps through activation of 
transforming growth factor (TGF)-β. 
3.3 Focal bone erosion in rheumatoid arthritis: The role of the glucocorticoid use 
In all inflammatory diseases, use of glucocorticoids (GC) is a common therapy. The use of 
GC, however, is associated with a variety of adverse effects,1 including the development of 
osteoporosis and fractures. In patients who have received GCs for longer than six months, 
the estimated glucocorticoid-induced osteoporosis (GIO) frequency is 50%41. The 
pathogenesis of GIO is multifaceted. Glucocorticoids have indirect effects on osteoporosis by 
inhibiting calcium absorption from the gastrointestinal track and decreasing the renal 
tubular reabsorption of calcium and consequentely secondary hyperparathyroidism. GCs 
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reduce growth hormone (GH) secretion and may alter the GH/insulin-like growth factor 
(IGF)-I axis. An important role may be played by skeletal IGF-I because GCs inhibit IGF-I 
transcription in osteoblasts. Glucocorticoids have direct effects on bone cells. GCs reduce the 
replication, differentiation and function of osteoblasts42 and increase the apoptosis rates of 
mature cells, thereby depleting the osteoblastic cell population and inhibiting the function of 
mature cells. Furthermore, in the presence of GCs, bone marrow stromal cells do not 
differentiate into osteoblasts; instead, these cells differentiate toward an adipocyte cell 
lineage. Moreover, GCs induce apoptosis in osteocytes and affect the functioning of these 
cells. GCs increase the expression of M-CSF and receptor activator of RANK-L. In addition, 
GCs decrease the expression of osteoprotegerin in stromal and osteoblastic cells. Through 
these mechanisms, GCs can induce the formation of osteoclasts and favor bone resorption. 
GCs also reduce the rate of apoptosis among mature osteoclasts. 
4. Diagnosis 
The initial evaluation of secondary osteoporosis should include a detailed history of clinical 
risk factors for fractures and the underlying medical conditions and medications that cause 
bone loss, a thorough physical. Patients with decreased bone density usually have no 
specific abnormal physical findings. Those with vertebral compression fractures will have 
kyposis, protruding abdomen and height loss. Back tenderness is usually only present after 
an acute fracture. Gait speed and grip strength are often reduced in patients who have or are 
about to have a hip fracture. Visual acuity should be checked in geriatric patients because it 
is a risk factor for falling. 
Based on these initial findings and the clinical index of suspicion, further laboratory and 
imaging studies as well as invasive tests are required. examination and laboratory. 
Optimal evaluation consists of establishing the diagnosis of osteoporosis on the basis of 
bone mass assessment (BMD), establishing the fracture risk, and determining the need for 
therapy. Dual-energy x-ray absorptiometry (DXA) is the preferred technique to measure 
BMD, and is the technique used at most centers43. The hip and the spine  are the preferred 
site for BMD measurement due to the high predictive value of hip BMD for fracture risk. 
The World Health Organization (WHO) has established the following operational 
definition for osteoporosis based on BMD as measured by DXA (Fig. 4), commonly 
expressed as a T-score.  
The World Health Organization (WHO) has established criteria for making the diagnosis of 
osteoporosis, as well as determining levels that predict higher chances of fractures. These 
criteria are based on comparing the BMD of the patient with that of a typical healthy, young 
female's. BMD values that fall well below the average for the healthy, young female's (stated 
statistically as 2.5 standard deviations below the average) are diagnosed as osteoporotic. If a 
patient has a BMD value less than the healthy, young female, but not 2.5 standard 
deviations below the average, the bone is osteopenic. Osteopenic means decreased bone 
mineral density, but it's not as severe as osteoporosis.  
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Fig. 4. A scanner used to measure bone density with Dual Energy X-ray absorptiometry.  
Although these criteria are widely used, they were based on a Caucasian female, so there 
will be some differences when these levels are applied to non-Caucasian females or to males 
in general. Despite this flaw, BMD measurement is a common method that's helpful in all 
groups. Laboratory evaluation for secondary causes of osteoporosis should be considered 
when osteoporosis is diagnosed. Serum calcium, phosphorus, alkaline phosphatase, 
creatinine, vitamin D, complete blood count and thyroid stimulating hormone (TSH) levels 
are usually sufficient baseline tests. Further laboratory tests can be done as clinically 
appropriate, such as parathyroid hormone level, urine free cortisol, liver function tests, or 
serum immune electrophoresis. Biochemical indices of skeletal turnover could potentially be 
helpful in the diagnosis and monitoring of therapy.  
5. Treatment 
The treatment of inflammatory bone loss can be aimed at attempts to suppress bone 
resorption and to increase bone formation.  
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5.1 Calcium and vitamin D 
Both alfacalcidol (25 OH vitamin D3) and calcitriol (1,25 (OH)2 Vitamin D3) are used by 
some for the treatment of osteoporosis44. An adequate intake of calcium and  Vitamin D 
supplementation are recommended as vitamin D. Serum and urinary calcium, serum 
25OHD, and PTH concentrations should be used to evaluate hypovitaminosis D, secondary 
hyperparathyroidism and low net calcium balance. In randomized trials, the use of calcium 
and vitamin D alone had no significant benefit in bone density. However, these disturbances 
usually found in inflammatory diseases should be corrected to avoid the interference with 
anti-osteoporotic treatment efficacy. Calcium intake (from diet, added to supplementation) 
must be at least 1,200 mg/d, and vitamin D supplementation should be at least 800 UI/d if 
any of those disturbances are found. In addition, the efficacy of anti-osteoporotic drugs has 
only been demonstrated in the presence of vitamin D and calcium supplementation. 
Therapy should be titrated with doses that result in normocalcemia and serum 25-
hydroxyvitamin D concentrations of at least 30 ng/ml. In patients with normal renal 
function, a decrease in serum PTH levels from elevated to normal levels indicates that 25-
hydroxyvitamin D deficiency has been corrected. Some anti-epileptic drugs, e.g. phenytoin, 
phenobarbitone, primidone, and carbamazepine, increase hepatic metabolism of vitamin D, 
requiring higher vitamin D doses.  
5.2 Bisphosphonates 
Bisphosphonates have a strong affinity for bone apatite, which is the basis for their clinical 
use. They are potent inhibitors of bone resorption and produce their effect by reducing the 
recruitment and activity of osteoclasts and increasing their apoptosis. In general, 
alendronate (70 mg/week) and risedronate (35 mg/week) are reasonable antiosteoporotic 
drugs for secondary osteoporosis. However, many patients with osteoporosis secondary to 
gastrointestinal diseases or concurrent medications not tolerating, or adhering to, oral 
bisphosphonates and those in whom oral bisphosphonates are contraindicated may benefit 
from treatment with i.v. ibandronate or zoledronic acid. Many studies have shown that 
Alendronate and Zoledronate are able to reduce joint swelling and blood inflammatory tests 
(IL-1, IL-6, TNF-α, b2-microglobulin and erythrocyte sedimentation rate and C-reactive 
protein values) in various experimental arthritis animal models and in human studies. These 
medications reduce the macrophage production of TNF-α, IL-1 and nitric oxide (NO) and 
induce apoptosis of monocyte-macrophage-derived cell lines. These effects are in part 
dependent on RANKL inhibition and in part dependent on cytoplasmic events which 
involve protein-kinase C and iron ions. All these effects explain why, although 
bisphosphonates enhance proliferation of T-lymphocytes, they have been successfully used 
to treat bone loss secondary to RA45. The overall safety profile of bisphosphonates is 
favorable. Oral bisphosphonates are associated with mild gastrointestinal disturbances, and 
rarely cause esophagitis and ulcer. A recent study also showed an increase in esophageal 
cancer among chronic users. Intravenous zolendronate can induce a transient acute phase 
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reaction with fever, bone and muscle pain that ameliorates or disappears after subsequent 
courses. Osteonecrosis of the jaw has been described in cancer patients receiving high doses 
of intravenous pamidronate or zoledronate. Atrial fibrillation was noted to occur in a higher 
frequency after intravenous zolendronate, but a cause-effect relationship was not 
established and it was not seen in another study.  
5.3 Teriparatide 
Intermittent administration of PTH (for example, with daily subcutaneous injections) results 
in an increase of the number and activity of osteoblasts, leading to an increase in bone mass 
and in an improvement in skeletal architecture at both cancellous and cortical skeletal sites. 
The 1-34 N-terminal fragment (teriparatide) is used for the management of osteoporosis. 
Treatment with teriparatide has been shown to reduce significantly the risk of vertebral 
fractures and to reduce non-vertebral but not hip fractures46.The recommended dose is 20 
μg of teriparatide daily, given as a subcutaneous injection. The effect was initially seen in 
patients with severe osteoporosis and established vertebral fractures. Efficacy was later 
shown with osteoporosis even without fractures47.  
5.4 Stronzium ranelate 
Strontium ranelate is a recently approved agent in Europe, for the treatment of 
postmenopausal osteoporosis, to reduce the risk of vertebral and hip fractures (49). There is 
some evidence that strontium ranelate both inhibits bone resorption and stimulates bone 
formation, suggesting that the agent may uncouple the bone remodelling process. The 
recommended daily dose is a one 2-gram sachet once daily by mouth. The absorption of 
strontium ranelate is reduced by food, milk and its derivative products and the drug should 
be administered, therefore, between meals. Ideally, it should be taken at bedtime, preferably 
two hours after eating. Strontium ranelate is not recommended for patients with severe 
renal impairment (creatinine clearance below 30 mL/min).  
5.5 Denosumab 
Denosumab, a new drug under evaluation, acts as an anti-RANKL blocking osteoblast 
differention and slowing bone resorption similar to the OPG. Denosumab is a fully human 
monoclonal antibody that mimics the activity of osteoprotegerin. It binds to RANKL, 
thereby preventing RANKL from interacting with RANK and reducing its bone resorption.  
5.6 Raloxifene 
Raloxifene is part of Selective Estrogen Receptor Modulators (SERMs). They are a class of 
medications that act on the estrogen receptors throughout the body in a selective manner. 
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Normally, bone mineral density (BMD) is tightly regulated by a balance between osteoblast 
and osteoclast activity in the trabecular bone. Estrogen has a major role in regulation of the 
bone formation-resorption equilibrium, as it stimulates osteoblast activity48. Some SERMs 
such as raloxifene, act on the bone by slowing bone resorption by the osteoclasts. Raloxifene 
has the added advantage of reducing the risk of invasive breast cancer.  
6. Therapy in glucocorticoid treatment 
There are a number of guidelines regarding the management of GIO in patients who are 
receiving glucocorticoid treatment or that will be starting this therapy. We have analyzed 
the guidelines established by the American College of Rheumatology (ACR)49, and the 
Dutch Society of Rheumatology (DSR)50. A Cochrane Database Meta-Analysis concluded 
that calcium and vitamin D supplementation should be started in all patients who are 
administered glucocorticoids because of their low toxicity, low cost and the possible benefit 
in terms of fracture risk51. Vitamin D is a hormone that increases intestinal calcium 
absorption and increases its reabsorption in distal renal tubules. Serum levels of at least 30 
ng/mL (82 nmol/L), and optimally of 40–60 ng/mL, of 25-hydroxyvitamin D should be the 
target treatment regimen for GIO management. To achieve these levels, 1,000 to 2,000 IU of 
oral vitamin D daily may be necessary52. Bisphosphonates are indicated for the prevention 
and treatment of GIO and most guidelines recommend the use of these drugs. The 
prevention and treatment goals of bisphosphonate use are stabilized or increased bone 
mineral density, as well as reduced frequency of fractures. A study using risedronate 
showed a decrease in vertebral fractures after one year of treatment53. Currently, 
alendronate (70 mg/ week or 10 mg/day) and risedronate (35 mg/week or 5 mg/ day) are 
the only oral antiresorptive drugs that are recommended in GIO. Recently, zoledronic acid 
was approved for the prevention and treatment of GIO. In a multicenter, double-blind, 
double-dummy, randomized controlled trial that included 833 patients, a single 5 mg 
intravenous infusion of zoledronic caused a greater increase in bone mineral density than 
oral risedronate at 5 mg daily54. Bisphosphonate treatment is recommended while patients 
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mineral density, as well as reduced frequency of fractures. A study using risedronate 
showed a decrease in vertebral fractures after one year of treatment53. Currently, 
alendronate (70 mg/ week or 10 mg/day) and risedronate (35 mg/week or 5 mg/ day) are 
the only oral antiresorptive drugs that are recommended in GIO. Recently, zoledronic acid 
was approved for the prevention and treatment of GIO. In a multicenter, double-blind, 
double-dummy, randomized controlled trial that included 833 patients, a single 5 mg 
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are on glucocorticoids; however, in subjects with significant bone loss, therapy may need to be 
continued following the discontinuation of glucocorticoids. Caution needs to be exercised 
when considering the use of bisphosphonates in women of childbearing age with GIO,55 56  
given that bisphosphonates have an extended half-life and may cross the placenta with 
potentially unfavorable effects on fetal skeletal development. A recent review of 51 human 
cases examining exposure to bisphosphonates before or during pregnancy did not 
demonstrate skeletal abnormalities or other congenital malformations in the infants. Similarly, 
a related case-controlled study suggested that preconceptional and first-trimester use of 
bisphosphonates may pose limited fetal risk57. Saag et al., published a randomized multicenter 
trial to compare use of oral alendronate (10 mg/day) and subcutaneous teriparatide (20 
mg/day) over 18 months in patients with established GIO. The study showed that among 
patients with osteoporosis with a high risk for fracture, the bone mineral density increase in 
patients receiving teriparatide was greater than in those receiving alendronate58. 
7. Conclusion 
Localized bone loss in RA results from the activation of an inflammatory immune response, 
which increases both the number and the activity of osteoclasts.  
Osteoporosis in patients with rheumatoid arthritis is a silent disease that evolves in parallel 
with the underlying disease and gives a sign to exist only after the fracture. patients with 
rheumatoid arthritis are subject to chronic systemic inflammation and a chronic intake of 
corticosteroids. These elements form the basis of the osteoclastic process. The diagnosis and 
prevention becomes necessary to understand in all its aspects, the patient rheumatic disease 
and to avoid untoward developments. Therapy to prevent or reverse this bone loss should 
be directed at the suppression of inflammation, direct inhibition of osteoclastmediated bone 
resorption, or stimulation of osteoblastic bone formation.  
The challenge now is to determine if altering this inflammatory induced bone loss in RA will 
translate into reduced functional disability. The future is promising in this scientific arena. 
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1. Introduction 
In the last decade the use of Tumor Necrosis Factor- α inhibitors  including infliximab, 
etanercept, adalimumab; and lately certolizumab and golimumab, has revolutionized the 
treatment of rheumatoid arthritis (RA). These agents have been effective in reducing 
inflammatory activity and limiting joint destruction in patients with RA however their 
application has raised a number a safety concerns. Increased risk of infections is of 
predominant importance given these factors’ major role in altering host defense mechanisms.  
2. Infections in rheumatoid arthritis patients 
2.1 Background infection risk in patients with RA 
As infection adverse effects are common in patients with RA due to the underlying disease 
itself and/or concurrent medications used in its treatment such as immunosuppressants, it 
is of great importance to identify whether biological treatments increase this risk further 
(Furst 2010).  
Epidemiological studies prior the introduction of biological treatments have shown that 
patients with RA are at increased risk of certain types of infections including pulmonary 
infection, generalized sepsis, osteomyelitis, cellulitis, and septic arthritis with relative risks 
of infection - related mortality ranging from 5 to 15 (Mitchell, Spitz et al. 1986; Wolfe, 
Mitchell et al. 1994; Symmons, Jones et al. 1998). Nevertheless, the confounding influence of 
treatment with glycocorticoids and other disease –modifying antirheumatic drugs (DMRDs) 
is difficult to interpret. Disease it self leads to alterations in cellular immunity, including a 
decline in the number and function of T-suppressor and natural killer (NK) cells (Dobloug, 
Forre et al. 1982; Fox, Fong et al. 1984; Young, Adamson et al. 1984); changes that may 
predispose patients to infection. Other studies have suggested a genetic component to the 
risk of infection in RA. For example the incidence of urinary tract infection in patients with 
rheumatoid arthritis patients has been correlated with the number of risk alleles defined by 
single nucleotide polymorphisms in the genes for TNF-α, lymphotoxin–α and the Fcγ 
receptors 2A, 3A and 3B (Hughes, Criswell et al. 2004).  
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2.2 Bacterial infections 
2.2.1 Randomised controlled trials and extension studies of anti-TNF agents 
Infliximab 
The 1- year anti- TNF trial in Rheumatoid Arthritis with concomitant Therapy (ATTRACT 
study) reported similar incidences of infections among patients treated with infliximab (3 
or 10 mg/kg, given every 4 weeks or every 8 weeks) [1-5 patients (1–6%)] compared to 
patients receiving methotrexate (MTX) alone [5 patients (6%)]. (Maini, St Clair et al. 1999). 
The serious infections were described as bacterial infections, bronchitis, cellulitis, 
peritonitis, pneumonia, pyelonephritis and urinary tract infection, sepsis and tuberculosis, 
although the relative incidence of each of these infections was not reported. Notably, the 
frequency of any infection was significantly increased in patients receiving 10 mg/kg of 
infliximab, but not in those receiving 3 mg/kg. Similar incidence of serious infections was 
reported when ATTRACT was extended to 2 years (10-13%) (Maini, Breedveld et al. 2004). 
On the contrary, the incidence of serious infections in the 54 weak active controlled study 
of patients receiving infliximab for treatment of early onset RA (ASPIRE study) was 
significantly higher in the group receiving infliximab (3 or 6 mg/kg, given every 8 weeks 
in combination with MTX than in the group of patients receiving MTX monotherapy (St 
Clair, van der Heijde et at 2004. More specifically, serious infections included pneumonia, 
tuberculosis (TB), sepsis, bronchitis and septic bronchitis and occurred more commonly in 
patients receiving MTX -3 mg/kg infliximab [21 patients (5.6%)] or MTX -6 mg/kg 
infliximab [19 patients (5.0%)] than in those receiving MTX alone [6 patients (2.1%)] 
(P=0.02 and P=0.4, respectively). Among the serious infections, pneumonia occurred more 
frequently in the infliximab-treated patients than in those treated with MTX alone [15/749 
(2.0%) versus 0/291 (0.0%)]. According to the authors of the ASPIRE study most of these 
cases were community-acquired pneumonias that responded appropriately to antibiotic 
therapy. It has been suggested that the apparent differences in the incidence of severe 
infections between the ASPIRE and ATTRACT trials may reflect, at least partially, 
differences in study design. ASPIRE had substantially more patients enrolled (N=291-377 
per treatment arm, compared with 81-88 in ATTRACT) and in addition ASPIRE excluded 
patients that had prior treatment with MTX or anti-TNF while all patients in ATTRACT 
were receiving MTX at the time of the enrollment (Furst 2010). 
Etanercept 
With regards to etanercept, a 1 year study comparing MTX with 10 mg or 25 mg etanercept 
twice weekly reported similar number of patients with one or more infections in all 
treatment groups (Bathon, Martin et al. 2000). Interestingly, when the number of events that 
occurred per patient-year was analyzed, the rate of all types of infection was significantly 
higher among patients who received MTX than among those who received either dose of 
etanercept (1.9 vs. 1.5 events per patient-year, P=0.006). The frequency of upper respiratory 
tract infections was similar in the MTX group and the group assigned to receive 25 mg of 
etanercept, while the rate of infections at other sites in the respiratory tract was higher in the 
MTX group (1.3 vs. 1.0 events per patient-year, P=0.006). Infections requiring hospitalization 
or the intravenous administration of antibiotics occurred in less than 3% of patients in each 
group. There were no opportunistic infections, and no deaths from infections. When this 
study was extended to 2 years, similar incidences of serious infections in each treatment arm 
 
Infectious Complications of Anti-Tumour Necrosis Factor-α Therapy in Rheumatoid Arthritis 
 
95 
were reported and did not increase in frequency during the second year of the study 
(Genovese, Bathon et al. 2002). Over the 2-year study period, 21 patients had infections that 
required hospitalization or use of intravenous antibiotics, including 9 patients in the MTX 
group, 5 patients in the 10 mg etanercept group, and 7 patients in the 25 mg group. The 
types of serious infection observed in the second year were similar to those reported in the 
first year and included cellulitis (1 patient each in all 3 treatment groups), bronchitis (1 
patient in the 10 mg group), pneumonia (1 patient in the 10 mg group), and cystitis (2 
patients in the 25 mg group); no cases of TB and no opportunistic infections were seen. 
Similarly, in a double-blind, randomized, clinical efficacy, safety, and radiographic study 
(TEMPO) involving 686 patients with active rheumatoid arthritis randomly allocated to 
treatment with etanercept 25 mg (administered subcutaneously twice a week), oral MTX (up 
to 20 mg every week), or the combination, similar incidences of infections and serious 
infections have been recorded in all treatment arms with no reports of TB or opportunistic 
infections (Klareskog, van der Heijde et al. 2004). Those results were sustained into the 2 
year follow up of the TEMPO trial showing similar rates of serious infections among all 
treatment groups (van der Heijde, Klareskog et al. 2006). Again, no cases of TB were 
reported but there was one case of bronchopulmonary aspergillosis in the combination 
therapy group. A similarly favorable safety profile for etanercept was reported from the 
ADORE study, which evaluated the efficacy and safety of combination etanercept and MTX 
versus etanercept alone in patients with RA with an inadequate response to MTX. The study 
showed comparable incidence of infections in the two arms and notably no cases of 
opportunistic infections or TB were reported in the combination group (van Riel, Taggart et 
al. 2006).  
Adalimumab 
The safety profile of adalimumab was initially evaluated in 3 double blind placebo 
controlled short term (24-26 weeks) trials reporting low incidence of serious infections (Furst, 
Schiff et al. 2003; van de Putte, Atkins et al. 2004; Weinblatt, Keystone et al. 2006). In a 
subsequent 52 weeks - long study comparing treatment with adalimumab (40mg every other 
week or 20 mg every week) plus concomitant MTX in patients with active RA who had an 
inadequate response to MTX, the proportion of patients with serious infections was higher 
in the group receiving adalimumab (3.8%) than in those receiving MTX (0.5%) (P≤0.02), and 
was highest in the patients receiving 40 mg adalimumab every other week (Keystone, 
Kavanaugh et al. 2004). Adjusting for exposure time, serious infections occurred at a rate of 
0.06 patients / patient-year with adalimumab 40 mg every other week, 0.03 patients per 
patient-year with adalimumab 20 mg weekly, and 0.01 patients per patient-year with MTX 
alone. One patient treated with adalimumab 40 mg every other week was diagnosed as 
having primary TB of the cervical lymph nodes, and nodes, was withdrawn from the study 
and successfully treated. At baseline, this patient had a negative tuberculin purified protein 
derivative (PPD) test result and a normal chest radiograph. One patient treated with 
adalimumab 40 mg every other week plus MTX was diagnosed with histoplasmosis 
infection after 78 days of treatment, and was subsequently withdrawn from the study and 
successfully treated with antifungal therapy. This patient lived in an area which was 
endemic for histoplasmosis infection. One patient treated with adalimumab 40 mg every 
other week was diagnosed as having herpes zoster and developed encephalitis, which 
resolved but resulted in mild lower extremity weakness. In the 2- year multicenter, double  
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blind, active Comparator-controlled study designed to compare the efficacy and safety of 
adalimumab plus MTX versus MTX monotherapy or adalimumab monotherapy in patients 
with early, aggressive RA who had not previously received MTX treatment (PREMIER 
study), the overall rate of infectious adverse events (AEs) did not differ significantly among 
the 3 treatment groups (123, 110, and 119 events per 100 patient-years in the combination 
therapy, adalimumab monotherapy, and MTX monotherapy groups, respectively) 
(Breedveld, Weisman et al. 2006). The rate of serious infections in the adalimumab 
monotherapy group was significantly lower than that in the combination treatment group, 
but not significantly different compared with the MTX monotherapy group. Notably, 
serious infections were more common in the combination therapy arm with 9 serious 
infections reported, including 3 pulmonary infections (1 case of pleural TB) and 1 case each 
of sinus infection, wound infection, septic arthritis, infected hygroma, cellulitis, and urinary 
tract infection. In the adalimumab monotherapy arm, serious infections included 1 case each 
of pneumonia, cellulitis, and septic arthritis. In the MTX monotherapy arm, the 7 serious 
infections consisted of 2 cases of pneumonia and 1 each of septic arthritis, sinusitis, abscess, 
bacteremia, and parotitis. The long term safety of adalimumab was investigated in the 4- 
year open-label extension of the ARMADA trial (Weinblatt, Keystone et al. 2006). The rate of 
serious infections was slightly lower throughout the entire study than in the blinded period 
alone with the most common serious infections reported being pneumonia, urinary tract 
infections and septic arthritis. A PPD skin test was performed at the screening visit for all 
patients. Standard chest radiographs were also taken at the screening visit and at week 24. 
Notably, at baseline, 11/271 (4.1%) randomized patients had positive PPD results at 
screening, including 9/209 (4.3%) adalimumab treated patients and 2/62 (3.2%) placebo 
treated patients. These patients were treated with TB prophylaxis in accordance with routine 
medical practice. No cases of TB or other opportunistic infections were reported. The safety 
profile of adalimumab was analyzed further in a cumulative analysis of data from 10050 
patients who participated in randomized controlled trials, open label extensions, and two 
phase IIIb open label trials, representing 12506 patient-years (PYs) of adalimumab exposure 
(Schiff, Burmester et al 2006). The rate of serious infections in the clinical trial safety 
database as of April 2005 was 5.1/100 PYs. This rate is nearly identical to that observed in 
August 2002 (4.9/100 PYs) and was similar to rates reported for the general RA population. 
Four cases of histoplasmosis were reported, all in endemic areas (0.03/100 PYs). No cases of 
coccidioidomycosis have been reported in RA clinical trials.  
2.2.2 Registry data, observational data and chart reviews 
The safety profile of anti-TNF agents in the everyday clinical practice was elucidated further 
by registry data analysis, observational studies and chart reviews. Data derived from these 
studies could be highly informative; however the lack of a standard comparator, strict 
inclusion and exclusion criteria and the inherent differences in patient characteristics with 
respect to ethnic, geographical and socio-economical characteristics often reduce their 
credibility and, produce desperate results and do not allow direct comparisons among 
different studies. Nevertheless, these studies become important when they investigate 
specific or relatively rare types of infections and raise specific concerns with regards to 
infections in certain population groups (Furst 2010).  
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In the German registry study, data of 512 patients receiving etanercept, 346 patients 
receiving infliximab, 70 patients receiving anakinra, and 601 control patients treated with 
disease-modifying antirheumatic drugs were analyzed. After adjusting for confounding 
factors, the relative risks of serious AEs were 2.2 [95% CI (confidence interval) 0.9–5.4] for 
patients receiving etanercept and 2.1 (95% CI 0.8–5.5) for patients receiving infliximab, 
compared to those treated with DMARDs. Respiratory tract infections were the most 
frequent followed by skin and subcutaneous tissue infections, influenza like illness, herpes 
virus infections, and urinary tract infections. Lower respiratory tract infections were the 
most common serious infections (Listing, Strangfeld et al. 2005). Updated results from the 
British Register for Biologic Therapies (BSRBR) (Galloway, Hyrich et al. 2011) also showed 
in contrary to previous reports (Dixon, Watson et al. 2006) that anti-TNF therapy is 
associated with a small but significant overall risk of serious infections. The adjusted hazard 
ratio (adjHR) for serious infections in the anti-TNF cohort was 1.2 (95% CI 1.1, 1.5). The risk 
did not differ significantly between the three agents adalimumab, etanercept and infliximab 
and it was highest during the first 6 months of therapy [adjHR (Hazard Ratio) 1.8, 95% CI 
1.3-2.6]. This was in accordance with the work of Askling and Dixon who reviewed all 
available studies on infection risk associated with anti-TNF therapy in RA and found that 
the risk was highest in the first few months but declined later during the course of treatment 
(Askling and Dixon 2008). It has been proposed that this variation in risk may reflect 
biological functions (anti-TNF therapy causing early infections in susceptible individuals), 
or bias (clinicians having a lower threshold for treating infections early in therapy). In 
addition the depletion of susceptible individuals (a healthy user effect) by withdrawing 
patients who develop an infection from the anti-TNF cohort may reduce the apparent risk of 
the drug through subsequent patient selection bias. Furthermore, as patients become 
established on anti-TNF therapy, their RA becomes better controlled and other confounding 
factors such as mobility may improve or their dose of steroids may be reduced thus 
contributing to the complexity of interpretation (Askling and Dixon 2008; Galloway, Hyrich 
et al. 2011).  
Registries and chart reviews can be particularly useful in identified specific infectious risks 
for susceptible patients. For example, data from the French registry estimated the relative 
risk of legionellosis when receiving treatment with a TNF-α antagonist to be between 16.5 
and 21.0, compared with the relative risk in France overall (Tubach, Ravaud et al. 2006).  
2.2.3 Case reports 
Numerous case reports have raised awareness to rare bacterial infections in RA patients 
treated with anti-TNF. These included reports on reactivation of brucellosis (Jimenez, 
Colmenero et al. 2005), Capnocytophaga cynodegmi-related cellulitis (Gerster and Dudler 
2004), Roseomonas mucosa induced septic arthritis (Sipsas, Papaparaskevas et al. 2006), and 
Propionebacterim acnes-related endogenous endophthalmitis (Montero, Ruiz-Moreno et al. 
2006). 
2.2.4 Meta-analyses 
One solution to the lack of precision in the estimates of harm derived from individual 
randomized trials is to pool their results using meta-analysis. Results however from the two 
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blind, active Comparator-controlled study designed to compare the efficacy and safety of 
adalimumab plus MTX versus MTX monotherapy or adalimumab monotherapy in patients 
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of sinus infection, wound infection, septic arthritis, infected hygroma, cellulitis, and urinary 
tract infection. In the adalimumab monotherapy arm, serious infections included 1 case each 
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year open-label extension of the ARMADA trial (Weinblatt, Keystone et al. 2006). The rate of 
serious infections was slightly lower throughout the entire study than in the blinded period 
alone with the most common serious infections reported being pneumonia, urinary tract 
infections and septic arthritis. A PPD skin test was performed at the screening visit for all 
patients. Standard chest radiographs were also taken at the screening visit and at week 24. 
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medical practice. No cases of TB or other opportunistic infections were reported. The safety 
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patients who participated in randomized controlled trials, open label extensions, and two 
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Four cases of histoplasmosis were reported, all in endemic areas (0.03/100 PYs). No cases of 
coccidioidomycosis have been reported in RA clinical trials.  
2.2.2 Registry data, observational data and chart reviews 
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In the German registry study, data of 512 patients receiving etanercept, 346 patients 
receiving infliximab, 70 patients receiving anakinra, and 601 control patients treated with 
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factors such as mobility may improve or their dose of steroids may be reduced thus 
contributing to the complexity of interpretation (Askling and Dixon 2008; Galloway, Hyrich 
et al. 2011).  
Registries and chart reviews can be particularly useful in identified specific infectious risks 
for susceptible patients. For example, data from the French registry estimated the relative 
risk of legionellosis when receiving treatment with a TNF-α antagonist to be between 16.5 
and 21.0, compared with the relative risk in France overall (Tubach, Ravaud et al. 2006).  
2.2.3 Case reports 
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2.2.4 Meta-analyses 
One solution to the lack of precision in the estimates of harm derived from individual 
randomized trials is to pool their results using meta-analysis. Results however from the two 
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existing meta-analyses studies on anti-TNF therapy and risk of infection are disparate. A 
meta-analysis of nine randomized, controlled studies including 3493 patients with RA who 
received anti-TNF antibody treatment (infliximab and adalimumab) and 1512 patients who 
received placebo reported a doubled risk of serious infection [odds ratio (OR) 2.0, 95% CI 
1.3–3.1] and a tendency towards a dose–response association (Bongartz, Sutton et al. 2006). 
On the contrary, a second meta-analysis of five published, placebo-controlled trials 
involving a total of 2945 randomized patients, who received at least one dose of abatacept 
(0.5, 2 or 10 mg/kg) (n=1960) or placebo (n=985) for a duration of treatment ranging 
between 24 and 48 weeks did not reveal a statistically significant increased risk of serious 
infection for abatarcept (Salliot, Dougados et al. 2009). The 49 serious infections reported in 
the abatacept cohort were mainly broncho-pulmonary, streptococcal and pyogenic 
septicaemia, staphylococcal arthritis, abscesses, gastrointestinal infections (6 of whom 3 
diverticulitis), dermatological infections (six of whom one was a cellulitis) and 
pyelonephritis. One case of unconfirmed TB and one case of pulmonary aspergillosis were 
reported. The last patient (who had a history with TB and pulmonary fibrosis) died with 
aspergillosis and Pseudomonas aeruginosa septicaemia.  
2.3 Tuberculosis and opportunistic infections 
As shown earlier, the incidence of TB in pre-registration clinical trials has been low. It was 
only after licensing of these medications that post-marketing surveillance registers showed 
results suggestive a strong association between ant-TNF treatment and TB. Keane et al 
analysed data from the US Food and Drug Administration’s ( FDA) Adverse Event 
Reporting System (AERS) for reports of TB with infliximab from its licensure in 1998 
through May 29, 2001 (Keane, Gershon et al. 2001). There were 70 reported cases of TB after 
treatment with infliximab for a median of 12 weeks. In 48 patients, TB developed after three 
or fewer infusions and 40 of the patients had extrapulmonary disease (17 had disseminated 
disease, 11 lymph-node disease, 4 peritoneal disease, 2 pleural disease, and 1 each 
meningeal, enteric, paravertebral, bone, genital, and bladder disease). An estimated rate of 
24.4 cases of tuberculosis per 100 000 in the USA compared with a background rate in 
American patients with RA who had not received the drug of 6.2 cases per 100000 was 
calculated. The rather atypical presentation of the disease (e.g. extrapulmonary 
dissemination), the temporal relation between development of active tuberculosis and the 
start of therapy, the age of the patients (median, 57 years), the small number of cases with 
reported recent exposure to TB, and the low incidence of TB in the countries from which the 
reports were received suggested reactivation of the disease (Keane, Gershon et al. 2001).  
As of March, 2002, 121000 patients had been treated with etanercept worldwide with about 
94% of the use in the USA. In a search of the FDS’s AERS database reported up to March 
2002, Mohan and co-workers detected 25 cases of tuberculosis that occurred during or after 
etanercept therapy (Mohan, Cote et al. 2004). Patients with etanercept-associated TB were 
fewer but clinically similar to those with infliximab-associated TB (Keane, Gershon et al. 
2001). The numbers of patients who had been exposed to etanercept and infliximab were 
roughly similar, yet the TB rate for US patients using etanercept was lower than that for 
patients using infliximab (∼10 vs. ∼41 cases/100000 patient-years of exposure). It has been 
proposed that this difference might be due to the divergent ways in which the 2 agents 
neutralize TNF-α, the use of MTX concurrently with infliximab (as indicated for RA in the 
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infliximab package insert), differences in proportions of international patients treated with 
the 2 agents, or other factors (Gardam, Keystone et al. 2003; Mohan, Cote et al. 2004). 
Overall, in a large systematic review of infectious complications of TNF antagonists 
extracted from 35275 distinct reports from the AERS database between for January 1998–
September 2002, granulomatous infections were reported at rates of ∼239 per 100000 
patients who received infliximab and ∼74 per 100,000 patients who received etanercept (P 
<0.001) (Wallis, Broder et al. 2004). TB was the most frequently reported disease, occurring 
in ∼144 and ∼35 per 100,000 infliximab-treated and etanercept-treated patients, respectively 
P<0.001. Candidiasis, coccidioidomycosis, histoplasmosis, listeriosis, nocardiosis, and 
infections due to nontuberculous mycobacteria were reported with significantly greater 
frequency among infliximab-treated patients. 72% of these infection occurred 90 days after 
starting infliximab treatment, and 28% occurred after starting etanercept treatment P<0.001. 
These data indicated a relative risk of granulomatous infection that was >3 among patients 
who received infliximab compared to those who received etanercept. The clustering of 
reports shortly after initiation of treatment with infliximab was consistent with reactivation 
of latent infection.  
Geographical associations between anti-TNF therapy and specific granulomatous diseases 
have been suggested. For example, disseminated histoplasmosis has been reported more 
frequently in endemic regions in the US (Lee, Slifman et al. 2002). In a review of the FDA 
passive surveillance database, nine cases of invasive disseminated histoplasmosis associated 
with infliximab and 1 associated with etanercept were reported. In patients treated with 
infliximab, manifestations of histoplasmosis occurred within 1 week to 6 months after the first 
dose and typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis. All 
patients had received concomitant immunosuppressive medications in addition to infliximab 
or etanercept, and all resided in histoplasmosis endemic regions of central US (Lee, Slifman et 
al. 2002). Similarly, anti-TNF therapy was shown to be associated with increased reports of 
leishmaniasis in endemic areas in Europe (Xynos, Tektonidou et al. 2009).  
A major factor that has influenced data relating to the risk of TB associated with biological 
treatments has been the introduction of vigorous screening of patients participating in 
clinical trials; hence rates for newer biological agents such as abatarcept may be biased. 
Screening for TB exposure with PPD skin testing or newer interferon-based serum tests 
(although their optimal use in this setting is not yet clear) should be performed before 
beginning therapy with anti-TNF agents (Winthrop and Chiller 2009). Anergy is known to 
occur in patients with RA or Crohn’s disease, and the possibility of false-negative skin tests 
should be taken into consideration. Nevertheless from a therapeutic point of view, since the 
implementation of strict guidelines (e.g. BTS recommendations, 2005) with regards to 
screening patients for exposure risks and treating latent TB prior to initiation of any 
biological treatment, the risk of tuberculosis has decreased. This is depicted in the data from 
the Spanish Registry showing that these strategies have resulted in dropping the rates of 
active TB in RA patients by 83% reaching those observed for RA patients not treated with 
TNF antagonists (Carmona, Gomez-Reino et al. 2005). 
2.3.1 TNF-α pathophysiology and infections 
TNF is essential for granuloma formation and maintenance which are key components of 
host defences against intracellular pathogens (Furst, Wallis et al. 2006). TNF can support 
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existing meta-analyses studies on anti-TNF therapy and risk of infection are disparate. A 
meta-analysis of nine randomized, controlled studies including 3493 patients with RA who 
received anti-TNF antibody treatment (infliximab and adalimumab) and 1512 patients who 
received placebo reported a doubled risk of serious infection [odds ratio (OR) 2.0, 95% CI 
1.3–3.1] and a tendency towards a dose–response association (Bongartz, Sutton et al. 2006). 
On the contrary, a second meta-analysis of five published, placebo-controlled trials 
involving a total of 2945 randomized patients, who received at least one dose of abatacept 
(0.5, 2 or 10 mg/kg) (n=1960) or placebo (n=985) for a duration of treatment ranging 
between 24 and 48 weeks did not reveal a statistically significant increased risk of serious 
infection for abatarcept (Salliot, Dougados et al. 2009). The 49 serious infections reported in 
the abatacept cohort were mainly broncho-pulmonary, streptococcal and pyogenic 
septicaemia, staphylococcal arthritis, abscesses, gastrointestinal infections (6 of whom 3 
diverticulitis), dermatological infections (six of whom one was a cellulitis) and 
pyelonephritis. One case of unconfirmed TB and one case of pulmonary aspergillosis were 
reported. The last patient (who had a history with TB and pulmonary fibrosis) died with 
aspergillosis and Pseudomonas aeruginosa septicaemia.  
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As shown earlier, the incidence of TB in pre-registration clinical trials has been low. It was 
only after licensing of these medications that post-marketing surveillance registers showed 
results suggestive a strong association between ant-TNF treatment and TB. Keane et al 
analysed data from the US Food and Drug Administration’s ( FDA) Adverse Event 
Reporting System (AERS) for reports of TB with infliximab from its licensure in 1998 
through May 29, 2001 (Keane, Gershon et al. 2001). There were 70 reported cases of TB after 
treatment with infliximab for a median of 12 weeks. In 48 patients, TB developed after three 
or fewer infusions and 40 of the patients had extrapulmonary disease (17 had disseminated 
disease, 11 lymph-node disease, 4 peritoneal disease, 2 pleural disease, and 1 each 
meningeal, enteric, paravertebral, bone, genital, and bladder disease). An estimated rate of 
24.4 cases of tuberculosis per 100 000 in the USA compared with a background rate in 
American patients with RA who had not received the drug of 6.2 cases per 100000 was 
calculated. The rather atypical presentation of the disease (e.g. extrapulmonary 
dissemination), the temporal relation between development of active tuberculosis and the 
start of therapy, the age of the patients (median, 57 years), the small number of cases with 
reported recent exposure to TB, and the low incidence of TB in the countries from which the 
reports were received suggested reactivation of the disease (Keane, Gershon et al. 2001).  
As of March, 2002, 121000 patients had been treated with etanercept worldwide with about 
94% of the use in the USA. In a search of the FDS’s AERS database reported up to March 
2002, Mohan and co-workers detected 25 cases of tuberculosis that occurred during or after 
etanercept therapy (Mohan, Cote et al. 2004). Patients with etanercept-associated TB were 
fewer but clinically similar to those with infliximab-associated TB (Keane, Gershon et al. 
2001). The numbers of patients who had been exposed to etanercept and infliximab were 
roughly similar, yet the TB rate for US patients using etanercept was lower than that for 
patients using infliximab (∼10 vs. ∼41 cases/100000 patient-years of exposure). It has been 
proposed that this difference might be due to the divergent ways in which the 2 agents 
neutralize TNF-α, the use of MTX concurrently with infliximab (as indicated for RA in the 
 
Infectious Complications of Anti-Tumour Necrosis Factor-α Therapy in Rheumatoid Arthritis 
 
99 
infliximab package insert), differences in proportions of international patients treated with 
the 2 agents, or other factors (Gardam, Keystone et al. 2003; Mohan, Cote et al. 2004). 
Overall, in a large systematic review of infectious complications of TNF antagonists 
extracted from 35275 distinct reports from the AERS database between for January 1998–
September 2002, granulomatous infections were reported at rates of ∼239 per 100000 
patients who received infliximab and ∼74 per 100,000 patients who received etanercept (P 
<0.001) (Wallis, Broder et al. 2004). TB was the most frequently reported disease, occurring 
in ∼144 and ∼35 per 100,000 infliximab-treated and etanercept-treated patients, respectively 
P<0.001. Candidiasis, coccidioidomycosis, histoplasmosis, listeriosis, nocardiosis, and 
infections due to nontuberculous mycobacteria were reported with significantly greater 
frequency among infliximab-treated patients. 72% of these infection occurred 90 days after 
starting infliximab treatment, and 28% occurred after starting etanercept treatment P<0.001. 
These data indicated a relative risk of granulomatous infection that was >3 among patients 
who received infliximab compared to those who received etanercept. The clustering of 
reports shortly after initiation of treatment with infliximab was consistent with reactivation 
of latent infection.  
Geographical associations between anti-TNF therapy and specific granulomatous diseases 
have been suggested. For example, disseminated histoplasmosis has been reported more 
frequently in endemic regions in the US (Lee, Slifman et al. 2002). In a review of the FDA 
passive surveillance database, nine cases of invasive disseminated histoplasmosis associated 
with infliximab and 1 associated with etanercept were reported. In patients treated with 
infliximab, manifestations of histoplasmosis occurred within 1 week to 6 months after the first 
dose and typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis. All 
patients had received concomitant immunosuppressive medications in addition to infliximab 
or etanercept, and all resided in histoplasmosis endemic regions of central US (Lee, Slifman et 
al. 2002). Similarly, anti-TNF therapy was shown to be associated with increased reports of 
leishmaniasis in endemic areas in Europe (Xynos, Tektonidou et al. 2009).  
A major factor that has influenced data relating to the risk of TB associated with biological 
treatments has been the introduction of vigorous screening of patients participating in 
clinical trials; hence rates for newer biological agents such as abatarcept may be biased. 
Screening for TB exposure with PPD skin testing or newer interferon-based serum tests 
(although their optimal use in this setting is not yet clear) should be performed before 
beginning therapy with anti-TNF agents (Winthrop and Chiller 2009). Anergy is known to 
occur in patients with RA or Crohn’s disease, and the possibility of false-negative skin tests 
should be taken into consideration. Nevertheless from a therapeutic point of view, since the 
implementation of strict guidelines (e.g. BTS recommendations, 2005) with regards to 
screening patients for exposure risks and treating latent TB prior to initiation of any 
biological treatment, the risk of tuberculosis has decreased. This is depicted in the data from 
the Spanish Registry showing that these strategies have resulted in dropping the rates of 
active TB in RA patients by 83% reaching those observed for RA patients not treated with 
TNF antagonists (Carmona, Gomez-Reino et al. 2005). 
2.3.1 TNF-α pathophysiology and infections 
TNF is essential for granuloma formation and maintenance which are key components of 
host defences against intracellular pathogens (Furst, Wallis et al. 2006). TNF can support 
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host immunity through the secretion of chemokines, up-regulation of adhesion molecules 
and the induction of macrophage apoptosis. While TNF blockers may therefore interfere 
with these important immune functions, other less predictable immune effects have been 
seen with these agents. In particular, TNF-blockers have been shown to diminish interferon 
(IFN)-γ effects and stimulate apoptosis of key immune cells, including monocytes, CD4+ T 
helper cells and Mtb-reactive CD8+ T cells. Anti-TNF therapy is also associated with 
increased regulatory T cell (Treg) function, which has been linked with susceptibility to TB 
(Harris and Keane 2010). TNF-α neutralization in mice has resulted in fatal reactivation of 
persistent tuberculosis characterized by a moderately increased tissue bacillary burden and 
severe pulmonic histopathological deterioration that was associated with changes indicative 
of squamous metaplasia and fluid accumulation in the alveolar space (Mohan, Scanga et al. 
2001). 
2.4 Postoperative infections 
Although several studies have attempted to address the risk of postoperative infection, 
limited statistical precision has been a major concern. The largest study reported a 50% (but 
not statistically significant) increased risk of surgical site infections for those patients who 
continued therapy peri-operatively (den Broeder, Creemers et al. 2007). Nevertheless, 
considering the morbidity of orthopedic surgical site infections (especially prosthesis 
infections) as compared to a transient surge in disease activity, withholding anti-TNF agents 
peri-operatively appears to be the most reasonable and prudent approach at present 
(Bongartz 2007).  
2.5 Viral infections 
Reactivation of Hepatitis B (HBV) infection is a well described complication of 
immunosuppression in the setting of organ transplantation or cancer chemotherapy, 
occurring in up to 50% of patients where concomitant anti-viral treatment is not applied 
(Shale, Seow et al. 2010). The use of anti-TNF medications has been reported in isolated case 
reports, case series and chart reviews with a variety of outcomes ranging from apparent 
viral clearance to fatal hepatitis. In a comprehensive review of these cases by Zingarelli at al 
involving 27 HBV-infected patients treated with anti-TNF agents, HBV reactivation was 
documented in 14% of patients treated with lamivudine compared with 73% of patients not 
receiving HBV prophylaxis (Zingarelli, Frassi et al. 2009) thus suggesting that the use of 
prophylactic lamivudine could help reducing the risk of HBV reactivation. More recently, 
interesting data with regards to the relative safety of anti-TNF agents in HBV carriers were 
presented by Charpin et al (Charpin, Guis et al. 2009). Their cohort included 21 patients with 
serologically cured HBV infection, that is HBsAg –ve plus anti-HBc +ve patients and results 
were suggestive that anti-TNF therapy appeared to be safe during the a limited follow up 
period of three years. Nevertheless, about 30% of patients involved in this study had 
significant lower antibody titers over the follow up period which may be relevant during 
long-term follow up (Jansen 2010). Similar findings we reported by others over a shorter 
follow up period of 2 years (Vassilopoulos, Apostolopoulou et al. 2010) yet the decrease in 
antibody titers observed in the later study was comparable to that observed in a control 
group of patients treated with MTX alone, indicating no apparent specific effect of anti-TNF 
on HBV protective immunity.  
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Anti-TNF therapy for RA in the setting of Hepatitis C (HCV) infection could be of particular 
interest in light of the existing evidence suggesting a role for inflammatory cytokines 
including TNF-α in the mediating hepatocyte destruction in chronic CMV (Parke and 
Reveille 2004). It may therefore carefully assumed that anti-TNF agents may be safer in 
patients infected with HCV rather than HBV (Shale, Seow et al. 2010) and furthermore this 
notion has been tested in a phase 2 randomised, double-blind, placebo-controlled study 
where etanercept given for 24 weeks as adjuvant therapy to interferon and ribavirin was 
shown to significantly improve virological response among patients with chronic HCV and 
was associated with decreased incidence of most adverse effects associated with interferon 
and ribavirin (Zein 2005). Although overall experience to date with anti-TNF agents in the 
chronic HCV setting suggests an acceptable short-term safety profile (Marotte, Fontanges et 
al. 2007), long-term issues remain to be clarified.  
The safety of anti-TNF therapy in HIV is a controversial subject. TNF inhibition in the 
setting of HIV induced immunosuppression does not appear appealing in view of the 
potential role for TNF-α in the host defence against infections. Notably, in an early report, 
the use of etanercept in HIV positive patient with psoriasis and CD4 count of <200/mm3 
was associated with polymicrobial infections prompting termination of the treatment 
(Aboulafia, Bundow et al. 2000). Subsequent reports though have shown a favourable safety 
profile (Kaur, Chan et al. 2007; Cepeda, Williams et al. 2008), yet clinical decisions should be 
taken cautiously; careful consideration of the risks and benefits for the individual patient 
would be needed and close clinical and virological monitoring should always be warranted.  
The safety of TNF inhibitors in patients with herpes virus (HSV) infections has also been 
considered. In particular the risk of herpes zoster infection in patients with RA is twice as 
much even in the absence of therapy (Wolfe, Michaud et al. 2006; Smitten, Choi et al. 2007) 
and severe herpes zoster infections have been reported in randomised controlled trials and 
their open-label follow up studies in patients with RA receiving the TNF inhibitors 
infliximab or adalimumab (Lipsky, van der Heijde et al. 2000; Furst, Schiff et al. 2003; 
Keystone, Kavanaugh et al. 2004; Maini, Breedveld et al. 2004). A study by Strangfeld et al 
(Strangfeld, Listing et al. 2009) addressed the question whether this association actually 
represents a true association between TNF inhibitors reactivation of latent viral infections or 
simply reflects the increased risk of herpes zoster infection in RA patients (Bongartz and 
Orenstein 2009). In this prospective cohort the investigators identified 86 episodes of herpes 
zoster among 5040 patients from the German biologics register RABBIT, receiving anti-TNF 
agents or conventional DMARDs. Adjusted for age, RA severity and glucocorticoid use, a 
significant increased risk was observed for treatment with the monoclonal antibodies (HR, 
1.82 [95% CI, 0.73-2.55]), although this risk was lower than the threshold (of 2.5) for clinical 
significance. No significant associations were found for etanercept use (HR 1.36, 95% CI 
0.73-2.55) or for anti-TNF treatment (HR 1.63, 95% CI 0.97-2.74) as a class. Equally 
important, the incidence rate of multidermatomal and ophthalmic zoster was higher in 
patients taking TNF inhibitors implying severe disease often requiring hospitalisation 
(Bongartz and Orenstein 2009). Nevertheless, anti-TNF therapy can generally be restarted 
following temporary interruption and conventional anti-viral therapy until the skin lesions 
are completely healed (Wendling, Streit et al. 2008). Isolated varicella infections have also 
been reported in RA patients receiving anti-TNF therapy (Vonkeman, ten Napel et al. 2004; 
Choi, Kim et al. 2006; Lee, Kim et al. 2007). Notably the rash in one of these cases was 
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host immunity through the secretion of chemokines, up-regulation of adhesion molecules 
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seen with these agents. In particular, TNF-blockers have been shown to diminish interferon 
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considering the morbidity of orthopedic surgical site infections (especially prosthesis 
infections) as compared to a transient surge in disease activity, withholding anti-TNF agents 
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(Bongartz 2007).  
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Anti-TNF therapy for RA in the setting of Hepatitis C (HCV) infection could be of particular 
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taken cautiously; careful consideration of the risks and benefits for the individual patient 
would be needed and close clinical and virological monitoring should always be warranted.  
The safety of TNF inhibitors in patients with herpes virus (HSV) infections has also been 
considered. In particular the risk of herpes zoster infection in patients with RA is twice as 
much even in the absence of therapy (Wolfe, Michaud et al. 2006; Smitten, Choi et al. 2007) 
and severe herpes zoster infections have been reported in randomised controlled trials and 
their open-label follow up studies in patients with RA receiving the TNF inhibitors 
infliximab or adalimumab (Lipsky, van der Heijde et al. 2000; Furst, Schiff et al. 2003; 
Keystone, Kavanaugh et al. 2004; Maini, Breedveld et al. 2004). A study by Strangfeld et al 
(Strangfeld, Listing et al. 2009) addressed the question whether this association actually 
represents a true association between TNF inhibitors reactivation of latent viral infections or 
simply reflects the increased risk of herpes zoster infection in RA patients (Bongartz and 
Orenstein 2009). In this prospective cohort the investigators identified 86 episodes of herpes 
zoster among 5040 patients from the German biologics register RABBIT, receiving anti-TNF 
agents or conventional DMARDs. Adjusted for age, RA severity and glucocorticoid use, a 
significant increased risk was observed for treatment with the monoclonal antibodies (HR, 
1.82 [95% CI, 0.73-2.55]), although this risk was lower than the threshold (of 2.5) for clinical 
significance. No significant associations were found for etanercept use (HR 1.36, 95% CI 
0.73-2.55) or for anti-TNF treatment (HR 1.63, 95% CI 0.97-2.74) as a class. Equally 
important, the incidence rate of multidermatomal and ophthalmic zoster was higher in 
patients taking TNF inhibitors implying severe disease often requiring hospitalisation 
(Bongartz and Orenstein 2009). Nevertheless, anti-TNF therapy can generally be restarted 
following temporary interruption and conventional anti-viral therapy until the skin lesions 
are completely healed (Wendling, Streit et al. 2008). Isolated varicella infections have also 
been reported in RA patients receiving anti-TNF therapy (Vonkeman, ten Napel et al. 2004; 
Choi, Kim et al. 2006; Lee, Kim et al. 2007). Notably the rash in one of these cases was 
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atypical (Choi, Kim et al. 2006) stressing the need for high index of suspicion upon 
diagnosing primary varicella infection in susceptible patients with atypical skin lesions.  
Finally, although a prospective study involving 15 patients with refractory forms of RA 
under treatment with infliximab (3 mg/kg) did not show evidence of lymphotropic 
herpesviruses reactivation (CMV, HHV-6, HHV-7, HHV-8, EBV) in RA patients (Torre-
Cisneros, Del Castillo et al. 2005), two isolated case reports have associated infliximab with 
HHV8 related Kaposi’s sarcoma (Cohen, Horster et al. 2003) and cytomegalovirus (CMV) 
retinitis (Haerter, Manfras et al. 2004). 
2.6 Response to vaccination 
As patients with RA receiving conventional DMARDs and biologics are at increased risk of 
vaccine preventable diseases such as respiratory tract infections caused by H. Influenza and 
S. Pneumoniae, safety and efficacy evaluation of vaccines in this setting is of paramount 
importance. The use of TNF inhibitors in particular has raised specific concerns with regards 
to their potential influence on antibody responses to vaccination. The potential influence of 
anti-TNF inhibition on the efficacy of influenza vaccination was evaluated in a prospective 
cohort study involving 149 patients with RA including 50 patients treated with TNF 
blockers (etanercept or infliximab) in combination with MTX, 62 patients receiving TNF 
blockers alone or with other DMARDs and 37 patients treated with MTX alone plus 18 
healthy controls (Kapetanovic, Saxne et al. 2007). Vaccination with trivalent vaccine resulted 
in better serological response in RA patients treated with MTX without TNF inhibitors 
compared with those receiving TNF inhibitors alone or in combination with MTX and/or 
other DMRDS. Nevertheless, the immune response according to the authors was sufficiently 
large to warrant influenza vaccination to all RA patients regardless of treatment. Similar 
results were reported by others (Fomin, Caspi et al. 2006). Equally reassuring were results 
from studies investigating the efficacy of pmeumococcal vaccine in RA patients receiving 
anti-TNF therapy. In one study, immune response to 23-valent pneumococcal vaccine was 
better in patients treated with TNF inhibitors without MTX compared to those treated with 
TNF inhibitors in combination with MTX or MTX alone. Response rates were 50, 31 and 13% 
for the TNF inhibition without MTX, TNF inhibition with MTX and MTX groups 
respectively (Kapetanovic, Saxne et al. 2006). In a different prospective cohort of RA patients 
receiving either adalimumab or placebo, investigators reported that following 
pneumococcal vaccination, the percentage of patients achieving a vaccine response were 
similar in the adalimumab and placebo groups [37.4% and 40.4%, respectively; 95% CI -
16.2%, 10.3%]. Equally similar was the percentage of patients with protective antibody titres 
in both treatment groups (adalimumab: 85.9%, placebo: 81.7%) (Kaine, Kivitz et al. 2007 ). 
Thus, anti-TNF therapy should not deter physicians from offering patients with RA 
vaccination against H. Influenza and S. Pneumoniae.  
3. Conclusions and future directions 
TNF-α blockade strategies have revolutionized the treatment RA, raising though safety 
concerns with regards to increased risk for infections. Although pre-registration clinical 
trials for TNF inhibitors showed no clear increased risk for infections, long term clinical 
trials and post registrations studies have shown a small but consistent increase in infection 
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risk in patients treated with anti-TNF therapy compared to those treated with conventional 
DMARDs. Common infections involve sites as the respiratory tract, skin and soft tissue and 
the urinary tract. The risk of M. tuberculosis infection also appear to be increased with the 
use of these agents and is highest during the first 6 months of therapy, most probably 
reflecting reactivation of latent TB. Screening patients for exposure risks and latent TB prior 
to the initiation of anti-TNF therapy and administration of standard chemo-prophylaxis has 
decreased the incidence of new TB cases. Other opportunistic infections such as 
histoplasmosis, coccidioidomycosis and leishmaniasis may occur following geographical 
criteria, indicating increased incidence of these illnesses in endemic areas. In view of the 
increased infectious risk associated with these agents, we should reiterate the importance of 
efficient pre-treatment screening and close monitoring of patients throughout their 
treatment. Physicians should be aware of infectious diseases endemic to their geographic 
area and be vigilant for unusual presentation of symptoms and signs of infectious illnesses. 
They should stop biologic therapy when these occur, treat those infectious complications 
promptly and report such cases to regulatory or public health authorities where 
appropriate. As new biological agents are developed and reach the market place, large scale 
post marketing surveillance with registry studies and other observational studies will be 
needed to establish the long term safety profile of these novel therapies. 
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2005; Jeffcoate, 2008; Molines et al., 2010). In this sense, Mabilleau et al. studied isolated 
peripheral blood monocytes from diabetic Charcot patients, diabetic controls and healthy 
controls and demonstrated that resorption in acute CNO is related to an increase in RANKL-
mediated osteoclastic activity (Mabilleau et al., 2008).  
The usual initial presentation of acute CNO is a swelling, tender and warm involved joint 
and there is usually a temperature difference greater than 2ºC when compared with the 
contralateral joint (Jude & Boulton, 2001; Petrova & Edmonds, 2008). The whole clinical 
picture can simulate an infection in its appearance. The chronic CNO is painless, without a 
temperature difference and characterized by established deformity. 
The aim of this chapter is to review the usefulness of biochemical bone markers and the 
image features for both diagnosis and for follow-up after treatment of CNO with 
bisphosphonates (pamidronate).  
2. Imaging and biochemical markers of turnover in diagnosis of Charcot 
neuro-osteoarthropathy 
Although the diagnostic is based on clinical findings, conventional radiography, 
radionucleide scintigraphy and magnetic resonance imaging (MRI) are the more common 
modalities used for helping to the diagnosis of CNO.  
2.1 Plain radiography 
X-plain radiographs are usually the first exam used and they are useful for anatomical 
information. However they are neither sensitive nor specific to differentiate acute CNO 
changes from osteomyelitis.  
In early stages, the presence of effusion with minimal subluxation and fracture-bone 
fragmentation should alert to the physician to the possibility of CNO. These initial changes 
may progress to collapse, resorption and subchondral bone fragmentation, bone 
proliferation with sclerosis and osteophytosis, intra-articular bone fragments, complete 
subluxation, massive soft tissue enlargement and effusion and fracture of neighboring bones 
(Resnick & Niwayama).  
The Eichenholtz classification (Eichenholtz, 1966) modified by Shibata et al. (Shibata et al., 
1990) describe a correlation between clinical findings and radiographic features (table 1). 
 
Stage 0 early phase acute symptoms no changes 
Stage 1 development 
stage 
acute symptoms osteopenia, bone destruction, debris 
formation, 
fragmentation of the subchondral bone ,  
capsular distention, subluxations 
,dislocations 
Stage 2 coalescence 
stage 
decreased symptoms resorption of debris, bony sclerosis ,  
fusion of bone fragments 
Stage 3  reconstruction 
stage 
resolved bony remodeling, rounding of fragments 
Table 1. Eichenholtz classification modified by Shibata. 
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Medical literature focused on radiology findings describe two patterns of CNO: a 
hypertrophic pattern characterized by joint destruction and bone fragmentation, debris 
formation, sclerosis and osteophytosis, such as osteoarthritis and an atrophic pattern 
showing osseous resorption and joint disorganization that may appear similar to septic 
arthritis, so, differential diagnosis between atrophic CNO and septic arthritis may be 
difficult. Frequently, patients present a combination of hypertrophic and atrophic patterns 
(Aliadabi et al., 2003; Jones et al., 2000). 
In the diabetic population, destructive or resorptive bony abnormalities can predominate 
depending on the location of CNO. At the mid-foot or tarsometatarsal joints (Lisfranc) [the 
most common localization representing about 60%(Brodsky)], bone fragmentation, sclerosis 
with fracture-dislocation and complete disintegration of one or more tarsal bone are 
frequently found. This may lead to a collapse of the longitudinal arch and increased load 
bearing on the cuboid, resulting in a “rocker-bottom” deformity. If the metatarsophalangeal 
joints are affected, bone resorption is the predominant feature, leading to a disappearance, 
partial or complete, of the metatarsal heads and proximal phalanges. Finally, the hindfoot 
and ankle, although less frequent, it may be affected with fragmentation, eburnation and 
dislocation of the affected bones.  
In summary, the five D’s describe the radiological features of CNO: joint distension, 
dislocations, debris, disorganization and increased density (Rajbhandari et al., 2002), being 
the presence of multiples fractures the most suggestive radiologic pattern of CNO. 
2.2 Radionucleide scintigraphy 
Three imaging phases 99Technetium bone scan (99Tc-scan) are highly sensitive (91%) for osseus 
pathology but lacks specificity (54%) for the diagnosis of CNO (Aliadabi et al., 2003; Sella, 
2009; Schauwecker et al., 1988). The scintigraphy is positive in all 3 phases, reflecting an 
increased bone turnover, a similar situation to that found in other conditions such as 
osteomyelitis. In these cases, in order to improve the specificity of the test to rule out infection 
the labeled white cell scans (99Tc-WBC, HMPAO, 111In-WBC) can be used. These scintigraphy 
techniques show increased activity at the site of infection, reaching a specificity of 60-86% 
depending on the studies and on the radiotracer used to label white cells (Sella, 2009).  
A fourth phase or 24-hour phase image 99Tc-scan can be used to improve the localization of 
the affected site when there is too much background activity. 
The 67Ga/bone imaging study is not reliable for diagnosing osteomyelitis because 67Ga also 
accumulates in sterile CNO (Glynn, 1981; Knight et al. 1988). 
Given its high sensitivity, the scintigraphy may be useful in early diagnosis although can 
not rule out the presence of a coexisting infection. However it has two major limitations: 
sometimes may not differentiate bone infection from that of adjacent soft tissues due to low 
resolution, and the presence of peripheral ischemia can limit sensitivity.  
2.3 Magnetic resonance imaging  
The role of MRI for diagnostic imaging of the diabetic foot is increasing due to its 
advantages over scintigraphy and radiographs but its use is still unclear.The T1-weighted 
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sequences show anatomical references, both normal or abnormal, while T2- and STIR- (short 
tau inversion recovery) weighted sequences are better to demonstrate edema and 
inflammatory changes in the soft tissues and bone.  
Some possible algorithms have been proposed (Giurato & Uccioli, 2006) but it is usually 
considered that MRI is not necessary in patients with evidence of CNO on plain radiographs 
and no clinical signs of infection (Giurato & Uccioli, 2006; Marcus et al., 1996). 
CNO may present with two types of changes on MRI, depending on the evolution time of 
the process. Acute CNO shows a low signal intensity within bone marrow on T1-weighted 
sequences and high signal intensity on T2- and STIR-weighted sequences, findings that are 
similar to those observed in osteomyelitis. In a chronic CNO, besides cortical fragmentation, 
joint deformity and dislocation, typically appears a low signal intensity in the bone marrow 
on both T1- and T2-weighted sequences consistent with osteosclerosis on plain radiography. 
Another finding in chronic CNO is cyst-like lesions in the bone marrow which appear as 
well-defined clearly marginated low signal lesions on T1-weighted images and as high 
signal intensity on T2-weighted images (Beltran et al. 1990; Marcus et al., 1996).  
MRI may also be useful to early diagnosis when patients present acute symptoms and no 
changes in plain radiographs can be detected (stage 0 of Eichenholtz classification). In these 
cases, MRI may detect early events, such as bone edema, occult fractures and joint effusion 
(Chantelau & Poll, 2006; Edmonds et al., 2006; Greenstein et al., 2002).  
Bone and soft tissue infection involving the foot is particularly common in patients with 
diabetes mellitus, and in these patients, CNO often coexists. The differentiation between 
these two entities is difficult. There are some MRI features that help to differentiate acute 
CNO from osteomyelitis: bone marrow signal damage and edema pattern, distribution of 
the changes, presence of deformity and soft tissue changes (ulcers, abscess or sinus tracts) 
(Lederman & Morrison, 2005; Lederman et al., 2002; Tan & Teh, 2007). Ahmadi et al., in a 
retrospective review of contrast-enhanced MRI study of 128 neuropathic feet joints in 63 
diabetic patients with a suspicion of osteomyelitis, found that the presence of sinus tract, 
the presence of soft-tissue fluid collection and extensive bone marrow abnormality  
were MRI features commonly present in a superimposed infection (Ahmadi et al., 2006) 
(table 2). 
Several studies demonstrate that MRI has a high sensitivity (77-100%) and specificity (80-
100%) for osteomyelitis. Furthermore, in osteomyelitis MRI has a positive predictive power 
of 93% and almost a negative predictive power of 100% according to studies that compared 
MRI results to bone biopsy, which is considered the gold standard for diagnosing 
osteomyelitis (Levine et al., 1994; Marcus et al., 1996). However there are no studies 
assessing neither the sensitivity nor specificity of MRI detecting osteomyelitis in CNO 
patients.  
The use of gadolinium in CNO is controversial (Marcus et al.,1996; Morrison et al., 1993)  
although may be useful to complete the soft tissue study (abscesses, sinus tracts, cellulitis). 
In summary, MRI is a useful, non-invasive tool for the early diagnosis of CNO and may 
have utility for detecting a superimposed infection, being the soft tissue alteration the most 
specific finding.  
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High intensity T2-  
and STIR- 
Acute CNO Chronic CNO 
 Low intensity T1-
High intensity T2-  
and STIR-
Low intensity T1- 
Low intensity T2- 
and STIR- 
 Diffuse edema Periarticular and subcondral edema 
Distribution Focal bone involvement Several bone affected
 Weight bearing regions Predominant midfoot involvement 
Deformity Not common Common
 Soft tissue features
 Frequently involved: sinus tracts, 
cellulitis, abscess
Infrequently  involved
Table 2. Differential MRI patterns between osteomyelitis and Charcot neuro-
osteoarthropathy. 
2.4 Biochemical markers of bone turnover 
Biochemical markers of bone turnover are often altered in CNO. There are few studies done, 
most of them evaluating the changes of these markers after treatment, mainly 
bisphosphonates. Some studies on bone turnover markers show an increase of these 
parameters in acute CNO, indicating an unspecific increased in bone activity. Gough et al. 
measured the pyridoline cross-linked carboxy-terminal telopeptide domain of type 1 
collagen (1CTP) and carboxy-terminal propeptide of type 1 collagen (P1CP), both validated 
as markers of bone resorption and formation respectively, in diabetic patients with acute 
CNO, chronic CNO, diabetic controls and non-diabetic controls subjects (Gough et al., 1997). 
Serum 1CTP was significantly raised in the dorsal venous arch of the acute CNO feet 
compared to chronic CNO, diabetic controls and non-diabetic controls. The authors did not 
find any significant difference in serum P1CP levels in any group. These levels of 1CTP and 
P1CP suggest an increase in osteoclastic activity without concomitant increase of 
osteoblastic function. Selby et al. found an increase in bone-specific alkaline phosphatase 
(bone formation marker) with no significant changes among the others biochemical 
parameters studied: osteocalcin, urinary hydroxyproline, urinary desoxypyridinoline ( Selby 
et al., 1998). Increased levels of urinary cross-linked N-telopeptides of type 1 collagen (NTX) 
have been also demonstrated in CNO patients (Edelson et al., 1996).  
In summary, there are few studies focused on bone markers in CNO. The data suggest an 
increase of them in acute CNO especially of resorption parameters. However, it seems that 
the role of bone markers for the diagnosis is yet to be determined.  
3. Imaging and biochemical markers of bone turnover after medical treatment 
of Charcot neuro-osteoarthropathy 
Although the cornerstone of treatment of CNO is immobilization, there are some studies 
that demonstrate the clinical benefit of bisphosphonates. The improvement with 
bisphosphonates appears to be sooner compared to patients with conventional therapy 
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osteoarthropathy. 
2.4 Biochemical markers of bone turnover 
Biochemical markers of bone turnover are often altered in CNO. There are few studies done, 
most of them evaluating the changes of these markers after treatment, mainly 
bisphosphonates. Some studies on bone turnover markers show an increase of these 
parameters in acute CNO, indicating an unspecific increased in bone activity. Gough et al. 
measured the pyridoline cross-linked carboxy-terminal telopeptide domain of type 1 
collagen (1CTP) and carboxy-terminal propeptide of type 1 collagen (P1CP), both validated 
as markers of bone resorption and formation respectively, in diabetic patients with acute 
CNO, chronic CNO, diabetic controls and non-diabetic controls subjects (Gough et al., 1997). 
Serum 1CTP was significantly raised in the dorsal venous arch of the acute CNO feet 
compared to chronic CNO, diabetic controls and non-diabetic controls. The authors did not 
find any significant difference in serum P1CP levels in any group. These levels of 1CTP and 
P1CP suggest an increase in osteoclastic activity without concomitant increase of 
osteoblastic function. Selby et al. found an increase in bone-specific alkaline phosphatase 
(bone formation marker) with no significant changes among the others biochemical 
parameters studied: osteocalcin, urinary hydroxyproline, urinary desoxypyridinoline ( Selby 
et al., 1998). Increased levels of urinary cross-linked N-telopeptides of type 1 collagen (NTX) 
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bisphosphonates appears to be sooner compared to patients with conventional therapy 
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(immobilization) (Anderson et al., 2004). Most studies use pamidronate, although 
alendronate has been demonstrated to be useful in one study (Pitocco et al., 2005). The 
optimal treatment regimen of pamidronate remains to be defined. Multiples observational 
studies have been published using different doses and duration, and all of them have 
demonstrated some clinical improvement (Navqi et al., 2008; Selby et al., 1994; Young, 1999). 
Furthermore, some reports have also shown an improvement in radiological changes (Guis 
et al., 1999) and/or decrease of biochemical bone turnover markers. 
Jude et al. published the first trial of pharmacologic treatment, a randomized, double-
blinded, placebo-controlled study in 39 active CNO patients (Jude et al., 2001). Twenty-one 
patients recieved a single infusion of 90 mg of pamidronate and this group showed a 
significantly reduction in all biochemical markers analized (bone-specific alkaline 
phosphatase (BSAP) and urine deoxypyridoline cross-linked (D-pyr)) that persisted until 24 
weeks in the case of BSAP. However, after 12 months follow-up, both biomarkers rose 
toward baseline levels.  
Comparable results were obtained in 11 patients during treatment with alendronate 70 mg 
once a week over 6 months, in a randomized controlled double blind study. A clinical 
improvement was observed and, 1CTP and urinary hydroxyproline levels, as indicators of 
bone resorption, showed a significant decrease in the treated group after treatment (Pitocco 
et al., 2005).  
Some case reports have demonstrated healing or stabilization of changes on plain 
radiography after intravenous pamidronate (Guis et al., 1999; Naqvi et al., 2008; Young, 
1999).  
In a short communication, Mc Gill et al. reported that bone uptake scintigraphy and skin 
temperature improved over 12 months with immobilization (McGill et al., 2000), but there 
are no studies evaluating changes in neither MRI nor bone scintigraphy after 
bisphosphonate treatment.  
Bem and collages determined quantitative bone scan parameters (ratio of foot and whole-
body uptake and blood flow velocity) and markers of bone turnover (1CTP and BSAP) in 42 
CNO patients (21 with acute and 21 with non-acute CNO) (Bem et al., 2010). The authors 
observed that there was a significant correlation between bone scintigraphy parameters and 
bone turnover markers. In addition, in acute CNO, there was a significant reduction of both 
scintigraphy parameters and levels of 1CTP and BSAP after treatment with calcitonin.  
Schlossbauer and col. published the first report on quantitative assessment of signal 
alterations on constrast-enhanced MRI in CNO stage 0, before and after treatment with 
pressure-relieving means (Schlossbauer et al., 2008). In this study they analyzed the clinical 
symptoms of 13 patients with acute CNO and compared with MRI findings at baseline and 
after 4-month follow-up. They found a significant correlation between bone marrow edema 
and soft tissue edema and pain, with a significant decrease of these parameters after 
treatment. Thus, they concluded that MRI in early stage of CNO provides valuable 
information on the activity of the disease.  
Our group published an open, prospective therapeutical study with a 12-month follow-up 
including 7 consecutive patients (four diabetic, two with syringomielia and one with an 
autonomic neuropathy) with active CNO seen over a period of 3 years (Moreno et al., 2007). 
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Patients included in this protocol received three intravenous infusions of pamidronate at 0, 2 
and 4 months and traditional immobilization methods. Two diabetic patients had a 
concomitant septic arthritis in the affected joint and they received also antibiotic treatment. 
Biochemical markers of bone remodeling, radiological exam and 99Tc-scan were performed 
before and after 12 months treatment. The bone remodeling markers study included blood 
alkaline phosphatase (ALP) and BSAP, urinary crosslinks NTX, pyridoline (pyr) and D-pyr. 
Clinical symptoms improved after the first infusion. Although in most cases the bone basal 
remodeling markers were within normal range values, a clear decrease in almost all of these 
remodeling markers was observed after treatment in all patients, reaching statistical 
significance for NTX and urinary pyr, suggesting that the blocking of the osteoclastic 
activity may play an important role in the physiopathology of CNO, as observed in previous 
studies. All patients, except one with a siringomyelia, showed signs of radiological healing 
with a marked sclerosis and reconstruction of the cortical bone (figure 1). In one case 
pamidronate was administered very early, avoiding the progression and preventing the 
occurrence of radiological changes during the follow-up period (figure 2). Quantitative 
scintigraphy was performed only in 3 cases, showing a decrease in radiotracer uptake after 
treatment although it did not become completely normal. In agreement with previous 
studies, pamidronate improved not only clinical signs but also stopped the progression of 
disease in most cases. 
 
Fig. 1. Patient with a Charcot foot and concomitant septic arthritis. Note before pamidronate 
treatment the presence of bone fragmentation, subluxation, loss of defined contours and 
eburnation and after 6-months treatment sclerosis and defined contours.  
Before treatment After treatment 
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Fig. 2. Patient with a known CNO secondary to syringomielia involving 1st right MCP 
(arrow). She developed a 3rd MCP swelling joint, early detected with scintigraphy. Initial 
radiography did not show any changes. Treatment was administered very early avoiding 
established deformities. 
4. Conclusions 
 early diagnosis in CNO is difficult and needs a high index of suspicion 
Before treatment After treatment 
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 99Tc bone scan scintigraphy and MRI are useful in order to establish early diagnosis 
 99Tc bone scan scintigraphy and MRI can help to detect superimposed infection, a 
condition quite common in diabetic patients   
 biomarkers of bone turnover are increased in acute phase, especially resorptive ones. 
However, their utility for monitoring treatment response remains to be established  
 bisphosphonate treatment appears to be effective not only for clinical improvement but 
also for disease outcome  
 early diagnosis and treatment may be important to avoid late structural damage 
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1. Introduction 
Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the lymphocytic 
infiltration of salivary and lacrymal glands leading to xerostomia and keratoconjunctivitis 
sicca (KCS). The prevalence of SS is variable but recent studies have estimated it to be between 
0.1-0.6%(Goransson et al., 2011; Trontzas & Andrianakos, 2005). As such, SS occurs in middle-
aged patients with a high female predominance of 9 to 1 (Fox, 2005). SS is classified either as 
primary (pSS) when occurring alone or secondary (sSS) to other autoimmune diseases such as 
rheumatoid arthritis or systemic lupus erythematosus. Besides the involvement of exocrine 
glands entailing the classical sicca syndrome, systemic manifestations resulting from the 
lymphocytic infiltration of organs can be present in up to 20% of cases. There are actually no 
specific diagnostic criteria for SS, but for clinical studies and teaching purposes, SS is classified 
according to the American-European classification criteria, which include subjective and 
objective criteria of xerostomia and KCS as well as the presence of autoimmune antibodies and 
histopathological salivary gland involvement. Because of the lack of a “gold standard” for SS, 
the standard of reference being actually used is clinical diagnosis made by an experienced 
clinician. The lack of specific diagnostic tests combined with the high frequency of sicca 
symptoms in the general population makes the diagnosis of SS even more complicated. This 
holds true especially in early disease where the symptoms and signs are usually mild and 
might explain the time delay for the diagnosis of SS. The importance of making the diagnosis 
of pSS is cardinal because of the increased risk of developing lymphoma and serious systemic 
complications. In an endeavor to increase the likelihood of diagnosis of SS, newer diagnostic 
tools have been devised such as ultrasound sonography of salivary glands, magnetic 
resonance imaging of parotid glands as well as epigenetic biomarkers. 
2. Pathophysiology of Sjögren’s syndrome 
Even if tremendous progress in the field of research has been made to unveil the different 
mechanistic processes underlying the development of SS, the initial triggering events of the 
disease have yet to be unearthed. Central to the pathophysiology of SS is chronic perpetual 
stimulation of the autoimmune system. Both B and T cells are implicated in the pathogenesis 
of the SS, even though the mechanisms underlying humoral and cellular abnormalities are 
not yet known (Delaleu et al., 2008; Mariette & Gottenberg, 2010). 
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It is actually believed that a combination of several factors is responsible for triggering 
disease initiation and perpetuation. In genetically predisposed individuals, psychological or 
physical stress and hormonal factors can lead to the activation of epithelial cells and to the 
up regulation of toll-like receptors. Initiation of disease is promoted by altered glandular 
architecture such as extracellular matrix modification favoring infiltration by cytokines, 
chemokines and lymphocytes. Up regulation of toll-like receptors leads to T cell activation 
and ensuing secretion of pro-inflammatory cytokines. Furthermore, activated epithelial cells 
not only can act as antigen presenting cells leading to the activation of T and B cells, but also 
activate dendritic cells through up regulation of proapoptotic molecules harboring the 
formation of exosomes and thereby also further activating B cells. In advanced stages of the 
disease process, enhanced B-cell activating factor (BAFF) activation and secretion leads to 
disproportionate activation of B cells thereby favoring aberrant lymphocyte homing, 
increased glandular destruction, formation of germinal centers and ensuing lymphoma 
(Figure 1)(Manoussakis & Kapsogeorgou, 2010). 
3. Clinical characteristics of SS 
The most frequent symptoms of SS include the triad of fatigue, polyarthralgia and sicca 
symptoms. Because of the higher frequency of these symptoms in the general population, 
many patients are often diagnosed as having fibromyalgia. 
 
Fig. 1. Mechanisms underscoring the pathogenesis of SS. In the setting of appropriate 
genetic background, the conjuncture of viral aggression, hormones and environmental 
factors is thought to initiate epithelium activation which in turn, leads to T cell activation 
and hence pro-inflammatory cytokines secretion thereby further perpetuating activation of 
epithelial cells. This results in exosomes formation, dendritic cells (DC) activation and 
secretion of type I IFN and BAFF leading to B cell stimulation and proliferation, leading to 
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aberrant lymphocyte homing, T cell cytotoxicity, apoptosis and autoantibodies formation 
and further glandular destruction. BAFF: B-cell activating factor; Dc dendritic cells; IFN: 
interferon; IL-1: interleukin-1; TNF-: tumor necrosis factor . 
The most prominent clinical feature of SS is the sicca syndrome of xerostomia and 
keratoconjunctivitis sicca (KCS) resulting from lymphocytic infiltration of salivary and 
lachrymal glands. The sicca syndrome is often extended to other organs and might result in 
skin dryness, vaginal dryness resulting in dyspareunia, and respiratory tract dryness. 
3.1 Xerostomia 
More than 90% of patients with SS complain of symptoms resulting from functional 
alteration of salivary glands. Patients often complain of unpleasant taste, difficulties in 
eating dry food, the need to drink more water or difficulties in controlling dentures. In the 
early stages of SS, the mouth may appear to be moist, but with disease progression, pooling 
of saliva in the floor of the mouth disappears, thereby unveiling the lines of contact between 
frothy saliva and oral soft tissue. With disease progression and especially in advanced 
stages of SS, the oral mucosa becomes extremely dry and tends to form wrinkles. The 
surface of the tongue becomes red and lobulated with partial or complete depapillation. The 
symptoms of xerostomia extend to a painful syndrome with the sensation of permanent 
burns, soreness, taste alteration, “clicking quality” in the speech of patients with SS, tongue 
fissuring, dysphagia and angular cheilitis. Gross accumulation of plaque might prevail. 
Infections by staphylococcus aureus or pneumococcus can result in acute sialadenitis. With 
further disease progression, teeth decay, periodontal infections, increased incidence of 
candidiasis infections and ultimately loss of teeth are possible complications (Fox, 2005, 
Kassan & Moutsopoulos, 2004). 
3.2 Keratoconjunctivitis sicca 
Ocular dryness in SS, also known as keratoconjunctivitis sicca (KCS), is often less prominent 
than xerostomia. A detailed anamnestic investigation is necessary to detect ocular dryness 
symptoms. The main complaint of KCS is foreign-body sensation, but other symptoms such 
as grittiness, thick rope like secretions at the inner canthus, photosensitivity, burns, and 
sensation of having a veil before the eyes, absence of tears after irritation or emotion are all 
frequent features of KCS. Ocular dryness is due to the lymphocytic infiltration of lacrimal 
glands leading to diminished lacrimal flow and tear composition, thereby altering corneal 
and conjunctival epithelia, characterizing the known condition of keratoconjunctivitis sicca 
(KCS). In more severe disease, functional disability with visual impairment occurs. 
Complications of KCS include corneal ulcerations that can lead to perforations and 
iridocyclitis (Fox, 2005). 
3.3 Systemic manifestations  
3.3.1 Musculoskeletal manifestations 
Approximately 70% of patients with SS complain of articular manifestations. The main 
articular features are predominantly arthralgia while arthritis is less frequent (Fauchais et 
al., 2010). Polyarthralgia is relapsing and remitting. Symmetric, non-erosive, polyarthritis 
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affecting the small joints can also be observed and can even precede the sicca syndrome. The 
frequency of arthritis in SS has been shown to be nearing 17%. More recently, it has been 
observed that subclinical synovitis might be more important with the use of 
ultrasonography and that the frequency of arthritis is around 25%(Iagnocco et al., 2010). 
Myalgias are also a frequent feature, accompanied with asthenia, fatigue and muscle 
tenderness, realizing a fibromyalgia-like syndrome (Mavragani & Moutsopoulos, 2010).  
3.3.2 Respiratory manifestations 
Diminished secretion from nasal epithelial cells results in nasal crusting, epistaxis and 
recurrent sinusitis. Due to xerotrachea, patients complain of a dry non-productive cough 
and dyspnea. In more than 50% of SS patients, dry irritating cough was present without any 
radiographic abnormalities. Bronchial hyperreactivity due to lymphocytic infiltration might 
result in small airways obstruction and contribute to the development of cysts and bullae 
(Parke, 2008). 
Interstitial lung disease (ILD) is a classic feature of SS. The clinical manifestations include 
cough, dyspnea on exertion, bilateral pulmonary infiltrates on plain chest radiographs and 
other abnormalities on computer tomography scanner such as wall thickening at the 
segmental bronchi. With disease progression, fibrosis and neutrophilic alveolitis are present 
(Parambil et al., 2006). 
Lymphocytic interstitial pneumonia (LIP), previously considered as a hallmark of lung 
involvement for SS, forms part of the spectrum of ILD. As such, LIP is the corollary of 
bronchus associated lymphoid tissue proliferation (BALT). LIP is found in approximately 
1% of patients who have SS. Even if LIP is steroid- responsive, approximately 5% of patients 
who have LIP progress to develop overt lymphoma, and the 5-year mortality for these 
patients can rise up to 50% (Parambil et al., 2006). 
Patients with SS are at increased risk of developing lymphoma, usually low grade MALT 
lymphoma. Up regulation of the proliferation of BALT might result into malignant 
transformation with the development of primary pulmonary lymphoma. Typically these 
patients present with few clinical symptoms such as cough, mild weight loss, and dyspnea 
on exertion. Strikingly, these minimal symptoms are unparalleled by the severe 
radiographic changes encompassing micronodules, nodular bilateral and confluent 
infiltrates, thickening of bronchial walls, air bronchograms and ground glass images (Parke, 
2008). 
Pulmonary hypertension is a very rare finding in patients with SS. Only 17 cases have been 
documented in the literature. Prolonged vasospasm and vasculature remodeling have been 
assigned to contribute to the development of this pathology (Launay et al., 2007). 
3.3.3 Renal manifestations 
Tubulointerstitial nephritis is the most predominant clinical manifestation of renal 
involvement in SS. This is characterized by distal tubular acidosis (type 1) and less 
frequently proximal tubular acidosis (type II) (Fanconi syndrome) (Bossini et al., 2001). 
Renal biopsy typically reveals interstitial lymphocytic infiltration. Most of the patients 
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present with hyposthenuria and hypokalemic, hyperchloremic distal renal tubular acidosis 
reflecting interstitial infiltration and destruction by lymphocytes. Distal tubular acidosis 
might be clinically silent but significant untreated renal tubular acidosis can lead to renal 
stones, nephrocalcinosis, and compromised renal function. 
Glomerulonephritis is very rare in SS. When it occurs it is often due to cryoglobulinemia. 
Histopathological examination of the kidney shows proliferative glomerulonephritis 
(Aasarod et al., 2000). 
3.3.4 Cutaneous features 
Besides the classical features of dry skin, other skin manifestations might also be present. 
Purpura might be present in up to 30% of patients presenting as petechiae frequently localized 
on the lower limbs. They follow a remitting and relapsing course and are associated with 
worse prognosis of SS. Vasculitis is detected in approximately 10% of patients with pSS 
(Ramos-Casals et al., 2004). It is characterized by a high predominance of leucocytoclastic 
vasculitis, with life threatening vasculitis being related to cryoglobulinemia. These symptoms 
usually resolve with corticosteroids. Other manifestations of vasculitis in SS include recurrent 
urticaria and skin ulcerations. Cryoglobulinemia can be present in SS patients, and can present 
with a clinical picture of purpura. Other skin manifestations include erythema nodosa, vitiligo, 
and digital ulcers (Kittridge et al; 2011). One of the most characteristic non-vasculitic 
cutaneous manifestations of SS are polycyclic, photosensitive cutaneous lesions. These lesions 
are clinically similar to those observed in cutaneous lupus erythematosus. 
3.3.5 Neurological manifestations  
The spectrum of neurological disorders associated with SS is broad ranging from peripheral 
neuropathy to central nervous involvement. The frequency of neurological involvement in 
SS is relatively low (<5%). In up to 80% of cases, neurological involvement might even 
precede the diagnosis of SS (Segal et al., 2008). 
3.3.5.1 Central nervous system involvement 
 CNS involvement in SS is very much identical to that of systemic lupus erythematosus. As 
such, the clinical manifestations include hemiparesis, cranial neuropathy and more often 
optic nerve neuropathy, brainstem and cerebellar disorders, movement disorders, epilepsia. 
Spinal cord syndromes encompass transverse myelitis, Brown-Sequard syndrome and 
progressive myelitis. Due to the presence of optic neuropathy and myelitis, a diagnosis of 
multiple sclerosis is often evoked. Furthermore, MRI imaging discloses hyperintense lesions 
in the white matter. Neuromyelitis optica (also known as Devic’s disease) is often associated 
with SS and is characterized by recurrent episodes of myelitis and optic neuropathy. 
The clinical features of neuropsychiatric syndrome include often cognition, anxiety, mood 
changes, and depression and sleep disorders (Lafitte et al., 2001). 
3.3.5.2 Peripheral nervous system involvement 
Peripheral neuropathy is much more frequent than CNS involvement ranging up to 30% of 
cases. In most of the cases (93%), peripheral neuropathy precedes the diagnosis of SS. 
Sensory neuronopathy is considered to be distinctive of SS but sensorimotor neuropathy, 
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affecting the small joints can also be observed and can even precede the sicca syndrome. The 
frequency of arthritis in SS has been shown to be nearing 17%. More recently, it has been 
observed that subclinical synovitis might be more important with the use of 
ultrasonography and that the frequency of arthritis is around 25%(Iagnocco et al., 2010). 
Myalgias are also a frequent feature, accompanied with asthenia, fatigue and muscle 
tenderness, realizing a fibromyalgia-like syndrome (Mavragani & Moutsopoulos, 2010).  
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Diminished secretion from nasal epithelial cells results in nasal crusting, epistaxis and 
recurrent sinusitis. Due to xerotrachea, patients complain of a dry non-productive cough 
and dyspnea. In more than 50% of SS patients, dry irritating cough was present without any 
radiographic abnormalities. Bronchial hyperreactivity due to lymphocytic infiltration might 
result in small airways obstruction and contribute to the development of cysts and bullae 
(Parke, 2008). 
Interstitial lung disease (ILD) is a classic feature of SS. The clinical manifestations include 
cough, dyspnea on exertion, bilateral pulmonary infiltrates on plain chest radiographs and 
other abnormalities on computer tomography scanner such as wall thickening at the 
segmental bronchi. With disease progression, fibrosis and neutrophilic alveolitis are present 
(Parambil et al., 2006). 
Lymphocytic interstitial pneumonia (LIP), previously considered as a hallmark of lung 
involvement for SS, forms part of the spectrum of ILD. As such, LIP is the corollary of 
bronchus associated lymphoid tissue proliferation (BALT). LIP is found in approximately 
1% of patients who have SS. Even if LIP is steroid- responsive, approximately 5% of patients 
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assigned to contribute to the development of this pathology (Launay et al., 2007). 
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Glomerulonephritis is very rare in SS. When it occurs it is often due to cryoglobulinemia. 
Histopathological examination of the kidney shows proliferative glomerulonephritis 
(Aasarod et al., 2000). 
3.3.4 Cutaneous features 
Besides the classical features of dry skin, other skin manifestations might also be present. 
Purpura might be present in up to 30% of patients presenting as petechiae frequently localized 
on the lower limbs. They follow a remitting and relapsing course and are associated with 
worse prognosis of SS. Vasculitis is detected in approximately 10% of patients with pSS 
(Ramos-Casals et al., 2004). It is characterized by a high predominance of leucocytoclastic 
vasculitis, with life threatening vasculitis being related to cryoglobulinemia. These symptoms 
usually resolve with corticosteroids. Other manifestations of vasculitis in SS include recurrent 
urticaria and skin ulcerations. Cryoglobulinemia can be present in SS patients, and can present 
with a clinical picture of purpura. Other skin manifestations include erythema nodosa, vitiligo, 
and digital ulcers (Kittridge et al; 2011). One of the most characteristic non-vasculitic 
cutaneous manifestations of SS are polycyclic, photosensitive cutaneous lesions. These lesions 
are clinically similar to those observed in cutaneous lupus erythematosus. 
3.3.5 Neurological manifestations  
The spectrum of neurological disorders associated with SS is broad ranging from peripheral 
neuropathy to central nervous involvement. The frequency of neurological involvement in 
SS is relatively low (<5%). In up to 80% of cases, neurological involvement might even 
precede the diagnosis of SS (Segal et al., 2008). 
3.3.5.1 Central nervous system involvement 
 CNS involvement in SS is very much identical to that of systemic lupus erythematosus. As 
such, the clinical manifestations include hemiparesis, cranial neuropathy and more often 
optic nerve neuropathy, brainstem and cerebellar disorders, movement disorders, epilepsia. 
Spinal cord syndromes encompass transverse myelitis, Brown-Sequard syndrome and 
progressive myelitis. Due to the presence of optic neuropathy and myelitis, a diagnosis of 
multiple sclerosis is often evoked. Furthermore, MRI imaging discloses hyperintense lesions 
in the white matter. Neuromyelitis optica (also known as Devic’s disease) is often associated 
with SS and is characterized by recurrent episodes of myelitis and optic neuropathy. 
The clinical features of neuropsychiatric syndrome include often cognition, anxiety, mood 
changes, and depression and sleep disorders (Lafitte et al., 2001). 
3.3.5.2 Peripheral nervous system involvement 
Peripheral neuropathy is much more frequent than CNS involvement ranging up to 30% of 
cases. In most of the cases (93%), peripheral neuropathy precedes the diagnosis of SS. 
Sensory neuronopathy is considered to be distinctive of SS but sensorimotor neuropathy, 
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sensory neuropathy, autonomic neuropathy, monoeuritis multiplex are amongst other 
features of peripheral nervous system involvement.  
Trigeminal neuropathy is one of the most common vignettes of neurological involvement in 
SS, which can be either uni or bilateral, but, in essence, is a pure form of sensory 
neuropathy. It is characterized by painful paresthesias of the face and hypoesthesia (Lafitte 
et al., 2001). 
3.3.6 Gastrointestinal features 
The manifestations of gastrointestinal tract are not very specific and include esophageal 
dysmotility and gastro-intestinal reflux. Patients often complain of dysphagia, nausea and 
epigastric pain. Subclinical pancreatic involvement is present in approximately 25% of cases. 
There are no specific liver abnormalities, which can be attributed to SS, but autoimmune 
hepatitis and primary biliary cirrhosis can be associated diseases (Mavragani and 
Moutsopoulos, 2010, Fox, 2005). 
3.3.7 Thyroid disease 
Hashimoto’s thyroiditis is a commonly present in SS. Thirty to fifty percent of patients with 
SS has anti-thyroid antibodies and elevated basal thyroid stimulating hormone levels 
(Ramos-Casals et al., 2000). 
3.3.8 Laboratory manifestations 
3.3.8.1 Non-specific laboratory manifestations 
Several hematological features such as anemia, leucopenia and thrombopenia can exist. 
Mild anemia of chronic disease is present in up to 25% of cases but might also result from 
hemodilution due to polyclonal hypergammaglobulinemia (Tzioufas & Voulgarelis, 2007). 
Leucopenia < 4000/mm3 is present in 30% of cases. Hypergammaglobulinemia is most 
frequent occurring in 80% of cases. In certain cases of major hypergammaglobulinemia, a 
hyperviscosity syndrome can be present (Fox RI, 2005). 
Erythrocyte sedimentation rate is often elevated because of polyclonal 
hypergammaglobulinemia. In most of the cases serum IgG are increased, while IgA and IgM 
are normal. If hypogammaglobulinemia exists, lymphoma should be excluded. In 10% of 
cases, a monoclonal protein is observed. Type II and type III cryoglobulinemia are present in 
5% of SS patients (Ramos-Casals et al., 1998). 2-microglobulinemia is significantly 
increased in the sera of patients suffering from SS. There is significant positive correlation 
between 2-microglobulinemia levels and disease activity (Skopouli et al., 2000, Gottenberg 
et al., 2005, Theander et al., 2006, Pertovaara & Korpela, 2011). Serum free light chains have 
been found to be increased in SS and correlate with disease activity (Gottenberg et al., 2007). 
Rheumatoid factor is found in 50% of cases in primary SS. 
3.3.8.2 Autoimmune laboratory manifestations 
Anti nuclear antibodies are frequently observed in the serum of SS patients. Anti-SSA 
autoantibodies are found in 30 to 50% of sera of patients with SS, while anti-SSB 
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autoantibodies are found in 20 to 30% of cases. In the majority of cases the presence of anti-
SSB autoantibodies is associated with the presence of anti-SSA antibodies. Extraglandular 
manifestations are usually predominant in patients presenting with these autoantibodies. 
Antibodies against -fodrin have been exclusively (>95%) found in the sera of SS patients in 
only one German study while other studies have shown a relatively low sensitivity of 30% 
(Willeke et al., 2007). Because of the absence of adequate commercially available kit, this test 
is not routinely performed (Witte, 2005). Recently, new autoantibodies directed against the 
muscarinic receptors M3 and the proteasomes have been described in patients with SS (Feist 
et al., 1999, He et al., 2011). Abnormalities complement C4 levels are often associated with 
the presence of cryoglobulinemia. 
3.3.9 Lymphoma  
Patients with SS have a 20 to 40-fold risk of developing non-Hodgkin lymphoma (NHL) as 
compared to the general population (Voulgarelis et al., 1999,Theander et al., 2006, 
Voulgarelis & Moutsopoulos, 2008). NHL has a prevalence of about 4% in SS and occurs 
classically following a median of 7.5 years after its initial diagnosis (Skopouli et al., 2000). 
Various histologic subtypes of NHL for patients with SS have been described, including 
follicle center lymphomas, lymphoplasmacytoid lymphomas, diffuse large B-cell 
lymphomas (DLBCLs), and – in particular – mucosa-associated lymphoid tissue (MALT) 
lymphomas. 
Extranodal marginal zone (MZ) B-cell lymphomas of the MALT type are the most frequent 
type of lymphomas in SS. Generally, MALT lymphomas follow an indolent course, 
frequently located in both mucosal and non mucosal extranodal sites, a common 
denominator being the presence of epithelium suggesting that the intrinsic feature of these 
cells is homing to epithelia rather than mucosa (Pelstring et al., 1999). Most of the organs in 
which MALT lymphomas arise are devoid of lymphoid tissue, and in the majority of cases 
MALT acquisition precedes lymphoma development. All of these lymphomas appear to 
derive from neoplastic transformation of MZ B lymphocytes in spite of the fact that they are 
associated with several infectious agents or autoimmune disorders such as SS or Hashimoto 
thyroiditis (Royer et al., 1997). The histological features of MALT lymphoma closely mimic 
those of Peyer's patch lymphoid tissue and include: (1) reactive lymphoid follicles, with or 
without colonization by neoplastic cells; (2) MZ and/or monocytoid B-cells (centrocyte-like 
cells) that infiltrate the overlying epithelium (lymphoepithelial lesions); (3) small  
B-lymphocytes; and (4) plasma cells, which might or not be of malignant origin. 
In most cases MZ lymphomas of the MALT type in patients with SS are either primary low-
grade or localized (stage I and II) with extranodal manifestations. The clinical course of the 
majority of NHL lymphoma is indolent and the clinical characteristics include small tumor 
burden and good performance status.  The salivary glands are the most commonly affected 
site, but other extranodal sites – such as the stomach, nasopharynx, skin, liver, kidney, and 
lung – can also be involved. Twenty per cent of patients display involvement of more than 
one extranodal site at diagnosis, indicating that these lymphomas migrate preferentially to 
other mucosal sites, thereby emphasizing the importance for complete staging procedures in 
patients with SS with MALT lymphomas. Even if the lymphoma rarely involves peripheral 
lymph nodes, it frequently disseminates to locoregional lymph nodes. Presenting symptoms 
are the result of major gland enlargement, mainly bilateral parotid gland enlargement. The 
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sensory neuropathy, autonomic neuropathy, monoeuritis multiplex are amongst other 
features of peripheral nervous system involvement.  
Trigeminal neuropathy is one of the most common vignettes of neurological involvement in 
SS, which can be either uni or bilateral, but, in essence, is a pure form of sensory 
neuropathy. It is characterized by painful paresthesias of the face and hypoesthesia (Lafitte 
et al., 2001). 
3.3.6 Gastrointestinal features 
The manifestations of gastrointestinal tract are not very specific and include esophageal 
dysmotility and gastro-intestinal reflux. Patients often complain of dysphagia, nausea and 
epigastric pain. Subclinical pancreatic involvement is present in approximately 25% of cases. 
There are no specific liver abnormalities, which can be attributed to SS, but autoimmune 
hepatitis and primary biliary cirrhosis can be associated diseases (Mavragani and 
Moutsopoulos, 2010, Fox, 2005). 
3.3.7 Thyroid disease 
Hashimoto’s thyroiditis is a commonly present in SS. Thirty to fifty percent of patients with 
SS has anti-thyroid antibodies and elevated basal thyroid stimulating hormone levels 
(Ramos-Casals et al., 2000). 
3.3.8 Laboratory manifestations 
3.3.8.1 Non-specific laboratory manifestations 
Several hematological features such as anemia, leucopenia and thrombopenia can exist. 
Mild anemia of chronic disease is present in up to 25% of cases but might also result from 
hemodilution due to polyclonal hypergammaglobulinemia (Tzioufas & Voulgarelis, 2007). 
Leucopenia < 4000/mm3 is present in 30% of cases. Hypergammaglobulinemia is most 
frequent occurring in 80% of cases. In certain cases of major hypergammaglobulinemia, a 
hyperviscosity syndrome can be present (Fox RI, 2005). 
Erythrocyte sedimentation rate is often elevated because of polyclonal 
hypergammaglobulinemia. In most of the cases serum IgG are increased, while IgA and IgM 
are normal. If hypogammaglobulinemia exists, lymphoma should be excluded. In 10% of 
cases, a monoclonal protein is observed. Type II and type III cryoglobulinemia are present in 
5% of SS patients (Ramos-Casals et al., 1998). 2-microglobulinemia is significantly 
increased in the sera of patients suffering from SS. There is significant positive correlation 
between 2-microglobulinemia levels and disease activity (Skopouli et al., 2000, Gottenberg 
et al., 2005, Theander et al., 2006, Pertovaara & Korpela, 2011). Serum free light chains have 
been found to be increased in SS and correlate with disease activity (Gottenberg et al., 2007). 
Rheumatoid factor is found in 50% of cases in primary SS. 
3.3.8.2 Autoimmune laboratory manifestations 
Anti nuclear antibodies are frequently observed in the serum of SS patients. Anti-SSA 
autoantibodies are found in 30 to 50% of sera of patients with SS, while anti-SSB 
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autoantibodies are found in 20 to 30% of cases. In the majority of cases the presence of anti-
SSB autoantibodies is associated with the presence of anti-SSA antibodies. Extraglandular 
manifestations are usually predominant in patients presenting with these autoantibodies. 
Antibodies against -fodrin have been exclusively (>95%) found in the sera of SS patients in 
only one German study while other studies have shown a relatively low sensitivity of 30% 
(Willeke et al., 2007). Because of the absence of adequate commercially available kit, this test 
is not routinely performed (Witte, 2005). Recently, new autoantibodies directed against the 
muscarinic receptors M3 and the proteasomes have been described in patients with SS (Feist 
et al., 1999, He et al., 2011). Abnormalities complement C4 levels are often associated with 
the presence of cryoglobulinemia. 
3.3.9 Lymphoma  
Patients with SS have a 20 to 40-fold risk of developing non-Hodgkin lymphoma (NHL) as 
compared to the general population (Voulgarelis et al., 1999,Theander et al., 2006, 
Voulgarelis & Moutsopoulos, 2008). NHL has a prevalence of about 4% in SS and occurs 
classically following a median of 7.5 years after its initial diagnosis (Skopouli et al., 2000). 
Various histologic subtypes of NHL for patients with SS have been described, including 
follicle center lymphomas, lymphoplasmacytoid lymphomas, diffuse large B-cell 
lymphomas (DLBCLs), and – in particular – mucosa-associated lymphoid tissue (MALT) 
lymphomas. 
Extranodal marginal zone (MZ) B-cell lymphomas of the MALT type are the most frequent 
type of lymphomas in SS. Generally, MALT lymphomas follow an indolent course, 
frequently located in both mucosal and non mucosal extranodal sites, a common 
denominator being the presence of epithelium suggesting that the intrinsic feature of these 
cells is homing to epithelia rather than mucosa (Pelstring et al., 1999). Most of the organs in 
which MALT lymphomas arise are devoid of lymphoid tissue, and in the majority of cases 
MALT acquisition precedes lymphoma development. All of these lymphomas appear to 
derive from neoplastic transformation of MZ B lymphocytes in spite of the fact that they are 
associated with several infectious agents or autoimmune disorders such as SS or Hashimoto 
thyroiditis (Royer et al., 1997). The histological features of MALT lymphoma closely mimic 
those of Peyer's patch lymphoid tissue and include: (1) reactive lymphoid follicles, with or 
without colonization by neoplastic cells; (2) MZ and/or monocytoid B-cells (centrocyte-like 
cells) that infiltrate the overlying epithelium (lymphoepithelial lesions); (3) small  
B-lymphocytes; and (4) plasma cells, which might or not be of malignant origin. 
In most cases MZ lymphomas of the MALT type in patients with SS are either primary low-
grade or localized (stage I and II) with extranodal manifestations. The clinical course of the 
majority of NHL lymphoma is indolent and the clinical characteristics include small tumor 
burden and good performance status.  The salivary glands are the most commonly affected 
site, but other extranodal sites – such as the stomach, nasopharynx, skin, liver, kidney, and 
lung – can also be involved. Twenty per cent of patients display involvement of more than 
one extranodal site at diagnosis, indicating that these lymphomas migrate preferentially to 
other mucosal sites, thereby emphasizing the importance for complete staging procedures in 
patients with SS with MALT lymphomas. Even if the lymphoma rarely involves peripheral 
lymph nodes, it frequently disseminates to locoregional lymph nodes. Presenting symptoms 
are the result of major gland enlargement, mainly bilateral parotid gland enlargement. The 
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clinical picture in these patients is not characterized by the classical presence of B symptoms 
(fever, night sweats and weight loss) and bone marrow infiltration is rare. However, in 
disseminated disease more than one extranodal site is usually involved. The clinical and 
biological factors heralding imminent lymphoma are low C4/C3 levels, palpable purpura, 
high 2-microglobulin levels, CD4 lymphocytopenia, parotid gland swelling and persistent 
enlargement and hypocaptation on salivary scintigraphy, presence of germinal centers in 
salivary glands, mixed monoclonal cryoglobulinemia, leg ulcers, peripheral neuropathy, 
splenomegaly and the presence of serum or urine monoclonal bands (Theander et al., 2006, 
Skopouli et al., 2000). More recently, it has been shown that hypocomplementemia and 
lymphocytopenia at diagnosis of SS were the strongest predictors of developing lymphoma 
(Solans-laqué et al., 2011). Consequently, the presence of NHL should be considered at the 
initial assessment of a patient with SS depicting clinical signs such as significant 
enlargement of the salivary glands, lymphadenopathy, splenomegaly, skin vasculitis, and 
peripheral neuropathy. 
In certain cases, lymphomas in patients with SS might progress towards a less differentiated 
cell type. The transition from benign chronic lymphoepithelial sialadenitis (LESA) to 
indolent extranodal MZ lymphomas of the MALT type and – possibly – to high-grade 
lymphoma (e.g. DLBCL), is generally considered to represent a multi-step, antigen-driven 
process. Transformation of MALT lymphoma to DLBCL is heralded by the emergence of an 
increased number of transformed blasts that form sheets or clusters and finally form a 
confluence effacing the preceding MALT lymphoma. Most high-grade lymphomas in 
salivary glands are DLBCLs. It is not known how many of the DLBCLs arise from pre-
existing MALT lymphomas and how many are of nodal type or represent transformation of 
follicular lymphomas. There are several lines of evidence from immunohistochemical, 
karyotypic, and genotypic studies that the supervening large-cell lymphomas arise from the 
same clone as the low-grade lymphomas. As such, it can be implied that most of the high-
grade lymphomas could represent a blastic variance of either MZ B-cell or follicular-center-
cell lymphomas.  The clinical manifestation during transformation to high-grade lymphoma 
is purported by further nodal and extranodal dissemination. Whilst MALT lymphoma in 
patients with SS carries a good prognosis, the histologic transformation to high grade 
lymphoma is not with a median overall survival estimated to be only 1.8 years (Voulgarelis 
et al., 1999). 
In summary, NHLs in SS are dichotomized into two categories: the first relating to the 
majority of patients who develop an indolent extranodal MZ lymphoma and the second, less 
frequent, relating to those developing high-grade aggressive lymphomas, such as de novo or 
secondary DLBCLs. 
4. Diagnostic tools for SS 
4.1 Sialometry and sialochemistry 
Salivary flow rates can be measured clinically for whole saliva or for separate secretions 
from the parotid or submandibular and sublingual glands, with or without stimulation. 
Patients with clinically overt SS have reduced flow. However, flow rates depend on many 
factors, such as age, sex, medication, and time of day. For analytical purposes, whole saliva 
is of limited value as it detects neither dysfunction of any of the separate salivary glands nor 
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gland specific sialochemical changes (Kalk et al., 2001). In patients with SS, lower 
submandibular/sublingual flow rates were observed as compared to controls. Measuring 
submandibular/sublingual flow rates may contribute to an early diagnosis of SS. In 
contrast, parotid flow rates are decreased in SS and Non-SS sicca patients. Sialochemistry of 
collected glandular saliva samples may show several characteristic changes in electrolytes 
and proteins (enzymes) in SS (Van der Reijden Kwaak et al., 1996). The Na+ concentration 
level in the parotid glandular saliva is six fold higher in SS patients as compared to non-SS 
and healthy volunteers (Kalk et al., 2001). 
4.2 Sialography 
Sialography consists in the radiography of the salivary glands and its associated ducts 
following the injection of a contrast radiopaque substance. This technique enables the 
assessment of the anatomical changes occurring in the salivary gland ductal system. The 
procedure of sialography is indeed invasive in that it necessitates the cannulation of the 
salivary gland and ductal system being evaluated. Two types of radiocontrast substance can 
be utilized: fat soluble and water-soluble compounds. Water-soluble contrast media are 
usually preferred in that they induce less localized inflammation in contrast to fat-soluble 
compounds, which provide better radiographic imaging and contrast but can entail chronic 
inflammatory changes if leakage of the product occurs. 
The changes observed in SS consist of salivary glands duct dilatations, duct strictures, 
sialectasis and occasionally peripheral duct narrowing. The sensitivity of parotid 
sialography ranges from 48%to 86% and specificity values stretching from 61% to 100%. 
4.3 Salivary gland scintigraphy 
Salivary scintigraphy is a valid and non-invasive procedure to assess the involvement of 
salivary glands in patients with xerostomia. After intravenous 99mTc-sodium pertechnetate 
administration, sequential images of the head, on anterior projection, are acquired during a 
variable time interval, usually between 20 and 40 minutes. The images are then stored and 
glandular regions of interest (ROI) and a background ROI, usually in the skull, are manually 
drawn. Computer software generates time–activity curves for each major salivary gland. 
Time–activity curves are divided in two phases: the uptake phase, corresponding to the 
accumulation of the tracer by the glandular parenchyma, the duration of which depends on 
the protocol; and the excretion phase, initiated by the administration of a salivary stimulus, 
usually lemon juice, which corresponds to the tracer elimination through the oral cavity, 
providing information on the patency of salivary ducts and the overall functional integrity 
of the system (Vinagre et al., 2009). Abnormal salivary scintigraphy findings include 
delayed uptake, reduced concentration and/or delayed uptake of the tracer, according to 
the method proposed by Schall (Schall et al., 1971). According to the Schall classification, 
salivary gland functional impairment is classified into four grades, following the intensity of 
uptake and activity present at the mouth after administration of the salivary stimulus; grade 
1 classified as normal tracer uptake and grade 4 as complete absence of uptake and mouth 
activity. This widely diffused classification is considered the standard method for salivary 
scintigram interpretation but is observer dependent. The overall sensitivity and specificity of 
salivary scintigraphy is 54% and 98% respectively (Kohn et al., 1992). The most common and 
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clinical picture in these patients is not characterized by the classical presence of B symptoms 
(fever, night sweats and weight loss) and bone marrow infiltration is rare. However, in 
disseminated disease more than one extranodal site is usually involved. The clinical and 
biological factors heralding imminent lymphoma are low C4/C3 levels, palpable purpura, 
high 2-microglobulin levels, CD4 lymphocytopenia, parotid gland swelling and persistent 
enlargement and hypocaptation on salivary scintigraphy, presence of germinal centers in 
salivary glands, mixed monoclonal cryoglobulinemia, leg ulcers, peripheral neuropathy, 
splenomegaly and the presence of serum or urine monoclonal bands (Theander et al., 2006, 
Skopouli et al., 2000). More recently, it has been shown that hypocomplementemia and 
lymphocytopenia at diagnosis of SS were the strongest predictors of developing lymphoma 
(Solans-laqué et al., 2011). Consequently, the presence of NHL should be considered at the 
initial assessment of a patient with SS depicting clinical signs such as significant 
enlargement of the salivary glands, lymphadenopathy, splenomegaly, skin vasculitis, and 
peripheral neuropathy. 
In certain cases, lymphomas in patients with SS might progress towards a less differentiated 
cell type. The transition from benign chronic lymphoepithelial sialadenitis (LESA) to 
indolent extranodal MZ lymphomas of the MALT type and – possibly – to high-grade 
lymphoma (e.g. DLBCL), is generally considered to represent a multi-step, antigen-driven 
process. Transformation of MALT lymphoma to DLBCL is heralded by the emergence of an 
increased number of transformed blasts that form sheets or clusters and finally form a 
confluence effacing the preceding MALT lymphoma. Most high-grade lymphomas in 
salivary glands are DLBCLs. It is not known how many of the DLBCLs arise from pre-
existing MALT lymphomas and how many are of nodal type or represent transformation of 
follicular lymphomas. There are several lines of evidence from immunohistochemical, 
karyotypic, and genotypic studies that the supervening large-cell lymphomas arise from the 
same clone as the low-grade lymphomas. As such, it can be implied that most of the high-
grade lymphomas could represent a blastic variance of either MZ B-cell or follicular-center-
cell lymphomas.  The clinical manifestation during transformation to high-grade lymphoma 
is purported by further nodal and extranodal dissemination. Whilst MALT lymphoma in 
patients with SS carries a good prognosis, the histologic transformation to high grade 
lymphoma is not with a median overall survival estimated to be only 1.8 years (Voulgarelis 
et al., 1999). 
In summary, NHLs in SS are dichotomized into two categories: the first relating to the 
majority of patients who develop an indolent extranodal MZ lymphoma and the second, less 
frequent, relating to those developing high-grade aggressive lymphomas, such as de novo or 
secondary DLBCLs. 
4. Diagnostic tools for SS 
4.1 Sialometry and sialochemistry 
Salivary flow rates can be measured clinically for whole saliva or for separate secretions 
from the parotid or submandibular and sublingual glands, with or without stimulation. 
Patients with clinically overt SS have reduced flow. However, flow rates depend on many 
factors, such as age, sex, medication, and time of day. For analytical purposes, whole saliva 
is of limited value as it detects neither dysfunction of any of the separate salivary glands nor 
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gland specific sialochemical changes (Kalk et al., 2001). In patients with SS, lower 
submandibular/sublingual flow rates were observed as compared to controls. Measuring 
submandibular/sublingual flow rates may contribute to an early diagnosis of SS. In 
contrast, parotid flow rates are decreased in SS and Non-SS sicca patients. Sialochemistry of 
collected glandular saliva samples may show several characteristic changes in electrolytes 
and proteins (enzymes) in SS (Van der Reijden Kwaak et al., 1996). The Na+ concentration 
level in the parotid glandular saliva is six fold higher in SS patients as compared to non-SS 
and healthy volunteers (Kalk et al., 2001). 
4.2 Sialography 
Sialography consists in the radiography of the salivary glands and its associated ducts 
following the injection of a contrast radiopaque substance. This technique enables the 
assessment of the anatomical changes occurring in the salivary gland ductal system. The 
procedure of sialography is indeed invasive in that it necessitates the cannulation of the 
salivary gland and ductal system being evaluated. Two types of radiocontrast substance can 
be utilized: fat soluble and water-soluble compounds. Water-soluble contrast media are 
usually preferred in that they induce less localized inflammation in contrast to fat-soluble 
compounds, which provide better radiographic imaging and contrast but can entail chronic 
inflammatory changes if leakage of the product occurs. 
The changes observed in SS consist of salivary glands duct dilatations, duct strictures, 
sialectasis and occasionally peripheral duct narrowing. The sensitivity of parotid 
sialography ranges from 48%to 86% and specificity values stretching from 61% to 100%. 
4.3 Salivary gland scintigraphy 
Salivary scintigraphy is a valid and non-invasive procedure to assess the involvement of 
salivary glands in patients with xerostomia. After intravenous 99mTc-sodium pertechnetate 
administration, sequential images of the head, on anterior projection, are acquired during a 
variable time interval, usually between 20 and 40 minutes. The images are then stored and 
glandular regions of interest (ROI) and a background ROI, usually in the skull, are manually 
drawn. Computer software generates time–activity curves for each major salivary gland. 
Time–activity curves are divided in two phases: the uptake phase, corresponding to the 
accumulation of the tracer by the glandular parenchyma, the duration of which depends on 
the protocol; and the excretion phase, initiated by the administration of a salivary stimulus, 
usually lemon juice, which corresponds to the tracer elimination through the oral cavity, 
providing information on the patency of salivary ducts and the overall functional integrity 
of the system (Vinagre et al., 2009). Abnormal salivary scintigraphy findings include 
delayed uptake, reduced concentration and/or delayed uptake of the tracer, according to 
the method proposed by Schall (Schall et al., 1971). According to the Schall classification, 
salivary gland functional impairment is classified into four grades, following the intensity of 
uptake and activity present at the mouth after administration of the salivary stimulus; grade 
1 classified as normal tracer uptake and grade 4 as complete absence of uptake and mouth 
activity. This widely diffused classification is considered the standard method for salivary 
scintigram interpretation but is observer dependent. The overall sensitivity and specificity of 
salivary scintigraphy is 54% and 98% respectively (Kohn et al., 1992). The most common and 
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early scintigraphic abnormality observed in SS is the impairment of excretion, followed by a 
decrease in tracer accumulation, reflecting glandular parenchyma destruction. The 
preferential involvement of the submandibular glands in SS and the decrease of non-
stimulated salivary secretion by these glands are correlated to the degree of xerostomia. 
Recently, quantitative evaluation of salivary gland dysfunction has been developed and 
there is data supporting the fact that quantitative salivary scintigraphy can detect minimal 
salivary glands abnormalities, detecting as low as 25% of glandular destruction and is 
therefore important to identify glandular dysfunction in early SS (Bohuslavizki et al., 1995). 
4.4 Tear function tests 
4.4.1 Schirmer’s test 
The Schirmer’s test consists in assessing the function of the lachrymal gland. The Schirmer’s 
I test consists in measuring the amount of wetting on a strip of filter paper placed in the 
lower eyelid over 5 minutes. In the normal non-anesthetized eye, at least 15mm of wetting is 
expected in patients younger than 40 years old, and at least 10mm of wetting is expected in 
elderly patients. If no anesthetic is placed onto the eye, the expected wetting of the filter 
strip sums up to at least 10 mm in a healthy patient younger than 40 years and at least 5 mm 
in a patient older than 40years. The schirmer’s I test is considered to be anormal if it results 
in less than 5 mm of wetting confirms the clinical diagnosis of dry eye syndrome. A result of 
6–10 mm of wetting suggests a dry eye problem (Lemp, 2000). The Schirmer’s II test is quite 
similar to the I test, the difference being that a cotton swab is used to trigger the tear reflex 
inside the nose. 
The phenol red thread test has been developed to obviate the disadvantages of Schirmer's 
test by eliminating the need for anesthesia. Three millimeters of a fine dye-impregnated 75 
mm cotton thread is placed under the lateral one fifth of the inferior palpebral lid margin for 
15 seconds; alkalinity changes its color to bright orange from tear contact. Direct stimulation 
of the nasociliary nerve through irritation of the nasopharynx confirms the presence or 
absence of reflex tearing. More recently the combination of the phenol red thread test with 
the Schirmer’s test was found to be highly predictive of severe ocular sicca syndrome (De 
Monchy et al., 2011). 
Hyperosmolarity is a common endpoint for all dry eye syndromes and its measurement is a 
sensitive, but not specific, test since it does not distinguish between tear-deficient and tear-
sufficient dry eye. Other rarely performed tests for reduced tear function include 
fluorophotometry for decreased protein content, lysozyme levels, ocular ferning, impression 
cytology, and lactoferrin assays. 
4.4.2 Diagnostic dye evaluation 
Fluorescein is a large molecule unable to traverse normal corneal epithelial tight junctions. 
In advanced dry eye syndrome, these junctions are disrupted, allowing characteristic diffuse 
subepithelial or punctate staining. Rose Bengal, a derivative of fluorescein, in a 1% solution 
or impregnated strips stains devitalized epithelial cells. Alternatively, lissamine green stains 
for cell death or degeneration, as well as cell-to-cell junction disruption, but does not irritate 
the eye. Van Bijsterveld created a grading scale for rose Bengal dye that divides the ocular 
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surface into three zones: nasal bulbar conjunctiva, cornea, and temporal bulbar conjunctiva, 
each graded 0–3 (0, none; 3, confluent staining) (Van Bijsterveld, 1969). A maximum of nine 
can be obtained and a score ≥ 4 is considered as positive test. The Van Bijsterveld score is the 
most specific ocular test for evaluation of SS (Kalk et al., 2002). 
4.4.3 Tear film stability 
Tear film instability can be due to either tear deficiency or evaporative dry eye syndrome. In 
tear breakup time, fluorescein dye is instilled and the time interval is measured between a 
complete blink to the first appearance of a dry spot in the precorneal tear film. As such, tear 
breakup time shorter than the blink interval of 5 seconds could imply ocular surface damage 
while very short tear breakup time (less than 2 seconds) is suggestive of KCS. 
4.5 Salivary gland biopsy 
The histopathology of labial salivary glands is a key feature in the diagnosis of SS. A widely 
accepted criterion for histopathological confirmation of SS is focal lymphocytic sialadenitis 
of the labial salivary glands. Minor labial salivary glands biopsy is performed by midline 
incision (of about 1.5-2.0 cm) of lower lip under local anesthesia. Four to six lobules of minor 
salivary glands are harvested because of prominent variation in the degree of inflammatory 
and destructive involvement of salivary glands and lobes (Greenspan et al., 1974) 
Assessment of inflammatory infiltrates in the salivary gland is based on the number of foci 
present in the glands, classified as the focus score (FS) (Greenspan et al., 1974). The FS is the 
number of foci per 4mm2 of salivary gland section. The FS represents an extension of the 
grade 4 classification of labial salivary gland biopsies of Chisholm and Masson (Table 1). 
The FS is graded from 0 to 12, with a FS of 0 representing the absence of one focus, while a 
FS of 12 represent those specimens where the foci are so numerous that they have become 
confluent. A FS  1 is considered as positive for the diagnosis of SS. It has to be underlined 
that a FS  1 can also be observed in other systemic autoimmune diseases such as RA, SLE 
and in 5-10% of healthy subjects thereby reducing its specificity for SS (Bodeutsch et al., 
1992, Lindahl & Hedfors, 1989; Lindahl et al., 1989). Moreover, the sensitivity of FS is 
reduced in smokers and in patients taking corticosteroids ((Manthorpe et al., 2000), 
(Zandbelt et al., 2001). The combination of FS  1 and immunological staining for IgA has 
been shown to increase the diagnostic specificity for SS (Zandbelt et al., 2002). Indeed, the 
presence of a Fs  1 and quantitative immunohistogical staining of IgA < 70%, had greater 
sensitivity and specificity than the FS alone. 
 
Grade Lymphocytes and plasma cells per 4mm2 of gland tissue 
0 Absent 
1 Slight infiltrate 
2 Moderate infiltrate or less than 50 lymphocytes/4mm2 
3 One focus per 4mm2 
4 More than one focus per 4 mm2 
Table 1. represents the grading of labial salivary gland biopsies according to the 
classification by Chisholm and Mason (Chisholm & Mason, 1968). 
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early scintigraphic abnormality observed in SS is the impairment of excretion, followed by a 
decrease in tracer accumulation, reflecting glandular parenchyma destruction. The 
preferential involvement of the submandibular glands in SS and the decrease of non-
stimulated salivary secretion by these glands are correlated to the degree of xerostomia. 
Recently, quantitative evaluation of salivary gland dysfunction has been developed and 
there is data supporting the fact that quantitative salivary scintigraphy can detect minimal 
salivary glands abnormalities, detecting as low as 25% of glandular destruction and is 
therefore important to identify glandular dysfunction in early SS (Bohuslavizki et al., 1995). 
4.4 Tear function tests 
4.4.1 Schirmer’s test 
The Schirmer’s test consists in assessing the function of the lachrymal gland. The Schirmer’s 
I test consists in measuring the amount of wetting on a strip of filter paper placed in the 
lower eyelid over 5 minutes. In the normal non-anesthetized eye, at least 15mm of wetting is 
expected in patients younger than 40 years old, and at least 10mm of wetting is expected in 
elderly patients. If no anesthetic is placed onto the eye, the expected wetting of the filter 
strip sums up to at least 10 mm in a healthy patient younger than 40 years and at least 5 mm 
in a patient older than 40years. The schirmer’s I test is considered to be anormal if it results 
in less than 5 mm of wetting confirms the clinical diagnosis of dry eye syndrome. A result of 
6–10 mm of wetting suggests a dry eye problem (Lemp, 2000). The Schirmer’s II test is quite 
similar to the I test, the difference being that a cotton swab is used to trigger the tear reflex 
inside the nose. 
The phenol red thread test has been developed to obviate the disadvantages of Schirmer's 
test by eliminating the need for anesthesia. Three millimeters of a fine dye-impregnated 75 
mm cotton thread is placed under the lateral one fifth of the inferior palpebral lid margin for 
15 seconds; alkalinity changes its color to bright orange from tear contact. Direct stimulation 
of the nasociliary nerve through irritation of the nasopharynx confirms the presence or 
absence of reflex tearing. More recently the combination of the phenol red thread test with 
the Schirmer’s test was found to be highly predictive of severe ocular sicca syndrome (De 
Monchy et al., 2011). 
Hyperosmolarity is a common endpoint for all dry eye syndromes and its measurement is a 
sensitive, but not specific, test since it does not distinguish between tear-deficient and tear-
sufficient dry eye. Other rarely performed tests for reduced tear function include 
fluorophotometry for decreased protein content, lysozyme levels, ocular ferning, impression 
cytology, and lactoferrin assays. 
4.4.2 Diagnostic dye evaluation 
Fluorescein is a large molecule unable to traverse normal corneal epithelial tight junctions. 
In advanced dry eye syndrome, these junctions are disrupted, allowing characteristic diffuse 
subepithelial or punctate staining. Rose Bengal, a derivative of fluorescein, in a 1% solution 
or impregnated strips stains devitalized epithelial cells. Alternatively, lissamine green stains 
for cell death or degeneration, as well as cell-to-cell junction disruption, but does not irritate 
the eye. Van Bijsterveld created a grading scale for rose Bengal dye that divides the ocular 
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surface into three zones: nasal bulbar conjunctiva, cornea, and temporal bulbar conjunctiva, 
each graded 0–3 (0, none; 3, confluent staining) (Van Bijsterveld, 1969). A maximum of nine 
can be obtained and a score ≥ 4 is considered as positive test. The Van Bijsterveld score is the 
most specific ocular test for evaluation of SS (Kalk et al., 2002). 
4.4.3 Tear film stability 
Tear film instability can be due to either tear deficiency or evaporative dry eye syndrome. In 
tear breakup time, fluorescein dye is instilled and the time interval is measured between a 
complete blink to the first appearance of a dry spot in the precorneal tear film. As such, tear 
breakup time shorter than the blink interval of 5 seconds could imply ocular surface damage 
while very short tear breakup time (less than 2 seconds) is suggestive of KCS. 
4.5 Salivary gland biopsy 
The histopathology of labial salivary glands is a key feature in the diagnosis of SS. A widely 
accepted criterion for histopathological confirmation of SS is focal lymphocytic sialadenitis 
of the labial salivary glands. Minor labial salivary glands biopsy is performed by midline 
incision (of about 1.5-2.0 cm) of lower lip under local anesthesia. Four to six lobules of minor 
salivary glands are harvested because of prominent variation in the degree of inflammatory 
and destructive involvement of salivary glands and lobes (Greenspan et al., 1974) 
Assessment of inflammatory infiltrates in the salivary gland is based on the number of foci 
present in the glands, classified as the focus score (FS) (Greenspan et al., 1974). The FS is the 
number of foci per 4mm2 of salivary gland section. The FS represents an extension of the 
grade 4 classification of labial salivary gland biopsies of Chisholm and Masson (Table 1). 
The FS is graded from 0 to 12, with a FS of 0 representing the absence of one focus, while a 
FS of 12 represent those specimens where the foci are so numerous that they have become 
confluent. A FS  1 is considered as positive for the diagnosis of SS. It has to be underlined 
that a FS  1 can also be observed in other systemic autoimmune diseases such as RA, SLE 
and in 5-10% of healthy subjects thereby reducing its specificity for SS (Bodeutsch et al., 
1992, Lindahl & Hedfors, 1989; Lindahl et al., 1989). Moreover, the sensitivity of FS is 
reduced in smokers and in patients taking corticosteroids ((Manthorpe et al., 2000), 
(Zandbelt et al., 2001). The combination of FS  1 and immunological staining for IgA has 
been shown to increase the diagnostic specificity for SS (Zandbelt et al., 2002). Indeed, the 
presence of a Fs  1 and quantitative immunohistogical staining of IgA < 70%, had greater 
sensitivity and specificity than the FS alone. 
 
Grade Lymphocytes and plasma cells per 4mm2 of gland tissue 
0 Absent 
1 Slight infiltrate 
2 Moderate infiltrate or less than 50 lymphocytes/4mm2 
3 One focus per 4mm2 
4 More than one focus per 4 mm2 
Table 1. represents the grading of labial salivary gland biopsies according to the 
classification by Chisholm and Mason (Chisholm & Mason, 1968). 
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Parotid gland biopsy can also be an adjunct diagnostic tool for the diagnosis of SS. Previous 
prospective studies have shown that the performance of minor salivary gland biopsy is 
comparable to parotid gland biopsy, which explains why parotid gland biopsy is less often 
performed (Pijpe et al. 2007,Wise et al., 1988).  As such, incisional parotid biopsy is not 
performed because of the fear of facial nerve injury, sialoceles and fistulae. One of the 
advantages of parotid gland biopsy over labial salivary gland biopsy is that 
lymphoepithelial islands or lymphoepithelial lesions (LELs) are often observed in parotid 
gland tissue of SS patients. These LELs, a characteristic histological feature of the major 
salivary glands in SS develop as a result of hyperplasia of ductal basal cells within a 
lymphocytic infiltrate. In addition, well-formed lymphoid follicles or germinal centers, often 
adjacent to ductal epithelium, can be found in the major salivary glands (Jordan & Speight, 
1996). 
4.6 New diagnostic tools in SS 
Ultrasonography is an inexpensive, noninvasive technique that is used to detect several 
abnormalities in the major salivary glands. The normal parotid gland appears 
homogeneous, with increased echogenicity relative to adjacent muscle on ultrasonography. 
Ultrasonography of salivary gland is a useful tool to detect anatomical changes in the 
parotid and submandibular glands, with similar diagnostic ability to sialography. 
Hypoechoic or anechoic areas are believed to represent lymphocytic infiltration, damaged 
salivary parenchyma, and dilated ducts. As the disease progresses, numerous cystic spaces 
appear, which most likely reflect progressive glandular destruction and prominent intra-
glandular sialectasis (Madani & Beale, 2006). Moreover, submandibular glands of patients 
with SS have a lower volume and increased parenchymal heterogenicity compared with 
normal individuals. Receiver operating characteristic (ROC) curve analyses showed that 
these findings could reliably discriminate patients from healthy individuals (specificity 
>90%), but could detect only one-half of patients with SS (sensitivity 48–64%). Detection of 
hypoechoic areas, echogenic streaks, cysts and irregular gland margins are highly 
suggestive of SS (Takagi et al., 2010). 
Similarly, parotid MRI can also prove to be an adjunct diagnostic tool to detect 
heterogeneity in the salivary glands and specific cystic lésions (Roberts et al., 2008). Niemela 
et al. recently showed that magnetic resonance sialography was the most sensitive method 
for detecting glandular changes (96%), followed by MRI (81%) and ultrasonography 
(78%)(Niemela et al., 2001). However, the changes detected did not correlate with saliva 
secretion, whereas the focus scores the intensity of lymphocytic infiltration in salivary gland 
biopsy specimens were related only to parotid MRI findings (Niemela et al., 2004). 
The involvement of epigenetic mechanisms in disease processes were established when 
DNA methylation was first identified as an important factor in tumor biology. Nevertheless, 
impaired epigenetic control has been linked to various autoimmune diseases including 
rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and SS ((Pan & 
Sawalha, 2009; Richardson, 2007). In salivary glands from SS patients undergoing 
extracellular matrix remodelling, mechanotransduction may affect epigenetic control of 
gene expression (Gonzalez et al., 2011a). Global DNA methylation of salivary glands from 
SS patients appears to be decreased, while specific genes appear to be hypermethylated (i.e: 
BP230) (Gonzalez et al., 2011b). Over-expression of 2 miRNAs (miR-574 and miR-768-3p) 
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also contributes to the epigenetic control of gene expression in salivary glands from SS 
patients (Alevizos et al., 2011). These two micro-RNAs were associated with high degree 
inflammation and correlated with the histological focus score. Moreover, the distinctive 
signatures of these micro-RNA’s could also distinguish SS patients from normal healthy 
controls (Alevizos & Illei, 2010). As such, they could represent future diagnostic and 
prognostic biomarkers of inflammation in SS patients. 
4.7 Diagnosis and classification criteria for SS 
SS is a complex autoimmune disease with protean nonspecific features, thereby hampering 
the diagnostic process. 
Because of this, many patients often remain either under diagnosed or diagnosis is made 
after a long lapse of time when full-fledged symptoms are obvious. The seminal importance 
of making an early diagnosis relies on the fact that appropriate treatment can be tailored 
and proper management of patients set down. Actually, there are no definite diagnostic 
criteria for SS and diagnosis is essentially based on the clinical insights of the experienced 
physician in the light of a set of biological and clinical manifestations. Even if classification 
criteria have been established for SS, they do not have a sensitivity and specificity of 100%, 
and therefore cannot be used as diagnostic criteria. As a general rule, classification criteria 
are used as diagnostic criteria in clinical studies in order to standardize diagnosis for 
patients participating in multicenter clinical studies and therefore enable analysis of data in 
an unbiased fashion, or for teaching purposes. The stumbling block for devising diagnostic 
criteria for SS as in other autoimmune diseases is the temporal progression of the clinical 
manifestations. In very early disease, the clinical manifestations are not overt, thereby 
fostering further hurdles in the adequate diagnosis. 
In 2002, an American–European consensus group was created and a new set of classification 
criteria for SS has been proposed (Table 2) (Vitali et al., 2002). These criteria comprise 
subjective criteria: ocular symptoms and oral symptoms, and objective criteria: ocular signs, 
histopathological signs (focus score ≥ 1), oral signs, and serological signs (presence of 
antinuclear antibodies: anti-SSA or anti-SSB). Patients are classified as SS if 4 of the 6 
mentioned criteria are present, as long as histopathology or serology is positive, or if 3 of 
any 4 objective criteria are present.  
1. Ocular symptoms 
Ocular symptoms are present if there is a positive answer to at least one of the 
following questions: 
 Have you had daily persistent, troublesome dry eyes for >3 months? 
 Do you have recurrent sensation of sand or gravel in the eyes? 
 Do you use tear substitutes > 3times daily? 
       
2. Oral symptoms  
Oral symptoms are present if there is a positive response to at least one of the 
following questions: 
 Do you have a daily feeling of dry mouth > 3 months? 
 Have you had recurrent or persistent swollen salivary glands as an adult? 
 Do you drink frequently liquids to help in swallowing dry food? 
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Parotid gland biopsy can also be an adjunct diagnostic tool for the diagnosis of SS. Previous 
prospective studies have shown that the performance of minor salivary gland biopsy is 
comparable to parotid gland biopsy, which explains why parotid gland biopsy is less often 
performed (Pijpe et al. 2007,Wise et al., 1988).  As such, incisional parotid biopsy is not 
performed because of the fear of facial nerve injury, sialoceles and fistulae. One of the 
advantages of parotid gland biopsy over labial salivary gland biopsy is that 
lymphoepithelial islands or lymphoepithelial lesions (LELs) are often observed in parotid 
gland tissue of SS patients. These LELs, a characteristic histological feature of the major 
salivary glands in SS develop as a result of hyperplasia of ductal basal cells within a 
lymphocytic infiltrate. In addition, well-formed lymphoid follicles or germinal centers, often 
adjacent to ductal epithelium, can be found in the major salivary glands (Jordan & Speight, 
1996). 
4.6 New diagnostic tools in SS 
Ultrasonography is an inexpensive, noninvasive technique that is used to detect several 
abnormalities in the major salivary glands. The normal parotid gland appears 
homogeneous, with increased echogenicity relative to adjacent muscle on ultrasonography. 
Ultrasonography of salivary gland is a useful tool to detect anatomical changes in the 
parotid and submandibular glands, with similar diagnostic ability to sialography. 
Hypoechoic or anechoic areas are believed to represent lymphocytic infiltration, damaged 
salivary parenchyma, and dilated ducts. As the disease progresses, numerous cystic spaces 
appear, which most likely reflect progressive glandular destruction and prominent intra-
glandular sialectasis (Madani & Beale, 2006). Moreover, submandibular glands of patients 
with SS have a lower volume and increased parenchymal heterogenicity compared with 
normal individuals. Receiver operating characteristic (ROC) curve analyses showed that 
these findings could reliably discriminate patients from healthy individuals (specificity 
>90%), but could detect only one-half of patients with SS (sensitivity 48–64%). Detection of 
hypoechoic areas, echogenic streaks, cysts and irregular gland margins are highly 
suggestive of SS (Takagi et al., 2010). 
Similarly, parotid MRI can also prove to be an adjunct diagnostic tool to detect 
heterogeneity in the salivary glands and specific cystic lésions (Roberts et al., 2008). Niemela 
et al. recently showed that magnetic resonance sialography was the most sensitive method 
for detecting glandular changes (96%), followed by MRI (81%) and ultrasonography 
(78%)(Niemela et al., 2001). However, the changes detected did not correlate with saliva 
secretion, whereas the focus scores the intensity of lymphocytic infiltration in salivary gland 
biopsy specimens were related only to parotid MRI findings (Niemela et al., 2004). 
The involvement of epigenetic mechanisms in disease processes were established when 
DNA methylation was first identified as an important factor in tumor biology. Nevertheless, 
impaired epigenetic control has been linked to various autoimmune diseases including 
rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and SS ((Pan & 
Sawalha, 2009; Richardson, 2007). In salivary glands from SS patients undergoing 
extracellular matrix remodelling, mechanotransduction may affect epigenetic control of 
gene expression (Gonzalez et al., 2011a). Global DNA methylation of salivary glands from 
SS patients appears to be decreased, while specific genes appear to be hypermethylated (i.e: 
BP230) (Gonzalez et al., 2011b). Over-expression of 2 miRNAs (miR-574 and miR-768-3p) 
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also contributes to the epigenetic control of gene expression in salivary glands from SS 
patients (Alevizos et al., 2011). These two micro-RNAs were associated with high degree 
inflammation and correlated with the histological focus score. Moreover, the distinctive 
signatures of these micro-RNA’s could also distinguish SS patients from normal healthy 
controls (Alevizos & Illei, 2010). As such, they could represent future diagnostic and 
prognostic biomarkers of inflammation in SS patients. 
4.7 Diagnosis and classification criteria for SS 
SS is a complex autoimmune disease with protean nonspecific features, thereby hampering 
the diagnostic process. 
Because of this, many patients often remain either under diagnosed or diagnosis is made 
after a long lapse of time when full-fledged symptoms are obvious. The seminal importance 
of making an early diagnosis relies on the fact that appropriate treatment can be tailored 
and proper management of patients set down. Actually, there are no definite diagnostic 
criteria for SS and diagnosis is essentially based on the clinical insights of the experienced 
physician in the light of a set of biological and clinical manifestations. Even if classification 
criteria have been established for SS, they do not have a sensitivity and specificity of 100%, 
and therefore cannot be used as diagnostic criteria. As a general rule, classification criteria 
are used as diagnostic criteria in clinical studies in order to standardize diagnosis for 
patients participating in multicenter clinical studies and therefore enable analysis of data in 
an unbiased fashion, or for teaching purposes. The stumbling block for devising diagnostic 
criteria for SS as in other autoimmune diseases is the temporal progression of the clinical 
manifestations. In very early disease, the clinical manifestations are not overt, thereby 
fostering further hurdles in the adequate diagnosis. 
In 2002, an American–European consensus group was created and a new set of classification 
criteria for SS has been proposed (Table 2) (Vitali et al., 2002). These criteria comprise 
subjective criteria: ocular symptoms and oral symptoms, and objective criteria: ocular signs, 
histopathological signs (focus score ≥ 1), oral signs, and serological signs (presence of 
antinuclear antibodies: anti-SSA or anti-SSB). Patients are classified as SS if 4 of the 6 
mentioned criteria are present, as long as histopathology or serology is positive, or if 3 of 
any 4 objective criteria are present.  
1. Ocular symptoms 
Ocular symptoms are present if there is a positive answer to at least one of the 
following questions: 
 Have you had daily persistent, troublesome dry eyes for >3 months? 
 Do you have recurrent sensation of sand or gravel in the eyes? 
 Do you use tear substitutes > 3times daily? 
       
2. Oral symptoms  
Oral symptoms are present if there is a positive response to at least one of the 
following questions: 
 Do you have a daily feeling of dry mouth > 3 months? 
 Have you had recurrent or persistent swollen salivary glands as an adult? 
 Do you drink frequently liquids to help in swallowing dry food? 
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3. Objective evidence of ocular involvement as defined by a positive result for at least 
one of the following tests: 
 Positive Schirmer’s test without anesthesia (5mm) 
 Rose Bengal or other ocular dye staining score (4 according to Van Bijsterveld’s 
scoring system) 
4. Histopathology 
 Focal lymphocyte sialoadenitis in minor salivary glands, evaluated by an expert 
histopathologist, with a focus score  1 (defined as a number of lymphocytic foci 
that are adjacent to normal appearing mucous acini and contain more than 50 
lymphocytes per 4mm2 of glandular tissue 
5. Objective evidence of salivary gland involvement defined as positive result of at least 
one of the following diagnostic tests: 
 Parotid sialography showing the presence of diffuse sialectasis (punctuate, 
cavitary or destructive pattern) without evidence of obstruction of major 
salivary ducts 
 Salivary scintigraphy showing delayed uptake, reduced concentration and/or 
delayed excretion of tracer 
6. Presence of autoantibodies to Ro/SSA or La/SSB, or both, in the serum. 
Exclusion Criteria 
 Past head and neck radiation treatment 
 Hepatitis C or HIV infection 
 Pre-existing lymphoma 
 Sarcoidosis 
 Graft versus host disease 
 Use of anticholinergic drugs 
Classification of Primary and secondary Sjögren’s syndrome 
In the absence of any underlying disease, primary Sjögren’s syndrome is defined as the 
presence of any four diagnostic criteria as long as either item4 (histopathology) or 
6(serologic autoantibody) is positive or as the presence of any 3 of the 4 objective criteria 
items (items 3,4,5,6). 
In the presence of any potentially associated disease (such as another autoimmune 
disease; systemic lupus erythematosus for example)), the presence of item 1or 2 plus any 
other 2 items 3,4 and 5 might be suggestive of secondary Sjögren’s disease. 
Table 2. American-European classification criteria for SS 
4.8 Differential diagnosis of SS 
The differential diagnosis of SS includes diseases that present with sicca symptoms and 
parotid gland enlargement. Sarcoidosis can mimic SS, but salivary gland biopsy usually 
depicts non-caseating granuloma and autoantibodies are absent and clinical features such as 
hilar lymphadenopathy, uveitis or hypercalcemia are more suggestive of sarcoidosis 
(Ramos-Casals et al., 2004). Other medical conditions masquerading as SS include 
lipoproteinemias (types II, IV and V), chronic graft-versus-host disease, amyloidosis, and 
infection with viruses such as human immunodeficiency virus (HIV), human T-lymphocytic 
virus-I (HTLV-I) and HCV. Patients with HIV infection may present with sicca 
manifestations, parotid gland enlargement, pulmonary involvement, and lymphadenopathy. 
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These patients have an increased prevalence of HLA-DR5 alloantigen (Itescu et al., 1990). 
The two diseases can easily be distinguished, as patients with HIV infection are usually 
young males, have no autoantibodies to Ro (SS-A) and La (SS-B), and the lymphocytic 
infiltrates of the salivary glands consist of CD8+ T cells. HCV can produce a chronic 
lymphocytic sialadenitis that ressembles SS (Haddad et al., 1992). These patients have a 
higher mean age, a lower prevalence of parotid gland enlargement and a higher prevalence 
of liver involvement than patients with pSS. However, patients with SS do not possess an 
increased frequency of antibodies to HCV in their sera. In cases with isolated dry mouth or 
dry eyes, other potential causes including deficiency disorders (vitamin A deficiency  
for example), drugs, infections, endocrinopathies, or degenerative diseases should be 
excluded. 
4.9 Measuring disease activity in SS 
In an attempt to provide tools to assess pSS patients in clinical practice as well as in 
therapeutic trials, several disease activity indices have been designed. These include the 
SSDAI (SS Disease Activity Index), SCAI (Sjögren’s Systemic Clinical Activity Index) and 
ESSDAI (EULAR SS Disease Activity Index). SSDAI and ESSDAI are global scores. SCAI is 
a composite score. Validity is a limitation for SSDAI and SCAI (Campar & Isenberg, 2010). 
ESSDAI is complemented by ESSPRI for the assessment of subjective features. It is more 
accurate in detecting changes in activity. Comparing the three disease activity indices, it 
was observed that for patients with improved activity, the 3 disease activity indices 
showed similar, large sensitivity to change. However, the ESSDAI seemed to detect 
changes in activity more accurately than other disease activity indexes. Notably, for 
patients with stable activity, the ESSDAI did not show erroneous improvement (Seror et 
al., 2010). The ESSDAI consists of 12 organ-specific domains, which are predominantly 
clinical; only 2 of them include haematological (cytopenias) or biological (clonal 
component, serum complement levels, serum IgG and cryoglobulins) findings (Seror et 
al., 2010). For each domain, features of disease activity were classified in 3 or 4 levels 




Constitutional 0-2 0=no symptoms; 1=mild fever and 5-10% weight 
loss; 2=severe fever and >10% weight loss 
Lymphadenopathy 0-3 0= absence of the following features; 1=Lymphadenopathy 
≥ 1 cm in any nodal region or ≥ 2 cm in inguinal 
region; 2=Lymphadenopathy ≥ 2 cm in any nodal region or 
≥ 3 cm in inguinal region, and/or splenomegaly (clinically 
palpable or assessed by imaging); 3=Current malignant B-
cell proliferative disorder 
Glandular 0-2 0=no glandular swelling; 1=Small glandular swelling with 
enlarged parotid (≤ 3 cm), or limited submandibular or 
lachrymal swelling; 2=Major glandular swelling with 
enlarged parotid (> 3 cm), or important submandibular or 
lachrymal swelling 
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3. Objective evidence of ocular involvement as defined by a positive result for at least 
one of the following tests: 
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 Parotid sialography showing the presence of diffuse sialectasis (punctuate, 
cavitary or destructive pattern) without evidence of obstruction of major 
salivary ducts 
 Salivary scintigraphy showing delayed uptake, reduced concentration and/or 
delayed excretion of tracer 
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infection with viruses such as human immunodeficiency virus (HIV), human T-lymphocytic 
virus-I (HTLV-I) and HCV. Patients with HIV infection may present with sicca 
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Constitutional 0-2 0=no symptoms; 1=mild fever and 5-10% weight 
loss; 2=severe fever and >10% weight loss 
Lymphadenopathy 0-3 0= absence of the following features; 1=Lymphadenopathy 
≥ 1 cm in any nodal region or ≥ 2 cm in inguinal 
region; 2=Lymphadenopathy ≥ 2 cm in any nodal region or 
≥ 3 cm in inguinal region, and/or splenomegaly (clinically 
palpable or assessed by imaging); 3=Current malignant B-
cell proliferative disorder 
Glandular 0-2 0=no glandular swelling; 1=Small glandular swelling with 
enlarged parotid (≤ 3 cm), or limited submandibular or 
lachrymal swelling; 2=Major glandular swelling with 
enlarged parotid (> 3 cm), or important submandibular or 
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Articular 0-3 0= no articular symptoms; 1=Arthralgias in hands, wrists, 
ankles and feet accompanied by morning stiffness (>30 
min); 2=1 to 5 (of 28 total count) synovitis; 3=≥ 6 (of 28 total 
count) synovitis. 
Cutaneous 0-3 0=absence of active cutaneous involvement; 1=Erythema 
multiforma; 2=Limited cutaneous vasculitis, including 
urticarial vasculitis, or purpura limited to feet and ankle, or 
subacute cutaneous lupus; 3=Diffuse cutaneous vasculitis, 
including urticarial vasculitis, or diffuse purpura, or ulcers 
related to vasculitis 
Pulmonary 0-3 0=absence of active pulmonary involvement; 1= Persistent 
cough or bronchial involvement with no radiographic 
abnormalities on radiography Or radiological or HRCT 
evidence of interstitial lung disease with: No breathlessness 
and normal lung function test; 2=Moderately active 
pulmonary involvement, such as interstitial lung disease 
shown by HRCT with shortness of breath on exercise 
(NHYA II) or abnormal lung function tests restricted to: 
70% >DLCO≥ 40% or 80%>FVC≥60%; 3=Highly active 
pulmonary involvement, such as interstitial lung disease 
shown by HRCT with shortness of breath at rest (NHYA 
III, IV) or with abnormal lung function tests: DLCO< 40% or 
FVC< 60%. 
 
Renal 0-3 0=Absence of currently active renal involvement with 
proteinuria< 0.5 g/d, no hematuria, no leucocyturia, no 
acidosis, or long-lasting stable proteinuria due to 
damage; 1=Evidence of mild active renal involvement, 
limited to tubular acidosis without renal failure or 
glomerular involvement with proteinuria (between 0.5 and 
1 g/d) and without hematuria or renal failure (GFR ≥60 
ml/min); 2=Moderately active renal involvement, such as 
tubular acidosis with renal failure (GFR <60 ml/min) or 
glomerular involvement with proteinuria between 1 and 
1.5 g/d and without hematuria or renal failure (GFR ≥60 
ml/min) or histological evidence of extra-membranous 
glomerulonephritis or important interstitial lymphoid 
infiltrate; 3=Highly active renal involvement, such as 
glomerular involvement with proteinuria >1.5 g/d or 
hematuria or renal failure (GFR <60 ml/min), or 
histological evidence of proliferative glomerulonephritis or 
cryoglobulinemia related renal involvement 
 






Muscular 0-3 0= absence of muscular involvement; 1=Mild active 
myositis shown by abnormal EMG or biopsy with no 
weakness and creatine kinase (N <CK ≤ 2N); 2=Moderately 
active myositis proven by abnormal EMG or biopsy with 
weakness (maximal deficit of 4/5), or elevated creatine 
kinase (2N<CK ≤4N); 3=Highly active myositis shown by 
abnormal EMG or biopsy with weakness (deficit ≤ 3/5) or 
elevated creatine kinase (>4N) 
 
 
PNS 0-3 0 = absence of PNS involvement; 1=Mild active peripheral 
nervous system involvement, such as pure sensory axonal 
polyneuropathy shown by NCS or trigeminal (V) 
neuralgia; 2= Moderately active peripheral nervous 
system involvement shown by NCS, such as axonal 
sensory-motor neuropathy with maximal motor deficit of 
4/5, pure sensory neuropathy with presence of 
cryoglobulinemic vasculitis, ganglionopathy with 
symptoms restricted to mild/moderate ataxia, 
inflammatory demyelinating polyneuropathy (CIDP) with 
mild functional impairment (maximal motor deficit of 
4/5or mild ataxia),Or cranial nerve involvement of 
peripheral origin (except trigeminal (V) 
neuralgia) ;3=Highly active PNS involvement shown by 
NCS, such as axonal sensory-motor neuropathy with 
motor deficit ≤3/5, peripheral nerve involvement due to 
vasculitis (mononeuritis multiplex etc.), severe ataxia due 
to ganglionopathy, inflammatory demyelinating 
polyneuropathy (CIDP) with severe functional 
impairment: motor deficit ≤3/5 or severe ataxia 
 
 
CNS 0-3 0= absence of CNS involvement; 1=Moderately active CNS 
features, such as cranial nerve involvement of central 
origin, optic neuritis or multiple sclerosis-like syndrome 
with symptoms restricted to pure sensory impairment or 
proven cognitive impairment; 3=Highly active CNS 
features, such as cerebral vasculitis with cerebrovascular 
accident or transient ischemic attack, seizures, transverse 
myelitis, lymphocytic meningitis, multiple sclerosis-like 
syndrome with motor deficit. 
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Hematological 0-3 0=absence of autoimmune cytopenia; 1=Cytopenia of auto-
immune origin with neutropenia (1000 < neutrophils < 
1500/mm3), and/or anemia (10 < hemoglobin < 12 g/dl), 
and/or thrombocytopenia (100,000 < platelets < 
150,000/mm3) Or lymphopenia (500 < lymphocytes < 
1000/mm3); 2= Cytopenia of auto-immune origin with 
neutropenia (500 ≤ neutrophils ≤ 1000/mm3), and/or 
anemia (8 ≤ hemoglobin ≤ 10 g/dl), and/or 
thrombocytopenia (50,000 ≤ platelets ≤ 100,000/mm3) Or 
lymphopenia (≤500/mm3) ;3=Cytopenia of auto-immune 
origin with neutropenia (neutrophils < 500/mm3), and/or 
or anemia (hemoglobin < 8 g/dl) and/or 
thrombocytopenia (platelets <50,000/mm3 
Biological 0-2 0=absence of any of the following biological feature; 
1=Clonal component and/or hypocomplementemia (low 
C4 or C3 or CH50) and/or hypergammaglobulinemia or 
high IgG level between 16 and 20 g/L; 2=Presence of 
cryoglobulinemia and/or hypergammaglobulinemia or 
high IgG level > 20 g/L, and/or recent onset 
hypogammaglobulinemia or recent decrease of IgG level 
(<5 g/L) 
 
Table 3. ESSDAI index for measuring disease activity in SS (modified according to Seror et 
al., 2010) 
4.10 Biological markers of disease activity in SS 
Biological biomarkers are of pivotal importance in determining which patients are at risks of 
developing systemic complications of SS and those who could benefit from therapeutic 
immunomodulation. Classical markers of inflammation such as C-reactive protein and 
erythrocyte sedimentation rate are of limited value to assess disease activity in SS. These 
past ten years, significant progress has been made in deciphering the molecular mechanisms 
underscoring the pathogenesis of SS. As such, the pivotal role of B-cell in pathophysiology 
of SS has been unearthed (Groom et al., 2002, Gottenberg et al., 2006, Mackay et al., 2007). 
The B-cell activating factor (BAFF) is significantly increased in the sera and in the salivary 
glands of pSS patients (Mariette et al., 2003, Lavie et al., 2004). BAFF levels in the sera of pSS 
patients correlate with the presence of anti-SSA autoantibodies and with the ESSDAI index. 
Serum beta macroglobulin, another marker of B lymphocyte activation, has been shown to 
be useful marker of disease activity in pSS, in that it correlated with the presence of disease 
flare as well as with the occurrence of extraglandular manifestations (Gottenberg et al., 
2005). More recently, the levels of serum beta-microglobulin have been observed to correlate 
with the ESSDAI index (Pertovaara & Korpela, 2011). Serum free light chains have also been 
detected to be increased in pSS patients and shown to correlate with disease activity 
(Gottenberg et al., 2007). Several studies are ongoing to evaluate other biomarkers of disease 
 
Diagnostic and Prognostic Features of Sjögren’s Syndrome 
 
141 
activity of pSS such as chemokines induced by interferon pathway and IL-21, and also other 
markers of B-cell activation are being currently investigated. 
5. Prognostic features of SS 
Much knowledge has been gathered these last ten years about the outcome of patients with 
SS. Although not a benign disease, primary SS has a slow insidious progression with no 
rapid deterioration in salivary gland function, systemic markers or dramatic changes in 
clinical manifestations (Gannot et al., 2000). Primary SS, as such is a relatively chronic stable 
condition, with only mild deterioration of main disease characteristics (Theander et al., 
2005). Significant loss of glandular function and quality of life are highlighted during the 
first years of disease (median of 6 years) and remain stable afterwards. The presence of 
immunological abnormalities such as the presence of anti-SSA autoantibodies, 
hypocomplementemia, increased levels of IgG, high focus scores and low unstimulated 
whole saliva, is associated with more severe glandular dysfunction (Haldorsen et al., 2008), 
Theander et al., 2005, Pijpe et al. 2007). It has to be underlined that even if the clinical course 
of the disease is usually stable, similarly to other autoimmune diseases, individual patients 
might present some flares and remissions. However, there are two exceptions to this 
classical benign course, which include a high incidence of lymphoma and the development 
of systemic manifestations, pertaining to a worsened prognostic significance. The presence 
of autoantibodies is correlated with the number of systemic manifestations and more 
specifically anti-SSA autoantibodies are the strongest predictors of extra-glandular 
manifestations (Ter Borg et al., 2011). Furthermore, serum free light chains and serum 2 
microglobulin are increased and correlate with extra-glandular involvement in pSS 
(Gottenberg et al., 2007; Gottenberg et al., 2005). These findings reflect that enhanced 
disturbance of the immune system portrayed by B-cell hyperactivity with 
hypergammaglobulinemia and autoantibody formation, is associated with systemic 
manifestations in primary SS. A steady clinical course is usually observed in patients with 
peri-epithelial lesions (tubulointerstitial nephritis, lung and liver involvement), while those 
presenting with extra-epithelial lesions such as polyneuropathy, vasculitis, 
glomerulonephritis, purpura and vasculitis, have increased morbidity and mortality 
(Skopouli et al., 2000, Ioannidis et al., 2002). The cardinal role of cryoglobulinemia has been 
underlined in this latter group of patients as being the harbinger of the extraepithelial 
manifestations. These extraepithelial characteristics are associated with a high risk of 
developing life-threatening conditions and require tailoring treatment with higher doses of 
corticosteroids and immunosuppressive agents. On the other hand, in patients presenting 
with peri-epithelial lesions, treatment requires less use of steroids and immunosuppressive 
drugs and a less frequent clinical monitoring is recommended.  
Several reports have noted an increased incidence of malignant non-Hodgkin lymphomas 
(NHL) in SS patients, with an estimated risk of up to 44 times greater as compared to 
general population (Kassan et al., 1978). This risk increases with disease duration, is 
maintained with time and is not related to the patient age at time of diagnosis of pSS 
(Solans-Laque et al., 2011). Several predictors of lymphoma development have been detailed 
and include anemia, lymphadenopathy, lymphopenia, hypocomplementemia, peripheral 
neuropathy, cutaneous vasculitis, bilateral parotid gland swelling, severe involvement in 
parotid scintigraphy, and cryoglobulinemia (Voulgarelis, Dafni, Isenberg, & Moutsopoulos, 
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(NHL) in SS patients, with an estimated risk of up to 44 times greater as compared to 
general population (Kassan et al., 1978). This risk increases with disease duration, is 
maintained with time and is not related to the patient age at time of diagnosis of pSS 
(Solans-Laque et al., 2011). Several predictors of lymphoma development have been detailed 
and include anemia, lymphadenopathy, lymphopenia, hypocomplementemia, peripheral 
neuropathy, cutaneous vasculitis, bilateral parotid gland swelling, severe involvement in 
parotid scintigraphy, and cryoglobulinemia (Voulgarelis, Dafni, Isenberg, & Moutsopoulos, 
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1999), (Brito-Zeron et al., 2007). It has been observed that patients with two of three 
following factors (parotid scintigraphy, vasculitis, hypocomplementemia) were associated 
with a lower survival as compared to patients with no factor. More recently, 
hypocomplementemia and lymphocytopenia were independent risk factors for developing 
lymphoma but only hypocomplementemia was related to earlier development of NHL and 
higher mortality ((Brito-Zeron et al., 2007; Solans-Laque et al., 2011). Furthermore, it has 
been also observed that the detection of germinal center-like lesions in pSS diagnostic 
salivary biopsies is a highly predictive marker of NHL (Theander et al., 2011). Patients with 
high-to-intermediated grade lymphoma have significantly worse survival while large tumor 
diameters and the presence of B symptoms are additional risk factors for increased mortality 
(Voulgarelis et al., 1999). 
6. Conclusions 
SS is a chronic autoimmune disease characterized by glandular and systemic manifestations. 
Because of the increased risk of developing lymphoma in pSS patients, making the diagnosis 
of SS is of pivotal importance. The herald of newer diagnostic tools could help clinicians and 
thereby provide significant relief to patients through earlier treatments. Deciphering 
mechanistic processes inherent to the pathophysiology of SS should in the future provide 
more sophisticated means for early diagnosis of SS. 
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1. Introduction 
1.1 General aspects of Sjögren’s syndrome  
1.1.1 Definition 
Sjögren’s syndrome (SS) is a chronic autoimmune disease associated with the production of 
autoantibodies and characterized by a progressive lymphocytic and plasma cell infiltration 
of the salivary and lacrimal glands leading to xerostomia and keratoconjunctivitis sicca (1). 
A Danish ophthalmologist named Henrik Sjögren in 1932 was the first one, who reported 
the triad of keratoconjunctivitis sicca, xerostomia, and rheumatoid arthritis and then Sjögren 
introduced the term keratoconjunctivitis sicca for this syndrome, to distinguish it from dry 
eyes caused by lack of vitamin A (2). It is characterized by lymphocytic infiltration and 
subsequent destruction of the exocrine glands (3–5) including those found in the nose, ears, 
skin, vagina, respiratory and gastrointestinal systems (6).  
1.2 Diagnosis 
1.2.1 Differential diagnosis 
The diagnosis of SS is not straightforward as many of the symptoms are subjective (Figure 1) (5).  
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1.2.2 Diagnostic criteria 
The criteria for diagnosis of SS remain controversial, and different diagnostic criteria have 
been proposed. The syndrome can present primary or secondary. Generally, SS is classified 
as secondary (SS-2) when it is associated with other autoimmune diseases such as 
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis and 
polymyositis and as primary (SS-1) when there is no other connective tissue disease (7, 8). 
There are at least 6 international diagnostic criteria, such as Fox criteria, San Diego criteria, 
San Francisco criteria, European criteria (EEC), American-European Consensus Group 
(AECG) criteria, and Copenhagen criteria. San Diego criteria requires evidence for an 
autoimmune process associated with destruction of salivary and lacrimal gland tissues 
while the Copenhagen and EEC study group have based their diagnostic criteria on clinical 
findings of dry eyes and mouth with no absolute requirement for gland biopsy or presence 
of autoantibodies.  
On the other hand, Sjögren’s Syndome Foundation (SSF) stressed that the classification 
criteria for Sjögren’s syndrome currently used by clinicians and researchers around the 
world is the American-European Consensus Classification Criteria (Table 1). Because many 
different criteria previously were used both within the U.S. and in other countries, the 
Sjögren’s Syndrome Foundation and members of the European Study Group on 
Classification Criteria brought international leaders in Sjögren’s together to develop 
consensus on one set of guidelines (9). SSF mentioned that that classification criteria is the 
strictest criteria available to prove a definitive diagnosis of Sjögren’s for research purposes. 
Physicians usually diagnose SS for clinical purposes on a more individual, medically 
intuitive and broader basis. However, none of them was approved by the World Health 
Organization, which suggested better diagnostic criteria should be established.  
1.3 Prevalance 
Sjögren’s syndrome occurs worldwide and in all ages. The peak incidence is in the fourth 
and fifth decades of life, with a female : male ratio of 9:1 (13). A number of studies have 
shown great variation in the frequency of Sjögren’s syndrome (14). Prevalence studies have 
demonstrated that sicca symptoms and primary Sjögren’s syndrome affects a considerable 
percentage of the population, with precise numbers dependent on the age group studied 
and on the criteria used (15). A cautious but realistic estimate from the studies presented 
thus far is that primary Sjögren’s syndrome is a disease with a prevalence not exceeding 
0.6% of the general population (15). 
1.4 Aetiology and pathogenesis 
The etiology of Sjogren’s syndrome remains unidentified (16). Interactions between 
environmental contributors such as viruses or stress in conjunction with genetic 
susceptibility factors and hormonal effects are currently believed to result in disease 
development (16, 17). Intrinsic activation of epithelium in various target organs was 
demonstrated (18), based on inappropriate expression of MHC molecules, overexpression of 
costimulatory molecules and capacity for cytokine production, and the term “autoimmune 
epithelitis” was proposed (19). In the context of SS, Epstein Barr, HTLV-1, Hepatitis-C and 
enteroviruses have been previously proposed as potential initiating factors of the SS 
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I. Ocular Symptoms (at least one) 
- Dry eyes >3 months? 
- Foreign body sensation in the eyes? 
- Use of artificial tears >3x per day? 
II. Oral Symptoms (at least one) 
- Dry mouth >3 months? 
- Recurrent or persistently swollen salivary glands? 
- Need liquids to swallow dry foods? 
III. Ocular Signs (at least one) 
- Schirmer's test, (without anesthesia) ≤5 mm/5 minutes 
- Positive vital dye staining (van Bijsterveld ≥4) 
IV. Histopathology Lip biopsy showing focal lymphocytic sialoadenitis 
- focus score ≥1 per 4 mm2)2 
V. Oral Signs (at least one) 
- Unstimulated whole salivary flow (≤1.5 mL in 15 minutes) 
- Abnormal parotid sialography3 
- Abnormal salivary scintigraphy4 
VI. Autoantibodies (at least one) 
- Anti-SSA (Ro) or Anti-SSB (La) 
For a primary Sjögren’s syndrome diagnosis: 
a. Any 4 of the 6 criteria, must include either item IV (Histopathology) or VI 
(Autoantibodies) 
b. Any 3 of the 4 objective criteria (III, IV, V, VI) 
For a secondary Sjögren’s syndrome diagnosis: 
In patients with another well-defined major connective tissue disease, the presence of one 
symptom (I or II) plus 2 of the 3 objective criteria (III, IV and V) is indicative of secondary 
SS. 
Exclusion Criteria 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency syndrome (AIDS) 
Pre-existing lymphoma 
Sarcoidosis 
Graft versus host disease 
Current use of anticholinergic drugs 
 
Table 1. American-European Consensus Classification Criteria accepted by Sjögren’s 
Syndome Foundation (9-12) 
(16, 20) However, the mechanisms that account for the epithelial activation remain stil 
unclear (16). Recent data suggest the central role of the type I interferon (IFN) system in the 
pathogenesis of many autoimmune disorders including SS (16).  
A genetic predisposition to SS has been suggested because of multiple reports of two or 
more members of the same family developing the syndrome (21). A family history of the 
disease puts people at an increased risk of developing SS compared to the general 
population (22). This is also supported by the development of SS in twins (22). A genetic 
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1.2.2 Diagnostic criteria 
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susceptibility may be required for the development of autoantibodies which are found in SS 
(22) and this may be associated with a link between polymorphic major histocompatibility 
complex (MHC) genes and the development of autoimmune diseases (21).  
High cDNAlevels in patients with SS may result with a disease at worst prognosis which 
should the clinician let to follow-up the patients with SS both, clinically and serologicallly 
(23). The study of Alevizos et al. revealed that microRNA are promising candidate 
biomarkers of inflammation and salivary gland dysfunction in patients with SS (24). Further 
exploration of the predicted pathways associated with decreased salivary flow in this study 
will provide insight into the pathophysiology of SS and may identify novel therapeutic 
targets (24-25). 
1.5 Complications 
SS systemic disease may affect many other body systems. The most serious complication of 
SS could be accepted as the increased incidence of malignant lymphoma (26). This 
fhenemenon was first reported in patients with SS in 1963 (26) and has been shown to be 44 
times higher than the general population in some studies (27). Additionally, multiple case 
reports supported the association of lymphoma with Sjögren syndrome and stressed 
lymphoma as the major complication in the progression of the disease (28, 29). When it 
occurs, patients with SS are accepted as they are in stage 3 who consist of %5 of the general 
SS population.  
Severeal studies have shown different involvements in patients with SS such as 
hematological system, respiratory system, cardiac, liver, pancreatic, renal, thyroid and 
finally exocrine glands involvements. Bayetto and Logan have summerized extraglandular 
manifestations of SS in a table perfectly (Table 2) (27, 57). 
 
Malaise Peripheral neuropathy Primary biliary cirrhosis 
Fatigue Autoimmune thyroiditis GI symptoms 
Fibromyalgia Renal tubular acidosis Respiratory diseases 
Fever Myositis Psychosis 
Arthralgia Chronic hepatitis Lymphadenopathy 
Synovitis Purpura Splenomegaly 
Raynaud’s phenomenon Vasculitis Lymphoma 
Table 2. Symptoms associated with extraglandular manifestations of Sjögren’s syndrome by 
(27, 57) 
Briefly, leucopenia (approximately 45% of all SS cases), thromboycytopenia (approximately 
25% of all SS cases), hemolytic anemia (approximately 5% of all SS cases) and lower 
thrombopoietin levels (approximately 20% of all SS cases) are accepted as hematological 
system involvement of the disease. Respiratory system involvement of the disease reveals 
interstitial lung disease (approximately 20% of all SS cases), pulmonary hypertension 
(approximately 12% of all SS cases) and multiple nodules (approximately 5% of all SS cases). 
pericardial effusion (approximately 15% of all SS cases) and atrioventricular conduction 
block (approximately 5% of all SS cases) are the cardiac complications of the disease. The 
liver damage could be seen almost one third of the patients with SS. Likewise approximately 
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one third of the patients with SS revealed hepatosplenomegaly. Elevated gamma-glutamyl 
transpeptidase, alaine transferase and alkaline phosphatase levels are seen approximately in 
one fifth of the patients with SS. Renal involvement in SS are relatively common. Proteinuria 
(approximately 20% of all SS cases), Renal tubular acidosis (approximately 15% of all SS 
cases) and kidney stones and/or renal calcification (approximately 10% of all SS cases) are 
the most important renal complications of the disease. Thyroid disorders are also common 
among the patients with SS (33% of all cases). Abnormal thyroid function was seen in one 
forfth of the whole SS population (30). 
1.6 Pediatric cases 
SS is very rare in childhood and is frequently undiagnosed (31). Literature search revealed 
200 pediatric cases of SS. The most important clinical manifestations in children with SS is 
the recurrent parotid swelling (31). Pathologic and laboratory findings are similar to those 
found in adults, with characteristic lymphocytic infiltration of exocrine glands, the presence 
of hypergammaglobulinemia, elevated erythrocyte sedimentation rate, and positive anti–SS 
antigen A, anti–SS antigen B, antinuclear antibody, and rheumatoid factor (32-34). 
Inflammation characterized by recurrent episodes of painful unilateral or bilateral parotid 
enlargement associated with swelling, fever, redness, and reduction in salivary flow (35-39). 
1.7 Management 
Sicca symptoms of the disease could be treated by using topical agents wheras 
extraglandular features are managed with glucocorticoids and immunosuppressive drugs 
(40). But, literature search revealed no evidence based therapeutic guidelines for the 
management of primary Sjögren syndrome which is also universally accepted (41). The 
results of one excellent systematic review about the treatment of SS shows that B cell 
targeted agents seem to be the most promising future therapy, especially rituximab, which 
has been used in more than 100 reported cases. Agents that block B cell–activating factor of 
the tumor necrosis factor family may also be a promising therapy (41, 42). Advances in 
knowledge of the molecular mechanisms involved in the etiopathogenesis of Sjögren’s 
syndrome may allow the development of more effective, highly selective therapies without 
the adverse effects often associated with standard, less-selective drugs (41). Today, current 
treatment options are decided upon a mix of personal experience, expert opinion, and 
reported studies (41). 
2. Oral aspects of Sjögren’s syndrome 
2.1 Saliva, glandular involvement, xerostomia and treatment 
2.1.1 Saliva  
Saliva is secreted from three major paired glands which are parotid, submandibular and 
sublingual glands and from hundreds of minor salivary glands which are localized over most 
parts of the oral mucosa (43). About 90% of mixed saliva is derived from three pairs of major 
salivary glands (parotid, submandibular and sublingual) and the remaining 10% is from 
numerous minor salivary glands distributed in the oral mucosa (43). In healthy humans, the 
daily production of whole saliva (mixed saliva) normally ranges from 0Æ5 to 1Æ5 L (43).  
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one third of the patients with SS revealed hepatosplenomegaly. Elevated gamma-glutamyl 
transpeptidase, alaine transferase and alkaline phosphatase levels are seen approximately in 
one fifth of the patients with SS. Renal involvement in SS are relatively common. Proteinuria 
(approximately 20% of all SS cases), Renal tubular acidosis (approximately 15% of all SS 
cases) and kidney stones and/or renal calcification (approximately 10% of all SS cases) are 
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found in adults, with characteristic lymphocytic infiltration of exocrine glands, the presence 
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parts of the oral mucosa (43). About 90% of mixed saliva is derived from three pairs of major 
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numerous minor salivary glands distributed in the oral mucosa (43). In healthy humans, the 
daily production of whole saliva (mixed saliva) normally ranges from 0Æ5 to 1Æ5 L (43).  
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The salivary secretion is mainly induced during eating (43). Stimulated saliva which is also 
called as reflex salivation helps the chewing of food, formation and swallowing of a food 
bolus and digestion of starch and lipids (43). Saliva takes also part in the detection of food 
taste through the diffusion of taste substances to taste receptors, chemical interaction with 
taste substances and changes in the sensitivity of taste receptors (43). On the other hand, 
resting saliva, which is a lesser amount of saliva, covers the surface of the oral and 
pharyngeal cavities (43). When compared to the stimulated saliva resting saliva is accapted 
as more important in the maintenance of oral health (43). Protection properties against 
bacteria  - viruses  fungi are based on the salivary anti-microbial action [such as lysozyme, 
peroxidase, secretory immunoglobulin A (IgA) and histatins] and also on adhesion (mucins) 
and rinsing properties (43). Saliva is also responsible by taking part in speech, denture 
holding, anticaries activity, controlling breath odour and maintaining the integrity of oral 
and gastrointestinal mucosa (43). 
Acinar cells produce saliva at first (43). Two types of these cells have been detected: serous 
and mucous cells (43). The parotid gland has serous acinar cells and secretes a thin, watery 
and amylase-rich saliva through its main excretory duct which is called as Stenson ductus; it 
opens onto the buccal mucosa near the upper molar teeth (43). The submandibular gland 
produces a more viscous and mucin-rich saliva and it consists of serous and mucous acinar 
cells whereas the sublingual gland has mucous acinar cells and also produces a viscous 
mucin rich saliva (43). 
The sympathetic and parasympathetic autonomic nervous systems control mainly the 
salivary secretion (44). The sympathetic nerve is mainly responsible for the secretion of 
proteins accompanied by exocytosis in acinar cells, while the parasympathetic nerve is 
mainly responsible for the secretion of water and electrolytes (44). These are adequate 
stimuli for salivation, and secreted saliva is called stimulated saliva (43). Saliva secreted in 
the absence of apparent sensory stimuli related to eating refers to resting or unstimulated 
saliva (43). This saliva may have two components; one is spontaneous secretion, which is the 
continuous production of small amounts of saliva without any extraneous stimuli (43). 
There are prominent differences between stimulated and resting salivary secretions in their 
flow rate and viscosity (43). The flow rate of resting whole saliva is far less than that of 
stimulated whole saliva, whereas the viscosity of resting whole saliva is 2–3 times that of 
stimulated whole saliva in healthy adults which implies that resting whole saliva is rich in 
mucins mainly secreted by sublingual, submandibular and palatal glands (45). Resting 
whole saliva contains a higher concentration of high-molecular-weight mucin (MG1) than 
stimulated whole saliva, whereas low-molecular weight mucin (MG2) shows similar 
concentrations under resting and stimulated conditions (46).  
One of two main roles of saliva in taste perception is the relatively short-term effect of saliva 
seen in the initial processes of taste perception (47). Taste substances should be dissolved in 
the salivary fluid layer to reach and stimulate taste receptors (43). The solubilization of taste 
substances in saliva, the chemical interaction between taste substances and salivary 
compositions, and the diffusion and dilution of taste substances in saliva are the ones which 
are responsible (43). Additionally, some components which can also stimulate taste 
receptors and  or change taste sensitivity by chemical interaction with the receptor are 
contained in the saliva (43). One other long-term effect of saliva is maintaining the health 
and function of the taste receptor site (43). 
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2.1.2 Glandular involvement 
Garcio-Carrasco et al. summarized the mechanism of gland-induced dysfunction in primary 
SS in their excellent review article (Figure 2) (58). 
 
Fig. 2. Main mechanisms of gland-induced dysfunction in pSS. INF, interferon; MMP, 
metalloproteinase (58). 
2.1.3 Xerostomia & treatment 
Xerostomia is defined as a subjective complaint of dry mouth that may result from deficient 
production of saliva (48). Xerostomic patients complain mostly about burning mouth, loss of 
taste, difficulty in swallowing, unpleasant taste and odor, oral dryness, increased thirst, 
chewing, speaking, gastroesophageal reflux, oral breathing, malfunction of removable 
prosthesis and sensitive teeth (49-54). Allec et al. concluded in their prospective cross-
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sectional descriptive observational study that patients with SS have voice, speech and 
swallowing abnormalities, not only associated with to xerosis but perhaps also to 
neurological abnormalities, probably secondary to the syndrome (55). On the other hand, 
subjective xerostomia has been reported in higher percentages (75.18% to 91.84%) in patients 
with SS (56). In addition to that, Skopouli et al. showed that the rate of dry mouth increased 
from 41% of patients at initial diagnosis to 84% 10 years after diagnosis (57). Salivary gland 
dysfunction appears due to progressing lymphocytic infiltration in salivary acini, which in 
turn leads to inflammatory reaction causing acinar atrophy and proliferation of connective 
tissue (58). Sometimes such pathological changes originate in the minor salivary glands and 
may result in early symptoms of xerostomia, which are less intense than those in cases when 
the major salivary glands are affected (48).  
Alcohol and smoking should be avoided and thorough oral hygiene is essential (40, 59). 
Saliva replacement products and sugarfree chewing gums may be effective for mild to 
moderate dry mouth (41). Oral pilocarpine and cevimeline are the treatment of choice for 
patients with SS (41). The doses that best balance efficacy and adverse effects are reported to 
be 5 mg every 6 hours for pilocarpine and 30 mg every 8 hours for cevimeline (41). In 
patients with contraindications or intolerance to muscarinic agonists, N-acetylcysteine may 
be an alternative (41). 
2.2 Risk of dental caries and erosions & treatment 
2.2.1 Risk of dental caries and erosions  
The reduced salivary flow and its altered composition influence the bacterial clearance in 
the oral cavity as well as the accumulation of dental plaque on teeth surfaces (60). In 
addition to that, the saliva loses its ability to buffer, lubricate, and perform antimicrobial 
duties which leads to an increase in mucosal friability and oral infection (61). Increased 
incidence of cervical, incisal, decays in cusps tips and root caries has been reported in 
patients with SS as a major dental problem (62). These types of decays are accepted as 
atypical or unusual dental decays. This is constant demineralization, a rapidly progressing 
(rampant) and aggressive form of dental decay (43). 
Mathews et al. mentioned in their excellent review article named ‘Oral manifestations of 
Sjögren's syndrome’ that dental plaque, consisting of more than 500 species of bacteria in a 
mature state, is a complex biofilm of microbes that adheres to the surfaces of teeth and 
provides a reservoir for oral microbial pathogens (61, 63, 64). Sjögren's syndrome increases a 
person's likelihood of contracting opportunistic infections and the proliferation of cariogenic 
micro-organisms (61, 65). Pederson et al. have reported that persons with primary Sjögren's 
syndrome have lower numbers of periopathogenic microorganisms and higher numbers of 
cariogenic and acidophilic micro-organisms in comparison with those found in control 
individuals (61, 66). Pederson et al. concluded in another study that patients with a labial 
salivary gland biopsy focus score of one or more (as per the American-European 
Classification Criteria) or the presence of RoSSA and La  SSB antibodies in serum, had a 
significantly higher DMFTDMFS score than patients without these two factors (67). 
Boutsi et al. mentioned in their study investigating dental and periodontal status of patients 
with SS that the number of cervical decay lesions correlated negatively with the salivary 
flow (56). It is known that because of reduced salivary flow, bacterial plaque accumulates 
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more rapidly on the tooth surface and especially at the marginal gingiva and crevicular 
areas which results in a higher prevalence of cervical caries (56). In patients with SS, an 
increased number of decayed and filled teeth surfaces have been referred previously by 
several investigators (62, 68). The very low salivary secretion rates, the decreased buffering 
effect and neutralization of bacterial acids as well as the high counts of lactobacilli and 
streptococci found in patients with SS, may be responsible for this effect (69). It is interesting 
that in their study, the number of cervical decay lesions correlated negatively with the 
salivary flow, while the number of distal or mesial decay lesions correlated negatively with 
age (56). It seems that the lack of salivary flow affects more extensively the cervical surfaces 
of the teeth, and predisposes them to a more rapid development of caries (56). 
2.2.2 Treatment 
Mese and Matsua stressed that patients should be advised to maintain impeccable hygiene, 
schedule frequent examinations and use topical fluoride regimens (43). The choice of the 
fluoride-delivery system varies with the clinical need and patient compliance (43). Common 
sources of fluoride in toothpaste are sodium monofluorophosphate and sodium fluoride (70-
72). But Mathews et al reported that even with excellent oral hygiene, individuals with 
Sjögren's syndrome have elevated levels of dental caries, along with the loss of many teeth 
early in the disease (61). Pedersen et al. reported that persons who brushed their teeth with 
toothpaste containing fluoride and visited their dentist more frequently still had higher 
numbers of missing, filled, and decayed teeth, along with a higher gingival index (66).  
2.3 Periodontal status & treatment 
2.3.1 Periodontal status 
The reduced salivary flow and its altered composition influence the bacterial clearance in 
the oral cavity, as well as the increased accumulation of dental plaque on tooth surfaces. 
Studies have demonstrated a higher gingival bleeding and plaque index in subjects with 
hyposalivation but without shown a correlation between salivary flow rate and gingival 
bleeding index or plaque index (73, 74).  
Few studies have managed to report an increased risk of periodontal disease in Sjögren’s 
syndrome (75-77). Ergun et al. had summarised the studies that evaluated the periodontal 
status of the patients with Sjögren’s syndrome (78) (Table 3).  
Number of the teeth (NT), bleeding on probing (BOP) (expressed as the % of sites which 
bled upon gentle probing), approximal plaque index (API) (expressed as the % of sites 
which presented plaque), probing pocket depth (PPD) were used in studies evaluating the 
periodontal status of patients with SS since they are easy to perform and produced adequate 
results for this kind of evaluation (78). Ergun et al. found out a significant difference 
between patients with SS and healthy controls in regard to API and BOP (78). This result is 
in agreement with the studies which have found that the API, PPD and BOP are 
significantly higher in SS patients than healthy subjects (75-77, 79). Other studies, however, 
have shown that SS patients are not at higher risk of having periodontitis (56, 79-83).  
It is well known that BOP is strongly corralated to API and both are correlated with tooth 
brushing efficiency (84). Ergun et al concluded that as there was no statistically significant 
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sectional descriptive observational study that patients with SS have voice, speech and 
swallowing abnormalities, not only associated with to xerosis but perhaps also to 
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HS (n=34) - S S - - - - - S Yes 
Table 3. Studies which evaluated the periodontal status of the patients with Sjögren’s 
syndrome (GCF: gingival creviculer fluid, DMF-T: decayed, missing, and filled permanent 
teeth, HS: healthy subjects, S: statistical significant; NS: not statistical significant) (78). 
difference between patients with SS and healthy controls regarding to their tooth brushing 
habits (p>0.05) it can be concluded that the significant difference in terms of API could have 
been occurred due to the low SFR levels of the subjects participated in the study group 
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which is in agreement with Marton et al. (75, 78). Their results indicate that patients with SS 
carry a higher risk of having periodontitis. 
There is a limited number of the studies regarding evaluation of the periodontal status of 
the subgroups of SS patients in terms of plaque accumulation, gingival inflammation and 
pocket depth. Most of these studies did not find a statistically significant difference between 
primary and secondary SS patients in terms of their periodontal status (56, 75, 82, 83, 85, 86). 
Najera et al. (77) found a significant difference in plaque index, but they did not find a 
statistically significant difference in gingival bleeding and periodontal pocket depth 
between SS-1 and SS-2 patients. The lack of difference in periodontal status between SS-1 
and SS-2 subjects may indicate that both types of SS do not play significant role in 
periodontal status (66, 78, 80).  
2.3.2 Treatment 
As mentioned before, the treatment of SS is palliative and turns to the xerostomia related 
complications. One of these is the increased periodontal damage seen in patients with SS as 
accepted as some authors who found out possible correlations between the disease and the 
periodontal status of this type of patients. The aim is to maintain impeccable hygiene by 
having regular follow-ups, teaching oral hygiene instructions and some topical applications. 
The treatment should be conservative aiming to reduce the bacterial clearance in the oral 
cavity, as well as the accumulation of dental plaque on tooth surfaces. 
2.4 Oral mucosal lesions  
Oral health status of patients with SS has been investigated in many studies, previously (56, 
75, 87-91). Subjective xerostomia has been reported in higher percentages (75.18% to 91.84%) 
in the patients with SS (56, 75, 88, 91). Additional dryness-related signs in patients with SS 
are angular chelitis, redness of the tongue, atrophy of filiform papilae (Figure 3 and 4), 
erythematous buccal mucosa (Figure 5), hardpalate and softpalate, difficulties and pain on 
swallowing, burning syndrome, sensitivity to acid and/or spicy food, dysgeusia and bitter 
taste (8, 87-93). Most of the subjective symptoms such as dry mouth feeling and dysphagia 
have been reported to be in direct correlation with the decreased salivary flow rate which 
could also affect the sensory process of swallowing that leads to pain and difficulties on 
swallowing (73, 94).  
Ergun et al have shown that oral objective and subjective signs on oral clinical examination 
are very common among patients with SS regardless its type. Similarly, a recent study 
demonstrated that oral health related quality of life was poor in patients with SS (95). The 
reason why dysgeusia was a common subjective symptom of SS-2 when compared with that 
of SS-1, could be related to the use of D-penicillamine which has found as common drug-
therapy for patients with RA. Dysgeusia was reported to be seen as a frequent problem of 
patients using D-penicillamine (96). 
Ergun et al have shown that oral examination of the patients with SS revealed no statistically 
significant difference between SS-1 and SS-2 patients in regard to presence of angular 
stomatitis, oral ulcerations, atrophic, reddened and dry mucosa, dysgeusia and atrophy of 
filiform papilla (78). Similar percentage of the two subgroups of SS complained about  
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have been reported to be in direct correlation with the decreased salivary flow rate which 
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demonstrated that oral health related quality of life was poor in patients with SS (95). The 
reason why dysgeusia was a common subjective symptom of SS-2 when compared with that 
of SS-1, could be related to the use of D-penicillamine which has found as common drug-
therapy for patients with RA. Dysgeusia was reported to be seen as a frequent problem of 
patients using D-penicillamine (96). 
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Fig. 3. Atrophy of filiform papillae 
 
Fig. 4. Redness of the tongue 
 




Fig. 5. Erythematous buccal mucosa 
subjective xerostomia, burning sensation, pain on swallowing and hypersensitivity. They 
observed significant differences between patients with SS and healthy subjects in terms of 









Angular Chelitis 8 (21.62%) 0 (0%) 0.005 (S) 
Oral Ulcerations 13 (35.13%) 0 (0%) 0.0001 (S) 
Atrophic  
Mucosa 28 (75.67%) 3 (8.10%) 0.0001 (S) 
Dry Mucosa 23 (62.16%) 1 (2.70%) 0.0001 (S) 
Reddened  
Mucosa 23 (62.16%) 5 (13.51%) 0.0001 (S) 
Atrophy of  
Filiform Papilla 18 (48.65%) 4 (10.81%) 0.001 (S) 
Xerostomia 32 (86.49%) 5 (13.51%) 0.0001 (S) 
Burning Sensation 29 (78.38%) 5 (13.51%) 0.0001 (S) 
Pain on Swallowing 23 (62.16%) 4 (10.81%) 0.0001 (S) 
Dysgeusia 30 (81.08%) 3 (8.10%) 0.0001 (S) 
Hypersensitivity 22 (59.46%) 0 (0%) 0.0001 (S) 
Table 4. Positive objective and subjective signs on oral clinical examination of the patients 
with SS (78) 
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2.5 Oral flora & treatment 
2.5.1 Oral flora 
A continuous flow of saliva is important in preventing oral colonization by Candida, as the 
constant flushing action of saliva may remove the unattached or loosely attached Candida 
from the oral cavity (86). It has been shown that high Candida albicans counts in saliva are 
associated with clinical signs of candidiasis (97). Also there has also been shown an inverse 
association between salivary flow rate and C. albicans counts in saliva (98-100). Various 
investigators have reported a high prevalence of oral Candida species in patients with SS 
when compared with those of healthy controls (90, 101-104), while others have found that 
there is no significant difference between patients with SS and healthy controls in terms of 
presence of candidiasis (86, 101). Most reports indicate that C. albicans is the predominant 
yeast isolated in gingival crevicular fluid and in periodontal pockets of the periodontal 
patients as well as in healthy subjects, although Candida glabrata and Candida tropicalis have 
also been found, albeit infrequently (33, 86, 100, 102, 104). Additionally, one study showed 
that C. albicans was detected in gingival crevicular fluid at one measurement site in one of 
the SS-1 subjects but not in the control group (79). 
Saliva has antibacterial, remineralizing, digestive, soft tissue reparative, lubricative, 
buffering, and cleansing properties. Therefore, decreased saliva production, which occurs in 
SS, can directly contribute to the oral and dental complications experienced by these 
patients. An inverse relationship between salivary flow rates and the level of Candida 
infection has been described, previously (86). Additionally, infection by C. albicans has been 
reported more frequently in individuals with SS than in the general population (87). While 
an even higher proportion of the total population (up to 60%) carry C. albicans in their 
mouths without clinical symptoms. The amount of the candidal load is important for 
development of candidiasis (105). As the quantification is essential for candidal assessment, 
we have detected the salivary Candida levels of the study population. Ergun et al have found 
out that Candida counts in saliva were statistically higher either in SS-1 or SS-2 patients as 
compared with that of the healthy control, which is in agreement with the results of other 
similar studies (78, 89, 99). 
For successful colonization and infection, adhesion to oral surfaces is necessity. C. albicans 
can adhere to epithelial cells of buccal mucosa, the tongue, tooth surfaces, various oral 
prostheses such as dentures, and other oral micro-organisms that have already colonized 
these surfaces. Clinically, C. albicans can be cultured from swabs of the buccal mucosa, 
tongue, teeth, denture surfaces, and dental plaque samples. The flushing effect of saliva and 
anti-candidal salivary components such as lysozyme, histatins, lactoferrin, and calprotectin 
are the innate host defenses which act to remove or kill invading yeasts (106). The decreased 
salivary flow means the decreased host defense. Ergun et al. showed that candidal 
colonization on the buccal epithelial and the dorsal tongue was found to be in higher in SS 
patients than in healthy controls. In colonized individuals with no clinical symptoms of 
candidiasis, C. albicans is most frequently found on the dorsum of the tongue. Although 
Almståhl & Wikström (107) did not find an increase of frequency of Candida in subjects with 
hyposalivation, those authors did not analyse Candida colonization on the tongue’s dorsal 
surface, which is the main ecological niche for Candida in the oral cavity.  
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Denture wearing is one of the major predisposing factor in humans for oral candidiasis. In 
denture wearers, the fitting surface of the denture is the main reservoir of the yeasts (108). 
Angular chelitis is commonly associated with denture-induced stomatitis. Ergun et al. 
stressed that no statistically significant difference was found between SS and healthy 
subjects on the prevalence of C. albicans colonization on dentures, palatinal and angular 
areas who use dentures with similar cleaning habits. Absence of normal salivary flow 
results with candidal colonization on the denture surfaces, palatinal mucosa and angular 
area in denture wearers even with normal or decreased salivary flow rate.  
As there is limited findings in healthy subjects, yeasts especially C. albicans have been 
recovered from periodontal pockets of patients with chronic periodontitis in different rates 
(7.1-19.6%) (104, 109-112). Brill considered gigngival crevicular fluid a transudate, a passage 
of fluid from bloodstream (113). But it’s also known that amount of gigngival crevicular 
fluid increases with periodontal disease and decreases during health (114). According to 
Cimasoni, gigngival crevicular fluid flow rate in slightly inflamed gingiva is about 0.1mg in 
3 minutes, which leads us to think that gigngival crevicular fluid renews itself continuously 
(115). Ergun et al concluded that population it is found that the subjects showed slight to 
moderate signs of inflammation (78). Finding only one subject (2.70%) in each group who 
has C. albicans colonization in the gigngival crevicular fluid, might be because of this 
continuous flow despite high scores of positive candida albicans colonization in different 
areas of the mouth. Rhodus and Michalowicz (25) found almost the same result in their pilot 
study, in which they compared the periodontal status and prevalence of sulcular C. albicans 
between subjects with SS-1 and healthy control subjects. 
Ergun et al have found out that there were direct correlations between positive candida 
albicans colonization on buccal area and dry mucosa, hypersensitivity and pain on 
swallowing with no spesific reason (78). Additionally, they have shown a weak correlation 
between Candida carriage in saliva and pain on swallowing (78). Volter et al. and Logemann 
et al. reported that xerestomia affects the sensory process of swallowing (94, 116). It is well 
known that positive Candida carriage in saliva is mostly the result of the lower levels of 
salivary flow rate. From this available evidence, it can be assumed that difficulties and pain 
on swallowing could occur due to positive Candida carriage in saliva. But more studies with 
higher number of patients with SS are needed to confirm or refute this association. 
2.5.2 Treatment 
Reduced saliva predisposes patients to an overgrowth of Candida albicans (43). This may be 
augmented by the use of dentures, smoking and diabetes (43, 51). Recurrent oral candidiasis 
can be treated with topical anti-fungal medications. Oral rinses with anti-fungal medications 
such as nystatin and fluconazole are effective in the treatment of oral candidiasis and for 
relieving oraldiscomfort (43, 117, 118). Management of chronic erythematous candidiasis 
and angle cheilitis can be based on the prescription of nystatin in tablets or solution (100,000 
IU 4-6 times a day), or miconazole gel 4 times a day (119). Removable dental prostheses 
should be treated separated by soaking in anti-fungal medication. Angular cheilitis can be 
treated with nystatin ointment or clotrimazole cream. Milillo et al. recently reported that 5% 
amorolfine anti-fungal varnish was effective for Candida-related denture stomatitis (120).  
 
Insights and Perspectives in Rheumatology 
 
162 
2.5 Oral flora & treatment 
2.5.1 Oral flora 
A continuous flow of saliva is important in preventing oral colonization by Candida, as the 
constant flushing action of saliva may remove the unattached or loosely attached Candida 
from the oral cavity (86). It has been shown that high Candida albicans counts in saliva are 
associated with clinical signs of candidiasis (97). Also there has also been shown an inverse 
association between salivary flow rate and C. albicans counts in saliva (98-100). Various 
investigators have reported a high prevalence of oral Candida species in patients with SS 
when compared with those of healthy controls (90, 101-104), while others have found that 
there is no significant difference between patients with SS and healthy controls in terms of 
presence of candidiasis (86, 101). Most reports indicate that C. albicans is the predominant 
yeast isolated in gingival crevicular fluid and in periodontal pockets of the periodontal 
patients as well as in healthy subjects, although Candida glabrata and Candida tropicalis have 
also been found, albeit infrequently (33, 86, 100, 102, 104). Additionally, one study showed 
that C. albicans was detected in gingival crevicular fluid at one measurement site in one of 
the SS-1 subjects but not in the control group (79). 
Saliva has antibacterial, remineralizing, digestive, soft tissue reparative, lubricative, 
buffering, and cleansing properties. Therefore, decreased saliva production, which occurs in 
SS, can directly contribute to the oral and dental complications experienced by these 
patients. An inverse relationship between salivary flow rates and the level of Candida 
infection has been described, previously (86). Additionally, infection by C. albicans has been 
reported more frequently in individuals with SS than in the general population (87). While 
an even higher proportion of the total population (up to 60%) carry C. albicans in their 
mouths without clinical symptoms. The amount of the candidal load is important for 
development of candidiasis (105). As the quantification is essential for candidal assessment, 
we have detected the salivary Candida levels of the study population. Ergun et al have found 
out that Candida counts in saliva were statistically higher either in SS-1 or SS-2 patients as 
compared with that of the healthy control, which is in agreement with the results of other 
similar studies (78, 89, 99). 
For successful colonization and infection, adhesion to oral surfaces is necessity. C. albicans 
can adhere to epithelial cells of buccal mucosa, the tongue, tooth surfaces, various oral 
prostheses such as dentures, and other oral micro-organisms that have already colonized 
these surfaces. Clinically, C. albicans can be cultured from swabs of the buccal mucosa, 
tongue, teeth, denture surfaces, and dental plaque samples. The flushing effect of saliva and 
anti-candidal salivary components such as lysozyme, histatins, lactoferrin, and calprotectin 
are the innate host defenses which act to remove or kill invading yeasts (106). The decreased 
salivary flow means the decreased host defense. Ergun et al. showed that candidal 
colonization on the buccal epithelial and the dorsal tongue was found to be in higher in SS 
patients than in healthy controls. In colonized individuals with no clinical symptoms of 
candidiasis, C. albicans is most frequently found on the dorsum of the tongue. Although 
Almståhl & Wikström (107) did not find an increase of frequency of Candida in subjects with 
hyposalivation, those authors did not analyse Candida colonization on the tongue’s dorsal 
surface, which is the main ecological niche for Candida in the oral cavity.  
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Denture wearing is one of the major predisposing factor in humans for oral candidiasis. In 
denture wearers, the fitting surface of the denture is the main reservoir of the yeasts (108). 
Angular chelitis is commonly associated with denture-induced stomatitis. Ergun et al. 
stressed that no statistically significant difference was found between SS and healthy 
subjects on the prevalence of C. albicans colonization on dentures, palatinal and angular 
areas who use dentures with similar cleaning habits. Absence of normal salivary flow 
results with candidal colonization on the denture surfaces, palatinal mucosa and angular 
area in denture wearers even with normal or decreased salivary flow rate.  
As there is limited findings in healthy subjects, yeasts especially C. albicans have been 
recovered from periodontal pockets of patients with chronic periodontitis in different rates 
(7.1-19.6%) (104, 109-112). Brill considered gigngival crevicular fluid a transudate, a passage 
of fluid from bloodstream (113). But it’s also known that amount of gigngival crevicular 
fluid increases with periodontal disease and decreases during health (114). According to 
Cimasoni, gigngival crevicular fluid flow rate in slightly inflamed gingiva is about 0.1mg in 
3 minutes, which leads us to think that gigngival crevicular fluid renews itself continuously 
(115). Ergun et al concluded that population it is found that the subjects showed slight to 
moderate signs of inflammation (78). Finding only one subject (2.70%) in each group who 
has C. albicans colonization in the gigngival crevicular fluid, might be because of this 
continuous flow despite high scores of positive candida albicans colonization in different 
areas of the mouth. Rhodus and Michalowicz (25) found almost the same result in their pilot 
study, in which they compared the periodontal status and prevalence of sulcular C. albicans 
between subjects with SS-1 and healthy control subjects. 
Ergun et al have found out that there were direct correlations between positive candida 
albicans colonization on buccal area and dry mucosa, hypersensitivity and pain on 
swallowing with no spesific reason (78). Additionally, they have shown a weak correlation 
between Candida carriage in saliva and pain on swallowing (78). Volter et al. and Logemann 
et al. reported that xerestomia affects the sensory process of swallowing (94, 116). It is well 
known that positive Candida carriage in saliva is mostly the result of the lower levels of 
salivary flow rate. From this available evidence, it can be assumed that difficulties and pain 
on swallowing could occur due to positive Candida carriage in saliva. But more studies with 
higher number of patients with SS are needed to confirm or refute this association. 
2.5.2 Treatment 
Reduced saliva predisposes patients to an overgrowth of Candida albicans (43). This may be 
augmented by the use of dentures, smoking and diabetes (43, 51). Recurrent oral candidiasis 
can be treated with topical anti-fungal medications. Oral rinses with anti-fungal medications 
such as nystatin and fluconazole are effective in the treatment of oral candidiasis and for 
relieving oraldiscomfort (43, 117, 118). Management of chronic erythematous candidiasis 
and angle cheilitis can be based on the prescription of nystatin in tablets or solution (100,000 
IU 4-6 times a day), or miconazole gel 4 times a day (119). Removable dental prostheses 
should be treated separated by soaking in anti-fungal medication. Angular cheilitis can be 
treated with nystatin ointment or clotrimazole cream. Milillo et al. recently reported that 5% 
amorolfine anti-fungal varnish was effective for Candida-related denture stomatitis (120).  
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As mentioned before dentures may not be suitable for patients SS; however, dentures could 
be the only restorative choice (43). The tongue adheres to and dislodges the denture, causing 
decreased retention of partial and totally removable prosthesis and resulting in abrasions, 
sore spots, ulceration and irritation, all unpleasant and painful experiences for the patient (4, 
43). Despite this, an implant-supported denture may be successful; however, the high cost of 
this denture could represent a problem for patients. If dryness is a continuous problem, the 
manufacture of dentures with reservoirs or chambers for artificial saliva is suggested for 
continuous delivery of saliva, although these dentures should not be worn during eating 
(43, 121-123).  
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1. Introduction 
Sjögren’s syndrome (SS) is a systemic chronic autoimmune disorder affecting exocrine 
organs such as the salivary and lacrimal glands. SS is characterized by severe dryness of the 
mouth and eyes due to inflammatory reactions against salivary and lacrimal glands, 
respectively. Dryness of other mucosal surfaces such as skin, gastrointestinal tract, lungs, 
and vagina, has also been observed. SS patients also exhibit systemic symptoms such as 
Raynaud’s phenomenon, arthritis, fatigue, peripheral neuropathies, and cognitive 
impairment. SS exists in two forms: primary SS, unassociated with other autoimmune 
disesases; and secondary SS, accompanied by another autoimmune disease such as 
scleroderma, rheumatoid arthritis, or systemic lupus erythematosus (Fox and Kang 1992). SS 
is the second most common autoimmune rheumatic disease, with a prevalence in the United 
States estimated at 2-4 million people (Kassan and Moutsopoulos 2004), with a female to 
male ratio of 9:1. Although SS affects men and children as well, it is most commonly seen if 
peri- or postmenopausal women. 
Diagnostic criteria for SS have been defined most recently by the modified American-
European Consensus Group (Vitali et al. 2002). These criteria include histological evaluation 
of a minor salivary gland for lymphocytic infiltration, serological presence of autoantibodies 
against SSA or SSB antigens, and assessment of ocular and oral symptoms. Oral 
involvement is assessed by the patient’s subjective symptoms of oral dryness, parotid 
sialography showing the presence of diffuse sialectasis, salivary scintigraphy showing 
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1. Introduction 
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Diagnostic criteria for SS have been defined most recently by the modified American-
European Consensus Group (Vitali et al. 2002). These criteria include histological evaluation 
of a minor salivary gland for lymphocytic infiltration, serological presence of autoantibodies 
against SSA or SSB antigens, and assessment of ocular and oral symptoms. Oral 
involvement is assessed by the patient’s subjective symptoms of oral dryness, parotid 
sialography showing the presence of diffuse sialectasis, salivary scintigraphy showing 
delayed uptake, reduced concentration, and/or delayed excretion of tracer, and/or the 
evaluation of unstimulated saliva production. Ocular involvement is assessed by the 
patient’s subjective symptoms of ocular dryness, a Schirmer’s test to measure tear secretion 
or a Rose Bengal test to measure the ocular surface abrasion in patients. 
Originally, it was thought that loss of secretory function, a clinical hallmark of SS, was due 
to apoptotic destruction of acinar cells mediated by CD8+ T lymphocytes in the lymphocytic 
infiltration in the salivary and lacrimal glands. However, research has demonstrated that 
transfer of human SS patient IgG to the B-cell deficient SS-prone NOD mouse resulted in 
altered saliva production in the absence of immune cell infiltration in the glands, indicating 
a role for autoantibodies in the functional impairment of secretory processes in SS 
(Robinson, Brayer et al. 1998). This resulted in a paradigm shift in the field, leading to the 
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belief that lymphocytic infiltration was not the only contributing factor to secretory 
dysfunction in SS. In addition to autoantibodies targeting muscarinic receptors, pro-
inflammatory cytokines have been shown to play a role in SS pathogenesis by contributing 
to damage of glandular tissue and secretory dysfunction. Nitric oxide production has also 
been implicated as a potential cause of loss of secretion, as loss of nitric oxide synthase 
activity in salivary glands paralleled the decline in salivary secretion. A role for apoptotic 
cell death of acinar cells still remains in SS pathogenesis, however; our group has 
demonstrated that increased apoptosis is detectable in the salivary glands of SS-prone mice 
prior to disease onset or lymphocytic infiltration (Bulosan et al. 2008). In this review, these 
mechanisms and other possibilities that can contribute to loss of secretory function in SS will 
be discussed in detail.  
2. Mechanisms 
The clinical hallmark of SS is dryness due to loss of secretory function in the salivary and 
lacrimal glands. However, the etiology of SS is still not understood. There are numerous 
underlying mechanisms thought to contribute to this loss of secretory function in salivary 
glands, though no single mechanism has been identified as the primary cause. Lymphocytic 
infiltration, autoantibodies targeting muscarinic receptors, pro-inflammatory cytokines, 
nitric oxide, and apoptotic cell death of acinar cells have all been implicated as potential 
causes of secretory dysfunction in the salivary glands.  
2.1 Lymphocytic infiltration and proinflammatory cytokines in the salivary glands 
SS is characterized by lymphocytic infiltration and aberrant activation of epithelial tissues, 
which appear in salivary and lacrimal glands. It has been reported that this lymphocytic 
infiltration within the salivary and lacrimal glands consists mostly of CD4+ T cells, B cells, 
and lesser numbers of CD8+ T cells (Robinson, Cornelius et al. 1998, ; Tapinos et al. 1998). 
Balance between T and B cells in the lymphocyte infiltrates varies according to disease 
progression in the mouse model of SS (Robinson, Cornelius et al. 1998, ; Tapinos et al. 1998). 
It has been shown that leukocytes expressing pro-inflammatory cytokines infiltrate the 
exocrine glands, and T cells are recruited first to the site of infiltration followed by B cells, 
establishing lymphocytic infiltrates (Kong et al. 1998). CD8+ T cells, which have been shown 
to have increased expression of adhesion molecules and Fas/FasL, can also directly kill 
acinar cells in the salivary glands. Salivary gland dryness and/or formation of lymphocytic 
infiltration may be the result of glandular destruction mediated by effector 
cytokines/chemokines from T and B cells, as well as cytotoxic effects of CD8+ T cells. 
2.1.1 Cytokines contributing to salivary gland dysfunction 
Tumor necrosis factor- α (TNF-α) is one of the proinflammatory cytokines produced in 
response to infection, tissue damage, and environmental challenges and also known as an 
Interferon-γ (IFNγ)-inducing cytokine along with IL-12 and IL-18 (Locksley 1993, ; Billiau 
1996). TNF-α production has been implicated in many human diseases including 
autoimmune diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE). TNF-α activated the extrinsic apoptotic pathway and 
induced upregulation of intercellular adhesion molecule-1 (ICAM-1) and CCL20 in human 
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salivary gland (HSG) cells in vitro (Wang et al. 2009). In addition, TNF-α can disrupt tight 
junction structure in salivary glands from SS patients, potentially resulting in secretory 
dysfunction (Ewert et al. 2010, ; Baker 2010). 
IL-18 and its inducer IL-12 are cytokines that play an important role in TH1 driven 
autoimmune responses and inflammatory tissue disease by activating IFNγ secretion. The 
elevation of these cytokines triggered the inflammatory response in SLE and RA patients 
(Mosaad et al. 2003). Increased circulating levels and salivary gland expression of IL-18 was 
observed in SS patients, and IL-18 was detected in periductal inflammatory foci and saliva 
as well (Bombardieri et al. 2004, ; Bulosan et al. 2009). In addition, increased labial salivary 
gland IL-18 levels in primary SS patients correlated with increased disease activity 
parameters (Bikker et al. 2010, ; Bombardieri et al. 2004). Moreover, salivary gland 
infiltration by macrophages and dendritic cells (DCs), along with the expression of IL-18 
and IL-12, appear to play active roles in the expansion and organization of infiltrative 
injuries and have a correlation with the lymphoma development in the patients with 
primary SS (Manoussakis et al. 2007). IL-12 transgenic mice showed decreased stimulated 
salivary flow by pilocarpine than in wild type controls. Also, IL-12 transgenic mice exhibited 
increased number and size of lymphocytic foci with increased anti-SSB/La antibodies, 
compared to glands from age-matched controls (Vosters et al. 2009). 
IFNγ is the major cytokine which is released from TH1 cells and regulates cell-mediated 
immune responses through activation of natural killer (NK) cells, macrophages, and CD8+ T 
cells. IFN-γ or receptor knockout mouse models (NOD. IFNγ-/- and NOD. IFNγR-/-) showed 
normal development of salivary glands, maintained secretory function, and failed to 
develop any SS-like phenotypes (Cha et al. 2004). However, its parental strain NOD and a 
recently developed SS mouse model C57BL/6.NOD-Aec1Aec2 showed retarded salivary 
gland growth and acinar cell apoptosis prior to disease onset and proceed to developing 
full-blown disease phenotype including loss of secretory function (Lee, Tudares, and 
Nguyen 2009). This indicates that IFN-γ plays an important role in loss of secretory function 
in SS. In addition, it has been found that IFNγ-induced T cells can produce chemokines 
(IFN-inducible protein 10 (IP-10)/CXCL9, CXCL10), which can attract NK cell and T cells in 
SS ductal epithelial cells (Ogawa et al. 2002, ; Ogawa et al. 2004). 
There are also cytokines released from TH2 cells that can play an important role in SS. 
Elevated levels of IL-4 were found in the serum of primary SS patients who have 
lymphocytic infiltration and ectopic germinal center formation in their minor salivary 
glands (Reksten et al. 2009). Studies using the NOD.IL4–/– and NOD.B10-H2b.IL4–/– mice 
indicated that IL-4 gene knockout mice have pathophysiological abnormalities and 
leukocyte infiltration in the salivary glands but salivary gland secretion was normal in the 
absence of IL-4 (Gao et al. 2006). Considering that IL-4 knockout mice fail to produce IgG1 
isotypic autoantibodies against cell surface receptor muscarinic type 3 receptor (M3R), 
isotypic anti-M3R autoantibody is critical in the development of secretory dysfunction (Gao 
et al. 2004). Moreover, purified IgG fractions isolated from the sera of Stat6 (downstream 
signal transduction factor of IL-4) knockout mice, which are unable to produce IgG1, were 
not able to inhibit saliva flow rates when infused to wild type control mice (C57BL/6) 
(Nguyen et al. 2007). Therefore, IL-4 can affect saliva secretion via antibody production and 
its isotype switching. 
 
Insights and Perspectives in Rheumatology 
 
172 
belief that lymphocytic infiltration was not the only contributing factor to secretory 
dysfunction in SS. In addition to autoantibodies targeting muscarinic receptors, pro-
inflammatory cytokines have been shown to play a role in SS pathogenesis by contributing 
to damage of glandular tissue and secretory dysfunction. Nitric oxide production has also 
been implicated as a potential cause of loss of secretion, as loss of nitric oxide synthase 
activity in salivary glands paralleled the decline in salivary secretion. A role for apoptotic 
cell death of acinar cells still remains in SS pathogenesis, however; our group has 
demonstrated that increased apoptosis is detectable in the salivary glands of SS-prone mice 
prior to disease onset or lymphocytic infiltration (Bulosan et al. 2008). In this review, these 
mechanisms and other possibilities that can contribute to loss of secretory function in SS will 
be discussed in detail.  
2. Mechanisms 
The clinical hallmark of SS is dryness due to loss of secretory function in the salivary and 
lacrimal glands. However, the etiology of SS is still not understood. There are numerous 
underlying mechanisms thought to contribute to this loss of secretory function in salivary 
glands, though no single mechanism has been identified as the primary cause. Lymphocytic 
infiltration, autoantibodies targeting muscarinic receptors, pro-inflammatory cytokines, 
nitric oxide, and apoptotic cell death of acinar cells have all been implicated as potential 
causes of secretory dysfunction in the salivary glands.  
2.1 Lymphocytic infiltration and proinflammatory cytokines in the salivary glands 
SS is characterized by lymphocytic infiltration and aberrant activation of epithelial tissues, 
which appear in salivary and lacrimal glands. It has been reported that this lymphocytic 
infiltration within the salivary and lacrimal glands consists mostly of CD4+ T cells, B cells, 
and lesser numbers of CD8+ T cells (Robinson, Cornelius et al. 1998, ; Tapinos et al. 1998). 
Balance between T and B cells in the lymphocyte infiltrates varies according to disease 
progression in the mouse model of SS (Robinson, Cornelius et al. 1998, ; Tapinos et al. 1998). 
It has been shown that leukocytes expressing pro-inflammatory cytokines infiltrate the 
exocrine glands, and T cells are recruited first to the site of infiltration followed by B cells, 
establishing lymphocytic infiltrates (Kong et al. 1998). CD8+ T cells, which have been shown 
to have increased expression of adhesion molecules and Fas/FasL, can also directly kill 
acinar cells in the salivary glands. Salivary gland dryness and/or formation of lymphocytic 
infiltration may be the result of glandular destruction mediated by effector 
cytokines/chemokines from T and B cells, as well as cytotoxic effects of CD8+ T cells. 
2.1.1 Cytokines contributing to salivary gland dysfunction 
Tumor necrosis factor- α (TNF-α) is one of the proinflammatory cytokines produced in 
response to infection, tissue damage, and environmental challenges and also known as an 
Interferon-γ (IFNγ)-inducing cytokine along with IL-12 and IL-18 (Locksley 1993, ; Billiau 
1996). TNF-α production has been implicated in many human diseases including 
autoimmune diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE). TNF-α activated the extrinsic apoptotic pathway and 
induced upregulation of intercellular adhesion molecule-1 (ICAM-1) and CCL20 in human 
 
Mechanisms of Salivary Gland Secretory Dysfunction in Sjögren’s Syndrome 
 
173 
salivary gland (HSG) cells in vitro (Wang et al. 2009). In addition, TNF-α can disrupt tight 
junction structure in salivary glands from SS patients, potentially resulting in secretory 
dysfunction (Ewert et al. 2010, ; Baker 2010). 
IL-18 and its inducer IL-12 are cytokines that play an important role in TH1 driven 
autoimmune responses and inflammatory tissue disease by activating IFNγ secretion. The 
elevation of these cytokines triggered the inflammatory response in SLE and RA patients 
(Mosaad et al. 2003). Increased circulating levels and salivary gland expression of IL-18 was 
observed in SS patients, and IL-18 was detected in periductal inflammatory foci and saliva 
as well (Bombardieri et al. 2004, ; Bulosan et al. 2009). In addition, increased labial salivary 
gland IL-18 levels in primary SS patients correlated with increased disease activity 
parameters (Bikker et al. 2010, ; Bombardieri et al. 2004). Moreover, salivary gland 
infiltration by macrophages and dendritic cells (DCs), along with the expression of IL-18 
and IL-12, appear to play active roles in the expansion and organization of infiltrative 
injuries and have a correlation with the lymphoma development in the patients with 
primary SS (Manoussakis et al. 2007). IL-12 transgenic mice showed decreased stimulated 
salivary flow by pilocarpine than in wild type controls. Also, IL-12 transgenic mice exhibited 
increased number and size of lymphocytic foci with increased anti-SSB/La antibodies, 
compared to glands from age-matched controls (Vosters et al. 2009). 
IFNγ is the major cytokine which is released from TH1 cells and regulates cell-mediated 
immune responses through activation of natural killer (NK) cells, macrophages, and CD8+ T 
cells. IFN-γ or receptor knockout mouse models (NOD. IFNγ-/- and NOD. IFNγR-/-) showed 
normal development of salivary glands, maintained secretory function, and failed to 
develop any SS-like phenotypes (Cha et al. 2004). However, its parental strain NOD and a 
recently developed SS mouse model C57BL/6.NOD-Aec1Aec2 showed retarded salivary 
gland growth and acinar cell apoptosis prior to disease onset and proceed to developing 
full-blown disease phenotype including loss of secretory function (Lee, Tudares, and 
Nguyen 2009). This indicates that IFN-γ plays an important role in loss of secretory function 
in SS. In addition, it has been found that IFNγ-induced T cells can produce chemokines 
(IFN-inducible protein 10 (IP-10)/CXCL9, CXCL10), which can attract NK cell and T cells in 
SS ductal epithelial cells (Ogawa et al. 2002, ; Ogawa et al. 2004). 
There are also cytokines released from TH2 cells that can play an important role in SS. 
Elevated levels of IL-4 were found in the serum of primary SS patients who have 
lymphocytic infiltration and ectopic germinal center formation in their minor salivary 
glands (Reksten et al. 2009). Studies using the NOD.IL4–/– and NOD.B10-H2b.IL4–/– mice 
indicated that IL-4 gene knockout mice have pathophysiological abnormalities and 
leukocyte infiltration in the salivary glands but salivary gland secretion was normal in the 
absence of IL-4 (Gao et al. 2006). Considering that IL-4 knockout mice fail to produce IgG1 
isotypic autoantibodies against cell surface receptor muscarinic type 3 receptor (M3R), 
isotypic anti-M3R autoantibody is critical in the development of secretory dysfunction (Gao 
et al. 2004). Moreover, purified IgG fractions isolated from the sera of Stat6 (downstream 
signal transduction factor of IL-4) knockout mice, which are unable to produce IgG1, were 
not able to inhibit saliva flow rates when infused to wild type control mice (C57BL/6) 
(Nguyen et al. 2007). Therefore, IL-4 can affect saliva secretion via antibody production and 
its isotype switching. 
 
Insights and Perspectives in Rheumatology 
 
174 
Recently, not only TH1 and TH2 effector cells but also TH17 cells, which mainly release pro-
inflammatory cytokine IL-17, are being investigated for their role in disease pathogenesis of 
many autoimmune diseases including SS. The presence of TH17 cells and TH17-associated 
cytokines, IL-6, IL-23, IL-17, and IL-1β were reported in the serum and minor salivary 
glands of primary SS patients (Nguyen et al. 2008, ; Sakai et al. 2008, ; Reksten et al. 2009, ; 
Katsifis et al. 2009). It is also known that IL-18 synergizes with IL-17 to induce secretion of 
pro-inflammatory cytokines IL-6 and IL-8 in human parotid gland cells (Sakai et al. 2008). 
Serum levels of IL-17, IL-6, and IL-23 were significantly elevated in primary SS. A recent 
study in which an adenovirus vector expressing IL-17 was infused into the salivary glands 
of wild type mice (C57BL/6J) demonstrated the appearance of lymphocytic infiltrates, 
increased proinflammatory cytokine levels, changes in antinuclear antibody profiles, and 
temporal loss of saliva flow after infusion (Nguyen et al. 2010). In the reverse approach, 
infusion of IL-17R:Fc-blocking factor into the SS mouse model to block IL-17 binding to IL-
17 receptor showed decreased lymphocytic infiltration in salivary glands, normalization of 
the antinuclear antibody repertoire, and increased saliva secretion (Nguyen et al. 2011). 
Therefore, these studies indicate that IL-17 is critical in inducing SS-phenotype in wild type 
mice. However, the mechanism by which IL-17 functions in altering secretory function in SS 
needs to be defined. 
2.1.2 B cell involvement in SS 
In addition to pathogenic T cells and cytokines, loss of B cell tolerance is critical in 
autoimmune diseases including SS. Levels of the B cell activating factor belonging to the 
TNF family (BAFF) in serum were higher in patients with SLE, RA and pSS than in normal 
individuals (Cheema et al. 2001, ; Groom et al. 2002, ; Zhang et al. 2001). BAFF 
overexpression caused self-reactive B cells at the transitional B cell stage and is responsible 
for B cell hyperactivity. It is known that over-expressing BAFF in BAFF-transgenic mice 
resulted in SLE-like disease with increased number of marginal-zone (MZ) like B cells, and 
at 16-18 months of age, these mice exhibited a SS-like disease with MZ like B cells in the 
salivary glands (Mackay et al. 1999, ; Groom et al. 2002). However, recent findings indicated 
that BAFF expression alone is not correlated with disease activity (Cheema et al. 2001, ; 
Zhang et al. 2001, ; Stohl et al. 2003). Nonetheless, BAFF influences the survival, 
proliferation, and differentiation of B cells in combination with IL-17 in patients with SLE 
and its combination can promote the persistence of self-reactive B cells (Doreau et al. 2009). 
As described above, T cells and B cells clearly contribute to SS onset and progression. 
However, activation of T cells and B cells are required for normal immune function, and the 
trigger for autoimmune reactivity in SS has yet to be identified. Also, studies using immune-
deficient mice revealed that secretory dysfunction and other salivary gland abnormalities 
can still occur in the absence of infiltrating immune cells and their cytokines. 
2.2 Autoantibodies targeting muscarinic receptors 
The assumption that secretory dysfunction in SS was a direct consequence of acinar tissue 
loss after lymphocytic infiltration was deeply ingrained in the SS research community for 
more than 60 years. However, more recently, our understanding of the pathogenesis of 
secretory dysfunction in SS has undergone a dramatic change. Questions arose concerning 
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SS patients with viable acinar tissue in their salivary glands but who still suffer from 
xerostomia. These observations suggest that the salivary gland secretory dysfunction in 
many SS patients is the result of a disruption of acinar cell function rather than acinar tissue 
destruction. 
 
Fig. 1. Immune cell infiltration in the salivary gland of 34 week old SS-prone  
C57BL/6.NOD-Aec1Aec2 male mouse.  
In addition to salivary gland lymphocytic infiltration, SS patients exhibit 
hypergammaglobulinemia with a range of autoanitbodies targeting cell surface, 
cytoplasmic, and nuclear proteins of exocrine tissue (Chan et al. 1991, ; Fox and Kang 1992, ; 
Haneji et al. 1997). Approximately 90% of patients are positive for antinuclear antibodies 
(ANA), the most common of which are directed against two ribonucleoprotein antigens 
known as Ro or SSA and La or SSB. These autoantibodies are included in the modified 
European–American Diagnostic Criteria for Sjögren’s Syndrome (Vitali et al. 2002), but are 
also found in other autoimmune diseases, particularly systemic lupus erythematosus (SLE). 
Autoantibodies to other immunoglobulins (known as rheumatoid factors) are also 
frequently found in SS. Primary SS (pSS) sera can also contain many different 
autoantibodies against organ or tissue specific autoantigens, including acetylcholine 
receptors, the carbonic anhydrase and thyroid peroxidase. Finally, autoantibodies directed 
against the cytoskeletal protein β-fodrin, and the muscarinic receptors M3, have also been 
described in primary SS, the latter of which we will focus on here. 
2.2.1 Muscarinic receptor function in salivary glands 
Acetylcholine (ACh) control of fluid secretion in salivary acinar cells is mediated through 
the G protien-linked muscarinic M3 receptor (M3R). ACh binds to M3R, which causes 
phospholipase C to generate inositol 1,4,5-trisphosphate (IP3). IP3 binds to and opens the 
IP3 receptor on the endoplasmic reticulum, which releases Ca2+. The increased concentration 
of intracellular Ca2+ activates the apical membrane Cl- channel and the basolateral  
K+ channel. Efflux of Cl- into the acinar lumen draws Na+ across the cells, and the osmotic 
gradient generates fluid secretion (Tobin, Giglio, and Lundgren 2009). Therefore, blocking 
or desensitizing muscarinic receptors is detrimental to this signaling pathway and 
ultimately results in loss of secretory function. 
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2.2.2 Initial characterization of anti-muscarinic antibodies 
In 1994, it was observed that in the NOD mouse model, which exhibits an autoimmune-
associated lymphocytic attack on the salivary glands and loss of secretory function, 
decreased response to beta-adrenergic receptor stimulation was related to a decrease in 
receptor density and changes in the level of intracellular second messenger signalling (Hu et 
al. 1994). It was hypothesized that these changes could be due to an autoantibody targeting 
the β1-adrenergic receptor present in the sera of NOD mice. 
In 1996, futher study of the NOD mouse model revealed a reduction in muscarinic receptor 
density on the salivary glands of prediabetic and diabetic NOD mice compared to BALB/c 
mice corresponding to reduced secretory function in the NOD (Yamamoto et al. 1996). 
Additionally, sera from the diabetic NOD but not the BALB/c immunoprecipitated 
radiolabeled muscarinic receptor, indicating the presence of autoantibody to the receptor in 
NOD mice (Yamamoto et al. 1996). 
Autoantibodies against M3R were first described in human SS patients in 1996 (Bacman et 
al. 1996). It was demonstrated that IgG present in the sera of primary SS patients could bind 
and activate muscarinic receptors of rat parotid glands (Bacman et al. 1996). They also 
demonstrated that the IgG fraction from the sera of pSS patients mimicked the biological 
effects of muscarinic cholingergic agonists by modifying intracellular events associated with 
specific receptor activation, such as decreasing cAMP and increasing phosphoinositide 
turnover (Bacman et al. 1996). These findings suggested that autoantibodies targeting M3R 
could potentially play a role in SS pathogenesis. 
 
Fig. 2. pSS IgG staining of hM3R-transfected Flp-In CHO cells. Flp-In CHO cells were 
transfected with hM3R and then incubated with pSS sera (1:50 dilution) containing  
anti-M3R autoantibodies. Fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
antibody at 1:250 dilution was used for detection. 
2.2.3 Roles for anti-muscarinic receptor antibodies in SS 
In 1998, Robinson, et al. were the first to demonstrate that transferring human SS patient IgG 
to NOD.Igµnull mice resulted in secretory gland dysfunction (Robinson, Brayer et al. 1998). 
NOD.Igµnull mice lack functional B lymphocytes, and therefore lack the IgG autoantibodies 
that are produced by their NOD counterparts and human SS patients. NOD.Igµnull mice do 
exhibit lymphocytic infiltration of the salivary and lacrimal glands, but fail to lose secretory 
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function. However, when treated with IgG from SS patient sera, a 54% reduction in saliva 
production was observed, while treatment with IgG from healthy control mice and healthy 
humans had no significant effect on secretory function (Robinson, Brayer et al. 1998). 
Furthermore, after prolonged treatment with SS IgG fractions, there was an increase in 
apoptotic cell death of salivary acinar cells (Robinson, Brayer et al. 1998). These data indicate 
that anti-M3R autoantibodies play a critical role in the clinical presentation of dryness in SS. 
Further evidence for anti-M3R autoantibody-mediated secretory dysfunction in NOD mice 
was presented in 2000. Infusion of monoclonal antibodies to mouse M3R into NOD-scid 
mice resulted in significantly reduced saliva secretion within 72 hours, while infusion with 
antibodies to Ro (SSA), La (SSB), or parotid secretory protein (PSP) had no effect on 
secretory function (Nguyen et al. 2000). Mechanistic studies revealed that translocation of 
aquaporin-5 to the plasma membrane was inhibited by anti-M3R antibodies, but not the 
other antibodies again showing a role for anti-M3R autoantibodies in SS pathogenesis 
(Nguyen et al. 2000).  
In 2004, Li, et al. demonstrated the inhibitory effects of autoantibodies from SS patients on 
muscarinic receptors by showing that carbachol-induced intracellular calcium release was 
inhibited by SS IgG treatment of HSG cells (Li et al. 2004). Aquaporin-5 trafficking to the 
apical membrane of rat parotid acinar cells was also inhibited by SS IgG (Li et al. 2004). 
Additionally, other groups found abnormal translocation of aquaporin-5 in the NOD mouse 
model of SS and in salivary glands of SS patients (Konttinen et al. 2005, ; Steinfeld et al. 
2001). However, these findings are somewhat controversial since others have shown no 
differences in the subcellular distribution of aquaporin-5 in salivary glands of primary SS 
patients (Beroukas et al. 2001, ; Tsubota et al. 2001). Our unpublished findings show a 
definite alteration in GFP-tagged aquaporin-5 trafficking in human salivary gland cells that 
were pre-treated with SS plasma compared to healthy control plasma. Taken together, these 
data further support a role for anti-muscarinic receptor autoantibodies in loss of secretory 
function in SS. 
The chronic effects of anti-M3R autoantibodies were examined in 2006 by analyzing the 
contraction of bladder smooth muscle strips from diseased NOD mice (Cha et al. 2006). The 
results indicated that the presence of anti-M3R autoantibodies in NOD mice resulted in a 
desensitization of M3R as measured by direct carbachol-induced responses and an 
accelerated loss of responses to repeated pilocarpine injections (Cha et al. 2006). This data 
supports the hypothesis that frequent use of pilocarpine by SS patients who have already 
progressed to M3R desensitization induced by anti-M3R autoantibodies will be less effective 
due to a desensitizing synergy between pilocarpine and anti-M3R autoantibodies. 
Anti-muscarinic receptor antibodies have also been shown to affect the autonomic nervous 
system. In 2000, it was demonstrated that sera from primary and secondary SS patients 
inhibited parasympathetic neurotransmission as measured by carbachol-stimulated bladder 
contraction using bladder and colon smooth muscle strips in vitro, while sera from healthy 
controls or SLE patients had no effect (Waterman, Gordon, and Rischmueller 2000). These 
findings suggest that autoantibodies targeting M3R may contribute to sicca symptoms as 
well as autonomic dysfunction such as bladder symptoms in some patients (Waterman, 
Gordon, and Rischmueller 2000).  
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In vivo evidence was presented in 2004, when passive transfer of SS IgG with anti-M3R 
activity to BALB/c mice resulted in an increased response to cholinergic stimulation of 
bladder smooth muscle (Wang et al. 2004). This cholinergic hyperresponsiveness was found 
to be specifically induced by anti-M3R antibodies following passive transfer (Wang et al. 
2004). These findings are consistent with the overactive bladder symptoms experienced by 
many SS patients, indicating that overactive bladder in SS is an autoantibody-mediated 
disorder of the autonomic nervous system that could also account for a broad range of 
cholinergic hyperresponsiveness. 
Most recently, it has been demonstrated that primary SS IgG with anti-M3R activity 
inhibited contraction of the smooth muscle of the GI tract and disrupted contractile motility 
in the colon (Park et al. 2011). These data may explain the widespread impairment of the GI 
tract in SS patients including delayed gastric emptying and abnormalities in colonic motility 
(Cai et al. 2008, ; Kovacs et al. 2003).  
2.2.4 Conclusions 
Overall, these findings strongly support a role for anti-M3R autoantibodies in the 
pathogenesis of SS. The data suggest that a number of primary and secondary SS patients 
have serum IgG capable of binding to and inhibiting muscarinic receptors on salivary acinar 
cells in vitro. However, due to the lack of a reliable screening assay, relatively few subjects 
have been tested, and the percentage of SS patients estimated to be positive for anti-
muscarinic antibodies varies wildly from 0 to almost 100%. Future studies in this field 
should focus on the development of a screening assay for anti-muscarinic antibodies to 
confirm the number of SS patients positive for these autoantibodies and establish or rule-out 
anti-M3R antibodies as a diagnostic marker for SS.  
2.3 Nitric oxide and nitric oxide synthase 
In 1986 nitric oxide (NO) was first described as endothelially derived relaxing factor (EDRF) 
(Palmer, Ferrige, and Moncada 1987). Subsequently, it has been shown to be involved in a 
multitude of diverse physiological and pathophsiological processes, including potential 
functions in the regulation of salivary gland secretion and in the development of secretory 
hypofunction. In vivo, NO is found to be synthesized in a wide variety of cell types by the 
enzyme NO synthase (NOS). There are three known isoforms of NOS, each produced from a 
distinct set of genes. The two constitutive isoforms are neuronal NOS (nNOS, NOS-1) and 
endothelial NOS (eNOS, NOS-3), whereby their names reflect the original tissues from 
which they were discovered. The functional activity of these two isoforms is dependent on a 
rise in Ca2+ and therefore generate low, transient, concentrations of NO. The other isoform, 
inducible NOS (iNOS, NOS-2), is mainly found in inflammatory cell types including: 
macrophages, neutrophils, and fibroblasts (Knowles and Moncada 1994). Expression of 
iNOS can be induced by bacterial lipopolysaccharides (LPS) and inflammatory cytokines. 
The concentrations of NO produced by iNOS are much greater than either eNOS or nNOS, 
and at levels that are typically cytotoxic and bactericidal (Kimura-Shimmyo et al. 2002).  
2.3.1 Sources of NO in human salivary glands 
The increased presence of nitrite (NO2-, the oxygenation product of NO) in the saliva of 
healthy individuals in response to stimulated secretion (Bodis and Haregewoin 1993) 
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implies a system by which endogenous, constitutively expressed, NO may be produced in 
glandular cells and in turn alter saliva secretion. Surprisingly, immunohistochemical 
analyses of human minor and major salivary glands revealed that nNOS is strongly 
restricted to the non-neuronal duct epithelium and only a minority of the major salivary 
gland nerve fibers (surrounding acini, tubuli, ducts and blood vessels) expressed nNOS 
(Soinila, Nuorva, and Soinila 2006). In addition, salivary gland acinar cells have been 
demonstrated to express NOS (Looms et al. 2002, ; Looms et al. 2000, ; Soinila, Nuorva, and 
Soinila 2006). Human labial salivary gland acinar cells possess NOS activity and exhibit a 
very low level of NO production without stimulation in vitro (Looms et al. 2000). 
Stimulation of NO production, with a concomitant rise in Ca2+, in human labial acinar cells 
was shown to be directly mediated through activation of β-adreneric receptors, which could 
not be mimicked by a rise in Ca2+ alone (Looms et al. 2000). As expected, the expression of 
eNOS in human minor and major salivary glands is restricted mostly to the vascular 
endothelium (Soinila, Nuorva, and Soinila 2006). The constitutive expression of NOS and 
NO in human salivary gland acini and ducts suggests a potential contribution to secretion. 
However, their exact roles in healthy salivary glands are still undetermined.  
2.3.2 Potential function of NO in secretion 
Saliva secretion signaling pathways and mechanisms have been studied closely, where the 
involvement of NO in these pathways is still of great interest. The classical signaling 
pathway involves autonomic receptor stimulation of acinar cells, which leads to increased 
IP3-mediated intracellular Ca2+ release from the endoplasmic reticulum and cAMP 
activation of protein phosphorylation. An additional receptor/channel involved in the 
release of Ca2+ from intracellular stores is the ryanodine receptor (RyR), of which, cyclic 
ADP-ribose (cADPR) has been suggested as an endogenous ligand (Galione, Lee, and Busa 
1991, ; Looms et al. 2001). One potential means by which endogenous NO exerts an effect in 
the salivary gland acinar cells is by binding to the heme moiety of soluble guanylyl cyclases 
(Denninger and Marletta 1999) thus activating the synthesis of cyclic guanosine 
monophosphate (cGMP), which can promote the synthesis of the Ca2+-mobilizing cADPR 
(Galione et al. 1993, ; Looms et al. 2001, ; Willmott et al. 1996). This NO-induced intracellular 
Ca2+ release is proposed to coordinate cellular activation and to have a role in determining 
the magnitude and time course of the secretory response (Caulfield et al. 2009, ; Harmer, 
Gallacher, and Smith 2001). Alterations in this response could play a role in salivary gland 
hypofunction via a disruption in the normal Ca2+ signaling pathways.  
2.3.3 Potential roles of NO and iNOS in exocrine hypofunction 
Evidence suggests that the loss of secretory function associated with SS may occur due to 
factors which alter Ca2+ signaling and not only through direct tissue destruction by 
infiltrating lymphocytes. One hypothesis for salivary gland exocrine hypofunction is based 
from the observation that the sera from NOD mice, prone to developing SS, were found to 
contain autoantibodies against β-adrenergic and muscarinic receptors (Hu et al. 1994, ; 
Yamamoto et al. 1996). The blockage of the β-adrenergic agonist binding down-regulated 
receptor density due to the chronic stimulation (Hu et al. 1994). Therefore, according to the 
previously described model for NO-induced Ca2+ release, saliva secretion could be 
diminished due to blockage of these receptors (Looms et al. 2002).  
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On the contrary, elevated nitrite is present at increased concentrations in SS patient saliva 
and serum compared to healthy controls (Konttinen et al. 1997, ; Wanchu et al. 2000). The 
effects of this possible elevation in NO concentration has been explored in recent 
experiments where the acute exposure of NO to human submandibular gland acinar cells 
were able to transiently (20-30 minutes) enhance Ca2+ signaling, but a more chronic 
exposure to NO eventually desensitized these cells to stimulation (Caulfield et al. 2009). The 
mechanism by which NO exerts its inhibitory effects on the stimulation of secretion is still 
not understood, but it is most likely not mediated through cGMP nor due to a depletion of 
the Ca2+ stores. It is hypothesized that the inhibition of activity could be due to the NO-
mediated nitrosylation of receptors or other proteins involved in the secretion signal 
transduction pathways (Caulfield et al. 2009). However, this relationship between increased 
nitrite concentrations and salivary gland hypofunction is more complicated, since other oral 
inflammatory disorders exhibit increased nitrite concentrations in saliva as well (Kendall et 
al. 2000, ; Kendall, Marshall, and Bartold 2001, ; Ohashi, Iwase, and Nagumo 1999).  
The role of iNOS in the loss of secretory function has also been investigated due to the pro-
inflammatory environment present in the salivary glands of SjS patients. As expected, iNOS 
expression is increased in resident cells of the labial salivary glands of patients with SS when 
compared to healthy controls (Konttinen et al. 1997). Cytokines (for example: IFN-γ, IL-18, 
IL-1β and TNF-α) or LPS induction of iNOS leads to a significant increase in NO production 
(Dinarello 1997, ; Kimura-Shimmyo et al. 2002, ; Liew 1994). NO production from iNOS is 
long-lasting and at relatively high concentrations when compared to the other two Ca2+-
dependent isotypes (Nathan and Xie 1994). This increased NO has been hypothesized to 
directly nitrosylate functional proteins and thus could induce cell death by potentially 
disrupting essential cellular processes (Kimura-Shimmyo et al. 2002, ; Sarih, Souvannavong, 
and Adam 1993). In another course of altering cellular functioning, the product of the 
reaction of NO with superoxide, peroxynitrite, has also been suggested to promote 
modulations of cell signaling and even produce oxidative injury (Pacher, Beckman, and 
Liaudet 2007). It has been shown in several cases how the upregulation of iNOS expression 
may ultimately lead to secretory hypofunction due to the accumulated damage from NO 
(Dawson, Fox, and Smith 2006, ; Kimura-Shimmyo et al. 2002, ; Konttinen et al. 1997, ; 
Takeda et al. 2003).  
2.4 Altered glandular homeostasis 
In addition to the immune cell-mediated mechanisms that contribute to secretory gland 
dysfunction, there is also evidence for altered glandular homeostasis in SS glands that 
appears even prior to disease onset. Specifically, aberrant expression and proteolytic 
cleavage of PSP, increased serine and cysteine protease enzyme activity, elevated numbers 
of apoptotic cells, enhanced matrix metalloproteinase activities in salivary gland lysates and 
decreased amylase activity and epidermal growth factor gene expression are all observed 
irrespective of the presence of lymphocytic infiltration or detectable autoimmune 
phenotype. Additionally, submandibular glands of NOD neonates revealed some 
genetically programmed glandular defects such as retarded salivary gland development. 
How these early defects influence the onset and development of SS is still under active 
investigation. 
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2.4.1 Defects in salivary glands of NOD mouse models after disease onset 
NOD mice develop chronic lymphocytic infiltration in the salivary glands that correlate 
with decreased saliva production concurrently with infiltration in the pancreas that results 
in phenotypes similar to insulin-dependent diabetes mellitus and SS. To differentiate 
between immune cell-mediated and non-immune cell-mediated mechanisms in the SS 
phenotype, salivary glands were characterized in NOD-scid mice and other NOD 
derivatives. 
In the absence of a functional immune system, the salivary flow rate of >20 week old NOD-
scid is similar to 10-12 week old mice (Robinson et al. 1996). However, saliva analysis 
revealed that epidermal growth factor (EGF, a product of submandibular gland ductal cells) 
and amylase (a product of salivary acinar cells) were significantly decreased in the saliva of 
>20 week old NOD-scid compared to 10-12 week old mice (Robinson et al. 1996). 
Additionally, PSP was detected in submandibular gland lysates of 10 week old NOD-scid 
and increased in quantity by 20 weeks of age, while PSP was not detected in control BALB/c 
glands, and (Robinson et al. 1996). Histological examination of NOD-scid submandibular 
glands revealed a progressive loss of acinar tissue and a decline in the acinar to ductal cell 
ratio in the absence of lymphocytic infiltrates (Robinson et al. 1996). These differences in 
salivary protein composition and glandular histology in the absence of lymphocytic 
infiltration indicate that glandular defects in the NOD genetic background may contribute to 
the onset of the autoimmune reaction in the salivary glands. 
Further analysis of these findings revealed increased cysteine protease activity in the saliva 
and gland lysates of 20 week old NOD and NOD-scid mice compared to age matched 
BALB/c or 8 week old NOD mice (Robinson et al. 1997). This increased activity was highest 
in the NOD-scid mice indicating that infiltrating immune cells are not responsible for these 
changes. Additional protease activity in the saliva and gland lysates of older NOD and 
NOD-scid mice generated an enzymatically cleaved PSP (Robinson et al. 1997). These 
findings suggest that proteolytic enzyme activity contributes to loss of exocrine gland 
tolerance by generating abnormally processed protein constituents. 
2.4.2 Defects in salivary glands of NOD mice prior to disease onset 
The changes in the protein composition of saliva, PSP expression, and protease activity in 
the absence of lymphocytic infiltration or functional immune cells indicate that innate 
genetic differences in the NOD salivary glands exist and may contribute to the SS 
phenotype. To further support this theory, salivary gland organogenesis was examined in 
neonatal NOD mice and compared to wild type mice (Cha et al. 2001). Histomorphological 
analyses of submandibular glands at 1 day postpartum revealed delayed morphological 
differentiation during organogenesis in NOD mice compared to wild type mice, acinar cell 
proliferation was reduced, and expression of Fas, FasL and bcl-2 were increased (Cha et al. 
2001). Prior to weaning (up to 21 days) the NOD strains showed increased matrix 
metalloprotease (MMP)-2 and MMP-9 activity (Cha et al. 2001). This altered glandular 
development may contribute to an environment capable of triggering autoimmunity. 
As mentioned previously, a role for interferon-γ (IFN-γ) in these pre-disease aberrations was 
discovered when neither NOD.IFNγ -/- and NOD.IFNγR-/- mice exhibited increased acinar 
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On the contrary, elevated nitrite is present at increased concentrations in SS patient saliva 
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phenotype. Additionally, submandibular glands of NOD neonates revealed some 
genetically programmed glandular defects such as retarded salivary gland development. 
How these early defects influence the onset and development of SS is still under active 
investigation. 
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cell apoptosis or abnormal salivary protein expression prior to disease (Cha et al. 2004). 
Strikingly, without these abnormalities, the NOD.IFNγ -/- and NOD.IFNγR-/- mice showed 
no autoimmune attack of the salivary glands at 20 weeks old (Cha et al. 2004). Also, NOD-
scid.IFNγ -/- mice, unlike NOD-scid and NOD, showed normal glandular morphogenesis at 
birth (Cha et al. 2004). These data suggest that IFN-γ has a critical role during the pre-
immune phase disease independent of effector functions of immune cells. 
 
Fig. 3. Increased epithelial cell death in the glands of disease-prone mice at 8 weeks and lack 
of direct colocalization of caspase-11 with TUNEL-positive cells. (A) TUNEL staining was 
performed on the prediseased salivary glands; upper panel at × 10 and lower panel at × 40 
magnifications. (B) Percentages of TUNEL-positive cells are shown as a bar graph. For each 
mouse, three slides were evaluated for TUNEL-positive cells, which were counted using a 
cell counter. (C) Caspase-3-positive cells (yellow arrows in b) were colocalized with 
TUNEL-positive cells (red arrows). White arrows indicate caspase-11-positive cell. 
Magnification, × 40. NC, negative control; PC, positive control treated with nuclease; 
TUNEL, transferase-mediated dUTP-biotin nick end labeling. Figure previously published 
in (Bulosan et al. 2009). 
The NOD mouse model was/is used extensively to study SS pathogenesis; however, this 
model is genetically predisposed to develop at least three autoimmune diseases. To create a 
primary SS mouse model that only exhibits SS-like phenotype, two chromosomal intervals 
from the NOD mouse that conferred sialadenitis were bred to non-autoimmune C57BL/6 
mice (Cha et al. 2002). These mice, designated C57BL/6.NOD-Aec1Aec2, enabled the study 
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of disease-associated genes alone, and were used to characterize early pathogenic events 
associated with SS-like disease through microarray analysis of gene expression in the 
salivary glands during the pre-disease stage (Killedar et al. 2006). Interestingly, 
C57BL/6.NOD-Aec1Aec2 exhibited upregulated genes encoding proteins associated with 
IFN-γ signal transduction pathway (Jak/Stat), TLR-3 (Irf3 and Traf6), and apoptosis (casp11 
and casp3) compared to C57BL/6 (Killedar et al. 2006).  
The upregulation of caspase-11 in 8 week old C57BL/6.NOD-Aec1Aec2 mice was detected in 
our study. Concomitantly, apoptotic cells were more readily detected in this mouse model 
compared to wild type mice. Further studies were then conducted to determine whether 
upregulated caspase-11 is responsible for this phenomenon. In these studies it was shown 
that the upregulated caspase-11 expression from the salivary glands activated caspase-1, but 
not caspase-3. In effect, apoptotic cells were not positive for caspase-11 staining, suggesting 
that caspase-11 plays an indirect role in increased apoptotic acinar cell death in the salivary 
glands before disease onset (Bulosan et al. 2009). This finding led to the hypothesis that 
inflammatory caspases, such as caspase-11 indirectly functions in apoptosis by activating 
caspase-1 and resulting in the subsequent release of proinflammatory cytokines into the 
glandular environment. This hypothesis was tested by co-culturing human salivary gland 
cells with a human monocyte cell line, THP-1, stimulated with LPS in the presence or 
absence of IFN-γ. In the presence of IFN-γ, there was an increased rate of HSG cell 
apoptosis, but when caspase-1 was knocked down by small interfering RNA in the THP-1 
cells, the rate of apoptosis in HSG cells was reversed back to normal (Bulosan et al. 2009). 
These data indicate that the increased caspase-11 expression in macrophages and dendritic 
cells present in the salivary glands of 8 week old C57BL/6.NOD-Aec1Aec2 mice may 
increase apoptotic cell death of surrounding acinar cells by activating capase-1, resulting in 
the secretion of pro-inflammatory cytokines IL-1β and IL-18. In other words, inflammatory 
caspases are essential in promoting a pro-inflammatory microenvironment and influencing 
salivary gland cell death prior to disease onset. 
2.4.3 Altered microRNA expression in SS 
MicroRNAs (miRNAs) are small non-coding RNA molecules that post-transcriptionally 
regulate gene expression by binding to the 3’ untranslated regions of specifc mRNAs and 
blocking translation or causing degradation. Recently, miRNAs have been implicated in a 
number of diseases including autoimmune disorders. In 2011, it is becoming clear that 
miRNAs may also play a role in SS, although that specific role has yet to be determined. 
Alevizos, et al. demonstrated that miRNA expression patterns can accurately distinguish 
salivary glands from control subjects and SS patients, and that comparing miRNA from 
patients with preserved or low saliva flow identified a set of differentially expressed 
miRNAs, indicating a potential role for miRNAs in secretory dysfunction of the salivary 
glands (Alevizos et al. 2011). Later in 2011, we reported that miR-146a is significantly 
overexpressed in the PBMCs of SS patients compared to healthy controls and in the salivary 
glands and PBMCs of 8 week old C57BL/6.NOD-Aec1Aec2 female mice compared to wild-
type mice (Pauley et al. 2011). It is particularly interesting that miR-146a is upregulated in 
the target tissues (salivary glands) at 8 weeks of age since this is prior to disease onset in this 
mouse model. These data suggest that miR-146a could play a role in early disease 
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immune phase disease independent of effector functions of immune cells. 
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mouse, three slides were evaluated for TUNEL-positive cells, which were counted using a 
cell counter. (C) Caspase-3-positive cells (yellow arrows in b) were colocalized with 
TUNEL-positive cells (red arrows). White arrows indicate caspase-11-positive cell. 
Magnification, × 40. NC, negative control; PC, positive control treated with nuclease; 
TUNEL, transferase-mediated dUTP-biotin nick end labeling. Figure previously published 
in (Bulosan et al. 2009). 
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primary SS mouse model that only exhibits SS-like phenotype, two chromosomal intervals 
from the NOD mouse that conferred sialadenitis were bred to non-autoimmune C57BL/6 
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pathogenesis in SS or could be a result of altered glandular homeostasis prior to disease 
onset. 
Taken together, it is becoming increasingly clear that innate differences in the salivary 
glands of SS contribute to disease onset and/or loss of secretory function. Developmental 
defects, altered glandular homeostasis in the absence of immune cell infiltrates, and a 
tendency towards a proinflammatory environment are all evident in the salivary glands of 
SS mouse models, sometimes even prior to disease onset. It remains to be seen how these 
changes develop, but one hypothesis is that chronic stimulation by pathogens can lead to 
subclinical changes in the glands. In this case, it will be critical to identify the signatures left 
behind by these pathogens, such as viral or bacterial footprints, in order to use them as early 
disease markers to detect individuals susceptible to developing SS. 
 
Fig. 4. Mechanisms contributing to secretory dysfunction in SS salivary glands. 
3. Conclusion  
In conclusion, it is evident that numerous mechanisms contribute to salivary gland 
dysfunction in SS. The initial trigger of autoimmune reactivity and which of these 
mechanisms, if any, are more important in SS pathogenesis remains to be seen. Also, it is 
unclear whether pre-existing genetic factors predetermine certain individuals to develop SS, 
or if there is a specific environmental or immunological trigger. It would be interesting and 
very informative to transplant the salivary glands of a pre-disease SS-prone mouse to a 
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wild-type mouse to see if the recipient would still develop SS. This would identify whether 
a systemic environment or a glandular environment is critical for the onset of SS. Hopefully, 
ongoing research in the field of SS will lead to a better understanding of how the different 
mechanisms of secretory hypofunction discussed here can be prevented or circumvented to 
improve the quality of life of SS patients. There is a great need for potential new therapeutic 
strategies that can either turn off the autoimmune reaction in the exocrine tissue or 
preserve/replace the glandular tissue to restore secretory function. 
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1. Introduction 
Sjögren’s syndrome (SS) is a chronic autoimmune disease characterised by epithelial cell 
destruction and by peri-epithelial B and T lymphocytic infiltration of multiple organ targets, 
and particularly of the exocrine glands. Salivary and lachrymal glands are emblematically 
involved, with dry mouth (xerostomia) and dry eyes (xerophtalmia) representing the clinical 
hallmarks of the disease. Moreover, despite the dominance of T cells in the glandular 
lesions, B cell activation plays a very prominent role as demonstrated by the presence of 
serum hypergammaglobulinemia, by the occurrence of a wide spectrum of autoantibodies 
(i.e., antinuclear antibodies, anti-Ro/SSA and anti-La/SSB antibodies, and Rheumatoid 
factor) and, in some cases, by the development of B cell lymphomas. High-throughput mass 
spectrometry approaches coupled with different separation techniques have been applied to 
several human rheumatic diseases in order to discover biomarkers and therapeutic targets 
by studying the proteome of biological fluids. We will describe our results obtained up to 
now on the proteomic analysis of whole saliva, particularly on how to distinguish primary 
and secondary SS manifestations. Moreover, we will report on the state of the art of 
proteomic studies of other biological fluids and of parotid gland tissues, focusing on the 
potentiality of proteomic applications in defining a panel of biomarkers useful in the 
diagnosis and therapy strategy of SS. 
2. Clinical aspects 
SS is a chronic inflammatory disease characterised by an autoimmune exocrinopathy of the 
lachrymal and salivary glands due to lymphocytic infiltrations. SS typically presents as dry 
eyes (xerophthalmia) and dry mouth (xerostomia). This process can manifest either as the 
independent phenomenon of primary SS or as a secondary when found in the context of 
another autoimmune process, most commonly rheumatoid arthritis, systemic lupus 
erythematosus or systemic sclerosis (Ramos-Casals et al., 2005a; Kassan & Moutsopoulos, 
2004). Given the overlap of SS with many other rheumatic disorders, it is sometimes difficult 
to determine whether a clinical manifestation is a consequence of only SS or is due to one of 
its overlapping disorders.  
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2.1 Incidence and causes of Sjögren’s syndrome 
With a population prevalence ranging from 0.5 to 3%, SS appears to be a rather common 
disease (Binard et al., 2007). SS can develop at any age, but is most common in elderly 
people. Onset typically occurs in the fourth to fifth decade of life. It is frequent in women, 
who account for 9 out of 10 cases. The cause of SS remains unknown, but there is growing 
scientific support for genetic (inherited) and environmental factors. The presence of 
activated salivary gland epithelial cells expressing Major Histocompatibility Complex class 
II molecules and the identification of inherited susceptibility markers suggest that 
environmental or endogenous antigens trigger a self-perpetuating inflammatory response in 
susceptible individuals. Viruses are possible candidates for environmental triggers since 
Sjögren-like syndromes are seen in patients infected with HIV, hepatitis C and HTLV-1. 
Damage and/or cell death due to viral infection or other causes may provide triggering 
antigens to Toll-like receptors in or on dendritic or epithelial cells, which, by recognising 
pathogen-associated patterns, are activated and begin producing cytokines, chemokines, 
and adhesion molecules. As T and B lymphocytes migrate into the gland, they themselves 
become activated by dendritic and epithelial cells, thereafter acting as antigen-presenting 
cells (Fox, 2005). Expressed antigens include SSA/Ro, SSB/La, alpha-fodrin and beta-fodrin, 
or cholinergic muscarinic receptors (Gottenberg et al., 2003). Recent studies suggest that the 
disease process of SS has a neuroendocrine component. Proinflammatory cytokines released 
by epithelial cells and lymphocytes may impair neural release of acetylcholine. In addition, 
Bolstad and colleagues (Bolstad et al., 2003) have focused on the role of apoptotic 
mechanisms in the pathogenesis of primary SS. A defect in Fas-mediated apoptosis, which is 
necessary for down-regulation of the immune response, can result in a chronic 
inflammatory destruction of the salivary gland, resembling SS. 
2.2 Symptoms of Sjögren’s syndrome 
Symptoms of SS can involve the glands and /or other organs of the body (extra glandular 
manifestations). Glandular or exocrine manifestations of SS result from the periepithelial 
lymphocytic infiltration of the salivary and lacrimal glands. Inflammation of the salivary 
glands can lead to mouth dryness, swallowing difficulties, dental decay, cavities, gum 
disease, mouth sores and swelling, and stones and/or infection of the parotid gland. Dry 
lips often accompany the mouth dryness. Extraglandular problems in SS include joint pain 
or inflammation, Raynaud's phenomenon, lung inflammation, lymph node enlargement, 
and kidney, nerve and muscle disease. A rare serious complication of SS is inflammation of 
the blood vessels (vasculitis), which can damage body tissues supplied by these vessels. A 
common disease that is occasionally associated with SS is autoimmune thyroiditis 
(Hashimoto's thyroiditis), while a small percentage of patients with SS develop cancer of the 
lymph glands (lymphoma). 
2.3 Diagnosis of Sjögren’s syndrome and classification criteria 
At present, the diagnosis of SS is based upon the combination of several clinical, serological, 
histological, and instrumental elements suggestive of both exocrine gland involvement and 
of typical laboratory abnormalities (antibodies anti-Ro/SSA and La/SSB). From a practical 
point of view, the diagnosis can be made according to the “American-European Consensus 
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Group Revised Classification Criteria, which were published in 2002 (Vitali et al., 2002) and 
revised in 2010 (Seror et al., 2010). Before their elaboration, there were several different 
concomitant criteria sets, varying in their emphasis, mostly on laboratory tests, on clinical 
features of dry eye and dry mouth, or on both. At that time, there was no uniform 
agreement on the diagnosis of primary SS, with substantial confusion in research 
publications and clinical-trial reports. The Revised Criteria exhibit approximately 95% 
sensitivity and specificity for SS, and due to their high specificity and sensitivity, they can be 
used as diagnostic criteria. They encompass the presence of subjective and objective sicca 
manifestations, antibodies to Ro/SS-A and La/SS-B antigens, and characteristic 
histopathologic findings in minor salivary glands with an average of 50 or more 
lymphocytes (focus) per 4 mmq of minor salivary gland samples. Of the 6 given criteria, 4 
must be present to establish a diagnosis of SS, with 1 of the 4 being an objective 
measurement (i.e., by histopathologic examination or antibody screening) (Vitali et al., 
2002). In their present state, the Classification Criteria are insufficient to make a clear 
diagnosis, and a certain proportion of patients may be misclassified, particularly in the early 
stages of the disorder, when the typical signs and symptoms are often lacking or are not 
entirely expressed. On the other hand, early diagnosis is crucial in avoiding destructive 
processes that frequently lead to a poor quality of life and early invalidity (Gran, 2002). 
Moreover, there is quite a weak correlation between clinical symptoms and the 
exocrinopathy measurements, and the assessment of organ involvement is currently limited 
to general markers of inflammation or organ function and needs profound improvement 
(Hay et al., 1998). Finally, no specific predictive factors of flares, disease relapses or disease 
outcomes have been described yet, even if unfavourable predictors have been thoroughly 
investigated, especially for lymphoproliferative disorders, which are the most serious 
complication in patients with SS (Gran, 2002; Manganelli et al., 2006; Voulgarelis et al., 1999). 
2.4 Extra-glandular Sjögren’s syndrome involvement 
SS involves primarily the exocrine glands. Extraglandular involvement falls into two general 
categories. Peri-epithelial infiltrative processes include interstitial nephritis, liver 
involvement, and bronchiolitis, and generally follow a benign course. Extra-epithelial extra-
glandular involvement in SS is related to B-cell hyper-reactivity, hyper-
gammaglobulinemia, and immune complex formation, and includes palpable purpura, 
glomerulonephritis, and peripheral neuropathy. These latter manifestations occur later in 
the course of SS and are associated with a higher risk of transformation to lymphoma 
(Tzioufas & Voulgarelis, 2007). The incidence of systemic vasculitis manifestation in SS is 
approximately 5-10% of patients with SS (Ramos-Casals et al., 2005b). Skin involvement 
mainly manifests in the form of vasculitis cutaneous purpura. These lesions are clinically 
identical to those found in patients affected by systemic lupus erythematosus. In addition, 
Raynaud’s phenomenon is a vascular condition with an incidence of 13% in patients with SS 
(Bayetto & Logan, 2010). 
3. Applicability of proteomic to study rheumatic diseases 
Proteomic approaches are expanding our ability to determinate changes in protein 
expression, and the technology used has rapidly evolved over the last decade allowing for 
more accurate quantitation of the differentially expressed proteins (Vanarsa & Mohan, 
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2010). In rheumatology, the application of proteomic in the search for potential biomarkers 
of the disease has produced a high number of reports concerning different diseases such as 
rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, osteoarthritis, 
333systemic sclerosis, and SS. Depending on the nature of the rheumatic disease, the choice 
of samples include saliva, serum, synovial fluid, urine, blood cells, cell lines (chondrocytes, 
synoviocytes, fibroblasts) or tissues (parotid glands, articular tissue, cartilage). Moreover, 
new applications have been found such as cerebro-spinal fluid in multiple sclerosis, 
peritoneal dialysate and haemodialysis fluid, broncoalveolar lavage fluid in interstitial lung 
disease. The aims have been to add new information about the disease pathogenesis and to 
identify protein biomarkers for non-invasive diagnosis, staging, and monitoring. A list of 
proteomic studies performed in rheumatic diseases in the last ten years is shown in table 1. 
Together, these studies underline the potentiality and applicability of proteomic in the study 
of rheumatic diseases. Unfortunately, there have not been any studies so far that have 
identified a panel of biomarkers with high specificity and sensitivity able to diagnose and 
predict rheumatic diseases.  
 
Rheumatic diseases References Samples Proteomic approach 
Osteoartritis De Ceuninck 
et al., 2005 
cartilage 2DE/tandem MS 
 Ruiz-Romero et 
al., 2005 
chondrocytes 2DE/MALDI-TOF 
 Gobezie  
et al., 2007 
synovial fluid 1DE/electrospray ionization 
tandem MS (LC-ESI-MS) 
 
 Wu et al., 2007 
 
cartilage 2DE/nano-LC-tandem MS 
 Guo et al., 2008 cartilage 2DE/linear ion trap-Fourier 
transform ion cyclotron 
resonance mass spectrometry 
 Lambrecht  
et al., 2008 
cartilage 2DE/tandem MS 
 
 Rosenthal  
et al., 2011 
cartilage nano-LC-tandem MS  
 de Seny  
et al., 2011 
serum SELDI-TOF-MS 
 Ma et al., 2011 cartilage 2DDIGE/MALDI/TOF/MS 
Spondyloarthritis Tilleman  
et al., 2005 
synovium 2DE/MALDI-TOF-ESI, 
tandem MS 
 Wright  
et al., 2009 
monocytes 2-DE/MALDI-TOF-MS 
 Liu et al., 2007 serum ESI-Q-TOF MS/MS 
 Li et al., 2010 serum 2-DE/MALDI-TOF-MS 
 Li et al., 2010 peripheral blood 
mononuclear cells 
2-DE/MALDI-TOF-MS 
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Rheumatic diseases References Samples Proteomic approach 
 Liao et al., 2004 serum, synovial 
fluid 
LC/MS/MS 
 Drynda  




 de Seny  
et al., 2005 
serum SELDI-TOF-MS 
 Hueber  
et al., 2005 
serum antigen-microarrays 
 Kim et al., 2006 synovial fluid 2DE/MALDI-TOF 
 Matsuo  
et al., 2006 
synovium 2DE/MALDI-TOF 
 Schulz  





 Hueber  
et al., 2007 
serum antigen- microarrays 
 de Seny  
et al., 2008 
serum SELDI-TOF-MS 
 Zheng  
et al., 2009 
plasma capillary reversed-phase –
HPLC/ion trap-FT-MS 
 Chang  
et al., 2009 
synovial tissues 2DE/MALDI-TOF 
 
 Bo et al., 2009 synovial fibroblasts 2DE/MALDI-TOF-MS 
 Giusti  
et al., 2010 
saliva 2DE/MALDI-TOF-MS 
 
 Li et al., 2010 serum 2DE/MALDI-TOF-MS 
 Baillet  
et al., 2010 
synovial fluid SELDI-TOF-MS 
 Matsuo  





et al., 2005 
serum SELDI-TOF-MS 
Systemic Sclerosis Fietta  





 Giusti  
et al., 2007 
saliva 2DE/MALDI-TOF 
 Aden  
et al., 2008 
skin 2DE /MALDI-TOF 
 Scambi  
et al., 2010 
serum 2DE/MALDI-TOF-MS 
+ Lupus erithematosus 
systemic 
Carlsson  
et al., 2011 
serum antibody microarray 
Lupus erithematosus 
systemic 
Pavon et al., 
2006 
plasma 2DE/MALDI-TOF-MS 
 Mosley  
et al., 2006 
urine SELDI-TOF-MS 
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Rheumatic diseases References Samples Proteomic approach 
 Zhang  
et al., 2008 
 
urine SELDI-TOF-MS 








 Lood et al., 2010 platelets antigen- microarrays 
 Wang  
et al., 2010 
peripheral blood 
mononuclear cells 
Isobaric tagging for relative 
and absolute protein 
quantification (iTRAQ)- 
multiple chromatographic 
fractionation and tandem 
mass spectrometry 
Sjogren’Syndrome Tomosugi 
et al., 2005 
tears SELDI-TOF-MS 
 Ryu  
et al., 2006 
parotid saliva SELDI-TOF-MS/2D-DIGE 
 Giusti  
et al., 2007 
whole saliva 2DE/MALDI-TOF 
 Stea  
et al., 2007 
parotid glands SDS-PAGE 
 Peluso  
et al., 2007 
whole saliva HPLC-ESI/MS 
 Hu et al., 2007b whole saliva 2DE/MALDI-TOF-MS/LC-
MS/MS 
 Fleissig et al., 
2009 
whole saliva 2DE/MALDI-TOF-MS 
 Hjelmervik  





 Hu  
et al.2011 
whole Saliva protein microarrays 
Fybromialgia Bazzichi 
et al., 2009 
whole saliva 2DE/MALDI-TOF 
+ Chronic Fatigue 
Syndrome 
Baraniuk  
et al., 2005 
cerebrospinal fluid capillary chromatography, 
quadrupole-time-of-flight 
mass spectrometry 
Table 1. Proteomics in Rheumatology 
4. Proteomic and Sjogren’s syndrome 
The majority of proteomic studies concerning SS chose saliva as the biological fluid (6 
papers), and only a limited number used tears (1 paper) or salivary gland tissue (3 paper).  
 




Histological and functional changes of the lachrymal gland might be reflected in proteomic 
patterns in tear fluids. In SS, a reduced production of aqueous tear was clarified when 
examined by the Schirmer test. Reduction of tear film stability as shown by the tear film 
break-up time test seems to be responsible for a disturbance of the quality of the mucus 
layer composition. However, there was no screening test for the changes in quality of tear 
components, which should accurately reflect the physiologic state of the lachrymal gland 
and the level of its function. The first proteomic trial for carrying out a determination of the 
disease biomarkers in tear fluid for SS was performed by Tomosugi and co-workers 
(Tomosugi et al., 2005). The authors, using surface-enhanced laser desorption/ionisation 
time-of-flight mass spectrometry, identified 10 potential novel proteins that differed 
between SS patients and control subjects. Seven were down regulated, and three correlated 
significantly with SS scores and epithelial damage of the ocular surface. Although these 
investigators have not yet identified the proteins, this study clearly demonstrates how such 
techniques can be applied in identifying specific protein profiles involved in the 
pathophysiological processes associated with SS.  
4.2 Parotid glands tissue 
Proteomic analysis has been applied not only to the study of salivary and lachrymal fluids, 
but also to the study of gland tissues because SS directly affects the glands and because 
autoantibodies characterising SS (anti-Ro/SSA and anti-La/SSB) are produced mainly in 
these affected tissues. Parotid gland extracts of SS patients were then analysed by combining 
conventional immunological methods (2DE and immunoblot) with mass spectrometry in 
order to evaluate modifications of known autoantigens (i.e., La/SSB), and in order to 
determine other targets of the autoimmune response in the parotid glands of SS patients. In 
the work by Stea and co-workers (Stea et al., 2007), in order to identify the isoforms of 
La/SSB in parotid glands of SS patients, an immunoblot with purified anti-La antibodies 
was performed after 2DE of parotid gland extracts from two SS patients. An extract from a 
human salivary gland epithelial cell line and a parotid gland extract from a patient with 
mixed parotid tumour were used as controls. The results of the study revealed that SS 
salivary glands contained high levels of post-translationally modified La/SSB autoantigen, 
degraded from 48 kDa to 34 kDa. The 48 kDa form of the protein was faintly recognised, in 
contrast to normal controls. Moreover, only five distinct La/SSB isoforms were detected in 
SS patients’ specimens, in contrast to seven isoforms in controls. Finally, a new potential 
autoantigen was identified in the parotid glands of SS. A protein at around 45 kDa was 
recognised as a target of autoantibodies by the SS sera. This protein was identified as human 
actin by combining conventional immunological methods and mass spectrometry. 
Moreover, Hjelmervik and colleagues (Hjelmervik et al., 2009) conducted a large-scale 
mapping of the minor salivary gland proteome, applying two complementary methods: the 
LC-ESI-MS/MS and 2DE. The main objective of their work was to achieve a large-scale 
delineation of the minor salivary gland proteome in samples from both SS patients and non-
SS controls. Heat shock proteins, mucins, carbonic anhydrases, enolase, vimentin, and 
cyclophillin B were among the proteins identified. Six proteins were exclusively identified in 
SS patients with respect the controls in particular alpha defensin 1 and calmodulin. A 
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system biology approach has been used by Hu and co-workers (Hu et al., 2009) to study 
parotid gland tissue samples obtained from patients with primary SS, from patients with SS 
/MALT lymphoma, and from subjects without primary SS. The tissue samples were 
assessed by gene-expression microarray profiling and proteomics analysis. The authors 
defined a panel of 8 candidate genes for distinguishing primary SS/MALT lymphoma from 
primary SS. Among the 115 proteins showing >3-fold elevated levels, 20 proteins were up-
regulated in primary SS parotid gland tissue samples as compared with non– primary SS 
control and primary SS/MALT lymphoma parotid gland tissue samples. Twenty-five 
proteins were up regulated in both primary SS and primary SS/MALT lymphoma samples 
as compared with non–primary SS control samples, and 70 proteins were up-regulated in 
primary SS/MALT lymphoma samples as compared with both non–primary SS control and 
primary SS samples. From a functional point of view, the proteins overexpressed in SS were 
related to the immune/defence response, apoptosis, cell-cell adhesion, and anti-oxidative 
stress, whereas many of the proteins with high expression in primary SS/MALT lymphoma 
were related to signal transduction, gene regulation, apoptosis, the immune response, and 
oxidative stress. 
4.3 Saliva 
Human saliva contains a large number of proteins and peptides, which have several 
important biological functions and potentially reflect both oral and systemic health 
conditions. Compared to blood, saliva possesses a smaller amount of proteins with a minor 
risk of non-specific interference. Saliva is an attractive medium for proteomic analysis for 
many different reasons. One of its major advantages is that salivary fluid can be obtained by 
using a non-invasive, simple, safe, and stress-free procedure that can be applied to large 
groups of subjects. The simple nature of saliva collection allows for repetition and multiple 
collection of saliva useful in early diagnosis, monitoring disease progression or treatment 
responses. Finally, this fluid undoubtedly reflects the salivary gland involvement that 
characterises SS disease (primary and secondary), which directly involves the oral cavity 
(Streckfus et al., 2007; Hu et al., 2007a). 
Six studies have been performed in SS, and they are quite different in their principal goals as 
well as in their general methodologies (Ryu et al., 2006; Giusti et al., 2007; Hu et al., 2007b; 
Peluso et al., 2007; Flesseig et al., 2009; Hu et al., 2011). Whole saliva or individual glands 
saliva have been examined, and samples were collected both in stimulated and 
unstimulated conditions. Moreover, differences were present in salivary protein preparation 
and separation. However, although the collection protocol was different, many common 
biomarkers for SS have been found from the five different papers such as actin, Ig gamma-1 
chain C region, beta-2 microglobulin, salivary amylase, carbonic anhydrase VI, prolactin 
inducible protein, calgranulins A and B, and fatty acid binding protein. Table 2 reports the 
proteomic studies performed up to now in saliva, distinguishing the source of this biofluid, 
and the type of proteomic approach. A list of potential biomarkers defined by these studies 
is also shown.  
First, we will report the results obtained in other studies, and then in the following 
paragraph we will discuss our findings.  
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-actin fragment, leukocyte elastase 
inhibitor, glutathione-S-transferase, 
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primary and secondary 
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risk of non-specific interference. Saliva is an attractive medium for proteomic analysis for 
many different reasons. One of its major advantages is that salivary fluid can be obtained by 
using a non-invasive, simple, safe, and stress-free procedure that can be applied to large 
groups of subjects. The simple nature of saliva collection allows for repetition and multiple 
collection of saliva useful in early diagnosis, monitoring disease progression or treatment 
responses. Finally, this fluid undoubtedly reflects the salivary gland involvement that 
characterises SS disease (primary and secondary), which directly involves the oral cavity 
(Streckfus et al., 2007; Hu et al., 2007a). 
Six studies have been performed in SS, and they are quite different in their principal goals as 
well as in their general methodologies (Ryu et al., 2006; Giusti et al., 2007; Hu et al., 2007b; 
Peluso et al., 2007; Flesseig et al., 2009; Hu et al., 2011). Whole saliva or individual glands 
saliva have been examined, and samples were collected both in stimulated and 
unstimulated conditions. Moreover, differences were present in salivary protein preparation 
and separation. However, although the collection protocol was different, many common 
biomarkers for SS have been found from the five different papers such as actin, Ig gamma-1 
chain C region, beta-2 microglobulin, salivary amylase, carbonic anhydrase VI, prolactin 
inducible protein, calgranulins A and B, and fatty acid binding protein. Table 2 reports the 
proteomic studies performed up to now in saliva, distinguishing the source of this biofluid, 
and the type of proteomic approach. A list of potential biomarkers defined by these studies 
is also shown.  
First, we will report the results obtained in other studies, and then in the following 
paragraph we will discuss our findings.  
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24 saliva autoantibodies: Bcl2 
modifying factor, cardiolipin, 
chromosome X orf56, hypothetical 
protein DKFZp761G2113, Jun 
dimerization protein p21SNFT, 
La/SS-B, Lectin galactoside binding 
soluble 3, Lectin galactoside binding 
soluble 7, Megacaryocite-associated 
tyrosine Kinase, melanoma antigen 
family B 4, mesenchyme homeobox 
1, NEFA-interacting nuclear protein, 
olfactory receptor family 6 N2, outer 
dense fiber of sperm tails 2, plasma 
membrane proteolipid, protein 
kinase C, ribosomal protein S6 
kinase, Ro52/SS-A, SERPINA 3, 
small inducible cytokine subfamily 
E1, testis specific 10, TAO kinase 3, 
transglutaminase, Unfrac whole 
histone 
Table 2. Saliva and Proteomic studies of Sjogren’s syndrome. 
The pilot study of proteomic applied to SS saliva was performed in 2006 by Ryu and co-
workers. Using SELDI-TOF and 2D difference gel electrophoresis (2D-DIGE), they analysed 
stimulated parotid saliva from five healthy volunteers, 41 primary SS patients, and 20 non-
SS subjects, including 15 non-SS subjects with complaints of xerostomia who, nonetheless, 
did not meet the diagnostic criteria for SS. Combining these two approaches, the authors 
focused their attention on ten differentially expressed proteins and, in particular, they 
identified significant increases of -2 microglobulin, lactoferrin, Ig -light chain, polymeric 
Ig receptor, lysozyme C, and cystatin C. They also found in the patient group a reduction of 
amylase, carbonic anhydrase VI and of two presumed proline-rich proteins. Moreover, they 
found no association between the focus score and any biomarker. Lactoferrin and  
2-microglobulin showed the greatest increases, but because their levels have been reported 
to increase also in other inflammatory diseases affecting salivary glands, the authors related 
these proteins to aspecific salivary gland inflammatory activity. More intriguingly, the 
increased levels of Ig -light chains were explained by the authors as being related to the 
increase in the intra-glandular immunoglobulin synthesis of the disease. Finally, the 
decrease of the two proline-rich proteins and -amylase were ascribed to acinar 
parenchymal damage, while the reduction in carbonic anhydrase VI was reported as in line 
with a recent report on its decreased gene expression in SS minor gland biopsies.  
Next, a profile of potential salivary proteomic and genomic biomarkers for SS was depicted 
by Hu and co-workers (Hu et al., 2007b). Sixteen WS proteins were found to be down-
regulated, and 25 WS proteins were found to be up-regulated in SS patients compared with 
matched healthy control subjects. Moreover, using gene chip followed by real time PCR 
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analysis of whole saliva, Hu and co-workers revealed factors such as interferon (IFN) and 
IFN-inducible protein G1P2 specifically expressed in SS patients. One of the important 
findings of this study was that many up-regulated genes were involved in the IFN pathway, 
suggesting the involvement of viral infection in SS pathogenesis.  
Peluso and colleagues (Peluso et al., 2007) analysed the differences in the salivary protein 
profiles of primary SS and secondary SS patients, and of control subjects using HPLC-ESI-
MS. The authors collected whole saliva specimens from 9 primary SS patients, 9 secondary 
SS patients (3 Rheumatoid Arthritis-2° SS; 3 systemic sclerosis-2° SS; 3 systemic lupus 
erythematosus-2° SS), and 10 healthy controls, and they analysed the levels and frequencies 
of 62 proteins. The analysis focused mainly on low molecular weight proteins represented 
by acid and basic proline-rich proteins, statherins, histatins, cystatins, lysozyme, and 
defensins. In the second part of the study, the authors examined the effect of pilocarpine on 
the salivary peptide and protein profiles in a subgroup of 6 primary SS patients. They found 
that the basic and acid proline-rich proteins and the statherins had the best response to the 
pilocarpine treatment, while the salivary cystatin and histatin protein classes were modified 
less. In the comparison between primary and secondary SS salivary profiles, the researchers 
outlined that patients with secondary SS showed a protein profile that was intermediate 
between that of the primary SS patients and the healthy subjects. In particular, salivary 
cystatins (C, S, S2, SA, and SN) and histatins (2, 3, 4, 7, 9, 11 and 12) were less frequently 
identifiable in primary and secondary SS patients versus controls. On the other hand,  
3 proteins (IB-6, P-B Des1-4, and -defensin 2) were identifiable in a significantly higher 
percentage of secondary SS patients than in the controls. In particular, -defensin 2 was 
found in 6 of the primary SS patients, in 3 of the 9 secondary SS patients, and in none of the 
controls. Finally, IB-1 and statherin showed significantly lower levels in secondary SS than 
in the controls. 
Additional information was reported by Flesseig and colleagues (Flesseig et al., 2009), who 
in a preliminary individual saliva sample analysis showed that SS patients (six SS patients as 
well as one symptomatic subject not fulfilling the criteria completely, and one who had 
developed follicular lymphoma) exhibited two patterns of protein expression with an 
indirect relation to the clinical serological or histological severity of disease.  
Recently, Hu and co-workers (Hu et al., 2011) have demonstrated the potential of the high-
throughput protein microarray approach in the discovery of autoantibody biomarkers for 
the non-invasive diagnosis of SS. Saliva autoantibodies present in patients with SS or 
systemic lupus erythematosus and healthy control subjects were profiled with protein 
microarrays. After comparison with controls (systemic lupus erythematosus and healthy 
subjects), statistical analysis of the microarray data revealed 24 autoantibody biomarkers 
that could differentiate SS from both control groups. A validation of four of these 
autoantibodies (anti-SSA, anti-SSB, anti-transglutamine, anti-histone) was performed using 
commercial ELISA kits. Although these are known autoantibodies in SS, they were usually 
tested in serum samples. The authors suggest that testing these autoantibodies in saliva may 
be valuable for the diagnosis of SS. Therefore, up to now a wide spectrum of proteins has 
been identified that might include both “true” disease biomarkers, as well as specific 
markers of tissue damage (i.e., actin) or inflammation (calgranulins). Therefore, we can 
hypothesise that further studies might shed some light on this aspect. 
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stimulated parotid saliva from five healthy volunteers, 41 primary SS patients, and 20 non-
SS subjects, including 15 non-SS subjects with complaints of xerostomia who, nonetheless, 
did not meet the diagnostic criteria for SS. Combining these two approaches, the authors 
focused their attention on ten differentially expressed proteins and, in particular, they 
identified significant increases of -2 microglobulin, lactoferrin, Ig -light chain, polymeric 
Ig receptor, lysozyme C, and cystatin C. They also found in the patient group a reduction of 
amylase, carbonic anhydrase VI and of two presumed proline-rich proteins. Moreover, they 
found no association between the focus score and any biomarker. Lactoferrin and  
2-microglobulin showed the greatest increases, but because their levels have been reported 
to increase also in other inflammatory diseases affecting salivary glands, the authors related 
these proteins to aspecific salivary gland inflammatory activity. More intriguingly, the 
increased levels of Ig -light chains were explained by the authors as being related to the 
increase in the intra-glandular immunoglobulin synthesis of the disease. Finally, the 
decrease of the two proline-rich proteins and -amylase were ascribed to acinar 
parenchymal damage, while the reduction in carbonic anhydrase VI was reported as in line 
with a recent report on its decreased gene expression in SS minor gland biopsies.  
Next, a profile of potential salivary proteomic and genomic biomarkers for SS was depicted 
by Hu and co-workers (Hu et al., 2007b). Sixteen WS proteins were found to be down-
regulated, and 25 WS proteins were found to be up-regulated in SS patients compared with 
matched healthy control subjects. Moreover, using gene chip followed by real time PCR 
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analysis of whole saliva, Hu and co-workers revealed factors such as interferon (IFN) and 
IFN-inducible protein G1P2 specifically expressed in SS patients. One of the important 
findings of this study was that many up-regulated genes were involved in the IFN pathway, 
suggesting the involvement of viral infection in SS pathogenesis.  
Peluso and colleagues (Peluso et al., 2007) analysed the differences in the salivary protein 
profiles of primary SS and secondary SS patients, and of control subjects using HPLC-ESI-
MS. The authors collected whole saliva specimens from 9 primary SS patients, 9 secondary 
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erythematosus-2° SS), and 10 healthy controls, and they analysed the levels and frequencies 
of 62 proteins. The analysis focused mainly on low molecular weight proteins represented 
by acid and basic proline-rich proteins, statherins, histatins, cystatins, lysozyme, and 
defensins. In the second part of the study, the authors examined the effect of pilocarpine on 
the salivary peptide and protein profiles in a subgroup of 6 primary SS patients. They found 
that the basic and acid proline-rich proteins and the statherins had the best response to the 
pilocarpine treatment, while the salivary cystatin and histatin protein classes were modified 
less. In the comparison between primary and secondary SS salivary profiles, the researchers 
outlined that patients with secondary SS showed a protein profile that was intermediate 
between that of the primary SS patients and the healthy subjects. In particular, salivary 
cystatins (C, S, S2, SA, and SN) and histatins (2, 3, 4, 7, 9, 11 and 12) were less frequently 
identifiable in primary and secondary SS patients versus controls. On the other hand,  
3 proteins (IB-6, P-B Des1-4, and -defensin 2) were identifiable in a significantly higher 
percentage of secondary SS patients than in the controls. In particular, -defensin 2 was 
found in 6 of the primary SS patients, in 3 of the 9 secondary SS patients, and in none of the 
controls. Finally, IB-1 and statherin showed significantly lower levels in secondary SS than 
in the controls. 
Additional information was reported by Flesseig and colleagues (Flesseig et al., 2009), who 
in a preliminary individual saliva sample analysis showed that SS patients (six SS patients as 
well as one symptomatic subject not fulfilling the criteria completely, and one who had 
developed follicular lymphoma) exhibited two patterns of protein expression with an 
indirect relation to the clinical serological or histological severity of disease.  
Recently, Hu and co-workers (Hu et al., 2011) have demonstrated the potential of the high-
throughput protein microarray approach in the discovery of autoantibody biomarkers for 
the non-invasive diagnosis of SS. Saliva autoantibodies present in patients with SS or 
systemic lupus erythematosus and healthy control subjects were profiled with protein 
microarrays. After comparison with controls (systemic lupus erythematosus and healthy 
subjects), statistical analysis of the microarray data revealed 24 autoantibody biomarkers 
that could differentiate SS from both control groups. A validation of four of these 
autoantibodies (anti-SSA, anti-SSB, anti-transglutamine, anti-histone) was performed using 
commercial ELISA kits. Although these are known autoantibodies in SS, they were usually 
tested in serum samples. The authors suggest that testing these autoantibodies in saliva may 
be valuable for the diagnosis of SS. Therefore, up to now a wide spectrum of proteins has 
been identified that might include both “true” disease biomarkers, as well as specific 
markers of tissue damage (i.e., actin) or inflammation (calgranulins). Therefore, we can 
hypothesise that further studies might shed some light on this aspect. 
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4.3.1 Our results 
In 2005, we began to study rheumatic diseases using a proteomic approach. In our studies, 
whole saliva was chosen as the biological fluid to discover specific disease biomarkers for 
primary and secondary manifestations of SS and also of other correlated rheumatic diseases 
such as systemic sclerosis (Giusti et al., 2007; Baldini et al., 2008), fybromialgia (Bazzichi et 
al., 2009) and rheumatoid arthritis (Giusti et al., 2010). In our work on SS, we analysed the 
whole saliva of 12 primary SS patients in comparison with 12 healthy controls by using 
quantitative 2DE experiments combined with MALDI-TOF-MS for protein identification 
(Giusti et al., 2007). In particular, in this study, by comparing the SS with control classes, we 
found that 4 proteins were unique to the control samples (carbonic anhydrase VI, cystatins 
S, C precursor and cystatin D), and 6 proteins were unique to the SS samples (calgranulin B, 
cyclophilin A, lipocalin-1 precursor, phosphatidyl ethanolammine binding protein, Ig kappa 
chain C region (IGKC), protein and Zinc--2 glycoprotein precursor). Moreover, in 
evaluating the mean ± SD of the percentage of the volume of each single protein of the 
analytical (not synthetic) gels, the authors also discovered that 10 protein spots were up-
regulated with > 2-fold changes (fatty acid binding protein (E-FABP), ACTB protein, -actin 
fragment, leukocyte elastase inhibitor, glutathione-S-transferase (GST), and 5 unidentified 
proteins). On the other hand, 4 were down regulated (-amylase precursor, cystatin SN 
precursor, keratin 6L, prolactin-inducible protein precursor) in SS patients compared with 
controls. These results confirmed the decrease of some of the typical acinar proteins and the 
increase of many inflammatory proteins. Moreover, they outlined the relevance of proteins 
not previously described i.e., PIP, keratin 6L, and lipocalin, as markers of acinar damage and 
oral environment alteration. This study was the basis for further investigations aimed at 
characterising possible differences in salivary protein profiles in patients who have 
connective tissue diseases associated with secondary SS. Therefore, we extended the study 
to refine the diagnostic power of a panel of candidate salivary biomarkers described in  
SS with respect to both healthy volunteers and pathological controls (sicca syndrome). 
Moreover, the aim of the study was also to explore the biological and pathogenetic functions 
of the putative salivary proteomic biomarkers, both in the local exocrinopathy and in the 
systemic inflammatory autoimmune systemic processes of SS. Our preliminary results, to be 
published, suggest that novel, non-invasively-collected salivary proteomic biomarkers 
might be helpful in an early and accurate characterisation of primary and secondary SS. In 
addition, some of the secondary SS identified biomarkers apparently reflected not only the 
SS component, but also the concomitant systemic autoimmune disorders, shedding new 
light on the potential diagnostic role of saliva in autoimmune diseases irrespectively of 
salivary gland involvement.  
The capacity of whole saliva to reflect systemic conditions was also suggested from the 
preliminary unpublished results of a case study on the salivary proteome of non-Hodgkin’ 
lymphomas. We observed that clinical and functional changes of the salivary glands driven 
by autoimmune and lymphoproliferative processes might be reflected in patients’ whole 
saliva proteins, and that there was a specific correspondence between clinical improvement 
and proteomic changes of the salivary peptide complex. These observations indicate the 
potential usefulness of proteomic analysis in discovering not only diagnostic but also 
prognostic and therapeutic biomarkers for patients with primary SS and non-Hodgkin’s 
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lymphomas. Therefore, we speculate that during the follow-up of patients with lymphomas, 
proteomic analysis might be able to use the salivary biomarkers as early predictors of 
treatment response. From the perspective of the research, the analysis of biomarker 
signatures in saliva could also help to clarify the pathogenetic pathways underlying 
lymphoproliferation in SS, leading to the development of new methods in early diagnosis 
and curative therapies. 
 
Fig. 1. Protein-protein interaction network of regulated pSS-associated proteins identified in 
at least two proteomic studies found differentially expressed in saliva. The STRING tool 
(http://string-db.org/) was used making the network with the following proteins: -2-
microglobulin, polymeric Ig receptor (PIGR), salivary acidic proline-rich phosphoprotein 1 
(PRH1) and 2 (PRH2), -amylase, carbonic anhydrase VI, Cystatin SA (CST2), Cystatin SN 
(CST1), Cystatin C (CST3), Cystatin S (CST4), Cystatin D (CST5), LCN1, Calgranulin A 
(S100A8), Calgranulin B (S100A9), Psoriasin (S100A7), Fatty acid-binding protein, epidermal 
(FABP5), IGKC (LOC652493), Ig -1 chain C region (IGHG1), -Actin (ACTB), Fc fragment of 
IgG, receptor, transporter (FCGRT), leukocyte immunoglobulin-like receptor (LILRB1), HLA 
class I histocompatibility antigen, alpha chain G (ENSG00000237216) , major 
histocompatibility complex class IA (HLA-A) major histocompatibility complex class IB 
(HLA-B) and glycoprotein hormones, alpha polypeptide (CGA). In the figure is shown the 
potential interaction with additional proteins with score values ranging from 0.993 to 0.999. 
The different clusters are indicated by the same colour. The thickness of the connecting lines 
indicates the level of confidence. 
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5. Conclusions  
SS lacks any true diagnostic criteria for primary and secondary manifestations as well as a 
set of activity criteria. The risk of misdiagnosis is still quite high, and it highlights the need 
for a more definitive set of tests and criteria to classify these patients. One possible solution 
is the proteomic approach, which might represent a promising tool to explore biomarkers 
for diagnostic aims. Until now, the studies performed have been carried out on parotid 
biopsies, tears, and saliva. Saliva represents an attractive medium for proteomic analysis 
because its composition is not complex, and it reflects more accurately the current state of 
the organism at any moment. Moreover, it presents many logistical advantages because the 
collection is not invasive, and may be repeated for monitoring over time. However, the 
identification of true biomarkers of primary and secondary SS is still in its infancy. The 
results obtained from different studies have not yet defined a conclusive panel of 
biomarkers useful in diagnostic purposes. Nonetheless, some conclusions can be drawn: SS 
patients showed a decrease of proteins of glandular origins and an increase of inflammatory 
proteins, while the salivary profile of secondary SS is intermediate between that of primary 
SS patients and healthy subjects. Figure 1 shows a representative interactive network 
obtained by STRING analysis among the proteins found differentially expressed in the 
proteomic studies performed in saliva. In addition to identifying proteins, we enlarged the 
network to obtain a large interactive network with more nodes. Interestingly, the figure 
shows that -2 microglobulin, which is the invariant chain of the Major Histocompatibility 
Complex class I molecules, considered as a marker of B cell activation, is the key node of the 
main cluster.  
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1. Introduction  
1.1 Definition of stress 
Hans Selye was the first to define stress as a non-specific response of the body to any 
demand made upon it (1936). It has been demonstrated that Selye's theory about the effects 
of stress is applicable to any type of stress (Stojanovich & Marisavljevich, 2008). Key organ 
of stress processes is the brain. It determines what individuals will experience as stressful, it 
orchestrates how individuals will cope with stressful experiences, and it changes both 
functionally and structurally as a result of stressful experiences (McEwen & Gianaros, 2011).  
Stress begins with a stimulus (stressor) that causes a reaction in the brain (stress perception), 
which subsequently activates physiologic systems in the body (stress response). The stress 
response system reacts with the release of neurotransmitters (norepinephrine etc.) and 
hormones (cortisol etc.) which serve to send an efferent message from the brain to the 
periphery in order to modulate the stressful event (Cutolo & Straub, 2006). 
It is clear that stress, originating in the cortex of the brain, must be converted into somatic 
signals, which can modulate the immune system or pain perception. These somatic signals 
typically start off in the highest centres of the autonomic nervous system (ANS) and the 
endocrine system within the hypothalamus (Cutolo & Straub, 2006). Selye was the first to 
describe the system by which the body copes with stress: the hypothalamus–pituitary–
adrenal system (HPA) (Stojanovich & Marisavljevich, 2008). The hypothalamus has close 
connections to the limbic system, which is responsible for the emotionalisation of 
psychological stress (whether it is perceived as positive eustress or negative distress). The 
major neuroendocrine response mediating stress adaptation relies on the activation of the 
HPA axis by stimulating corticotropin releasing hormone (CRH) and vasopressin (VP) from 
parvocellular neurons of the hypothalamic paraventricular nucleus. This leads in turn to 
stimulation of pituitary aderocorticotropic hormone (ACTH) secretion and increases in 
glucocorticoid secretion from the adrenal cortex. Basal production of glucocorticoids and its 
hypothalamic regulators together with transient increases during stress are essential for 
neuronal plasticity and normal brain function. While activation of the HPA axis is essential 
for survival during stress, chronic exposure to stress hormones can predispose to 
psychological, metabolic and immune alterations (Aguilera et al., 2011). 
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Selye is considered to be the first to demonstrate the existence of a particular stress disease, the 
stress syndrome, or the general adaptation syndrome (Stojanovich & Marisavljevich, 2008). 
These processes can be adaptive in the short term and may contribute to the dysregulation of 
the hormone status if persisting for a longer time. Moreover, they are involved in bidirectional 
signalling between the brain and the body as well as in stress-related mental and physical 
health conditions (McEwen & Gianaros, 2011). The chronic stress-induced dysregulation 
appears to be of sufficient magnitude to impact health (Gouin et al., 2008). 
Recent advances in psychoneuroimmunology have provided insight into the complex 
mechanisms by which stressors might affect the homeostasis and the body's immune system 
(de Brouwer et al., 2010). Stress challenges the organism's homeostatic mechanisms, 
triggering a cascade of events that should, normally, maintain or allow a return to 
equilibrium (Pêgo et al., 2010). Psychological stress can influence immunoregulatory circuits 
and the course of an inflammatory disease (Marshall GD Jr, 1997). Furthermore, cytokines 
generated by the immune system influence hormonal secretion and the central nervous 
system, producing specific behavioural changes accompanying infectious and inflammatory 
diseases (Straub et al., 2008). Psychological distress and immune dysregulation have been 
linked to each other in chronic stress, in disease and other major life events. 
It was shown that psychological stress is also thought to contribute to the aetiology, 
maintenance and exacerbation of rheumatic diseases (de Brouwer et al., 2010). Stress has 
been studied in several autoimmune rheumatic diseases, including systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) 
(Cutolo & Straub, 2006). Growing evidence supports the hypothesis that alterations of the 
stress response and interactions between the neuroendocrine and immune systems 
contribute to the pathogenesis of rheumatic diseases (Chikanza et al., 1992).  
2. Neurotransmitter-cytokine relationship 
The stress response is mediated by the sympathetic nervous system and it results in the 
release of some neurotransmitters (epinephrine, norepinephrine) that regulates the immune 
system at regional, local, and systemic levels (Felten et al., 1988).  
Immune organs including thymus, spleen, and lymph nodes are innervated by sympathetic 
nerves (Felten et al., 1988). Interruption of sympathetic innervation of immune organs has 
been shown to modulate the outcome of, and susceptibility to, inflammatory and infectious 
disease. Denervation of noradrenergic fibres of lymph nodes is associated with exacerbation 
of inflammation (Lorton et al., 1996), whereas systemic sympathectomy or denervation of 
joints is associated with decreased severity of inflammation (Eskandari et al., 2005).  
Immune cells also express neurotransmitter receptors, such as adrenergic receptors (alpha- 
or beta- subtype) on lymphocytes that allow them to respond to sympathetic 
neurotransmitters (Elenkov & Chrousos, 1999). Neural influences on the immune response 
may be due to direct synapse-like nerve-lymphocyte connections (Mix et al., 2007). Through 
stimulation of adrenergic receptors locally released norepinephrine or circulating 
catecholamines affect lymphocyte traffic, circulation, and proliferation, and, in turn, 
modulate cytokine production as well as functional activity of various lymphoid cells 
(Elenkov et al., 2000; Straub et al., 2000; Madden et al., 2001). 
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Cytokines are important factors connecting and modulating the immune and 
neuroendrocrine systems (Elenkov, 2005). Furthermore, cytokines and their receptors are 
expressed in the neuroendocrine system and exert their effects both centrally and 
peripherally (Benveniste et al., 1998). Systemic cytokines can affect the brain through several 
mechanisms, including active transport across the blood–brain barrier, through leaky areas 
in the blood–brain barrier in the circumventricular organs or through the activation of 
neural pathways such as the vagal nerve (Eskandari, 2005). For example, IL-6 and tumour 
necrosis factor (TNF)-a, released during an immune response and inflammation activate the 
central components of the stress system, alter neurotransmitter networks activity and induce 
fever, sleepiness, fatigue, loss of appetite and decreased libido. In addition, they activate the 
hepatic synthesis of acute phase proteins—changes referred to as ‘sickness behavior’ and 
‘acute-phase response’, respectively (Elenkov, 2005).  
Otherwise, administration of interleukin (IL)-1 in the periphery increases the turnover of 
norepinephrine in the hypothalamus; intracerebroventricular and peripheral injection of 
interferon (IFN)-α or IL-1β produces a long-lasting increase of the sympathetic activity of 
the splenic nerve and an increased turnover of norepinephrine in the spleen (Elenkov, 2000). 
Furthermore, it was shown that monoamine neurotransmitters, released in stress situations, 
represent a tonic sympathetic control on cytokine production and on the balance of pro-
inflammatory/anti-inflammatory cytokines (Szelényi & Vizi, 2007).  
Autoimmune diseases are characterized by common alterations of the T-helper (Th)1 versus 
Th2 cells and a shift towards pro-inflammatory cytokines. In RA the balance is skewed 
towards Th1 and an excess of IL-12 and TNF-α production, whereas Th2 activity and the 
production of IL-10 appear to be deficient (Segal et al., 1998).  
Neurotransmitters, through stimulation of the beta 2-adrenoreceptors (b2AR)-cAMP-protein 
kinase A pathway, inhibit the production of type 1/proinflammatory cytokines, such as  
IL-12, TNF-alpha, and IFN-gamma by antigen-presenting cells and Th1 cells, whereas they 
stimulate the production of type 2/anti-inflammatory cytokines such as IL-10 and 
transforming growth factor-beta. Through these mechanisms endogenous catecholamines 
may cause a selective suppression of Th1 responses and cellular immunity and a Th2 shift 
towards dominance of humoral immunity (Madden et al., 1995, Elenkov et al., 2000). On the 
other hand, in certain local responses and under certain conditions, catecholamines may 
actually boost regional immune responses through induction of IL-1, TNF-α, and IL-8 
production. Thus, activation of the sympathetic nervous system during an immune response 
might be aimed to confine the inflammatory response on the local level through induction of 
neutrophil accumulation and stimulation of more specific humoral immune responses. 
However, systemically the SNS may suppress Th1 responses and thus protect the organism 
from the detrimental effects of pro-inflammatory cytokines and other products of activated 
macrophages (Elenkov et al., 2000). Otherwise, norepinephrine and epinephrine, through 
stimulation of classic cytoplasmic/nuclear glucocorticoid receptors and β2-AR, respectively, 
suppress the production of IL-12 by antigen presenting cells (APCs) being the main inducer 
of Th1 responses (Elenkov et al., 2005). It was shown that an increase in disease activity 
among RA patients was associated with an increase in the level of stress experienced by 
these patients, suggesting that a stress induced increase in norepinephrine release might 
activate naive Th1 cells and/or increase their activity (Kin & Sanders, 2007).  
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Cytokines are important factors connecting and modulating the immune and 
neuroendrocrine systems (Elenkov, 2005). Furthermore, cytokines and their receptors are 
expressed in the neuroendocrine system and exert their effects both centrally and 
peripherally (Benveniste et al., 1998). Systemic cytokines can affect the brain through several 
mechanisms, including active transport across the blood–brain barrier, through leaky areas 
in the blood–brain barrier in the circumventricular organs or through the activation of 
neural pathways such as the vagal nerve (Eskandari, 2005). For example, IL-6 and tumour 
necrosis factor (TNF)-a, released during an immune response and inflammation activate the 
central components of the stress system, alter neurotransmitter networks activity and induce 
fever, sleepiness, fatigue, loss of appetite and decreased libido. In addition, they activate the 
hepatic synthesis of acute phase proteins—changes referred to as ‘sickness behavior’ and 
‘acute-phase response’, respectively (Elenkov, 2005).  
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the splenic nerve and an increased turnover of norepinephrine in the spleen (Elenkov, 2000). 
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production of IL-10 appear to be deficient (Segal et al., 1998).  
Neurotransmitters, through stimulation of the beta 2-adrenoreceptors (b2AR)-cAMP-protein 
kinase A pathway, inhibit the production of type 1/proinflammatory cytokines, such as  
IL-12, TNF-alpha, and IFN-gamma by antigen-presenting cells and Th1 cells, whereas they 
stimulate the production of type 2/anti-inflammatory cytokines such as IL-10 and 
transforming growth factor-beta. Through these mechanisms endogenous catecholamines 
may cause a selective suppression of Th1 responses and cellular immunity and a Th2 shift 
towards dominance of humoral immunity (Madden et al., 1995, Elenkov et al., 2000). On the 
other hand, in certain local responses and under certain conditions, catecholamines may 
actually boost regional immune responses through induction of IL-1, TNF-α, and IL-8 
production. Thus, activation of the sympathetic nervous system during an immune response 
might be aimed to confine the inflammatory response on the local level through induction of 
neutrophil accumulation and stimulation of more specific humoral immune responses. 
However, systemically the SNS may suppress Th1 responses and thus protect the organism 
from the detrimental effects of pro-inflammatory cytokines and other products of activated 
macrophages (Elenkov et al., 2000). Otherwise, norepinephrine and epinephrine, through 
stimulation of classic cytoplasmic/nuclear glucocorticoid receptors and β2-AR, respectively, 
suppress the production of IL-12 by antigen presenting cells (APCs) being the main inducer 
of Th1 responses (Elenkov et al., 2005). It was shown that an increase in disease activity 
among RA patients was associated with an increase in the level of stress experienced by 
these patients, suggesting that a stress induced increase in norepinephrine release might 
activate naive Th1 cells and/or increase their activity (Kin & Sanders, 2007).  
 
Insights and Perspectives in Rheumatology 
 
218 
Since β2-ARs are expressed on Th1 cells, but not on Th2 cells (Sanders et al., 1997), 
catecholamines do not affect directly the cytokine production by Th2 cells. In murine and 
human systems β2-AR agonists inhibit IFN-gamma production by Th1 cells, but do not 
affect IL-4 production by Th2 cells (Borger et al., 1998; Wahle et al., 2006). However, 
neurotransmitters through stimulation of β2-AR up-regulate the production of the anti-
inflammatory cytokine IL-6 and IL-10 by APCs (Elenkov, 2005). Administration of a β2AR 
antagonist or a β2AR agonist prior to or during the development of arthritis inhibits or 
exacerbates disease pathology, suggesting that NE stimulating β2AR on naive T and/or Th1 
cells modulate IFN-gamma production. As with the in vitro findings, the in vivo effects 
were found to depend on the time point when norepinephrine was released during the 
course of a disease (Kin & Sanders, 2007). The increased responsiveness of T cells from  
RA patients to β2AR stimulation following NE exposure might exacerbate IFN-gamma 
production and promote conditions for RA development and progression. Therefore, NE, 
which normally participates in a CD4- T cell response to maintain homeostasis by enhancing 
the baseline immune cell-regulated IFN-gamma response, may cause disease progression 
when the regulatory conditions controlling sympathetic nervous system/ β2AR activity 
have changed (Kin & Sanders, 2007). 
Otherwise, between RA patients and controls there was a highly significant distortion in the 
distribution of the beta2AR polymorphisms at codon 16 and to a lower extent at codon  
27 contributing together with the human leuokocyte antigen (HLA)-DR alleles to the genetic 
background of RA. Furthermore, polymorphisms of the beta2R gene may modulate the 
expression of anti citrullinated peptide (anti-CCP) antibodies further supporting the close 
interplay between the autonomic nervous system and the immune system (Malysheva et al., 
2008). Single nucleotide polymorphisms have been found to be associated with the β2AR 
expressed by cells of RA patients, suggesting that a change in the β2AR structure on a naive 
T and/or Th1 cell may heighten the level of cell responsiveness to NE (Kin & Sanders, 2007).  
In patients with RA, experimental stress did not change levels of inflammatory markers  
(IL-2, soluble IL-2 receptor, IL-4, IL-10 and IFN-γ) but TNF-α. Results for IL-6 were 
inconsistent (S.de Brouwer, 2010). In patients with SLE, experimental stress did not change 
levels of cytokines and other inflammatory markers (IL-2, IL-6, IL-10, IFN-γ, β-
adrenoceptors), although levels of IL-4 increased after stress (Jocobs et al., 2001). Patients 
with SLE differed from controls in their response to stress, having a larger increase in IL-4, 
smaller IL-10 and IFN-γ responses, and fewer β-adrenoceptors on monocytes (S. de 
Brouwer, 2010). In patients with JIA, stress did not affect IL-8 production, but increased IL-6 
production (Roupe et al., 2000). However, in healthy subjects stress increased IFN gamma 
and IL-10 levels (Jacobs et al., 2001; Motivala et al., 2008). Thus, although experimental stress 
does not seem to influence levels of certain cytokines and inflammatory markers in patients 
with rheumatic diseases (for example, sIL-2, IL-8, IL-10, IFN-γ, β-adrenoceptors), it does 
cause specific changes in c-reactive protein (CRP) and TNF-α in patients with RA, changes 
in IL-4 in patients with SLE, and changes in IL-6 in patients with JIA. These changes are not 
observed in controls (S. de Brouwer, 2010). Finally, the pharmacological manipulation of the 
sympathetic-immune interface is reviewed with focus on new therapeutic strategies using 
selective alpha(2)- and beta(2)-AR agonists and antagonists and inhibitors of 
phosphodiesterase type IV in the treatment of experimental models of autoimmune diseases 
(Elenkov et al., 2000). 
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3. Integration of stress hormones, cytokines and neurotransmitters 
Perception of an external stressful stimulus prompts the activation of various physiological 
systems that together define the body's stress response, which is aimed at re-establishing 
homeostasis (S. de Brouwer, 2010). Central to the maintenance of homeostasis is an 
appropriate response of the HPA axis as well as the sympathetic nervous system (Dunn & 
Swiergiel, 2008; Eskandari et al., 2003,). From animal models of arthritis as well as from 
clinical studies in RA patients a central role of the HPA axis in onset and severity of RA was 
suggested (Chikanza, 1992). In these patients an inadequate secretion of cortisol in the 
setting of a sustained inflammatory disease has been observed (Vassilopoulos & 
Mantzoukis, 2006). A hypoactive stress system may facilitate or sustain the Th1 shift in Th1-
mediated RA. A suboptimal production of cortisol is involved in the onset and/or 
progression of RA. Patients with RA have ‘‘inappropriately normal’’ or low plasma cortisol 
levels in the setting of severe, chronic inflammation, characterized by increased production 
of TNF-a, IL-1 and IL-6. This may actually facilitate or sustain the pro-inflammatory shift in 
this disease (Elenkov, 2005). The HPA axis has been evaluated in multiple forms in former 
studies of RA patients. Assuming that an inflammatory process up-regulates HPA axis 
function, cortisol levels are inappropriately normal in RA patients when cytokine levels are 
increased (Straub et al., 2008). The proposed defect could reside at various levels of the HPA 
axis, i.e. the hypothalamic level, the pituitary, and the adrenal gland. However, results of 
HPA axis tests in RA patients were inconclusive since steroid treatment, drugs including 
disease modifying antirheumatic drugs (DMARD) and disease duration might interfere with 
the results leading to conflicting results for ACTH levels and cortisol response in  
RA patients (Eijsbouts, 2005). 
Experimental psychosocial stress consistently increased autonomic activity, blood pressure 
and catecholamine levels in patients with RA and SLE, and increased neuroendocrine 
variables (cortisol and ACTH]) in patients with RA. Furthermore, after such stress exposure 
an increase in IL-4 level in patients with SLE, an increase in TNF-α in RA patients, and 
inconsistent findings for IL-6 were observed (S. de Brouwer, 2010). Exercise stress was 
characterised by decreased levels of cortisol whereas ACTH levels and growth hormone 
levels increased. Moreover, this stress elicited a different cytotoxic T cell response in patients 
with RA and SLE (Pool et al., 2004; Kurtais et al., 2006). 
The stress hormones, supposedly acting via β- and α-adrenergic as well as glucocorticoid 
receptors, down-regulate immune and inflammatory processes; however, these processes 
also influence the central nervous system (Ader et al., 1995; MacEwen, 1998). Circulating 
cytokines and activated immune cells, markers of inflammation, activate both (intermediates 
of) the HPA axis and the autonomic nervous system. Chronically elevated levels of 
cytokines, as occur during long-term inflammation, might lead to changes in HPA axis and 
ANS activity (Chrousos, 1995). Otherwise, circulating hormones or locally released 
neurotransmitters regulate major immune functions, such as antigen presentation, antibody 
production, lymphocyte activity, proliferation and traffic, and the secretion of cytokines 
including the modulation of Th1 or Th2 cytokine responses. During inflammation, 
activation of the stress system, through induction of a Th2 shift protects the organism from 
systemic "overshooting" with Th1/pro-inflammatory cytokines. Under certain conditions, 
however, stress hormones, substance P, adenosine triphosphate (ATP) and the activation of 
CRH/substance P-histamine axis may actually facilitate inflammation, through induction of 
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IL-1, IL-6, IL-8, IL-18, TNF-alpha and CRP production. Thus, a dysfunctional 
neuroendocrine-immune interface associated with abnormalities of the 'systemic anti-
inflammatory feedback' and/or 'hyperactivity' of the local pro-inflammatory factors may 
play a role in the pathogenesis of autoimmune diseases (Elenkov, 2008).  
Cytokines signalling to the brain can not only activate the HPA axis but also facilitate pain 
and induce a series of mood and behavioural responses generally termed sickness 
behaviour (Watkins & Maier, 2000). Cytokines, such as IL-1, IL-6, and TNF-alpha, are also 
produced in the brain (Sebire, 1993). These brain-derived cytokines can stimulate the HPA 
axis. For example, IL-1 stimulates the expression of the gene encoding CRH and thereby the 
release of the hormone from the hypothalamus, the release of AVP from the hypothalamus, 
and the release of ACTH from the anterior pituitary, IL-2 stimulates AVP secretion from the 
hypothalamus, IL-6 and TNF-alpha also stimulate ACTH secretion. Otherwise, in chronic 
inflammation there seems to be a shift from CRH-driven to arginine vasopressin (AVP)-
driven HPA axis response (Eskandari, 2005).  
CRH is the strongest known activator of the HPA axis which has been functionally 
implicated in the regulation of many endocrine functions, such as glucocorticoid release 
from the adrenal gland and associated endocrine-immune responses (Elenkov, 2008). CRH 
not only activates the pituitary-adrenal axis but also sets in motion a coordinated series of 
behavioural and physiologic responses, suggesting that the central nervous system may 
coordinate both behavioural and immunologic adaptation during stressful situations 
(Stermberg, 1992; O'Connor, 2000). CRH is positively regulated by catecholaminergic system 
(Eskandari, 2005). During an immune response certain cytokines, such as IL-1, IL-6, and 
TNF-a can signal the brain, which via a complex CRH-dependent pathway, triggers 
activation of both the SNS and the HPA axis (Elenkov, 2000). 
 Recently several polymorphisms in the highly conserved regulatory region of the CRH gene 
were described with the gene being located on chromosome 8q13. Three polymorphisms co-
segregated absolutely resulting in two alleles A1 and A2 with a further polymorphism being 
assigned as alleles B1 and B2. Population investigations demonstrated a distortion in the 
distribution of the resulting compound alleles A1B1, A2B1 and A2B2 between RA patients 
and healthy controls (Baerwald et al., 1997). In vitro studies revealed a different regulation 
of the CRH gene by these polymorphisms (Wagner et al., 2006). Furthermore, it was shown 
that the stress induced response of cortisol is differentially modulated by CRH promoter 
polymorphisms in RA patients. Thus, during insulin hypoglycemia test RA patients bearing 
the A2B2 allele exhibited an earlier CRH as well as ACTH peak compared to A1B1 positive 
patients. The integrated cortisol response to hypoglycemia expressed as area under the 
curve was significantly lower in RA patients with the A1B1 allele than in RA patients with 
the A2B2 allele. Moreover, there was a significant difference in the molar ratio cortisol to 
ACTH between controls and RA patients underlining the dissociation of the pituitary and 
the adrenal gland in patients with RA (Malysheva et al., 2011). 
4. Environmental factors in stress – disease interaction  
The concept of environment included different factors that could disturb the homeostatic 
state of health (Parniapour, 1990). A growing body of research in rheumatic diseases 
highlights the importance of environmental influences to the contribution of stress on 
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disease activity of rheumatic diseases. These influences include factors such as emotional 
distress, coping, and familial factors (Anthony & Schanberg, 2007), diet, and some socio-
economic factors (such as level of education, area of residence and income) may affect levels 
of pain and physical disability experienced by rheumatic patients (Symmons, 2003; 
Kobayshi et al., 2008). 
4.1 Family factors  
It was shown that the family environment is important in juvenile rheumatic diseases. Thus, 
diagnosis of a rheumatic disease in children was associated with depression in the mother 
and a composite measure of parental (mother and father) distress and passive coping. 
Children's emotional and behavioural functioning was not related to medical diagnosis, 
however, a mother’s depression and parental distress were associated with a child’s 
behavioural problems. This kind of distress was associated with child functioning and 
interventions to ameliorate parental distress may have beneficial effects on the children's 
behaviour and on parent’s reactions to their children (Frank et al, 1998). Furthermore, the 
social environment was found to operate on the core health outcome, i.e. pain severity in 
rheumatic diseases. Not only the status of being married but also the quality of the 
relationship in terms of long-term stress and emotional support may be useful prognostic 
factors in rheumatic diseases. Patient reports of negative spouse behaviour (such as 
avoidance and critical remarks) and baseline depression predicted worse pain outcome, and 
this association remained significant in analyses controlling for baseline pain. The level of 
formal education showed a weak correlation to disability, emotional support, and pain. 
Daily emotional support and social life domains associated with positive affect had an 
indirect influence on outcome. The absence of strong rather than weak social ties was the 
component of the loneliness construct linked to pain. These associations between social 
prognostic factors and pain severity, however, were mediated by psychological functioning 
at baseline (Waltz et al., 1999).  
4.2 Socioeconomic status 
One more important factor of environment is socioeconomic status. Although RA 
occurrence is more frequent in lower socioeconomic parts of the population, it was not 
identified as a significant risk factor in RA (Damjanovic et al., 2009). Otherwise, there is a 
lack of good quality studies of the epidemiology of rheumatic diseases in developing 
countries. It appears that a threshold level where higher socio-economic status is associated 
with reduced prevalence of rheumatic disease is not reached in developing countries. 
Therefore, differences in the prevalence between socio-economic groups can be undetected. 
A similar case can be made for overcrowding (Steer et al., 2002). However, the education 
level as risk factor is significantly related to RA occurrence (Damjanovic et al., 2009). 
Furthermore, socioeconomic disparities in patients with chronic musculoskeletal complains 
leading to increased pain may be attributable to both greater frequency of stressful financial 
events as well as greater vulnerability to economic hardship for those at the lower end of the 
socioeconomic spectrum. Conditions of economic hardship and daily ratings of financial 
worry both had significant detrimental effects on daily pain. Participants with greater levels 
of economic hardship reported greater pain severity in response to daily financial worries 
than their counterparts with little or no economic hardship. Further, participants in the 
 
Insights and Perspectives in Rheumatology 
 
220 
IL-1, IL-6, IL-8, IL-18, TNF-alpha and CRP production. Thus, a dysfunctional 
neuroendocrine-immune interface associated with abnormalities of the 'systemic anti-
inflammatory feedback' and/or 'hyperactivity' of the local pro-inflammatory factors may 
play a role in the pathogenesis of autoimmune diseases (Elenkov, 2008).  
Cytokines signalling to the brain can not only activate the HPA axis but also facilitate pain 
and induce a series of mood and behavioural responses generally termed sickness 
behaviour (Watkins & Maier, 2000). Cytokines, such as IL-1, IL-6, and TNF-alpha, are also 
produced in the brain (Sebire, 1993). These brain-derived cytokines can stimulate the HPA 
axis. For example, IL-1 stimulates the expression of the gene encoding CRH and thereby the 
release of the hormone from the hypothalamus, the release of AVP from the hypothalamus, 
and the release of ACTH from the anterior pituitary, IL-2 stimulates AVP secretion from the 
hypothalamus, IL-6 and TNF-alpha also stimulate ACTH secretion. Otherwise, in chronic 
inflammation there seems to be a shift from CRH-driven to arginine vasopressin (AVP)-
driven HPA axis response (Eskandari, 2005).  
CRH is the strongest known activator of the HPA axis which has been functionally 
implicated in the regulation of many endocrine functions, such as glucocorticoid release 
from the adrenal gland and associated endocrine-immune responses (Elenkov, 2008). CRH 
not only activates the pituitary-adrenal axis but also sets in motion a coordinated series of 
behavioural and physiologic responses, suggesting that the central nervous system may 
coordinate both behavioural and immunologic adaptation during stressful situations 
(Stermberg, 1992; O'Connor, 2000). CRH is positively regulated by catecholaminergic system 
(Eskandari, 2005). During an immune response certain cytokines, such as IL-1, IL-6, and 
TNF-a can signal the brain, which via a complex CRH-dependent pathway, triggers 
activation of both the SNS and the HPA axis (Elenkov, 2000). 
 Recently several polymorphisms in the highly conserved regulatory region of the CRH gene 
were described with the gene being located on chromosome 8q13. Three polymorphisms co-
segregated absolutely resulting in two alleles A1 and A2 with a further polymorphism being 
assigned as alleles B1 and B2. Population investigations demonstrated a distortion in the 
distribution of the resulting compound alleles A1B1, A2B1 and A2B2 between RA patients 
and healthy controls (Baerwald et al., 1997). In vitro studies revealed a different regulation 
of the CRH gene by these polymorphisms (Wagner et al., 2006). Furthermore, it was shown 
that the stress induced response of cortisol is differentially modulated by CRH promoter 
polymorphisms in RA patients. Thus, during insulin hypoglycemia test RA patients bearing 
the A2B2 allele exhibited an earlier CRH as well as ACTH peak compared to A1B1 positive 
patients. The integrated cortisol response to hypoglycemia expressed as area under the 
curve was significantly lower in RA patients with the A1B1 allele than in RA patients with 
the A2B2 allele. Moreover, there was a significant difference in the molar ratio cortisol to 
ACTH between controls and RA patients underlining the dissociation of the pituitary and 
the adrenal gland in patients with RA (Malysheva et al., 2011). 
4. Environmental factors in stress – disease interaction  
The concept of environment included different factors that could disturb the homeostatic 
state of health (Parniapour, 1990). A growing body of research in rheumatic diseases 
highlights the importance of environmental influences to the contribution of stress on 
 
The Pathogenetic Link Between Stress and Rheumatic Diseases 
 
221 
disease activity of rheumatic diseases. These influences include factors such as emotional 
distress, coping, and familial factors (Anthony & Schanberg, 2007), diet, and some socio-
economic factors (such as level of education, area of residence and income) may affect levels 
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sample who were not employed and who reported higher levels of economic hardship 
exhibited the most pain reactivity in response to daily financial worries. Economic hardship 
was associated not only with greater exposure to daily financial worries but also with 
greater vulnerability to pain on days when daily financial worries were experienced (Rios & 
Zautra, 2011). A prospective cohort study (1958 British Birth Cohort Study) demonstrated 
that the prevalence of shoulder, forearm, low back, knee and chronic widespread pain at 45 
years generally increased with lower social class. Persons in the lowest social class 
(compared to the highest) experienced nearly a threefold increase in the risk of chronic 
widespread pain (relative risk: 2.9, 95% CI 1.8 to 4.6). Social class during childhood also 
demonstrated a relationship with most regional pain and chronic widespread pain. With the 
exception of forearm pain, the magnitude of effect of childhood social status on reporting of 
pain in adulthood was less than that of adult social status. On multivariable analysis these 
relationships were partly explained by poor adult mental health, psychological distress, 
adverse life events and lifestyle factors (Macfarlane, 2009). Furthermore, there was an 
association between socioeconomic status, occupation, and hospitalization for RA. A total of 
13,820 male and 14,509 female hospitalizations for RA were analysed during the study. Men 
and women with an education level > 12 years had a significantly decreased incidence ratio. 
Occupation also played a role in these items studied with an increased incidence ratio 
among farmers, miners and quarry workers, electrical workers, other construction workers, 
and engine and motor operators for men. Among women, assistant nurses and religious, 
juridical, and other social-science-related workers had significantly increased incidence ratio 
in all 3 cohorts (Li et al, 2008).  
4.3 Education and life style 
It was proposed that such environmental factor as level of education was significantly 
inversely associated with the risk of RA, with a 2-fold lower risk of RA among those with 
the highest education compared with those having the lowest level of education. On the 
other hand, it is hypothesised that RF-positive and RF-negative RA have different 
“aetiologies” with factors related to educational level predominantly associated with the 
risk of RF-positive RA (Pedersem et al., 2006). 
Diet and food life style could also be an important environmental factor contributing to 
rheumatic diseases. For example, diet, nutrition, and weight loss have shown promise in 
alleviating some of rheumatic burden. These lifestyle changes may give patients a feeling of 
control over their disease as well as a non-pharmacologic means of treatment. In particular 
the role of the Mediterranean diet has to be recognised as a protective factor against RA  
(Li & Micheletti, 2011). The goals of dietary therapy in rheumatic diseases are alleviation of 
under- and malnutrition, inhibition of inflammation, prophylaxis of osteoporosis, as well as 
recognition and treatment of nutrient sensitivities or intolerances. Inhibition of 
inflammation in these patients is improved by modulating the omega-3/omega-6 fatty acids 
ratio in the diet. Reduction of dietary arachidonic acid is recommended. This 
polyunsaturated fatty acid is the main precursor of pro-inflammatory mediators which 
interact with chemokines und cytokines. Simultaneously, intake of anti-inflammatory 
omega-3 fatty acids is increased. Studies have shown that this dietary regimen results in an 
amelioration of symptoms in patients with inflammatory rheumatic diseases (Adam et al., 
2009). 
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The role of other types of environmental stress was studied in patients with different 
autoimmune diseases as well. For example, cognitive stressors elicited changes in 
leukocyte/lymphocyte counts, subsets of lymphocytes, and CRP levels in patients with RA 
(Geenen, 1998; Veldhuijzen van Zanten, 2005), and changes in leucocyte counts and cytoxic 
T cell numbers in patients with SLE (Hinrichsen, 1992). It has recently been demonstrated 
that thermal stress (Spa therapy) induces a reduction in the circulating levels of 
prostaglandin E2 (PGE2), leukotriene B4 (LTB4), IL-1β and TNF-α, important mediators of 
inflammation and pain in patients with rheumatic diseases (Fioravanti, 2011). It was shown 
that environmental desiccating stress can be involved in the pathogenesis of chronic dry eye 
syndrome by exposing shared epitopes in the cornea, conjunctiva, and the lacrimal gland 
that induce pathogenic CD4+T cells leading to lacrimal keratoconjunctivitis, which under 
normal circumstances is restrained by CD4(+)CD25(+) forkhead/winged helix transcription 
factor(+) regulatory T cells (Niederkorn et al., 2006).  
4.4 Climate conditions 
Some other environmental factors such as weather conditions and climate could be also 
important in rheumatic pain. For example, persons with osteoarthritis in urban Chicago 
exhibited more weather sensitivity than their rural counterparts in Grand Forks, North 
Dakota. Multiple regression analysis revealed that precipitation affected pain for urban 
subjects who identified weather as a pain-generating factor; barometric pressure, relative 
humidity and sunshine were significant factors influencing pain-related stress. Wind speed 
correlated with pain and pain-related stress; relative humidity and precipitation correlated 
with pain-related stress for urban subjects who did not perceive weather as a problem. 
Specific weather variables were not identified as affecting rural subjects' pain. However, 
temperature and barometric pressure affected pain-related stress in rural subjects who 
perceived weather as a problem (Laborde et al., 1986). However,  one systematic review of 
nine longitudinal observational studies (up to September 2009) dealing with the association 
of weather variables (temperature, relative humidity and atmospheric pressure) and 
severity of pain in RA could not demonstrate any significant effects. Individual analyses 
from two studies indicate that pain reporting in a minority (< 25%) of RA patients is 
influenced by temperature, relative humidity or atmospheric pressure. The studies to date 
do not show any consistent group effect of weather conditions on pain in RA. There is, 
however, evidence suggesting that pain in some individuals is more affected by the weather 
than in others, and that patients react in different ways to various weather conditions. Thus, 
the hypothesis that weather changes might significantly influence pain reporting in clinical 
care and research in some patients with RA cannot be rejected (Smedslund & Hagen, 2011). 
Otherwise, one population-based study demonstrated that pain is not an inevitable 
consequence of climatic conditions. Persons were less likely to report pain on days with > 
5.8 h of sunshine and with average temperature of > 17.5°C underlining a strong 
relationship between lack of sunshine, lower temperatures and pain reporting (Macfarlane 
et al, 2010). Interestingly, 84% of RA patients believe in an association between weather and 
rheumatism, while 57% claimed to have ability to forecast weather. The maximum 
contribution of weather on symptoms was 17.1 %. Of interest, the belief about a presence of 
an association between weather and arthritis was found to be stronger than its statistical 
power (Cay et al., 2011).  
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4.5 Cultural difference 
In addition, cultural differences in experiencing individual stress in RA patients were 
observed. In one study covering Polish and German RA patients it was demonstrated that in 
both countries, mental as well as physical health deteriorated resulting in about 50% of 
patients requiring support in everyday activities. 95% of Polish and 62% of German patients 
felt rejected from social activities. For the psychological stress perceived, functional capacity 
class 3 and male gender were shown to be predictive in Polish patients and living in a small 
town in German patients. In the Polish group, the tertiary/bachelor level of education was 
linked with lower distress level. RA has a serious impact on the mental health owing to a 
great disease burden (Bugajska et al., 2010).  
4.6 Other factors 
Interestingly, during a 15-year follow-up study of 74 female patients with RA two categories 
of RA were identified: a disease form less connected with genetic factors and more 
influenced by major psychodynamic conflict situations ('major conflict group') and a second 
form more associated with hereditary predisposition and less influenced by environmental 
psychosocial changes ('non-conflict group') (Rimón & Laakso,1985). In addition, a patient’s 
perspective of the causes and consequences of RA could underline the role of environmental 
factors in disease. Two descriptive categories  of patient’s understanding of disease could be 
identified: the category 'consequences beyond personal control' comprised not having a 
clue, being exposed to climatic change, being genetically exposed and unexpected effects of 
events; the category 'overloaded circumstances' involved work and family-related strain. 
Consequences beyond personal control implied that the patients could not prevent the 
disease and expressed their lack of understanding as to why they contracted it. Overloaded 
circumstances were described as strained situations that were both work and family factors 
related and could be influenced by the patient. Reasoning along these lines it is concluded 
that understanding the patients' own view of disease is needed in order to achieve a more 
successful medical care model (Bergsten et al., 2009). Identifying of how these factors 
contribute to the development of autoimmune diseases may further lead to better explaining 
the pathogenesis of rheumatic diseases (Symmons, 2003; Kobayshi et al., 2008). 
Finally, in one recent study of patients with psoriatic arthritis environmental factors such as 
lifting heavy loads of at least 100 pounds/hr (OR 2.8, 95% CI 1.51-5.05),  infections that 
required antibiotics (OR 1.7, 95% CI 1.00-2.77), and injuries (OR 2.1, 95% CI 1.11-4.01) were 
associated with the occurrence of arthritis. No association was found between psoriasis 
arthritis and alcohol consumption, vaccination, and female hormonal exposures (Eder et al., 
2011). 
5. Rheumatic diseases as a model of stress induced disease 
Despite more than twenty years of stress research in rheumatology, it is not completely 
understood whether stress induced neuroimmune dysfunctions play a causal role in the 
aetiology of rheumatic diseases or, in turn, rheumatic disease could change the stress 
reaction and thereby changing disease activity and worsening the outcome. However, 
epidemiological research increasingly suggests that exposure to traumatic stressors and 
psychological trauma is related to increased health care utilisation, adverse health outcomes, 
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the onset of specific diseases including rheumatic diseases, and premature death (Boscarino 
et al., 2004; Sommershof et al., 2009). 
5.1 Stress as pathogenetic factor of autoimmune diseases 
From results of 27 studies evaluating more than 3,000 patients with RA it was recognised 
that stress is an important risk factor in the pathogenesis of autoimmune diseases. Major life 
events (e.g. death of a spouse, severe long-term illness of a spouse, loss of a parent, divorce 
of parents, death of a parent or severe disease of a parent) lead to an intense release of stress 
mediators (large time integral of released neurotransmitters and hormones), whereas in 
minor life events (daily hassles with small intensity) only short-lived surges of 
neurotransmitters and hormones are expected. Therefore, it is suggested that 
neurotransmitters such as norepinephrine or stress hormones such as cortisol might have 
different effects on immune/inflammatory responses at high and low concentrations 
present during short or extended periods of time, respectively. Long-lasting (chronic) stress 
may lead to pro-inflammatory effects since no adequate long-term responses of stress axes 
(anti-inflammatory) are to be expected (Cutolo & Straub, 2006). Furthermore, major life 
events and chronic minor stress seem to be important factors in juvenile chronic arthritis 
and are significantly associated with the onset of the rheumatic disease. With respect to RA, 
stress may be a provoking factor. However, during the course of the disease, minor stress 
could aggravate SLE and RA (Herrmann et al., 2000). In contrast, strong major stress, which 
is likely accompanied by a large and long-lived release of stress axes mediators, was 
associated with a decrease in disease activity (Cutolo & Straub, 2006).  
5.1.1 Early life stress 
One study (follow up 1980 till 1996) examining the risk of RA in parents after the death of a 
child does not support an association between severe psychological stress and RA. The 
relative risk of first hospitalisation for RA was 0.88 [95% CI 0.63-1.24]. The risk was close to  
1 throughout the 18 years of follow-up (Li et al., 2005). Recent findings are consistent on the 
impact of early life stress on subsequent inflammatory responses. A predominant role for 
parent distress in children's adjustment to juvenile rheumatic disease was shown (Ryan et 
al., 2010). In one retrospective cohort study (follow–up 1995/1997 through 2005) of 15,357 
adults it could be demonstrated that 64% adults reported early life stress with at least one 
adverse childhood experience (ACE), including childhood physical, emotional, or sexual 
abuse; witnessing domestic violence; growing up with household substance abuse, mental 
illness, parental divorce, and/or an incarcerated household member. The event rate (per 
10,000 person-years) for a first hospitalization with any autoimmune disease was 31.4 in 
women and 34.4 in men. First hospitalizations for any autoimmune disease increased with 
increasing number of ACEs (p < 0.05). Persons with equal or more than 2 ACEs were at a 
100 % increased risk for rheumatic diseases compared to persons without any ACE  
(p < 0.05) (Dube et al., 2009). Patients with juvenile idiopathic arthritis reported having pain, 
stiffness, and fatigue on > 70% of days, with significant variability in symptom levels. 
Furthermore, significant same-day relationships between stress, mood, and disease 
symptoms were revealed. Specifically, daily fluctuations in both stress and mood were 
predictive of increased pain, stiffness, and fatigue. Increases in daily stress, mood, and 
disease symptoms were also significantly related to decreased participation in social 
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activities on a day-to-day basis (Schanberg et al., 2005). However, one study does not 
support the hypothesis that stressful life events and adverse childhood experiences play an 
aetiologic role in the development of rheumatic disease. The number and timing of 
occurrence of stressful life events, as well as their subjective immediate impact, did not 
differ between participants who developed RA and their matched controls. Termination of 
pregnancy was the only specific event individually associated with a higher risk of 
developing RA (OR 3.74; 95% CI 1.4-9.9). Negative childhood experiences were not 
associated with the risk of RA. However, RA cases reported significantly slower adaptation 
to the effects of adverse events than controls (Carette et al., 2000). 
5.1.2 Posttraumatic stress disorder 
Some studies have demonstrated a link between the traumatic stress exposures and 
posttraumatic stress disorder (PTSD) to rheumatic disorders. Recent finding indicate that 
victims of PTSD exhibit higher numbers of circulating T-cell lymphocytes and lower cortisol 
levels, suggesting that chronic sufferers of PTSD may be at risk for autoimmune diseases. In 
addition, patients with comorbid PTSD were more likely to have clinically higher T-cell 
counts, hyper-reactive immune responses on standardized delayed cutaneous 
hypersensitivity tests, higher immunoglobulin-M levels, and lower dehydroepiandrosterone 
levels (Stojanovich, 2008). It was also suggested that PTSD symptoms, as measured by 
impact of events scale, are strongly linked to chronic widespread pain (Arguelles, 2006). 
Otherwise, in one twin pair’s study it was shown that PTSD symptoms were associated with 
onset of adult RA. Even after adjustment for familial/genetic factors and other confounders, 
an association between PTSD symptoms and RA remained (Boscarino et al., 2010). 
Furthermore, cross-sectional data from the 2002 National Health Interview Survey, an  
in-person household interview survey, in adults with (n = 6,829) and without (n = 20,676) 
arthritis demonstrated that the prevalence of severe psychological distress (SPD) in adults 
with arthritis is significantly higher than in adults without arthritis (5.6 % vs. 1.8 % and 26.2 
% vs. 10.7 %, P < 0.001, respectively). In adults with arthritis, SPD was significantly 
associated with younger age, lower socioeconomic status, divorce/separation, recurrent 
pain, physical inactivity, having functional or social limitations, and having comorbid 
medical conditions. Adults aged 18 to 44 years were 6.5 times more likely to report SPD than 
those 65 years or older, and adults with recurrent pain were 3 times more likely to report 
SPD than those without recurrent pain. Serious psychological distress affects persons with 
arthritis and should be addressed in their treatment. Younger adults with arthritis, and 
those with recurrent pain or either functional or social limitations, may be at higher risk for 
SPD (Shih M, et al., 2006).  
5.2 Stress and modulation of rheumatic disease activity 
It was shown that perceived stress could be a predictor of rheumatic activity (Curtis et al., 
2005). Otherwise, psychological stress is thought to aggravate disease activity in RA, 
although the physiologic mechanisms are not clear. Thus it was shown that brief 
psychological stress can trigger increased production of TNF-alpha of stimulated monocytes 
in RA patients. The use of TNF-alpha antagonists protects against stress activation of 
cellular markers of inflammation in RA patients (Motivala et al., 2008). In two prospective 
studies on RA, disease flare-ups were linked to a higher number of interpersonal minor 
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stressors few days prior to the visit (Cutolo & Straub, 2006). In addition, it was shown that 
stress is a potentially important risk factor for the onset of adult Still's disease. Stressful life 
events (OR 2.56; 95% CI 1.18 to 5.52) in the year preceding the onset was significantly 
associated with increased risk for adult Still's disease (Sampalis et al., 1996). Likewise, a 
longitudinal study over a period of 5 years showed that RA patients with a higher daily 
stress level at baseline had a poorer outcome and significantly more bony erosions after 5 
years. Therefore, long-lasting (chronic) stress may lead to proinflammatory effects because 
no adequate long-term responses of stress axes (HPA – anti-inflammatory) are to be 
expected. Only 5 studies on about 150 RA patients did not support the link between minor 
stress and disease flares (Cutolo & Straub, 2006). However, it was shown that psychological 
distress and social support are more important than objectively assessed disease status in 
determining marital and sexual satisfaction in patients with RA (vam Lankfeld et al., 2004). 
In RA patients pain was the predominantly perceived stressor followed by limitation in 
mobility, difficulties in carrying out activities of daily living, helplessness, dependency on 
others, threat to self-esteem, interference in social activity, interference in family 
relationships, difficulties performing at work, and discomfort of the treatment (Mahat, 
1997). Interestingly, perceived stress had the strongest relationship with psychological well-
being of rheumatic patients (Treharne et al.,  2007). 
In a large population-based case-control study (1996–2003) with incident cases of RA (1,221 
cases and 1,454 controls) it could be shown that high psychological stress of job demands 
tended to be associated with a decreased risk of RA (OR = 0.8; 95 % CI = 0.6 – 1.0). 
Interestingly, low decision latitude was associated with an increased risk of RA (self-
reported data: OR = 1.6; 95 % CI = 1.2 – 2.2). Self-reported job strain was associated with a 
30% higher risk of RA, compared with relaxed working conditions (Benggsson et al., 2009). 
Similarly, in patients with osteoarthritis the relationship between social support, stress and 
functional status was of major importance. Thus, physical disability was associated with 
being older and having less tangible support; psychological disability was correlated with 
being younger, caucasian, and having less support; and pain was associated with being 
younger, caucasian and having less education. Self-esteem appeared to be the most, and 
appraisal the least, consistent social support dimension when predicting functional status. 
While exposure to stressors negatively affected functional status, its impact was greatest 
with respect to psychological disability (Weinberger et al., 1990).  
6. Therapeutic interventions 
Rheumatic diseases represent an important public health burden. To reduce the social and 
economic impact of these pathologies, an appropriate management of these conditions 
should be encouraged based on the use of established intervention strategies, including 
stress reduction approaches (Ottonello, 2007).  
6.1 Psychological approach 
In a recent metaanalysis of efficacy of psychological interventions in the treatment of RA 
patients 31 studies with 2021 patients could be included. There is consistent supportive 
evidence for the efficacy of disclosure therapy and cognitive behavioural therapy followed 
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activities on a day-to-day basis (Schanberg et al., 2005). However, one study does not 
support the hypothesis that stressful life events and adverse childhood experiences play an 
aetiologic role in the development of rheumatic disease. The number and timing of 
occurrence of stressful life events, as well as their subjective immediate impact, did not 
differ between participants who developed RA and their matched controls. Termination of 
pregnancy was the only specific event individually associated with a higher risk of 
developing RA (OR 3.74; 95% CI 1.4-9.9). Negative childhood experiences were not 
associated with the risk of RA. However, RA cases reported significantly slower adaptation 
to the effects of adverse events than controls (Carette et al., 2000). 
5.1.2 Posttraumatic stress disorder 
Some studies have demonstrated a link between the traumatic stress exposures and 
posttraumatic stress disorder (PTSD) to rheumatic disorders. Recent finding indicate that 
victims of PTSD exhibit higher numbers of circulating T-cell lymphocytes and lower cortisol 
levels, suggesting that chronic sufferers of PTSD may be at risk for autoimmune diseases. In 
addition, patients with comorbid PTSD were more likely to have clinically higher T-cell 
counts, hyper-reactive immune responses on standardized delayed cutaneous 
hypersensitivity tests, higher immunoglobulin-M levels, and lower dehydroepiandrosterone 
levels (Stojanovich, 2008). It was also suggested that PTSD symptoms, as measured by 
impact of events scale, are strongly linked to chronic widespread pain (Arguelles, 2006). 
Otherwise, in one twin pair’s study it was shown that PTSD symptoms were associated with 
onset of adult RA. Even after adjustment for familial/genetic factors and other confounders, 
an association between PTSD symptoms and RA remained (Boscarino et al., 2010). 
Furthermore, cross-sectional data from the 2002 National Health Interview Survey, an  
in-person household interview survey, in adults with (n = 6,829) and without (n = 20,676) 
arthritis demonstrated that the prevalence of severe psychological distress (SPD) in adults 
with arthritis is significantly higher than in adults without arthritis (5.6 % vs. 1.8 % and 26.2 
% vs. 10.7 %, P < 0.001, respectively). In adults with arthritis, SPD was significantly 
associated with younger age, lower socioeconomic status, divorce/separation, recurrent 
pain, physical inactivity, having functional or social limitations, and having comorbid 
medical conditions. Adults aged 18 to 44 years were 6.5 times more likely to report SPD than 
those 65 years or older, and adults with recurrent pain were 3 times more likely to report 
SPD than those without recurrent pain. Serious psychological distress affects persons with 
arthritis and should be addressed in their treatment. Younger adults with arthritis, and 
those with recurrent pain or either functional or social limitations, may be at higher risk for 
SPD (Shih M, et al., 2006).  
5.2 Stress and modulation of rheumatic disease activity 
It was shown that perceived stress could be a predictor of rheumatic activity (Curtis et al., 
2005). Otherwise, psychological stress is thought to aggravate disease activity in RA, 
although the physiologic mechanisms are not clear. Thus it was shown that brief 
psychological stress can trigger increased production of TNF-alpha of stimulated monocytes 
in RA patients. The use of TNF-alpha antagonists protects against stress activation of 
cellular markers of inflammation in RA patients (Motivala et al., 2008). In two prospective 
studies on RA, disease flare-ups were linked to a higher number of interpersonal minor 
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stressors few days prior to the visit (Cutolo & Straub, 2006). In addition, it was shown that 
stress is a potentially important risk factor for the onset of adult Still's disease. Stressful life 
events (OR 2.56; 95% CI 1.18 to 5.52) in the year preceding the onset was significantly 
associated with increased risk for adult Still's disease (Sampalis et al., 1996). Likewise, a 
longitudinal study over a period of 5 years showed that RA patients with a higher daily 
stress level at baseline had a poorer outcome and significantly more bony erosions after 5 
years. Therefore, long-lasting (chronic) stress may lead to proinflammatory effects because 
no adequate long-term responses of stress axes (HPA – anti-inflammatory) are to be 
expected. Only 5 studies on about 150 RA patients did not support the link between minor 
stress and disease flares (Cutolo & Straub, 2006). However, it was shown that psychological 
distress and social support are more important than objectively assessed disease status in 
determining marital and sexual satisfaction in patients with RA (vam Lankfeld et al., 2004). 
In RA patients pain was the predominantly perceived stressor followed by limitation in 
mobility, difficulties in carrying out activities of daily living, helplessness, dependency on 
others, threat to self-esteem, interference in social activity, interference in family 
relationships, difficulties performing at work, and discomfort of the treatment (Mahat, 
1997). Interestingly, perceived stress had the strongest relationship with psychological well-
being of rheumatic patients (Treharne et al.,  2007). 
In a large population-based case-control study (1996–2003) with incident cases of RA (1,221 
cases and 1,454 controls) it could be shown that high psychological stress of job demands 
tended to be associated with a decreased risk of RA (OR = 0.8; 95 % CI = 0.6 – 1.0). 
Interestingly, low decision latitude was associated with an increased risk of RA (self-
reported data: OR = 1.6; 95 % CI = 1.2 – 2.2). Self-reported job strain was associated with a 
30% higher risk of RA, compared with relaxed working conditions (Benggsson et al., 2009). 
Similarly, in patients with osteoarthritis the relationship between social support, stress and 
functional status was of major importance. Thus, physical disability was associated with 
being older and having less tangible support; psychological disability was correlated with 
being younger, caucasian, and having less support; and pain was associated with being 
younger, caucasian and having less education. Self-esteem appeared to be the most, and 
appraisal the least, consistent social support dimension when predicting functional status. 
While exposure to stressors negatively affected functional status, its impact was greatest 
with respect to psychological disability (Weinberger et al., 1990).  
6. Therapeutic interventions 
Rheumatic diseases represent an important public health burden. To reduce the social and 
economic impact of these pathologies, an appropriate management of these conditions 
should be encouraged based on the use of established intervention strategies, including 
stress reduction approaches (Ottonello, 2007).  
6.1 Psychological approach 
In a recent metaanalysis of efficacy of psychological interventions in the treatment of RA 
patients 31 studies with 2021 patients could be included. There is consistent supportive 
evidence for the efficacy of disclosure therapy and cognitive behavioural therapy followed 
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by maintenance therapy. Similarly, there is an evidence for improvement with behavioural 
therapy (> 6 weeks duration) in the short-term but conflicting evidence for its long-term 
efficacy. While there is some evidence for improvement with biofeedback-based 
interventions and relaxation therapy, there is conflicting evidence for the benefits of 
counselling, psychotherapy, mindfulness and meditation, and behavioural therapy of less 
than 6 weeks duration (Dissanayake & Bertouch, 2010).  
One possibility to reduce stress for patients with rheumatic diseases is cognitive-behavioural 
therapy aimed at minimisation of pain episodes and stressful events, improving quality of 
life and involving education, training in various types of relaxation approaches and other 
coping skills. Ideally the application of these skills includes the patient's home and work 
environment. It was shown that cognitive-behavioural therapy and stress management may 
be useful adjuvant therapy when treating the disease symptoms of children with 
polyarticular arthritis (Schanberg et al., 2005). Otherwise, patients with RA under greater 
perceived stress who do not use active coping strategies appear to be at risk of psychological 
comorbidity and may therefore benefit from interventions teaching specific active coping 
strategies (Treharne et al., 2007). A significant relationship between specific stressors and 
utilisation of coping strategies could be demonstrated: interference in family relationships 
and use of evasive coping strategies (p < 0.05), threat to self-esteem and use of both evasive 
and emotive coping strategies (Mahat, 1997). Interestingly, an active behavioural coping 
buffered an association of stress with depression, while active cognitive coping buffered the 
effect of baseline stress on life satisfaction after 6 months of intervention. Patients with RA 
under greater perceived stress who do not use active coping strategies appear to be at risk of 
psychological comorbidity and may therefore benefit from interventions teaching specific 
active coping strategies (Treharne et al., 2007). Optimistic and confronting coping strategies 
were found most frequently and perceived to be most effective against distress (Herrmann 
et al., 2000). Furthermore, a sample of patients with RA who completed a stress 
management training program (such as self-efficacy, coping strategies, and helplessness) 
had a decrease of pain and depression due to beneficial changes in the arenas of self-efficacy 
(the belief that one can perform a specific behaviour or task in the future), coping strategies 
(an individual's confidence in his or her ability to manage pain), and helplessness 
(perceptions of control regarding arthritis) (Rhee, 2000).  
Moreover, several studies suggest that the cognitive-behavioural approach is efficacious in 
RA and osteoarthritis in improving not only the psychological adjustment during the course 
of the disease but also physical function (Ottonello, 2007). It was demonstrated that 
psychosocial intervention (conventional psychotherapy or assertion/relaxation training) 
leads to improvement in functional status or disease activity of RA patients (Strauss et al., 
1986). Moreover, cognitive-behavioural therapy and mindfulness interventions that target 
responses to chronic stress, pain, and depression reduce pain and the pro-inflammatory IL-6 
improving the quality of everyday life for adults with RA (Zautra et al., 2008). 
Otherwise, cognitive behavioural interventions to facilitate patient adjustment could 
usefully include not only management of stress and its appraisal but also utilisation of social 
support resources (Curtis et al., 2005). Several longitudinal studies have demonstrated that 
stress appraisal and resultant coping responses affect health outcome and health-related 
quality of life in women. In addition to problem-focused coping, women often use 
distraction methods, seeking social support and faith or religious coping. Psychological 
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interventions in chronic medical conditions need to move beyond education and incorporate 
more cognitive behavioural components, at the same time addressing women's specific 
needs. Coping behaviours in response to the negative threat of a chronic or severe medical 
illness serve to reduce psychological distress (Rao, 2009). One of the important factors to 
sustain a psychological well-being is the social background; in particular functioning of the 
family is of outstanding importance for clinical and psychological outcomes (Herrmann et 
al., 2000). On the other hand, personality and social relationships play an important role in 
almost every aspect of stress and coping. Daily process methods are particularly useful in 
elucidating how these factors might influence both responses to and outcomes of stress 
(DeLongis & Holtzman, 2005). Furthermore, a randomized clinical trial to evaluate a 
psychological intervention and social support program in RA patients showed that the 
psychological intervention produced significant reductions in patients' pain behaviour and 
disease activity. Significant reductions were also observed in trait anxiety after treatment 
and at 6-month follow-up. The social support program produced a significant reduction in 
trait anxiety after treatment only (Bradlex et al., 1987). Moreover, in the European Research 
on Incapacitating Diseases and Social Support cohort of patients with early RA it was 
demonstrated that patients with a greater amount of specific social support or a stronger 
specific support network experienced less functional limitation and less psychological 
distress (Demange et al., 2004). Controlled studies of RA patients demonstrated that the 
ability of self-management behaviours (accommodation, active remediation, perseverance) 
can decrease impact of RA-related stressors (pain, fatigue, physical limitations, joint 
changes, and symptom unpredictability) to perform life activities (p < 0.01 - 0.0001) (Katz et 
al., 2005).  
6.2 Muscle relaxation training 
Otherwise, supervised muscle relaxation training exercised 30 minutes, twice a week for 10 
weeks in individuals with RA indicated improvements in the training group regarding self-
care according to the Arthritis Impact Measurement Scales 2, and in recreation and pastimes 
according to the Sickness Impact Profile-RA (p < 0.05) directly after the intervention. 
Mobility and arm function (p < 0.01) according to the Arthritis Impact Measurement Scales 
2, and muscle function of the lower limbs (p < 0.05) were improved after six months of 
training (Lundgren & Stenström, 1999). There has been an increasing interest in meditation 
as a mind-body approach, given its potential to alleviate emotional distress and promote 
improved well-being in a variety of populations (Young, 2011). A randomized, waitlist-
controlled pilot study of 4 month’s Mindfulness-Based Stress Reduction program showed a 
significant decrease of psychological distress and strengthening well-being in patients with 
RA (Pradhan, 2007).  
6.3 Tai chi 
It was also shown that Tai chi is beneficial in stress inhibition increasing daily activities in 
RA patients. Tai Chi is a traditional Chinese art which combines a multimodal, complex 
intervention that may include interaction of physical, cognitive, and ritualistic components 
(including, for example, elements of musculoskeletal efficiency, breathing, mindfulness, 
psychosocial interactions, rituals, and environment) (Wayne & Kaptchuk, 2008). Two 
randomised clinical trials (RCTs) and three non-randomized clinical trials about efficacy of 
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by maintenance therapy. Similarly, there is an evidence for improvement with behavioural 
therapy (> 6 weeks duration) in the short-term but conflicting evidence for its long-term 
efficacy. While there is some evidence for improvement with biofeedback-based 
interventions and relaxation therapy, there is conflicting evidence for the benefits of 
counselling, psychotherapy, mindfulness and meditation, and behavioural therapy of less 
than 6 weeks duration (Dissanayake & Bertouch, 2010).  
One possibility to reduce stress for patients with rheumatic diseases is cognitive-behavioural 
therapy aimed at minimisation of pain episodes and stressful events, improving quality of 
life and involving education, training in various types of relaxation approaches and other 
coping skills. Ideally the application of these skills includes the patient's home and work 
environment. It was shown that cognitive-behavioural therapy and stress management may 
be useful adjuvant therapy when treating the disease symptoms of children with 
polyarticular arthritis (Schanberg et al., 2005). Otherwise, patients with RA under greater 
perceived stress who do not use active coping strategies appear to be at risk of psychological 
comorbidity and may therefore benefit from interventions teaching specific active coping 
strategies (Treharne et al., 2007). A significant relationship between specific stressors and 
utilisation of coping strategies could be demonstrated: interference in family relationships 
and use of evasive coping strategies (p < 0.05), threat to self-esteem and use of both evasive 
and emotive coping strategies (Mahat, 1997). Interestingly, an active behavioural coping 
buffered an association of stress with depression, while active cognitive coping buffered the 
effect of baseline stress on life satisfaction after 6 months of intervention. Patients with RA 
under greater perceived stress who do not use active coping strategies appear to be at risk of 
psychological comorbidity and may therefore benefit from interventions teaching specific 
active coping strategies (Treharne et al., 2007). Optimistic and confronting coping strategies 
were found most frequently and perceived to be most effective against distress (Herrmann 
et al., 2000). Furthermore, a sample of patients with RA who completed a stress 
management training program (such as self-efficacy, coping strategies, and helplessness) 
had a decrease of pain and depression due to beneficial changes in the arenas of self-efficacy 
(the belief that one can perform a specific behaviour or task in the future), coping strategies 
(an individual's confidence in his or her ability to manage pain), and helplessness 
(perceptions of control regarding arthritis) (Rhee, 2000).  
Moreover, several studies suggest that the cognitive-behavioural approach is efficacious in 
RA and osteoarthritis in improving not only the psychological adjustment during the course 
of the disease but also physical function (Ottonello, 2007). It was demonstrated that 
psychosocial intervention (conventional psychotherapy or assertion/relaxation training) 
leads to improvement in functional status or disease activity of RA patients (Strauss et al., 
1986). Moreover, cognitive-behavioural therapy and mindfulness interventions that target 
responses to chronic stress, pain, and depression reduce pain and the pro-inflammatory IL-6 
improving the quality of everyday life for adults with RA (Zautra et al., 2008). 
Otherwise, cognitive behavioural interventions to facilitate patient adjustment could 
usefully include not only management of stress and its appraisal but also utilisation of social 
support resources (Curtis et al., 2005). Several longitudinal studies have demonstrated that 
stress appraisal and resultant coping responses affect health outcome and health-related 
quality of life in women. In addition to problem-focused coping, women often use 
distraction methods, seeking social support and faith or religious coping. Psychological 
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interventions in chronic medical conditions need to move beyond education and incorporate 
more cognitive behavioural components, at the same time addressing women's specific 
needs. Coping behaviours in response to the negative threat of a chronic or severe medical 
illness serve to reduce psychological distress (Rao, 2009). One of the important factors to 
sustain a psychological well-being is the social background; in particular functioning of the 
family is of outstanding importance for clinical and psychological outcomes (Herrmann et 
al., 2000). On the other hand, personality and social relationships play an important role in 
almost every aspect of stress and coping. Daily process methods are particularly useful in 
elucidating how these factors might influence both responses to and outcomes of stress 
(DeLongis & Holtzman, 2005). Furthermore, a randomized clinical trial to evaluate a 
psychological intervention and social support program in RA patients showed that the 
psychological intervention produced significant reductions in patients' pain behaviour and 
disease activity. Significant reductions were also observed in trait anxiety after treatment 
and at 6-month follow-up. The social support program produced a significant reduction in 
trait anxiety after treatment only (Bradlex et al., 1987). Moreover, in the European Research 
on Incapacitating Diseases and Social Support cohort of patients with early RA it was 
demonstrated that patients with a greater amount of specific social support or a stronger 
specific support network experienced less functional limitation and less psychological 
distress (Demange et al., 2004). Controlled studies of RA patients demonstrated that the 
ability of self-management behaviours (accommodation, active remediation, perseverance) 
can decrease impact of RA-related stressors (pain, fatigue, physical limitations, joint 
changes, and symptom unpredictability) to perform life activities (p < 0.01 - 0.0001) (Katz et 
al., 2005).  
6.2 Muscle relaxation training 
Otherwise, supervised muscle relaxation training exercised 30 minutes, twice a week for 10 
weeks in individuals with RA indicated improvements in the training group regarding self-
care according to the Arthritis Impact Measurement Scales 2, and in recreation and pastimes 
according to the Sickness Impact Profile-RA (p < 0.05) directly after the intervention. 
Mobility and arm function (p < 0.01) according to the Arthritis Impact Measurement Scales 
2, and muscle function of the lower limbs (p < 0.05) were improved after six months of 
training (Lundgren & Stenström, 1999). There has been an increasing interest in meditation 
as a mind-body approach, given its potential to alleviate emotional distress and promote 
improved well-being in a variety of populations (Young, 2011). A randomized, waitlist-
controlled pilot study of 4 month’s Mindfulness-Based Stress Reduction program showed a 
significant decrease of psychological distress and strengthening well-being in patients with 
RA (Pradhan, 2007).  
6.3 Tai chi 
It was also shown that Tai chi is beneficial in stress inhibition increasing daily activities in 
RA patients. Tai Chi is a traditional Chinese art which combines a multimodal, complex 
intervention that may include interaction of physical, cognitive, and ritualistic components 
(including, for example, elements of musculoskeletal efficiency, breathing, mindfulness, 
psychosocial interactions, rituals, and environment) (Wayne & Kaptchuk, 2008). Two 
randomised clinical trials (RCTs) and three non-randomized clinical trials about efficacy of 
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Tai chi in RA were published. The included RCTs reported some positive findings for Tai 
chi on disability index, quality of life, depression and mood for RA patients. Two RCTs 
assessed pain outcomes and did not demonstrate effectiveness on pain reduction compared 
with education plus stretching exercise and usual activity control. Currently there are few 
trials testing the effectiveness of Tai chi in the management of RA (Lee et al., 2007). It was 
demonstrated that Tai chi practice lead to improved lower-limb muscle function, confidence 
in moving, balance and less pain during exercise and in daily life, stress reduction, increased 
body awareness at the end of intervention and at 12 weeks follow-up in patients with RA 
(Uhlig et al., 2010). Furthermore, in one randomised controlled trial there was an ACR20 
(American College Rheumatology) response of 50 % in the Tai chi group compared with 0% 
in the control at 12 weeks (p = 0.03). Tai chi had greater improvements in the disability 
index (p = 0.01), vitality subscale of the Medical Outcome Study Short Form 36 (p = 0.01) 
and the depression index (p = 0.003). Similar trends to improvement were also observed for 
disease activity, functional capacity and health-related quality of life. It was concluded that 
Tai Chi appears safe and may be beneficial for functional class I or II RA (Wang, 2008). 
Despite certain limitations this exercise showed reduction of stress and improved quality of 
life and it can be recommended to patients with osteoarthritis and RA as a complementary 
and alternative medical approach (Wang, 2011). However, in the treatment of chronic 
conditions such as rheumatic diseases, particularly when it comes to complementary 
modalities such as tai chi, therapies are often used and studied in conjunction with other 
treatments. Although these heterogeneous interventions may better represent how care is 
delivered in real-world settings, they sometimes create problems when it comes to 
interpreting research findings (Yeh, 2008). Otherwise, the studies that are available are of 
low methodological quality. Taken together, evidence is not convincing enough to suggest 
that Tai chi is an effective treatment for RA. The value of Tai chi for this indication therefore 
remains unproven (Lee et al., 2007). 
6.4 Yoga 
Over the last 10 years, a growing number of research studies have shown that the practice of 
yoga can improve strength and flexibility, and may help control such physiological 
variables as blood pressure, respiration and heart rate, and metabolic rate to improve overall 
exercise capacity finally resulting in a benefit of yoga for people compromised by 
musculoskeletal disease (Raub, 2002). For example, it was demonstrated that 10-week yoga 
interventions in patients with RA significantly decreased the disability index, perception of 
pain and depression, and improved balance (Bosch et al., 2009). Another study of yoga 
showed improvements in mental health, vitality, and self-efficacy in a group of young 
patients with RA (age 18-36 years). Interviews demonstrated improvement in RA symptoms 
and functioning but uncertainty about whether the intervention affected pain (Ewans et al., 
2010). Otherwise, it was indicated that 12 sessions of Raj yoga carried out bi-weekly might 
improve significantly disease activity and disability index (Badsha et al., 2009). Furthermore, 
hand grip strength of both hands, measured with a grip dynamometer, increased in normal 
adults and children as well as in RA patients, but not in the corresponding control groups. 
Adult female volunteers and patients showed a greater improvement than corresponding 
adult males. This gender-based difference was not observed in children (Dash & Telles, 
2001). One pilot study of 8-week course of yoga in patients with osteoarthritis suggests that 
yoga may provide a feasible treatment option for previously yoga-naive, obese patients > 50 
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years of age and offers potential reductions in pain and disability.  Statistically significant 
reductions in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
Pain, WOMAC Physical Function, and Arthritis Impact Measurement Scales, patient and 
physician global assessments were demonstrated (Kolasinski et al., 2005). 
6.5 Acupuncture 
Acupuncture, which originated with traditional Chinese medicine, is another therapy option 
that reduces stress, relieves pain and promotes an increase in quality of life. Several 
systematic reviews have assessed the effectiveness of acupuncture for rheumatic conditions, 
often with contradictory conclusions. Relatively clear evidence emerged to suggest that 
acupuncture is effective for osteoarthritis, low back pain and lateral elbow pain to warrant 
positive recommendations of this therapy in routine care for such patients but being 
ineffective for RA (Ernst & Lee, 2010). In another systematic review it was shown that 
acupuncture with duration of 11 weeks results in a decrease in pain compared to controls; 
the mean or median changes of acupuncture-decreased tenderness of joints ranged from 1.5 
to 6.5. In addition, a significant reduction of morning stiffness (mean change - 29 minutes) 
was noted, but the difference was not statistically significant versus controls. With regard to 
inflammatory markers, a reduction in erythrocyte sedimentation ratio (mean change - 3.9 
mm/hour) and a CRP level reduction (mean change - 2.9 mg/dl) was observed. Despite 
some favourable results in active-controlled trials, conflicting evidence exists in placebo-
controlled trials concerning the efficacy of acupuncture for RA (Wang et al., 2008). 
Regarding anaesthesia, supportive acupuncture treatment is performed for postoperative 
pain based on promising results of rigorous randomised trials. Many unresolved questions 
remain, such as regarding specificity of concepts, indications, and optimum dose (Stör & 
Irnich, 2009). 
Individuals who are at risk to develop an autoimmune disease should be advised to refrain 
from lifestyle and activities that endanger their future health and quality of life. Different 
stress reactions should be discussed with patients, and obligatory questionnaires about 
trigger factors should include psychological stress in addition the usual suspects such as 
infection and trauma (Stojanovich et al., 2008). Stress reduction interventions can have a 
positive therapeutic effect in autoimmune disease patients leading to a reduction in the 
social and economic impact of rheumatic diseases. An appropriate management of these 
conditions should be encouraged based on the use of established intervention strategies. 
Physicians and patients should recognize the potential of stress to impact autoimmune 
diseases and that stress management should be integrated in a multidimensional treatment 
approach (McCray & Agarwal, 2011). 
7. Conclusion 
Rheumatic diseases are chronic inflammatory disorders of unknown aetiology and variable 
severity. It is now well known that several risk factors are contributing to aetiology and 
pathophysiology of rheumatic diseases, including genetic factors, sex hormones and 
environmental factors, e.g. infections and stress. An increasing number of studies could 
demonstrate that psychological stress and stress-related hormones are involved in immune 
modulation, which ultimately may result in autoimmune disease. Stress related hormones 
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Tai chi in RA were published. The included RCTs reported some positive findings for Tai 
chi on disability index, quality of life, depression and mood for RA patients. Two RCTs 
assessed pain outcomes and did not demonstrate effectiveness on pain reduction compared 
with education plus stretching exercise and usual activity control. Currently there are few 
trials testing the effectiveness of Tai chi in the management of RA (Lee et al., 2007). It was 
demonstrated that Tai chi practice lead to improved lower-limb muscle function, confidence 
in moving, balance and less pain during exercise and in daily life, stress reduction, increased 
body awareness at the end of intervention and at 12 weeks follow-up in patients with RA 
(Uhlig et al., 2010). Furthermore, in one randomised controlled trial there was an ACR20 
(American College Rheumatology) response of 50 % in the Tai chi group compared with 0% 
in the control at 12 weeks (p = 0.03). Tai chi had greater improvements in the disability 
index (p = 0.01), vitality subscale of the Medical Outcome Study Short Form 36 (p = 0.01) 
and the depression index (p = 0.003). Similar trends to improvement were also observed for 
disease activity, functional capacity and health-related quality of life. It was concluded that 
Tai Chi appears safe and may be beneficial for functional class I or II RA (Wang, 2008). 
Despite certain limitations this exercise showed reduction of stress and improved quality of 
life and it can be recommended to patients with osteoarthritis and RA as a complementary 
and alternative medical approach (Wang, 2011). However, in the treatment of chronic 
conditions such as rheumatic diseases, particularly when it comes to complementary 
modalities such as tai chi, therapies are often used and studied in conjunction with other 
treatments. Although these heterogeneous interventions may better represent how care is 
delivered in real-world settings, they sometimes create problems when it comes to 
interpreting research findings (Yeh, 2008). Otherwise, the studies that are available are of 
low methodological quality. Taken together, evidence is not convincing enough to suggest 
that Tai chi is an effective treatment for RA. The value of Tai chi for this indication therefore 
remains unproven (Lee et al., 2007). 
6.4 Yoga 
Over the last 10 years, a growing number of research studies have shown that the practice of 
yoga can improve strength and flexibility, and may help control such physiological 
variables as blood pressure, respiration and heart rate, and metabolic rate to improve overall 
exercise capacity finally resulting in a benefit of yoga for people compromised by 
musculoskeletal disease (Raub, 2002). For example, it was demonstrated that 10-week yoga 
interventions in patients with RA significantly decreased the disability index, perception of 
pain and depression, and improved balance (Bosch et al., 2009). Another study of yoga 
showed improvements in mental health, vitality, and self-efficacy in a group of young 
patients with RA (age 18-36 years). Interviews demonstrated improvement in RA symptoms 
and functioning but uncertainty about whether the intervention affected pain (Ewans et al., 
2010). Otherwise, it was indicated that 12 sessions of Raj yoga carried out bi-weekly might 
improve significantly disease activity and disability index (Badsha et al., 2009). Furthermore, 
hand grip strength of both hands, measured with a grip dynamometer, increased in normal 
adults and children as well as in RA patients, but not in the corresponding control groups. 
Adult female volunteers and patients showed a greater improvement than corresponding 
adult males. This gender-based difference was not observed in children (Dash & Telles, 
2001). One pilot study of 8-week course of yoga in patients with osteoarthritis suggests that 
yoga may provide a feasible treatment option for previously yoga-naive, obese patients > 50 
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years of age and offers potential reductions in pain and disability.  Statistically significant 
reductions in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
Pain, WOMAC Physical Function, and Arthritis Impact Measurement Scales, patient and 
physician global assessments were demonstrated (Kolasinski et al., 2005). 
6.5 Acupuncture 
Acupuncture, which originated with traditional Chinese medicine, is another therapy option 
that reduces stress, relieves pain and promotes an increase in quality of life. Several 
systematic reviews have assessed the effectiveness of acupuncture for rheumatic conditions, 
often with contradictory conclusions. Relatively clear evidence emerged to suggest that 
acupuncture is effective for osteoarthritis, low back pain and lateral elbow pain to warrant 
positive recommendations of this therapy in routine care for such patients but being 
ineffective for RA (Ernst & Lee, 2010). In another systematic review it was shown that 
acupuncture with duration of 11 weeks results in a decrease in pain compared to controls; 
the mean or median changes of acupuncture-decreased tenderness of joints ranged from 1.5 
to 6.5. In addition, a significant reduction of morning stiffness (mean change - 29 minutes) 
was noted, but the difference was not statistically significant versus controls. With regard to 
inflammatory markers, a reduction in erythrocyte sedimentation ratio (mean change - 3.9 
mm/hour) and a CRP level reduction (mean change - 2.9 mg/dl) was observed. Despite 
some favourable results in active-controlled trials, conflicting evidence exists in placebo-
controlled trials concerning the efficacy of acupuncture for RA (Wang et al., 2008). 
Regarding anaesthesia, supportive acupuncture treatment is performed for postoperative 
pain based on promising results of rigorous randomised trials. Many unresolved questions 
remain, such as regarding specificity of concepts, indications, and optimum dose (Stör & 
Irnich, 2009). 
Individuals who are at risk to develop an autoimmune disease should be advised to refrain 
from lifestyle and activities that endanger their future health and quality of life. Different 
stress reactions should be discussed with patients, and obligatory questionnaires about 
trigger factors should include psychological stress in addition the usual suspects such as 
infection and trauma (Stojanovich et al., 2008). Stress reduction interventions can have a 
positive therapeutic effect in autoimmune disease patients leading to a reduction in the 
social and economic impact of rheumatic diseases. An appropriate management of these 
conditions should be encouraged based on the use of established intervention strategies. 
Physicians and patients should recognize the potential of stress to impact autoimmune 
diseases and that stress management should be integrated in a multidimensional treatment 
approach (McCray & Agarwal, 2011). 
7. Conclusion 
Rheumatic diseases are chronic inflammatory disorders of unknown aetiology and variable 
severity. It is now well known that several risk factors are contributing to aetiology and 
pathophysiology of rheumatic diseases, including genetic factors, sex hormones and 
environmental factors, e.g. infections and stress. An increasing number of studies could 
demonstrate that psychological stress and stress-related hormones are involved in immune 
modulation, which ultimately may result in autoimmune disease. Stress related hormones 
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exert numerous effects on various immune functions, e.g. chronic mild stress (family or 
occupational stress) lead to proinflammatory effects thereby increasing disease activity. 
Emotional stress could be shown to modulate pain reception and to modify quality of life in 
patients with rheumatic diseases. Furthermore, a positive correlation between stress levels 
and the onset of rheumatic diseases could be demonstrated. Unfortunately, not only stress 
causes disease, but the disease itself also causes significant stress in the patients disturbing 
the physiological stress response. In this respect, it could be demonstrated that coping 
strategies reduce stress episodes with a positive impact on disease activity in patients with 
rheumatic diseases. However, more studies are warranted to further explore the 
pathophysiological implications of stress on onset and activity of chronic autoimmune 
diseases. In particular stress is now recognised as an important risk factor for the onset and 
even more for the modulation of disease activity in different rheumatic diseases. 
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1. Introduction 
Pain is defined as “an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage or described in terms of such a damage” (Merskey et al., 1986). It 
is a pivotal and the most impairing symptom in rheumatic diseases (Edwards et al., 2009; 
Fitzcharles et al., 2005; Sokka, 2003). Most patients consulting a rheumatologist suffer pain 
(Fitzcharles et al., 2005). Chronic pain influences physical and psychological status and 
causes impairment of quality of life as well as work disability (Dhanani et al., 2002; Kroenke 
et al., 2009; Skevington, 1998). For rheumatologists the assessment and treatment of pain is 
an integral part of daily patient care. Although remission of rheumatic diseases can be 
achieved with therapy with disease-modifying anti-rheumatic drugs (DMARDs) or 
biological pain can be still a troubling symptom. Pain is influenced by multiple factors such 
as genetics, experience, cultural and social background and psychological conditions (Gerez-
Simon et al., 1989; Martinez et al., 1995; Mogil, 1999). Comorbid depression is associated 
with inflammation and worsens experience of pain (Kojima et al., 2009). Pain perception 
enhances the elevation of pro-inflammatory cytokines and activates a cascade of 
neurohumoral processes which can be dysregulated in patients with rheumatic diseases 
(Bingham et al., 2009; Edwards et al., 2009; Fitzcharles et al., 2005).  
2. Types of pain and pathophysiology of pain in rheumatic diseases 
Pain perception and the development of chronic pain is a complex process of neural 
integration implying response of peripheral tissue damage and transduction of information 
in peripheral and central nervous system (Bingham et al., 2009). Adequate pain 
management requires subtile differentiation of rheumatic pain. Pain can be divided into 
various classifications depending on anatomical origin in the musculoskeletal system or 
special aspects in pathophysiology. Articular pain is distinguished from extra-articular pain 
which can be subdivided into muscular/musculotendinous or neurogenic pain. Muscular 
pain is caused by muscle stress due to protective posture, impaired joint-function or 
malposition, myositis or cortisone-induced myopathy. Neurogenic compression syndromes 
or entrapement syndromes induce neurogenic pain (Engel, 2008). Figure 1 demonstrates 
differentiation of rheumatic diseases depending on pain localization and systemic 
inflammatory response. Tissue damage and chronic inflammation is not solely responsible 
for pain perception in rheumatic diseases. Chronic rheumatic pain can also be categorized 
into nociceptive/inflammatory, peripheral neuropathic and central neuropathic/functional 
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pain (Goldenberg, 2010; Goldenberg et al., 2011; Winfield, 2008). Due to complex 
pathophysiology rheumatic pain is often of mixed type and the concept of central 
neuropathic pain is currently the focus of research, in particular in chronic pain syndromes 
like fibromyalgia and chronic low back pain. Classical nociceptive pain pathway/sensation 
starts with depolarization of A and C fibers acting as primary afferent neurons (Bingham et 
al., 2009). Tissue damage as occurring in systemic inflammatory or degenerative rheumatic 
diseases as well as localized tenosynovitis, bursitis or arthritis can induce firing of 
peripheral neurons (Winfield, 2008). Nociceptors activate ascending dorsal horn neurons 
(lateral and medial spinothalamic tract) which transfer the signal to brainstem and thalamus 
thereby projecting to the somatosensory cortex, hypothalamus and limbic system (Bingham 
et al., 2009; Goldenberg, 2010; Schaible et al., 2006). Afferent sensory neurons induce the 
release of neurotransmitters such as glutamate, substance P and -aminobutyric acid (GABA) 
in the dorsal horn influencing pain transmission (Bingham et al., 2009; Fitzcharles et al., 2005; 
Goldenberg, 2010). Interneurons and descending spinal pathways like periaqueductal gray, 
serotonergic as well as noradrenergic systems modulate the pain pathway. Cannabinoid 
receptors and opioid receptors have inhibitory effects (Bingham et al., 2009). Despite dense 
sensory and sympathetic innervation of joint capsules, ligaments, menisci, periosteum, 
synovial blood vessels and subchondral bone normal joints are not innervated (Fitzcharles et 
al., 2005). In inflammation primary afferent neurons are sensitized and silent nociceptors 
start firing (Bingham et al., 2009; Fitzcharles et al., 2005; Schaible et al., 2006). Their 
activation threshold decreases and they are activated even by gentle and nonpainful stimuli. 
This process is called peripheral sensitization (Bingham et al., 2009; Edwards et al., 2009; 
Fitzcharles et al., 2005). Inflammatory molecules such as prostanoids, TNF, chemokines, 
kinins and growth factors are produced in damaged tissue and stimulate primary afferent 
neurons (Bingham et al., 2009; Fitzcharles et al., 2005). Vice versa activated peripheral 
neurons release inflammatory mediators. This neurogenic inflammation maintains a 
“vicious circle” of persistent activation of nociceptive and immune system causing chronic 
rheumatic pain (Goldenberg et al., 2011). TNF has neurostimulatory properties by inducing 
upregulation of expression of substance P in the central nervous system (Grassi et al. 1994; 
Tonussi & Ferreira, 1999). Persistent activation of nociceptors and increasing production of 
neurotransmitters and prostanoids results in central sensitization especially in sensory 
neurons of the dorsal horn (Bingham et al., 2009; Fitzcharles et al., 2005; Goldenberg, 2010; 
Schaible et al., 2006). Sustained local inflammation induces peripheral and central 
sensitization as well as pathological nerve growth with innervation of cartilage contributing 
to development of chronic pain in rheumatic diseases (Kidd & Urban, 2001; Niissalo, 2002). 
Furthermore tissue damage or entrapment can affect nociceptors and peripheral 
neuropathic pain can develop (Bingham et al., 2009; Goldenberg, 2010; Schaible et al., 2006). 
Patients complain of electrical sensations, burning pain, coldness, numbness or itching. In 
rheumatoid arthritis chronic inflammation denervates the synovium and may cause 
neuropathic pain or sensations of joint swelling (Bingham et al., 2009). Central neuropathic 
pain former known as functional pain is characterized by chronic widespread pain in 
different regions of the body as observed in fibromyalgia. Usually no structural 
abnormalities can be identified. This type of pain is often accompanied by symptoms like 
fatigue, depression, sleep disturbance and memory difficulties. Dysfunction in central 
nervous system and imbalance of neurotransmitters like norepinephrine, γ-aminobutyric 
 





Fig. 1. Types of pain (Engel, 2008) 
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acid (GABA), serotonin, glutamate, and substance P can cause augmented central pain 
processing (Goldenberg et al., 2011). Functional neuroimaging studies could reveal that 
patients with central pain exhibit increased activity in brain regions involved in pain 
processing compared to healthy individuals (reviewed in Goldenberg et al., 2011). The 
stress-induced increase of cytokines like TNF could account for higher pain levels in 
patients with depression and anxiety (Dickens, 2002). Genetic and environmental factors like 
early life trauma, physical trauma, infections or emotional stress can contribute to the 
development of central neuropathic pain (Goldenberg et al., 2011). Central neuropathic pain 
is not only observed in patients with chronic pain syndromes like fibromyalgia but also seen 
in patients with osteoarthritis and rheumatoid arthritis (Hochman et al., 2010; Wendler et 
al., 2001). Patients with ankylosing spondylitis, psoriatic arthritis or osteoarthritis have a 
higher pain threshold compared with those of rheumatoid arthritis underlining the concept 
of sustained inflammation and pain perception in rheumatoid arthritis (Buskila et al., 1992; 
Gerecz-Simon et al., 1989). Allodynia or hyperalgesia are common sensations in patients 
with rheumatic diseases. Hypersensitivity to stimuli like gentle touching which are usually 
nonpainful is called allodynia. Hyperalgesia is defined as increased pain sensation due to 
lower pain threshold. The underlying pathophysiological factors are proposed to be changes 
in central pain processing and enhanced reactivity of immune mediators as seen in central 
and peripheral sensitization (Engel, 2008; Goldenberg et al., 2011; Winfield, 2008). Pain 
perception differs between rheumatic diseases and between individuals suffering from 
equal diseases making it difficult and challenging to distinguish the types of pain and to 
treat patients properly. The current concept of chronic rheumatic pain implies a complex, 
multifactorial pathophysiological model with nociceptive and neuropathic pain components 
called “mixed pain”. 
3. Pain assessment 
Assessment of pain is required before the initiation of treatment to record efficacy of 
therapy (Fitzcharles et al., 2005; Sokka, 2003; Wendler, 2010). The patient`s pain report is 
subjective and depends on emotion, cognition and behavior (Fitzcharles et al., 2005; 
Kojima et al., 2009; Sokka, 2003). Self-reporting questionnaires provide qualitative and 
quantitative assessment of pain and are validated for research purposes as well as for 
documentation of disease activity and effectiveness of therapy (Sokka, 2003). Pain 
assessment should be integrated in daily practice of rheumatologists during interview and 
examination and includes verbal and nonverbal communication such as movements and 
facial expression of the patients. Verbal rating scales, numeric rating scales, visual 
analogue scales or pictogram analogue scales have become widely used in clinical care 
(Sokka, 2003; Wendler, 2010). The pain visual analogue scale (VAS) is a reliable method 
for assessing the intensity of pain (Jensen et al., 1998; Sokka, 2003; Wendler, 2010). It is 
integrated in The Health Assessment Questionnaire (HAQ), a valid instrument for the 
measurement of functional disability, pain and global status (Fitzcharles et al., 2005; 
Sokka, 2003). The 10 cm scale is bordered on each side. The spectrum of pain ranges 
across a continuum from 0 (no pain) to 10 (very severe pain). In the numeric rating scale 
numbers describe the pain severity, therefore results are comparable for follow up. Figure 
2 shows the visual analogue and the numeric rating scale. 
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When analyzing pain scores physicians should take into account various rheumatic diseases. 
In rheumatoid arthritis pain scores correlate with radiographic and laboratory results 
whereas fibromyalgia patients suffer severe pain in the absence of structural damage 
(Sokka, 2003). The first consultation of patients with pain should include a detailed 
interview and neurological and musculoskeletal examination of the patient (American 
Society of Anesthesiologists, 2010; Fitzcharles et al., 2005). A general medical history and 
history about the onset, quality, intensity, distribution and duration of pain, ameliorating 
and aggravating factors, symptoms, social and psychological impacts as well as previous 
therapies should be evaluated (American Society of Anesthesiologists, 2010). Body schemes, 
e.g. in the McGill pain questionnaire, facilitate the assessment of patients with chronic 
rheumatic diseases suffering from pain in various parts of the body (Wendler, 2010). Pain 
diaries can activate patients to document pain character and its influence in motion and 
function as well as to recognize effectiveness of treatment (Wendler, 2010).  
4. Pain therapy in rheumatic diseases 
Once the rheumatologist has assessed the patient`s pain an adequate therapy has to be 
initiated. Optimal pain management should encompass multimodal interventions with 
pharmacological and non-pharmacological treatment strategies (American Society of 
Anesthesiologists, 2010; Fitzcharles et al., 2005). Non-pharmacological procedures include 
education, psychological care, physical and/or occupational therapy as well as joint 
protection and/or surgery. 
4.1 Non-pharmacological pain treatment 
Education has a tremendous effect on sufficient pain control in patients with rheumatic 
diseases. Information about the disease and therapeutic options can reduce the fear of long 
term consequences, such as loss of function, joint damage, chronic pain, and implications on 
social and family life. Self-management strategies provide patients with a wide range of 
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possibilities to influence their course of the disease. Exercise, joint protection techniques and 
appropriate use of pharmacological pain therapy encourage patients to cooperate with their 
attending physician (Goldenberg et al., 2011). 
For sufficient pain control the psychological status of the patient has to be evaluated (Kojima 
et al., 2009). Depression can worsen the perceived pain. Therefore rheumatoid arthritis 
patients describing severe pain without active disease could benefit from psychological 
therapy (Kojima et al., 2009). Additional cognitive behavioral therapy, biofeedback, 
relaxation training and self-care education can improve the patient`s well-being (American 
Society of Anesthesiologists, 2010; Kimura & Walco, 2007).  
Patients with rheumatic diseases are often physically inactive. Physiotherapy and exercise 
programs support mental and physical health (Kimura & Walco, 2007; Roddy et al., 2005). 
Patients with rheumatic diseases should always be encouraged to get exercise. Due to 
chronic pain they often feel weak and fatigue causes impaired activity. On the one hand 
patients fear exacerbation of musculoskeletal pain when moving. Consequently avoidance 
of exercise deteriorates muscle strength and physical condition. On the other hand excessive 
exercise aggravates fatigue and flares can occur. Mild exercise like walking, water aerobics, 
and bicycling, being appropriate for age and condition, can support physical fitness and 
comfort (Winfield, 2008). Physical therapy with heat or cold can reinforce therapeutic 
effects. In particular in nociceptive pain application of moderate heat (e.g. paraffin, packs, 
hydrotherapy) can improve pain control. In generalized pain syndromes sauna, baths, 
showers or hot mud can be effective. Cold therapy (e.g. packs, sprays or immersion) is 
recommended in acute pain states as seen in flares of rheumatic diseases (Winfield, 2008). 
Transcutaneous electrical nerve stimulation (TENS) is an independent option of physical 
therapy at home. 
Synovectomy and arthroplasty are therapeutic options in patients with continuous pain, 
joint deformity and functional loss (Kimura & Walco, 2007). The role of complementary 
therapies in pain management needs to be further examined (Fitzcharles et al., 2005). For 
optimal pain management a combination of different medications is often necessary. 
Rheumatologists have to prove efficacy of therapy and compliance of the patient. 
Discontinuation of treatment is required if side effects occur or if the therapy is ineffective.  
4.2 Pharmacological pain treatment 
Intra-articular injections, topical applications, selective and non-selective non-steroidal anti-
rheumatic drugs (NSAIDs), opioids as well as adjuvant drugs are therapeutic options for 
pain control. DMARDs like methotrexate, sulfasalazine, leflunomide and biologicals are 
prescribed to reduce disease activity and to maintain remission. Reduced disease activity is 
associated with improved functional status and reduced pain (Kimura & Walco, 2007). 
However, pain remains to be a leading symptom in patients with rheumatic diseases. Due to 
serious side effects of long-term application high dose corticosteroids should only be 
prescribed in severe, life-threatening disease. Intra-articular injections can help to reduce 
localized joint inflammation and pain (Kimura & Walco, 2007). The number of injections is 
limited to three per year (Bernau & Heeg, 2003). Avoidance of systemic side effects is an 
advantage of topical analgesics such as capsaicin or topical NSAIDs like diclofenac, 
ibuprofen, ketoprofen, and piroxicam. Although plasma concentration is low after 
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absorption local application can reduce mild to moderate pain in arthritis (Kroenke et al., 
2009; Mason et al., 2004).  
4.2.1 Non-selective and selective cyclooxygenase inhibitors 
Non-selective and selective cyclooxygenase inhibitors (coxibs) are potent analgesics with anti-
phlogistic properties and are successfully used in the treatment of degenerative and 
inflammatory joint diseases (Schaible et al., 2006; Unger & Baerwald, 2010). Table 1 shows the 
most common selective and non-selective COX-inhibitors. Application of NSAID results in 
inhibition of prostaglandin synthesis which sensitizes nociceptors in inflamed joints and 
thereby causing pain in arthritis (Schaible et al., 2006; Unger & Baerwald, 2010). Furthermore 
central sensitization is followed by prostaglandin E2 (PGE2) release in the dorsal horns of the 
spinal cord (Bingham et al., 2009; Fitzcharles et al., 2005). However, gastrointestinal, renal, 
cardiovascular side effects and hepato-toxicity as well as platelet inhibition restrict their 
application (Kimura & Walco, 2007; Kroenke et al., 2009; Unger & Baerwald, 2010). Studies 
show that coxibs and traditional NSAIDs do not significantly differ in their cardiovascular side 
effects (reviewed in Luttosch & Baerwald, 2011; Unger & Baerwald, 2010). Therefore these 
agents should be administered in a low dose and for a short term only. Naproxen, paracetamol 
or opioids seem to be an option for pain control in patients with cardiovascular risk factors 
and should be preferred in these groups (Kroenke et al., 2009; Luttosch & Baerwald, 2011; 
Unger & Baerwald, 2010). Coxibs should be preferred in patients with risk of gastrointestinal 
complications due to their lower risk of developing a serious adverse event compared to non-
selective cyclooxygenase-inhibitors (Unger & Baerwald, 2010). In persons 60 years or older, in 
those with gastrointestinal symptoms and in patients taking corticosteroids or antiplatelet 
agents a proton pump inhibitor should be coadministered with traditional NSAIDs, or a coxib 
should be prescribed (Kroenke et al., 2009). 
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Name Half-time Dose (mg) Peculiarity Contraindications 




Indometacin 2-3 h 50 1-3/day short term 
administration 
allergic reactions 
Acemetacin 4 h 30 1-3/day  





Phenylbutazon 70 h 200 1-2/day SLE, pyrazol-allergy, 
thyroid gland 
dysfunction is a 
contraindication 




Ibuprofen 2-3 h max. 800-
1200/day 
no combination with 
ASS 
ASS-acetylsalicyl acid, COX-cyclooxygenase, crea-clear.-creatinine-clearance, GI-gastrointestinal, OA-
osteoarthritis, RA-rheumatoid arthritis, SLE-systemic lupus erythematodes, SpA-ankylosing spondylitis 
Table 1. Characteristics of typical NSAIDs and coxibs (Unger & Baerwald, 2010) 
4.2.2 Opioid therapy 
If NSAIDs are insufficient or contraindications and interfering side effects, respectively, 
exist opioids can be considered for effective pain control (Pierer et al., 2010). However, 
side effects and potential addiction have previously restricted their use in pain therapy. 
Therefore opioid therapy should only be prescribed within a multimodal pain control 
concept in advanced inflammatory or degenerative disease if other analgesics are 
ineffective (Pierer et al., 2010; Siegel et al., 2008). Long term, controlled and randomized 
studies concerning opioid use in rheumatic diseases are lacking. In clinical practice a 
positive effect on sleep and musculoskeletal function especially in neuropathic pain, 
rheumatoid arthritis, osteoarthritis and low back pain can be observed (Pierer et al., 2010; 
Siegel et al., 2008). Opioids bind to opioid receptors found in the central and peripheral 
nervous system (Kimura & Walco, 2007, Lang et al., 2010; Siegel et al., 2008). Studies 
confirm that opioids show mild anti-inflammatory effects (reviewed in Kimura & Walco 
2007). Endogenous opioid peptides are released in inflamed regions and bind to 
upregulated peripheral opioid receptors thereby controlling intrinsic pain pathways 
(Lang et al., 2010). Tramadol is a weak opioid beneficial especially in osteoarthritis, low 
back pain and fibromyalgia (Fitzcharles et al., 2005; Goldenberg et al., 2011; Kroenke et al., 
2009). Nausea, vomiting, constipation, dizziness, somnolence, cognitive impairment, 
urinary retention and respiratory depression are major undesirable adverse effects 
(American Society of Anesthesiologists, 2010; Lang et al., 2010; Winfield, 2008). Therefore 
long term therapy is not recommended. In chronic nonmalignant pain only mild pain 
reduction is observed whereas functional outcome (unemployment, necessity of health 
care) is declining (Siegel et al., 2008). Pain intensity, vital parameters, musculoskeletal 
function, possible addiction and side effects have to be controlled regularly (Pierer et al., 
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2010; Winfield, 2008). Upon initiation of opioids the dosage has to be titrated within the 
first two to three weeks (Winfield, 2008). After six weeks a significant pain reduction 
should be documented (Pierer et al., 2010). If optimal pain relief is not occurring opioid 
rotation should be considered (Kroenke et al., 2009). Exacerbation of pain should always 
be evaluated and the causes should be detected prior to increasing the dosage. If effective 
pain control does not occur after three months opioid therapy should be stopped. To 
avoid withdrawal symptoms a daily reduction of 10 % is strongly recommended (Pierer et 
al., 2010). Opioids should not be administered in patients with a history of or current 
substance use disorders (Kroenke et al., 2009). In older patients or patients with renal or 
liver function impairment the dose has to be reduced 25 % to 50 % (Kroenke et al., 2009; 
Winfield, 2008). Opioids should be administered with caution in older patients due to 
high risk of falls leading to fractures. There are insufficient data about the effect of long 
term therapy with opioids (Pierer et al., 2010). The WHO Three-Step Model for Pain 
Management provides an international accepted approach for effective pharmacological 
pain therapy and is demonstrated in Figure 3. The starting therapy step depends on the 
severity of pain. If the first treatment is insufficient the following step of the model should 
be initiated. Adjuvant drugs including antidepressants and anticonvulsants can be 
combined with the medications of the Three-Step Model.  
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Winfield, 2008). Opioids should be administered with caution in older patients due to 
high risk of falls leading to fractures. There are insufficient data about the effect of long 
term therapy with opioids (Pierer et al., 2010). The WHO Three-Step Model for Pain 
Management provides an international accepted approach for effective pharmacological 
pain therapy and is demonstrated in Figure 3. The starting therapy step depends on the 
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4.2.3 Adjuvant drugs 
Tricyclic antidepressants like amitriptyline are the most commonly used adjuvant 
medications to treat patients with rheumatoid arthritis or ankylosing spondylitis 
(Fitzcharles et al., 2005). Adjuvant drugs play a major role in management of fibromyalgia 
and seem to be the most effective medications in this condition (Godfrey, 1996). Sleep, mood 
and fatigue are positively influenced. The anticonvulsants gabapentin and pregabalin 
provide pain relief especially in neuropathic pain (American Society of Anesthesiologists, 
2010; Kimura & Walco, 2007; Kroenke et al., 2009). They have neuromodulatory properties 
due to binding to calcium-channels in the central nervous system and inhibiting the release 
of neurotransmitters (American Society of Anesthesiologists, 2010; Kroenke et al., 2009). 
Cardiovascular side effects as well as somnolence or sedation can limit therapeutic 
application (American Society of Anesthesiologists, 2010; Kroenke et al., 2009). 
Antidepressants should be used with caution in older patients due to anticholinergic 
properties and the high risk of falls (Kroenke et al., 2009). Duloxetine and milnacipran 
interact with the serotonin and norepinephrine systems. Positive effects on pain und 
function could be demonstrated especially in fibromyalgia (Goldenberg et al., 2011). Figure 
4 shows a stepwise summary of pharmacological and non-pharmacological pain control in 
rheumatic diseases.  
 
Fig. 4. Pain therapy in rheumatic diseases (Winfield, 2008) 
4.2.4 Development of new medication 
Pharmacological pain management is restricted due to significant side effects or 
contraindications of NSAIDs and opioids. Development of new medication is in the focus of 
current research. Tapentadol hydrochloride is a µ-opioid-receptor agonist and 
norepinephrine reuptake inhibitor for the treatment of moderate and severe pain exhibiting 
less gastrointestinal side effects compared to traditional opioids and is effective in 
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neuropathic and/or inflammatory pain (Wade & Spruill, 2009). Cardiovascular and 
gastrointestinal side effects limit pain control with NSAIDs. Naproxcinod is a new 
developed COX inhibiting nitric oxide donator (CINOD) which shows an improved safety 
profile due to release of nitric oxide (NO) (Wallace et al., 2009). NO acts in the vasculature 
inducing positive effects on blood pressure and mucosal integrity in the gastrointestinal 
tract (Wallace et al., 2009). Further studies are needed to evaluate the role of dopaminergic 
agents, N-methyl-D-aspartate (NMDA) receptor antagonists,-aminobutyric acid (GABA) 
agonists, and 5-hydroxytryptamine 3 receptor antagonist in complex pain syndromes with 
central pain components (Goldenberg et al., 2011). 
5. Conclusion 
Pain is a cardinal symptom in patients with rheumatic disease. It impacts functioning, 
quality of life and causes disability. The pain is frequently multifactorial in origin and has 
both central and peripheral components. Disease activity is only marginally related to the 
extent of pain severity, and pain-related presentation can differ widely between individuals. 
Cognitions and emotions contribute to different perception of pain. Although remission of 
rheumatic diseases can be achieved with use of oral DMARDs or biological therapies, 
treatment of pain can be a challenge in every day practice. Assessment of pain is pivotal for 
monitoring therapy response and must take into account various factors. Non-
pharmacologic interventions, such as exercise and cognitive-behavioral therapy as well as 
the use of analgesics such as cyclooxygenase inhibitors or opioids should aim to achieve at 
better quality of life for patients with rheumatic diseases and should help to maintain 
function. 
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1. Introduction 
1.1 Transition of care 
Chronic rheumatic diseases in childhood are an important group of chronic conditions with 
often severe morbidity and carrying a major impact on growth and development for the 
affected individual. It is estimated that 30-70% of the patients have continuing disease 
activity or persisting limitations in functional ability or psychosocial function in their adult 
life (1-4).  
In most countries infants and children with rheumatic diseases are treated by specialist 
pediatric rheumatologists, nurses and physiotherapists. When such children with chronic 
diseases reach adulthood (usually between the age of 16 -24), transition to adult health care 
is needed. This transitional face coincides with the period in which adolescence, or puberty, 
takes place. Blum and colleagues coined a very useful definition for transition (5). They 
described transition as ‘the purposeful, planned movement of adolescents and young adults 
with chronic physical and medical conditions from child-centered to adult-oriented health 
care systems’  
The transfer to adult health service requires specific skills and knowledge from the health 
care providers. When ignored this may result in poor health indicators and loss to follow-up 
for adolescents with a chronic disease. Basically one needs to recognize that children with 
severe chronic diseases transgress into a two faced transition to become an adolescent with a 
chronic rheumatic condition that receives care from a team expert in both pediatric and 
adult rheumatology. Nowadays, it is generally believed that a multidimensional transition 
of care is needed (6;7).   
In the US a general statement was made by pediatricians and primary health care that 
transition leading to the transfer of care is one of six primary goals for youth with special 
healthcare needs {25} 
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diseases reach adulthood (usually between the age of 16 -24), transition to adult health care 
is needed. This transitional face coincides with the period in which adolescence, or puberty, 
takes place. Blum and colleagues coined a very useful definition for transition (5). They 
described transition as ‘the purposeful, planned movement of adolescents and young adults 
with chronic physical and medical conditions from child-centered to adult-oriented health 
care systems’  
The transfer to adult health service requires specific skills and knowledge from the health 
care providers. When ignored this may result in poor health indicators and loss to follow-up 
for adolescents with a chronic disease. Basically one needs to recognize that children with 
severe chronic diseases transgress into a two faced transition to become an adolescent with a 
chronic rheumatic condition that receives care from a team expert in both pediatric and 
adult rheumatology. Nowadays, it is generally believed that a multidimensional transition 
of care is needed (6;7).   
In the US a general statement was made by pediatricians and primary health care that 
transition leading to the transfer of care is one of six primary goals for youth with special 
healthcare needs {25} 
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Apart from these issues, other questions to be discussed in this chapter are: 
 What is the right time for this transfer of care and who plays a role in this process? 
 Which aspects of adolescence play a role in the transfer and transition of care? 
 What special preparations are needed for this transfer? 
 What does an ideal transition of care system look like? 
Most published descriptions of the organization of transition of care for rheumatic diseases 
refer specifically to Juvenile Idiopathic Arthritis (JIA). Therefore this chapter will also focus 
on JIA. For the other rheumatic diseases the JIA centered transition programme may serve 
usefull. However in such cases (for instance SLE, juvenile dermatomyositis, 
autoinflammatory syndromes) the team also needs to include renal and dermatological 
expertise.  
2. Factors influencing the transfer from pediatric to adult care 
2.1 Differences in culture of medical treatment and care in pediatrics and adult 
medicine 
In pediatric medicine, health care should not be limited to the patient’s disease. Other 
aspects of physical development should be taken into account such as growth and puberty. 
Education and social behavior in the presence of a chronic disease are equally important 
issues, not only for social development, but also for future opportunities in finding 
employment. Sport and exercise are important for maintaining social contacts as well as 
mental and physical health. Furthermore, parents and siblings are also involved in the 
disease process of the diseased child. Limitations caused by the disease may have an effect 
on the social life of the whole family.  
In adult medicine much attention is given to the rheumatic disease itself, the disease activity 
and side effects of medications. The impact of the disease on work, family and social life is 
less important and is hardly discussed by the medical doctor. When supporting staff like 
nurse practitioners, social workers or physiotherapists are available, these factors are taken 
into account, which certainly play an important part on issues such as staying in 
employment, self efficacy, compliance etc. The care for the patient is often structured in a 
supply-oriented fashion and can be divided into the available separate disciplines. (8;9).  If 
transition programmes are fully patient-oriented they will offer a merge of paediatric and 
adult care. 
 
Pediatric care Adult Care  
Family-focused (parents strongly 
involved) 
Patient-focused 
Generalist, interdisciplinary Multidisciplinairy 
Socially orientated Disease orientated 
Informal atmosphere, relaxed Formal atmosphere, to the point 
Attention for development, school and 
social functioning 
Accent on treatment, self-management and 
compliance 
Table 1. Differences in pediatric and adult care (8;9)  
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2.2 Who is involved in the transition process?   
First and foremost of course, is the adolescent suffering from the chronic (rheumatic) 
disease, the patient who is transferred to adult care.  
Secondly, the paediatric specialist, the person who is responsible for  handing over a 
complete medical file of the patient. The paediatric specialist is usually assisted by allied 
health professionals such as specialised physical therapists, psychologists and social 
workers. In addition, the paediatric services together with the adult services are involved in 
preparing the patient and the parents for the new situation at adult health care. 
The adult specialist needs to be prepared for looking after a young patient in adolescent age 
with a long medical history. Often the disease has already caused irreversible damage and 
influences growth and development, as well as functional and social performance. One 
needs to realise that the pattern of joint erosions are often different from adults with RA and 
that the uveitis so commonly seen in JIA is rare in RA. For young patients visiting the adult 
department with a relative short disease duration, without such effects of longstanding 
disease this is of course different. Also, the adult specialist needs to deal with a patient in the 
adolescence phase. Often the disease has had influence on growth and development, and 
functional and social outcome. This, however, is different for young patients attending the 
adult department who had a relatively short disease duration, and who haven’t displayed 
the effects of a longstanding disease.  
Finally, the parents and extended family who have been involved in the disease process for 
a long time as they have had to take care of the medication and appointments at the hospital 
and sometimes needed to give extra support in nursing their child. When growing up, the 
child needs less support. The parent is required to release the responsibilities and hand 
them over to their child. At the adult department all responsibilities must be taken on by the 
patient themselves. This requires a self confident, considerate and often independent person 
that is capable to self-manage all aspects of the disease. 
3. Aspects of transition 
3.1 The concept of self-management 
This is described as the transition of the patient from a dependant (childhood) state into a 
self caring adult person.    
As the young child grows up into adulthood via adolescence it will develop a set of tools to 
cope with this new situation. Such a transition into adulthood (defined by Hardoff (10)) is a 
period of biological, social and emotional change, in which the adolescent has 4 major tasks: 
 to consolidate their identity;  
 to achieve independence from their parents;  
 to establish adult relationships outside the family;  
 to find a vocation. 
The adolescent with a chronic disease, however, has additional tasks:  
 they have to cope with the disease; 
 the treatment and its functional limitations; 
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 they have to learn to do that independently from the support team which was available 
to them in their childhood, e.g. the parents and pediatric health services. 
Hence, it is not surprising that the value of self-management interventions that train 
patients to utilize relevant skills is the subject of increased attention (11), see ref White 
articles [5]. Self-management may be one means of bridging the gap between patients’ needs 
and the capacity of health and social care services to meet those needs. 
Self-management is generally held as one of the key elements in a transition program.  
But other skills are also important like communication, decision making and assertiveness 
(12-14). Patients in the adolescent ages were interviewed by Stinson et al (13) about their 
strategies of gaining control over managing their illness on their own. The two strategies 
that assisted the process of transition were:  
 gaining knowledge and skills to manage the disease and;  
 experiencing understanding through social support.  
The authors concluded that web-based interventions could be a promising tool in 
supporting the acquisition of knowledge (13). 
Table 2 summarizes the knowledge and skills needed for transition of the adolescent. These 
items can be prepared by the pediatric and adult health department workers including the 
specialist, but also parents and peers (healthy as well as those with a chronic disease) are 
important (12;15).  
I: Knowledge for transition 
Condition including effects on body, medical history and prognosis 
Therapy regimen including names, doses, side effects, rationale,  
risk of non-adherence 
Purposes of tests and procedures 
Relevant medical terminology 
Specific issues, e.g., antibiotic prophylaxis, immunizations 
Role of health care providers, what they do, and how to access their services 
Meaning of transition 
Differences between pediatric and adult health care 
Healthy lifestyles in terms of exercise, nutrition, sun exposure etc 
Impact of drugs and alcohol on condition and therapy 
Impact of condition and therapy on sexual and reproductive health 
Impact of condition and therapy on education and vocation  
II: Skills for transition 
Health:  
Feeling confident to see health professional independent of parents 
Accessing health care independently, including booking appointments, seeking advice 
and refilling prescriptions 
Self management of their condition 
Adherence to  therapy and appointments 
Pain and fatigue management skills 
Transition of Care in Rheumatology:  




Independent living skills, self care, meal preparation, hobbies 
Peer support including independent social life and social competencies 
Educational/ vocational: 
Communication skills 
Vocational education, work experiences, (part-time) jobs 
Table 2. Knowledge and skills needed for transition (12, 15): 
Recently several internet based programs for increasing self-management have been 
developed (16;17). 
Interestingly, in a recent survey in our outpatient population of 142 adolescents (age 10-27 
years) with JIA , internet is widely used (97.9% of the patients had access to internet) and 77% 
were daily on the internet. However, only 26% surfed for information about their disease.  
The time to start the self-efficacy process with gaining knowledge about disease and related 
issues should be as young as possible. This will help them to cope with their disease later on 
in life, its limitations and the opportunities that arise, for instance in finding suitable 
employment, social activities they can partake in, the importance of taking their medication 
and monitoring their own health including making own appointments and  independently 
visiting the clinic (15). Data from a UK study supported an early start to transition, whereby 
11-14 year-old patients with JIA showing maximum improvement in disease knowledge 
after 12 months of participation in a transitional care program, which was significantly 
higher than that of a 17-year-old patient at baseline (18).  
3.2 Documentation of disease activity of JIA patients 
Despite its name juvenile, JIA is not a disease in childhood only, it may persist into 
adulthood. In retrospective and cross sectional studies which have been published, complete 
remission after at least 10 years of disease duration is described in 33-67% of the patients, 
depending on JIA subtype, and patient population (2;4;19-22). The prognosis is better in the 
oligoarticular persistent subtype and worse in the systemic group.  
Due to higher rates of remission, it is expected that patients with the oligoarticular persistent 
subtype are lost to follow up. A selection bias of patients after longer disease duration is 
therefore to be expected. Results of the disease activity of patients with very long disease 
duration should therefore be analyzed with care as most of the long-term outcome studies 
of patients with JIA are retrospective and cross-sectional.  
Further in this chapter we will highlight the aspect of the tools used to measure disease 
activity. 
3.3 Medication history 
Prognosis in RA has improved enormously these last years since intensive combination 
treatment regimes have been introduced (23). Complete remission is now noted, low DAS 
scores or other activity scores are commonly used to control disease activity (24;25). Only 
very recently remission criteria for RA are defined, but studies using these criteria are not 
published yet (26). 
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Similar to adults, treatment for JIA has improved dramatically in the past 20 years. Outcome 
of older patients is therefore hard to compare with younger patients. Patients are treated 
differently over time and between centers. Before the introduction of MTX and  SASP in the 
1990’s patients were treated with aspirin and corticosteroids.  
From the 1990’s on the pyramid was dismantled (27). The introduction of DMARDs like 
MTX and SASP changed prognosis (28;29) (30;31) 
Another true revolution was the use of “biologicals” in JIA. Instead of controlling the 
disease nowadays physicians aim at curing the disease. Especially the follow up of the 
group of JIA patients in remission without medication, as defined by Wallace (32) will show 
us in due time whether this is indeed possible. 
Following the initial description of the effects of etanercept in adult patients with RA, the 
first study in children treated with etanercept was described in 2000 by Lovell et al (33). 
Other biological therapies for children were described in later years. Biological treatment 
like adalimumab and abatacept, first used successfully in adults with RA are now 
prescribed to younger patients with JIA. Other biologic agents were not studied in a way 
that enabled FDA or EMA registration and such drugs are thus still used off label in 
children. 
3.4 Compliance 
Compliance is generally defined as a patient's adherence to a recommended course of 
treatment. Other words used are agreement, conformity, cooperation, respect, submission. 
Agreement, conformity are difficult terms for adolescents, as they are searching for methods 
to become independent from the usual carers (parents, but indeed sometimes also the 
doctor). It is not surprising that compliance in this patient group on their way to 
independence can be low.  
Corticosteroids with known side-effects as a moonface and disfiguring striae have low 
compliance rates. The combination of alcohol and MTX is not advised, which in turn, can 
cause delay in therapy. Compliance can be a huge problem in severe, probably life 
threatening systemic diseases like SLE or systemic JIA.  
In the long term, compliance may have an influence on the outcome of JIA patients. As 
adolescents have a low compliance rate in visiting their doctor, their patient data are lost in 
the follow-up phase. Changing schools or finding a job sometimes also causes a migration, 
similarly, when disease activity is quite low, the patients don’t make new appointments.  
Exact figures are therefore not known.    
Kroll described the factors that comprise treatment adherence. In his view, the facilitating 
strategies are child-centered information, therapy management, behavior modification and 
parental monitoring (34). Modern techniques can be helpful in improving compliance like 
internet-based self management programs with telephone support (17) or electronically 
monitored adherence to medication(35). 
Increasing compliance can be supported by parents and other (health) carers. 
Notwithstanding the above , the main advice for the parent is to “let the patient go”.  
Transition of Care in Rheumatology:  




Several studies have been done to evaluate educational and occupational outcome of young 
adults with JIA. Results are conflicting in different countries. 
In the USA (36) educational and occupational outcome after a median disease duration of 
12.6 years, were similar to adult peers. In Canada, educational level was lower for female 
patients and unemployment rates were higher(20). 
In the UK, Foster et al and Packham et al evaluated in different studies educational 
attainment and employment status. They concluded excellent educational attainment but a 
high rate of unemployment among the patients (37;38).  
In Germany, also educational achievements of patients were higher but rate of 
unemployment was lower compared with the age-matched population (4).  
The long-term outcome studies evaluated all JIA subtypes, although median disease 
duration was longer in the UK studies (12.6 years versus 21 and 28 years). Whether lower 
functional outcome plays a role in unemployment ratio is not known as this is not 
investigated in all studies. 
In some countries more support is given to persons with disabilities. It may be that JIA 
patients receive sickness or disability benefit and are therefore not included in 
unemployment figures. 
3.6 Psychological aspects  
Psychological and social aspects as well as coping strategies are well documented in 
younger children with JIA (39;40).  
Only a few long term outcome studies in adolescents and adults with juvenile arthritis have 
been published. Significantly impaired physical health but no psychosocial health 
differences were found compared to the general (Norwegian) population(41). Patients with 
significant disabilities (Steinbrocker class III or IV) (42) or longstanding disease activity (43), 
show psychological distress in about one-third of the cases.  
Despite reported psychological problems only few patients show social adjustment 
problems (4;19)). Overall, the literature on psychological outcome has shown contradictory 
conclusions. This may be due to  variations of  the measures used, time since onset of 
disease, inclusion or omissions of controls, the study design, and disease severity or degree 
of disability. The age seems  particularly important because psychosocial adjustment may 
change as patients pass through life’s developmental stages(44). 
3.7 Long term outcome of JIA 
In longterm follow up studies approximately half of the patients have active disease and/or 
changes in body structures to a variable extent. Approximately one-third of the patients 
rated themselves as being functionally limited (3). Little is known about long-term effects of 
medication, especially the more recently introduced DMARD’s and biologicals.  
Complete remission in JIA is achieved in 33-67% of the patients, depending on the subtype.  
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In JIA remission criteria are defined by Wallace et al (32). One of the main differences with 
adult health care is that complete remission in JIA is defined as “no disease activity”, no 
active joints and low sedimentation rate and or CRP with low physician’s global assessment. 
In adult health care remission used to be defined by low DAS scores but some disease 
activity may persist. 
Remission per subtype JIA 
- Systemic     47-76% 
- Oligo persistent/extended    35-57% 
- Polyarticular RF+   0-15% 
- Polyarticular RF –   30-46% 
- Enthesitis related   18% 
- Psoriatic     33% 
(2;4;19;20). 
In the past few years, the prognosis for RA has improved enormously since the introduction 
of intensive combination treatment regimes (23). Complete remission has not been noted, 
low DAS scores or other activity scores are commonly used to judge disease activity (24;25). 
However, for instance for patients with JIA the aim of the pediatrician is to reach complete 
remission of the disease. This is in sharp contrast to the generally accepted disease activity 
within adult rheumatology. Until very recently, in adult RA new remission criteria have 
been defined, although new studies using these criteria have not been published yet (26). 
The long term complications of JIA and RA are different. Adequate control of inflammation 
has made Felty syndrome and amyloidosis nowadays very rare complications in JIA, 
whereas it occurs in 1.4% of adults with RA. In RA, residing functional disability is higher 
(HAQ >0: is seen in 36% - 72% of patients), as are erosions and other radiological changes 
like growth deformities, fusion, osteopenia (seen in 25%- 68%).(2;3;19;21;45).  
3.8 Developmental aspects  
Research has been carried out on the impact of JIA later on in the life of its patients, and 
important differences between healthy adolescents and young adults suffering from JIA 
have been found.  
For instance in studies done in Europe one of the aspects is the growth difference in JIA 
patients. In Germany, girls final height is 2 cm shorter than their peers, for boys this is 1 cm 
(46). In Great Britain, the final height differential is much larger, 4 cm in girls and  4 cm in 
boys, compared to their peers (47). In the Netherlands, a study is ongoing on the 
developmental aspects of adolescents with JIA. We found 2 cm decrease in the final height 
of girls, and only 0,5 cm for boys. Research on growth differences in the United States or 
South America hasn’t been carried out yet. 
Growth and final height depends on several aspects. 
Malnutrition is common among patients with a chronic disease. Further influence on final 
height are the age at which the puberty starts, and the clinical progression of puberty and 
growth spurt (48;49). Possibly abnormalities in the growth hormone axis plays a role (49-51). 
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A number of (retrospective) studies have been carried out amongst adult women with JIA 
and the potential influence of JIA on sexuality and fertility and indirectly, on their number 
of children. No randomized controlled trials are known, all data were retrospectively 
collected. Conclusions of the authors were that the number of successful pregnancies is 
comparable to healthy controls, although in our observation this conclusion may be too 
hasty. The number of miscarriages was not mentioned in any (retrospective) studies, and 
also fecundity (time to conceive) was not taken into account. More research needs to be done 
in adult patients (1;52;53). 
3.9 Transfer of a complicated medical history      
Failure to coordinate care between providers of the pediatric and adult health system 
adversely affects both quality and efficiency of care. Planning, information and warnings to 
the next care provider are very important. Documentation of relevant information is 
important in view of the multidisciplinary nature of transitional care. One can imagine the 
results of prescribing wrong dosage of for example MTX or TNF blockers on internal organs. 
Also when medication history is insufficient (eg not mentioning cyclofosfamide) severe 
physical problems are to be expected. 
In a study carried out in the UK it was shown that detailed and extensive documentation 
significantly improved following participation in a transitional care research program 
(15). 
Nowadays with the support of electronic patient files these problems should be of the past, 
but these modern techniques are not widely available yet. A summary of medical history 
and used medication on the past and current medical problems can overcome this problem. 
Social and psychological issues must also be explained and transferred to social workers 
within the adult department.  
3.10 Transfer of knowledge from pediatrician to adult physician     
In 2002, a consensus document on transition of care was approved by the American 
Academy of Pediatrics, The American Academy of Family Physicians, and the American 
College of Physicians-American Society of Internal Medicine (54).  This consensus statement 
states that all young people with special health care needs such as rheumatic diseases 
should have the following: a professional with the appropriate transition care knowledge 
and skills who attends to the unique challenges of health care transition; a written health 
care transition plan by the age of 14 including a constantly updated medical summary that 
is portable and accessible to the youth and family; care guided by the primary and 
preventive care guidelines for al adolescence and young adults; and affordable, continuous 
health coverage.  
Unfortunately, in 2005, a survey done in Pennsylvania, USA, to evaluate the consensus 
statement in practice, revealed that 57% of the practices had not started any of the transition 
guidelines (55).  
Also outside the US, the availability of appropriately trained staff and in-service training to 
maintain staff members’ skills and knowledge in adolescence is considered important. In a 
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Delphi study done in the UK, availability of professionals who were knowledgeable in 
transitional care was reported to be best practice (56). 
However, well trained staff in knowledge of adolescence is rare. 
McDonagh described the unmet skills and training needs in health professionals dealing in 






n (%)  
Perceived knowledge of 
available 
information/resources 
(Very low/low)  
n (%)  
Perceived importance of 





Suicide risk 15 (68) 13 (59) 19 (86) 
STDs/HIV/hepatitis 12 (54) 7 (33) 17 (77) 
Gay/lesbian sexuality* 11 (52) 16 (76) 13 (59) 
Drug use 10 (45) 13 (59) 20 (91) 
Eating disorders 9 (41) 11 (52) 20 (91) 
Physical/sexual abuse 9 (41) 6 (27) 20 (91) 
Dating/vulnerability 9 (41) 17 (77) 17 (77) 
Vocation/employment 7 (32) 9 (41) 20 (91) 
Contraception/safe 
sex 
6 (27) 8 (36) 19 (86) 
Parental conflict 5 (23) 12 (55) 18 (82) 
Driving 5 (23) 9 (41) 18 (82) 
Alcohol use 4 (18) 9 (41) 21 (95) 
Smoking 4 (18) 7 (32) 20 (91) 
Body image* 3 (14) 15 (68) 21 (95) 
Peer relations 3 (14) 12 (55) 19 (86) 
Nutrition 3 (14) 3 (14) 21 (95) 
Depression/anxiety 2 (9) 8 (36) 21 (95) 
Psychosomatic 
complaint 
2 (9) 4 (18) 20 (91) 
Education* 2 (9) 5 (23) 19 (86) 
Exercise 0 (0) 0 (0) 20 (91) 
Table 3. (57) Respondents’ perceived skill/comfort level in dealing with adolescent issues, 
their perceived knowledge of resources and their importance in a rheumatology clinic  
(n = 22)  
4. Adaptations from pediatric to adult health care   
JIA is a heterogeneous group of 7 diseases, comprising from systemic JIA, oligo-articular 
and poly-articular JIA, enthesitis related JIA (also called juvenile spondylarthropathy), 
psoriatic arthritis and undifferentiated JIA (58). Only the extended oligo-articular JIA and 
poly-articular JIA can fit in the diagnosis RA with regards to disease symptoms.  
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The definition of Rheumatoid Arthritis used to be strict, (ACR criteria 1987), but recently this 
definition is considered to be imprecise, since also early arthritis with relative short disease 
duration is treated as RA. However, the term is generally used to describe a symmetrical, 
persistent, and destructive poly-arthritis often associated with a  rheumatoid factor or with 
positive results in tests for anti-cyclic citrullinated peptide (anti-CCP) antibodies (59).  
4.1 Different scoring methods 
Most studies describing long term outcome of JIA patients use adult outcome parameters to 
show for example disease activity, functional outcome or psychosocial outcome ((1;3;20).  
But are  those the right tools to compare  the disease activity in each individual patient from 
the start of their disease into their adult life? Or even, can we use these parameters to 
compare RA patients with JIA?  
Pediatric multicenter trials have developed a uniformly accepted way of measuring disease 
activity (60). The initial ACR scores for children (Ped-ACR 30-50-70-90) were adapted from 
the adult scores (ACR 30-50-70 and 90%). It should be noted however that these ACR/Printo 
scores were specifically designed for measuring change induced by medication. More recent 
tools such as JADAS include a single point total score similar to the adult DAS instead of 
measuring the percentage of change to baseline values.  Most used variations in adults with 
RA are DAS 28 and DAS 44 (61;62). In pediatric rheumatology in 2009 the Juvenile DAS is 
introduced, variations are the JADAS 10, 27 and 71. The Correlations between the 3 JADAS 
versions was comparable, but better than the DAS 28 and the CDAI (Clinical Disease 
Activity Index).  
Functional outcome at pediatric age is measured by the Childhood Health Assessment 
Questionnaire, a derivative from the Health Assessment Questionnaire, which is used for 
adults. We have compared both questionnaires and used the same adolescents and young 
adults with JIA. Despite strong correlations in consistency, and independent of age, we 
found a lack of agreement for the outcome of CHAQ and HAQ (63).  This implies that the 
functional outcome as measured by the CHAQ is not directly comparable to the HAQ when 
measured at the same time. Direct matching is therefore not possible. Further research in 
follow-up data is ongoing. When following the patient at an adult age for a longer period, as 
will be done in transition phase, outcome parameters will have to be comparable to those 
measured at pediatric age. 
A multidimensional assessment questionnaire was proposed including physical, 
psychosocial and compliance aspects (JAMAR) (64). The JAMAR includes 15 parent or 
patient-centered measurements or items that assess well-being, pain, functional status, 
health-related quality of life, morning stiffness, disease activity, disease status and course, 
joint disease, extra-articular symptoms, side effects of medications, therapeutic compliance, 
and satisfaction with illness outcome. The JAMAR is proposed for use as both a proxy-
report and a patient self-assessment report, with the suggested age range of 7-18 years for 
use as a self-assessment report. However even this multidimensional score does not 
measure in detail the consequence of certain limitations for participation in daily life 
activities. The full impact of certain limitations can only be learned from our patients.  
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4.2 Models for transition of care 
Transition of care for the adolescent with a chronic disease is complex. Many people are 
involved, the patient, his or her parents, the pediatrician and the adult specialist. Often also 
other co-workers like social workers or physiotherapists are involved. Therefore a number 
of health service models have been proposed, including the patient-focussed model, a 
disease-focussed model, hospital-based model, a team-based outside the health service, a 
named person, a voluntary organisation and a primary care model (65).  
For patients with rheumatic diseases 3 units have described their programs in literature (66-
68), all disease focussed models.  
While et al developed the disease focussed model of transition further and described 4 
models (table) 
 
Models of transition for evaluation 
Direct transition (communication and information sharing only) 
Sequential transition (includes the development of new services like adolescent clinics) 
Developmental transition (includes skill training and support system development) 
Professional transition (transfer of expertise only) 
Table 4. (11) 
When summarizing the most important needs for transition the following key components 
for the organisation of care can be  noted (12):  
 Future focused, patient-centered 
 Inclusive for parents/ caregivers 
 Early start (11-14 years) 
 Multidisciplinary, paediatric and adult services, social workers, education 
 Dynamic and flexible process in a resilience framework (ITP, Individual Transitional 
Plan) 
 Coordinated, uninterrupted health care 
 Age and developmentally appropriated 
 Skills training for the young person in communication, decision making, 
assertiveness, self-management 
5. Complications in transition of care 
5.1 Complications for the patient      
Complications of transition have been well described(6). During transition a whole list of 
topics needs to be discussed with the adolescent and this is usually the cause of such 
complications. Some of these topics are for example self care and communication skills: 
medication is not prescribed because the patient doesn’t ask for a recipe; the patient gets 
pregnant while taking MTX because contraceptives haven’t been discussed. 
McDonagh suggested a list of topics to be discussed during transition of care are(6):  
 decision making  
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 independent visits 
 phoning with own queries 
 communication skills 
 self care including compliance 
 level of parental concern 
It is suggested that quality of medical care for young people with chronic disease 
deteriorates after transfer to adult services has taken place (69). 
Potential explanations of deteriorating quality of medical care could be due to: 
- reduced therapy goals (low disease activity instead of remission) 
- reduced compliance of the adolescent 
- insufficient transfer of care by the pediatric and adult health services 
A complication in insufficient transfer of medical care of the adolescent with a rheumatic 
disease can be that the patient is lost in the medical system and not returning to a medical 
clinic for rheumatic diseases (either returning back to the pediatrician or visiting a different 
adult department). 
It is not clear how many patients are lost in their follow up after their transition to adult 
health care. Even in large outcome studies of adult patients with JIA exact numbers can not 
be determined (2-4). 
There are numerous reasons why these patients are missing from the medical system after 
their transfer to adult health care: 
- Their disease may be in remission 
- They may have moved or even migrated abroad  
- There is insufficient availability of (adequate) rheumatologists 
- There is insufficient preparation for adult health care (failure of transition of care 
process) 
- Non compliance of the patient:  
Too busy with study, new home, new friends or new job to visit a rheumatologist 
Loss of confidence in adult care 
No interest in own health 
Incapacity to deal with independent self-care 
Apart from the risk of no-shows, there are potential problems that the patient finds it 
difficult to cope with such as: 
- their persistent disease activity to which insufficient attention is given 
- their reduced functional ability whereby no additional help is offered 
- the side effects of their medication 
- psychological symptoms like depression 
- insufficient self care, ongoing dependency on parents or partner 
In pediatric health care, the medical approach is from a multi-disciplinary perspective 
whereby the patient’s whole well-being is taking into account.  
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whereby the patient’s whole well-being is taking into account.  
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5.2 Complications for the carers   
Most adult rheumatologists are not trained in adolescent medicine and the subjects 
associated with adolescence and their subsequent handling of the rheumatic disease. Also 
some professionals may simply not like looking after adolescents and find their non-
compliance and uncommunicative behaviors an irritation in an adult clinic (6). 
The adolescent patient (as any other healthy person of this age range) requires special 
attention as he or she is in a period of transition from a dependant to an independent state. 
At adolescence the child’s focus shifts away from family to peers. This important move 
should be no different for chronically ill adolescents. Adolescents begin to adopt a multitude 
of new social and emotional roles and learn to cope with altered bodily functions. 
Adolescents with a chronic disease are constantly struggling with independence. At the 
same time, their illness often keeps them tied physically, emotionally and financially to their 
families. 
Moreover, a chronic disease like JIA or its treatment may interfere with the normal growth 
process like muscle strength and sexual maturity (70).  
Factors which play a role during normal adolescence are 
 Independence and assertiveness 
 Peer relationships 
 School at work 
 Physical appearance 
 Sexuality 
 Death and dying 
Besides culture differences, adult rheumatology services are frequently different from 
pediatric rheumatology services in the following aspects(6): 
- Time available for consultation 
- Continuity of care in terms of the same doctor at consecutive visits 
- Format of referrals to allied professionals, usually by short paper referrals rather than 
detailed in person overview during a meeting of the rheumatology team. 
When these issues are not taken into account during the transition phase transfer, problems 
are expected.  
6. Future developments 
6.1 Optimal organization of transition of care   
Papers and textbooks dealing with transition of care often provide interesting descriptions, 
theories and hypothesis rather than solid empirical data. The importance of a transition 
program for adolescents with JIA is widely recognized but the lack of solid data from 
studies to base the policy on is remarkable. Just very few studies have been published with 
data to support current programs (14). Most published studies evaluating transitional care 
have been for patients with diabetes mellitus, with programs targeted at improving patient 
education, staff continuity or delivery of service. 
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This existing evidence supports the use of educational programs, joint pediatric and adult 
clinics and specific young adult clinics. Evidence for patients with rheumatic disease 
however have not been published yet, most likely because outcome markers for these 
chronic diseases are rather complex, while in diabetes disease specific biochemical 
indicators like HbA1c are used.  
When summarizing the most important needs for transition in rheumatology, the following 
key components can be distinguished(7;12;71):  
 Medical care in the transition phase should be focused on the future of the adolescent 
patient, and centred around the young adult 
 Health care should include parents as well as support health staff 
 Start of the transitional process should be addressed at the start of the adolescence (11 – 
14 years)  
 The medical approach should be from a multidisciplinary perspective, and include both 
paediatric and adult services, as well as social workers and educational experts 
 It should be a dynamic and flexible process in a resilient framework (ITP, Individual 
Transitional Plan)  
 Coordinated, uninterrupted health care 
 Appropriate for age and developmental stage 
 Include skills training for the young person in communication, decision making, 
assertiveness, self-management(72) 
 Make plans for the future (peer support including independent social life and 
social competencies, education, housing)  
 Policy regarding contact after transfer to adult services 
 Evaluation process: audit; regular review of policy; participation of young people and 
parent in evaluation and future development of the service 
 Where possible, linking families to share information and experiences 
Regarding the medical documentation and administrative transfer an electronic patient file 
will be very helpful. Important information is then always available for every health care 
provider. Wherever possible, during the visits, the patient can also ask for the recall of the 
summary of the appointments as well as their blood test results, therefore creating an 
excellent knowledge of disease.  
Individualized transition plans (ITP) are important for a successful transfer to adult health 
care. Such plans need to incorporate items on the basic domain on organs and their function 
(pain, swelling, LOM), then activities of daily life (walking, sitting, standing, self hygiene) 
and participation in the society (walking to school, work, computer use, cooking, house-
cleaning, relations); (adapted from the international classification of functioning (73)). The 
young person has to be trained in knowledge and skills during transition. The skills and 
knowledge can be prepared by the pediatric and adult health department workers including 
the specialist, but may also include and important support from parents and peers (healthy 
as well with a chronic disease) (15).  
During the transition phase the ITP should be reviewed regularly by the transition 
coordinator. Omissions are easily identified and additional attention can be given to the 
patient.  
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And last but not least we need to include the patient’s opinion and learn to listen to them. 
This is not as obvious as it seems, as illustrated by the experience of describing disease 
activity of psoriasis. Where doctors measure numbers of plaques and percentage of affected 
skin area, our (adolescent) patients only care about skin lesions in their faces. From their 
viewpoint it can be stated that only if facial lesions regress, there is significant disease 
improvement. 
In order to create a substantial foundation based on factual data that results in a successful 
transfer in rheumatic diseases we need to define: 
What is the best parameter to measure a successful transfer:  
Would this be disease activity results, functional outcome or psychosocial parameters?  
Furthermore, we need to determine which test (pediatric or adult version) will be used to 
measure the parameter in adolescent age. 
When successful transfer is defined, research can be done to consider the right timing, for 
the individual patient, in a transition phase guided by both pediatric and adult carers with 
the inclusion of parents and peer support.  
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